cholesterol, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, cholesterol

Aarsetoey H, Ponitz V, Grundt H, Staines H, Harris WS, Nilsen DW. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J. Nutr. 139: 507-513 (2009). *
Aasheim ET, Bjorkman S, Sovik TT, Engstrom M, Hanvold SE, Mala T, Olbers T, Bohmer T. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am. J. Clin. Nutr. 90: 15-22 (2009). *
Abad-Lacruz A, Fernandez-Banares F, Cabre E, Gil A, Esteve M, Gonzalez-Huix F, Xiol X, Gassull MA. The effect of total enteral tube feeding on the vitamin status of malnourished patients with inflammatory bowel disease. Int. J. Vitam. Nutr. Res. 58: 428-435 (1988).
Abba K, Sudarsanam TD, Grobler L, Volmink J. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst. Rev. 4: CD006086 (2008).
Abbatecola AM, Evans W, Paolisso G. PUFA supplements and type 2 diabetes in the elderly. Curr. Pharm. Des. 15: 4126-4134 (2009).
Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman SE. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. J. Diabetes Complications Jun 22 [Epub ahead of print] (2009).
Aberle J, Fedderwitz I, Klages N, George E, Beil FU. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm. Metab. Res. 39: 395-397 (2007).
Aberle J, Flitsch J, Beck NA, Mann O, Busch P, Peitsmeier P, Beil FU. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol. Genet. Metab. 95: 188-191 (2008). *
Abifadel M, Rabes JP, Jambart S, Halaby G, Gannage-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Aydenian H, Junien C, Munnich A, Boileau C. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum. Mutat. 30: E682-E691 (2009). *
Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, De Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M. 24(S)-Hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281: 12799-12808 (2006). *
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H. Chronic inflammatory autoimmune disorders and atherosclerosis. Ann. N. Y. Acad. Sci. 1107: 56-67 (2007). *
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Lymphoplasmacytic chronic cholecystitis and biliary tract disease in patients with lymphoplasmacytic sclerosing pancreatitis. Am. J. Surg. Pathol. 27: 441-451 (2003).
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Diffuse lymphoplasmacytic chronic cholecystitis is highly specific for extrahepatic biliary tract disease but does not distinguish between primary and secondary sclerosing cholangiopathy. Am. J. Surg. Pathol. 27: 1313-1320 (2003).
Abrahamsson A, Gafvels M, Reihner E, Bjorkhem I, Einarsson C, Eggertsen G. Polymorphism in the coding part of the sterol 12alpha-hydroxylase gene does not explain the marked differences in the ratio of cholic acid and chenodeoxycholic acid in human bile. Scand. J. Clin. Lab. Invest. 65: 595-600 (2005). *
Abrahamsson A, Krapivner S, Gustafsson U, Muhrbeck O, Eggertsen G, Johansson I, Persson I, Angelin B, Ingelman-Sundberg M, Bjorkhem I, Einarsson C, Hooft FM. Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. Atherosclerosis 182: 37-45 (2005).
Abumweis SS, Jones PJ. Cholesterol-lowering effect of plant sterols. Curr. Atheroscler. Rep. 10: 467-472 (2008).
Acalovschi M, Tirziu S, Chiorean E, Krawczyk M, Grunhage F, Lammert F. Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids 44: 521-526 (2009).
Acosta-Perez G, Maximina Bertha Moreno-Altamirano M, Rodriguez-Luna G, Javier Sanchez-Garcia F. Differential dependence of the ingestion of necrotic cells and TNF-alpha/IL-1beta production by murine macrophages on lipid rafts. Scand. J. Immunol. 68: 423-429 (2008). *
Adachi T, Nakagawa H, Hagiya Y, Yasuoka T, Ishikawa T. Transport-metabolism interplay: LXR-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells. Mol. Pharm. 6: 1678-1688 (2009). *
Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 49: 241-268 (2008). *
Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 48: nihpa41041 (2008). *
Adighibe O, Arepalli S, Duckworth J, Hardy J, Wavrant-De Vrieze F. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol. Aging 27: 1431-1434 (2006).
Agarwal DK, Choudhuri G, Saraswat VA, Negi TS, Kapoor VK, Saxena R. Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination. Gut 35: 112-116 (1994). *
Agte VV, Tarwadi KV. Combination of diabetes and cataract worsens the oxidative stress and micronutrient status in Indians. Nutrition 24: 617-624 (2008). *
Aguirre AL, Center SA, Randolph JF, Yeager AE, Keegan AM, Harvey HJ, Erb HN. Gallbladder disease in Shetland sheepdogs: 38 cases (1995-2005). J. Am. Vet. Med. Assoc. 231: 79-88 (2007).
Ahmad Z. The uses and properties of almond oil. Complement. Ther. Clin. Pract. 16: 10-12 (2010).
Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am. J. Ther. 14: 49-62 (2007).
Ahmed RA, Murao K, Imachi H, Yu X, Li J, Wong NC, Ishida T. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes. Endocrine 35: 233-242 (2009).
Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int. J. Cancer 123: 1733-1740 (2008). *
Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J. Biol. Regul. Homeost. Agents 17: 29-45 (2003).
Akaogi J, Barker T, Kuroda Y, Nacionales DC, Yamasaki Y, Stevens BR, Reeves WH, Satoh M. Role of non-protein amino acid L-canavanine in autoimmunity. Autoimmun. Rev. 5: 429-435 (2006).
Akerlund JE, Bjorkhem I, Angelin B, Liljeqvist L, Einarsson K. Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism. Gut 35: 1116-1120 (1994). *
Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J. Eur. Acad. Dermatol. Venereol. 21: 1330-1332 (2007). *
Akimoto T, Kobayashi S, Tamura N, Ohsawa T, Kawano T, Tanaka M, Hashimoto H. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 56: 601-609 (2005).
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22: 2607-2619 (2002). *
Akoume MY, Perwaiz S, Yousef IM, Plaa GL. Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats. Toxicol. Sci. 73: 378-385 (2003). *
Akoume MY, Tuchweber B, Plaa GL, Yousef IM. The role of mdr2 in manganese-bilirubin induced cholestasis in mice. Toxicol. Lett. 148: 41-51 (2004). *
Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U. Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J. Clin. Neurosci. 15: 393-397 (2008).
Al Senaidy AM. Serum vitamin A and beta-carotene levels in children with asthma. J. Asthma 46: 699-702 (2009).
Al-Attas OS, Al-Daghri NM, Al-Rubeaan KA, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc. Diabetol. 8: 20 (2009).
Al-Zahrani AM, Al-Raddadi RM. Nutritional knowledge of primary health care physicians in Jeddah, Saudi Arabia. Saudi Med. J. 30: 284-287 (2009).
Alazmi WM, Fogel EL, Watkins JL, McHenry L, Sherman S, Lehman GA. The effect of biliary sphincterotomy on serum cholesterol level in postcholecystectomy patients: a pilot study. Can. J. Gastroenterol. 21: 81-84 (2007). *
Albahrani AI, Usher J, Marks E, Ranganath L, Shenkin A. Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report. J. Med. Case Reports 1: 51 (2007). *
Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54: 987-993 (2005). *
Albers M, Blume B, Schlueter T, Wright MB, Kober I, Kremoser C, Deuschle U, Koegl M. A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J. Biol. Chem. 281: 4920-4930 (2006). *
Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 107: 565-573 (2001). *
Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. 49: 855-862 (2008).
Albrecht C, Elliott JI, Sardini A, Litman T, Stieger B, Meier PJ, Higgins CF. Functional analysis of candidate ABC transporter proteins for sitosterol transport. Biochim. Biophys. Acta 1567: 133-142 (2002). *
Aldamiz-Echevarria L, Sanjurjo P, Elorz J, Prieto JA, Perez C, Andrade F, Rodriguez-Soriano J. Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia. J. Inherit. Metab. Dis. 29: 58-63 (2006). *
Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic Milutinovic A, Kovacevic N, Krstic S, Popovic D. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J. Gastroenterol. 15: 591-594 (2009). *
Alfter K, von Kugelgen I, Haenisch B, Frieling T, Hulsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. 29: 181-186 (2009). *
Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med. Sci. Monit. 14: PI66-PI74 (2008). *
Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS ONE 4: e5724 (2009). *
Alkofer BJ, Chiche L, Khayat A, Deshayes JP, Lepage A, Saloux E, Reznik Y. Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: report of the first case and review of the literature. Transplant. Proc. 37: 2250-2252 (2005). *
Aller R, De Luis DA, Fernandez L, Calle F, Velayos B, Izaola O, Gonzalez Sagrado M, Conde R, Gonzalez JM. Influence of Ala54Thr polymorphism of fatty acid-binding protein 2 on histological alterations and insulin resistance of non alcoholic fatty liver disease. Eur. Rev. Med. Pharmacol. Sci. 13: 357-364 (2009).
Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, Izaola O, Sagrado MG, Conde R, Gonzalez JM. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig. Dis. Sci. 53: 1088-1092 (2008). *
Alles N, Soysa NS, Hussain MA, Tomomatsu N, Saito H, Baron R, Morimoto N, Aoki K, Akiyoshi K, Ohya K. Polysaccharide nanogel delivery of a TNF-alpha and RANKL antagonist peptide allows systemic prevention of bone loss. Eur. J. Pharm. Sci. 37: 83-88 (2009).
Allocca M, Crosignani A, Battezzati PM, Gritti A, Podda M. Hypercholesterolaemia is not associated with increased carotid-artery intima and media thickness in primary biliary cirrhosis. J. Hepatol. 40 Suppl. 1: 159 (2004).
Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55: 1795-1800 (2006). *
Almeida LB, Giudici KV, Jaime PC. Dietary intake and dyslipidemia arising from combination antiretroviral therapy for HIV infection: a systematic review. Arq. Bras. Endocrinol. Metabol. 53: 519-527 (2009).
Almendingen K, Fausa O, Hostmark AT, Bratlie J, Morkerid L, Aabakken L, Vatn MH. Serum nutrients and habitual dietary intake in colectomized FAP patients in Norway. Eur. J. Nutr. 48: 129-136 (2009). *
Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *
Alonso L AG. Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann. Hepatol. 5: 184-186 (2006). *
Alpy F, Legueux F, Bianchetti L, Tomasetto C. START domain-containing proteins: a review of their role in lipid transport and exchange. Med. Sci. (Paris) 25: 181-191 (2009).
Alpy F, Tomasetto C. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J. Cell. Sci. 118: 2791-2801 (2005). *
Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24: 1803-1823 (2007). *
Alrefai WA, Sarwar Z, Tyagi S, Saksena S, Dudeja PK, Gill RK. Cholesterol modulates human intestinal sodium-dependent bile acid transporter. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G978-G985 (2005). *
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).
Altenburg JD, Siddiqui RA. Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB-231 breast cancer cells. Mol. Cancer Res. 7: 1013-1020 (2009).
Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 204: 232-235 (2002).
Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204 (2004). *
Alvarez F. Treatments in chronic cholestasis in children. Ann. Nestle [Engl.] 66: 127-135 (2008).
Alvaro A, Rosales R, Masana L, Vallve JC. Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids. J. Nutr. Biochem. May 13 [Epub ahead of print] (2009). *
Alves Cde A, Lima DS. Cystic fibrosis-related dyslipidemia. J. Bras. Pneumol. 34: 829-837 (2008).
Aly A, Carlson K, Johansson C, Kirstein P, Rossner S, Wallentin L. Lipoprotein abnormalities in patients with early primary biliary cirrhosis. Eur. J. Clin. Invest. 14: 155-162 (1984).
Amaral JD, Sola S, Steer CJ, Rodrigues CM. Role of nuclear steroid receptors in apoptosis. Curr. Med. Chem. 16: 3886-3902 (2009).
Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res. 50: 1721-1734 (2009). *
Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5: 30-33 (2006). *
Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG. The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J. Clin. Apheresis 2: 219-223 (1985).
Ambrosi P, Drici MD, Herpin D, Pathak A. The best of clinical pharmacology in 2006. Arch. Mal. Coeur. Vaiss. 100 Spec. No. 1: 99-102 (2007).
Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA. Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res. Clin. Pract. 67: 175-179 (2005).
Ames PR, Matsuura E, Batuca JR, Ciampa A, Lopez LL, Ferrara F, Iannaccone L, Delgado Alves J. High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus Jan 11 [Epub ahead of print] (2010).
Amigo L, Castro J, Miquel JF, Zanlungo S, Young SG, Nervi F. Inactivation of hepatic microsomal triglyceride transfer protein protects mice from diet-induced gallstones. Gastroenterology 131: 1870-1878 (2006). *
Amrouche Ch, Jamoussi Kamoun H, Trabelsi N, Blouza Chabchoub S. Latent autoimmune diabetes in Tunisian adults (LADA): identification of autoimmune markers. Tunis. Med. 86: 316-318 (2008).
An S, Jang YS, Park JS, Kwon BM, Paik YK, Jeong TS. Inhibition of acyl-coenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytes. Exp. Mol. Med. 40: 407-417 (2008). *
Anand PK, Kaul D. Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microbiol. Lett. 250: 137-144 (2005). *
Anandan R, Mathew S, Sankar TV, Viswanathan Nair PG. Protective effect of n-3 polyunsaturated fatty acids concentrate on isoproterenol-induced myocardial infarction in rats. Prostaglandins Leukot. Essent. Fatty Acids 76: 153-158 (2007). *
Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J. Med. Virol. 80: 209-216 (2007).
Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat. Immunol. 1: 156-162 (2000). *
Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor and liver X receptor in mouse liver. Mol. Pharmacol. 66: 1440-1452 (2004). *
Andersson S, Gustafsson N, Warner M, Gustafsson JA. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc. Natl. Acad. Sci. U.S.A. 102: 3857-3862 (2005). *
Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A. Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J. Pharmacol. Exp. Ther. 311: 420-425 (2004). *
Ange-van Heugten KD, Burns R, Verstegen MW, Jansen WL, Ferket PR, van Heugten E. Evaluation of diabetes determinants in woolly monkeys (Lagothrix lagotricha). J. Anim. Physiol. Anim. Nutr. (Berl.) 91: 481-491 (2007). *
Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J. Clin. Invest. 70: 724-731 (1982). *
Angelin B, Eriksson M, Parini P, Rudling M. Bile acids and lipoproteins. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 31. June 18-19 (2004). *
Angelin B, Ewerth S, Einarsson K. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels. J. Lipid Res. 24: 461-468 (1983). *
Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).
Angulo P. Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19 (2003). *
Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK, Alrefai WA. Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G489-G497 (2008). *
Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, Baldini M, Delle Volpe A, Lambertenghi Deliliers G. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 41: 797-804 (2008).
Annilo T, Tammur J, Hutchinson A, Rzhetsky A, Dean M, Allikmets R. Human and mouse orthologs of a new ATP-binding cassette gene, ABCG4. Cytogenet. Cell. Genet. 94: 196-201 (2001).
Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes - insight from the FIELD study. Curr. Pharm. Des. 15: 537-552 (2009).
Antalis CJ, Arnold T, Lee B, Buhman KK, Siddiqui RA. Docosahexaenoic acid is a substrate for ACAT1 and inhibits cholesteryl ester formation from oleic acid in MCF-10A cells. Prostaglandins Leukot. Essent. Fatty Acids 80: 165-171 (2009). *
Anthonisen EH, Berven L, Holm S, Nygard M, Nebb HI, Gronning-Wang LM. The nuclear receptor LXR is O-GlcNAc modified in response to glucose. J. Biol. Chem. Nov 20 [Epub ahead of print] (2009). *
Antsaklis G, Lewin MR, Sutor DJ, Cowie AG, Clark CG. Gallbladder function, cholesterol stones, and bile composition. Gut 16: 937-942 (1975). *
Appel LJ. Dietary approaches to reduce blood pressure. J. Anim. Physiol. Anim. Nutr. (Berl.) 89: 433 (2005). *
Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177: 3028-3034 (2006). *
Arai T, Kim HJ, Chiba H, Matsumoto A. Interaction of fenofibrate and fish oil in relation to lipid metabolism in mice. J. Atheroscler. Thromb. 16: 283-291 (2009). *
Arai T, Kim HJ, Chiba H, Matsumoto A. Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice. J. Atheroscler. Thromb. 16: 674-683 (2009).
Arakawa T, Kita Y, Niikura T. A rescue factor for Alzheimer's diseases: discovery, activity, structure, and mechanism. Curr. Med. Chem. 15: 2086-2098 (2008).
Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81: 1269-1304 (2001). *
Araujo FA, Rocha MA, Mendes JB, Andrade SP. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed. Pharmacother. Sep 8 [Epub ahead of print] (2009).
Aravindhan K, Webb CL, Jaye M, Ghosh A, Willette RN, Dinardo NJ, Jucker BM. Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. J. Lipid Res. 47: 1250-1260 (2006). *
Archer A, Lauter G, Hauptmann G, Mode A, Gustafsson JA. Transcriptional activity and developmental expression of liver X receptor (lxr) in zebrafish. Dev. Dyn. 237: 1090-1098 (2008). *
Arendt BM, Mohammed SS, Aghdassi E, Prayitno NR, Ma DW, Nguyen A, Guindi M, Sherman M, Heathcote EJ, Allard JP. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J. Nutr. 139: 691-695 (2009). *
Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662-669 (2008). *
Arias-Vasquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, van Duijn CM. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 8: 189-193 (2007).
Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Ren. Fail. 29: 713-719 (2007).
Armendariz AD, Krauss RM. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr. Opin. Lipidol. 20: 106-111 (2009).
Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation. J. Immunol. 184: 173-183 (2010).
Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; the Swiss HIV Cohort Study. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics 17: 755-764 (2007).
Arnon R, Yoshimura T, Reiss A, Budai K, Lefkowitch JH, Javitt NB. Cholesterol 7-hydroxylase knockout mouse: a model for monohydroxy bile acid-related neonatal cholestasis. Gastroenterology 115: 1223-1228 (1998). *
Arraiz N, Bermudez V, Prieto C, Sanchez MP, Escalona C, Sanz E, Rondon N, Reyes F, Velasco M. Association between apoliprotein E gene polymorphism and hypercholesterolemic phenotype in Maracaibo, Zulia State, Venezuela. Am. J. Ther. Dec 16 [Epub ahead of print] (2009).
Arraiz N, Bermudez V, Rondon N, Reyes F, Borjas L, Sol�s E, Mujica E, Prieto C, Reyna N, Velasco M. Novel mutations identification in exon 4 of LDLR gene in patients with moderate hypercholesterolemia in a Venezuelan population. Am. J. Ther. Dec 16 [Epub ahead of print] (2009).
Arrese M, Miquel JF, Ananthanarayanan M. BetaKlotho: a new kid on the bile acid biosynthesis block. Hepatology 43: 191-193 (2006). *
Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids 37: 935-940 (2002).
Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl. Acad. Sci. U.S.A. 106: 262-267 (2009). *
Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).
Arzuaga X, Ren N, Stromberg A, Black EP, Arsenescu V, Cassis LA, Majkova Z, Toborek M, Hennig B. Induction of gene pattern changes associated with dysfunctional lipid metabolism induced by dietary fat and exposure to a persistent organic pollutant. Toxicol. Lett. 189: 96-101 (2009). *
Asaki T, Aoki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Bioorg. Med. Chem. 16: 981-994 (2008). *
Asleh R, Blum S, Kalet-Litman S, Alsheik J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57: 2794-2800 (2008). *
Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99: 1419-1425 (2006). *
Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin. Investig. Drugs 17: 969-972 (2008).
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am. J. Cardiol. 80: 608-613 (1997). *
Attaran M, Schneider A, Grote C, Zwiens C, Flemming P, Gratz KF, Jochheim A, Bahr MJ, Manns MP, Ott M. Regional and transient ischemia/reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor deficient Watanabe rabbits. J. Hepatol. 41: 837-844 (2004). *
Attie AD, Flowers MT, Flowers JB, Groen AK, Kuipers F, Ntambi JM. Stearoyl-CoA desaturase deficiency, hypercholesterolaemia, cholestasis and diabetes. Novartis Found. Symp. 286: 47-53 (2007).
Austria JA, Richard MN, Chahine MN, Edel AL, Malcolmson LJ, Dupasquier CM, Pierce GN. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J. Am. Coll. Nutr. 27: 214-221 (2008).
Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, Tremblay A. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor upregulates ABC sterol transporters and cholesterol efflux in macrophages through a PPARgamma-dependent pathway. Mol. Endocrinol. 20: 3165-3178 (2006). *
Avezov SA, Mansurov FKh. Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 55-58 (2004).
Avezov SA, Mansurova FKh. Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 46-49 (2004).
Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol. Biol. 477: 259-276 (2009).
Axelson M. Studies on biosynthetic pathways to bile acids in human liver cells. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 22. June 18-19 (2004). *
Axelson M, Mork B, Everson GT. Bile acid synthesis in cultured human hepatoblastoma cells. J. Biol. Chem. 266: 17770-17777 (1991). *
Ayaki Y, Kok E, Javitt NB. Cholic acid synthesis from 26-hydroxycholesterol and 3-hydroxy-5-cholestenoic acid in the rabbit. J. Biol. Chem. 264: 3818-3821 (1989). *
Ayaori M, Sawada S, Yonemura A, Iwamoto N, Ogura M, Tanaka N, Nakaya K, Kusuhara M, Nakamura H, Ohsuzu F. Glucocorticoid receptor regulates ATP-binding cassette transporter-A1 expression and apolipoprotein-mediated cholesterol efflux from macrophages. Arterioscler. Thromb. Vasc. Biol. 26: 163-168 (2006). *
Azambuja MI. Connections: can the 20th century coronary heart disease epidemic reveal something about the 1918 influenza lethality? Braz. J. Med. Biol. Res. 41: 1-4 (2008). *
Aziz A, Xiao CW, Cockell KA, Sarwar Gilani G, Cruz-Hernandez C, Nimal Ratnayake WM. Impact of dietary protein on lipid metabolism in hamsters is source-dependent and associated with changes in hepatic gene expression. Br. J. Nutr. 100: 503-511 (2008). *
Baba MI, Kaul D, Grover A. Importance of blood cellular genomic profile in coronary heart disease. J. Biomed. Sci. 13: 17-26 (2006). *
Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, Sambucetti L. PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol. Res. 50: 237-246 (2004). *
Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080 (1992).
Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc. Health Risk Manag. 1: 317-331 (2005).
Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 27: 412-424 (2007).
Badid N, Baba Ahmed FZ, Merzouk H, Belbraouet S, Mokhtari N, Merzouk SA, Benhabib R, Hamzaoui D, Narce M. Oxidant/antioxidant status, lipids and hormonal profile in overweight women with breast cancer. Pathol. Oncol. Res. Sep 3 [Epub ahead of print] (2009).
Bae JS, Rezaie AR. Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thromb. Res. Aug 14 [Epub ahead of print] (2009). *
Bai D, Brar P, Holleran S, Ramakrishnan R, Green P. Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. Scand. J. Gastroenterol. 40: 183-187 (2005). *
Baiocchi L, Alpini G, Glaser S, Angelico M, Alvaro D, Francis H, Marzioni M, Phinizy JL, Barbaro B, LeSage G. Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholeresis is augmented in bile duct ligated rats. J. Hepatol. 38: 136-147 (2003).
Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J. Pak. Med. Assoc. 59: 512-515 (2009).
Baker AD, Malur A, Barna BP, Ghosh S, Kavuru MS, Malur AG, Thomassen MJ. Targeted PPARgamma deficiency in alveolar macrophages disrupts surfactant catabolism. J. Lipid Res. Jan 11 [Epub ahead of print] (2010). *
Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin. Proc. 69: 923-929 (1994).
Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M. Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G251-G260 (2005). *
Balcerzyk A, Zak I, Krauze J. Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease. Acta Cardiol. 62: 233-238 (2007).
Balcerzyk A, Zak I, Krauze J. Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease. Arch. Med. Res. 38: 545-550 (2007).
Baldan A, Bojanic DD, Edwards PA. The ABCs of sterol transport. J. Lipid Res. 50: S80-S85 (2009). *
Baldan A, Tarr P, Lee R, Edwards PA. ATP-binding cassette transporter G1 and lipid homeostasis. Curr. Opin. Lipidol. 17: 227-232 (2006).
Baldo-Enzi G, Baiocchi MR, Grotto M, Floreani AR, Zagolin M, Chiaramonte M, Cera F, Fellin R. Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects. Dig. Dis. Sci. 33: 1201-1207 (1988).
Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189: 19-30 (2006).
Balkova K, Gbelska Y. ABC transporter proteins in multidrug resistance of microorganisms. Epidemiol. Mikrobiol. Imunol. 56: 129-139 (2007).
Ballatori N, Fang F, Christian WV, Li N, Hammond CL. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G179-G186 (2008). *
Ballatori N, Li N, Fang F, Boyer JL, Christian WV, Hammond CL. OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Front. Biosci. 14: 2829-2844 (2009).
Balmer M, Dufour J. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med. Wkly. 138: 415-419 (2008). *
Banerjee A, Hussainzada N, Khandelwal A, Swaan PW. Electrostatic and potential cation-pi forces may guide the interaction of extracellular loop III with Na+ and bile acids for human apical Na+-dependent bile acid transporter. Biochem. J. 410: 391-400 (2008). *
Banos G, Perez-Torres I, El Hafidi M. Medicinal agents in the metabolic syndrome. Cardiovasc. Hematol. Agents Med. Chem. 6: 237-252 (2008).
Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 59 Suppl. 7: 31-55 (2008). *
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278: 32852-32860 (2003). *
Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 717-726 (2002). *
Barbier O, Trottier J, Kaeding J, Caron P, Verreault M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell. Biochem. 326: 3-8 (2009). *
Barbosa FA, de Labio RW, de Oliveira S Rigolin V, Minett T, Bertolucci PH, de Arruda Cardoso Smith M, Payao SL. Apolipoprotein A-V gene polymorphism -1131T>C and Alzheimer's disease. J. Alzheimers Dis. 10: 365-369 (2006).
Barcelo-Coblijn G, Collison LW, Jolly CA, Murphy EJ. Dietary alpha-linolenic acid increases brain but not heart and liver docosahexaenoic acid levels. Lipids 40: 787-798 (2005).
Barcelo-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J. Neurochem. 101: 132-141 (2007).
Barcelo-Coblijn G, Murphy EJ. Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. Prog. Lipid Res. 48: 355-374 (2009). *
Barnard ND, Noble EP, Ritchie T, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green AA, Ferdowsian H. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition 25: 58-65 (2009). *
Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *
Barre DE. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes - a mini-review. J. Oleo. Sci. 56: 319-325 (2007). *
Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am. J. Cardiol. 102: 1040-1045 (2008). *
Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br. J. Dermatol. 129: 704-707 (1993).
Baruch Y, Brook JG, Eidelman S, Aviram M. Increased concentration of high density lipoprotein in plasma and decreased platelet aggregation in primary biliary cirrhosis. Atherosclerosis 53: 151-162 (1984).
Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister E, Wheeler M, Adeli K. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. 297: E462-E473 (2009). *
Bassett CM, Rodriguez-Leyva D, Pierce GN. Experimental and clinical research findings on the cardiovascular benefits of consuming flaxseed. Appl. Physiol. Nutr. Metab. 34: 965-974 (2009). *
Basso F, Freeman LA, Ko C, Joyce C, Amar MJ, Shamburek RD, Tansey T, Thomas F, Wu J, Paigen B, Remaley AT, Santamarina-Fojo S, Brewer HB Jr. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J. Lipid Res. 48: 114-126 (2007). *
Bassols J, Moreno-Navarrete JM, Ortega F, Ricart W, Fernandez-Real JM. LIGHT is associated with hypertriglyceridemia in obese subjects and increased cytokine secretion from cultured human adipocytes. Int. J. Obes. (Lond.) Sep 29 [Epub ahead of print] (2009).
Basu A, Devaraj S, Jialal I. Dietary factors that promote or retard inflammation. Arterioscler. Thromb. Vasc. Biol. 26: 995-1001 (2006). *
Bate C, Marshall V, Colombo L, Diomede L, Salmona M, Williams A. Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Abeta(1-42). Neuropharmacology 54: 934-943 (2008).
Bate C, Tayebi M, Diomede L, Salmona M, Williams A. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol. 6: 39 (2008). *
Bateson MC, Hill A, Bouchier IA. Analysis of response to ursodeoxycholic acid for gallstone dissolution. Digestion 20: 358-364 (1980).
Bateson MC, Ross PE, Murison J, Bouchier IA. Effect of prolonged feeding with chenodeoxycholic acid on bile in patients with and without gallstones. Gut 18: 599-605 (1997). *
Bateson MC, Ross PE, Murison J, Saunders JH, Bouchier IA. Ursodeoxycholic acid therapy and biliary lipids - a dose-response study. Gut 21: 305-310 (1980). *
Battochio AP, Sartori MS, Coelho CA. Water-soluble extract of Coleus barbatus modulates weight gain, energy utilization and lipid metabolism in secondary biliary cirrhosis: an experimental study in young rats. Acta Cir. Bras. 20: 229-236 (2005).
Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc. Natl. Acad. Sci. U.S.A. 106: 16764-16769 (2009). *
Bayliss M, Somers G. Isolation and culture of human hepatocytes. Methods Mol. Med. 107: 249-268 (2004).
Bays H. Clinical overview of omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am. J. Cardiol. 98: S71-S76 (2006). *
Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr. Med. Res. Opin. Feb 15 [Epub ahead of print] (2010).
Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin. Proc. 85: 122-128 (2010).
Bazzichi L, Ghiadoni L, Rossi A, Bernardini M, Lanza M, De Feo F, Giacomelli C, Mencaroni I, Raimo K, Rossi M, Mazzone AM, Taddei S, Bombardieri S. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Mol. Med. 15: 402-406 (2009). *
Beattie AD, Sherlock S. Ascorbic acid deficiency in liver disease. Gut 17: 571-575 (1976). *
Beckebaum S, Klein C, Varghese J, Sotiropoulos GC, Saner F, Schmitz K, Gerken G, Paul A, Cicinnati VR. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Aliment. Pharmacol. Ther. 30: 834-842 (2009). *
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Ch Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol. Drug Saf. 19: 75-81 (2009).
Bedu E, Wahli W, Desvergne B. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin. Ther. Targets 9: 861-873 (2005).
Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, Remaley AT, Saba JD, Proia RL. S1P lyase deficiency disrupts lipid homeostasis in liver. J. Biol. Chem. Jan 24 [Epub ahead of print] (2010). *
Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J. Clin. Endocrinol. Metab. Jan 8 [Epub ahead of print] (2010). *
Bell Iii TA, Kelley K, Wilson MD, Sawyer JK, Rudel LL. Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice. Arterioscler. Thromb. Vasc. Biol. 27: 1396-1402 (2007).
Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol. Hepatol. 17: 137-140 (2005). *
Belli DC, Fournier LA, Lepage G, Yousef I, Roy CC. S-Adenosylmethionine prevents total parenteral nutrition-induced cholestasis in the rat. J. Hepatol. 21: 18-23 (1994).
Bellosta S, Bernini F. Modulation of macrophage function and metabolism. Handb. Exp. Pharmacol. 170: 665-695 (2005).
Beltowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc. Ther. 26: 297-316 (2008).
Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr. Drug Saf. 4: 209-228 (2009).
Ben-Ari Z, Schafer Z, Sulkes J, Manhaim V, Tur-Kaspa R, Fainaru M. Alterations in serum leptin in chronic liver disease. Dig. Dis. Sci. 47: 183-189 (2002). *
Ben-Ari Z, Tur-Kaspa R, Schafer Z, Baruch Y, Sulkes J, Atzmon O, Greenberg A, Levi N, Fainaru M. Basal and post-methionine serum homocysteine and lipoprotein abnormalities in patients with chronic liver disease. J. Investig. Med. 49: 325-329 (2001).
Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. Am. J. Clin. Nutr. 67: 912-918 (1998). *
Bendlova B, Vejralkova D, Vcelak J, Lukalova P, Burkonova D, Kunelova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M. PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2. Physiol. Res. 57 Suppl. 1: S77-S90 (2008). *
Benito P, Caballero J, Moreno J, Gutierrez-Alcantara C, Munoz C, Rojo G, Garcia S, Soriguer FC. Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clin. Nutr. 25: 581-587 (2006).
Bennett DJ, Cooke AJ, Edwards AS. Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis. Recent Patents Cardiovasc. Drug Discov. 1: 21-46 (2006).
Benno P, Leijonmarck CE, Monsen U, Uribe A, Midtvedt T. Functional alterations of the microflora in patients with ulcerative colitis. Scand. J. Gastroenterol. 28: 839-844 (1993).
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134: 97-111 (2008). *
Benson MK, Devi K. Influence of omega-6/omega-3 rich dietary oils on lipid profile and antioxidant enzymes in normal and stressed rats. Indian J. Exp. Biol. 47: 98-103 (2009).
Bentinger M, Turunen M, Zhang XX, Wan YJ, Dallner G. Involvement of retinoid X receptor alpha in coenzyme Q metabolism. J. Mol. Biol. 326: 795-803 (2003). *
Benton JL, Ding J, Tsai MY, Shea S, Rotter JI, Burke GL, Post W. Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 193: 352-360 (2007).
Berard AM, Dumon MF, Darmon M. Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion. FEBS Lett. 559: 125-128 (2004). *
Berg KK, Madsen HO, Garred P, Wiseth R, Gunnes S, Videm V. The additive contribution from inflammatory genetic markers on the severity of cardiovascular disease. Scand. J. Immunol. 69: 36-42 (2009). *
Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *
Bergasa NV. Treatment of the pruritus of cholestasis. Curr. Treat. Options Gastroenterol. 7: 501-508 (2004).
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *
Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J. Lipid Res. 43: 486-494 (2002). *
Berger K, Stogbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB, Funke H. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum. Genet. 121: 169-178 (2007). *
Bergheim I, Harsch S, Mueller O, Schimmel S, Fritz P, Stange EF. Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J. Lipid Res. 47: 42-50 (2006). *
Berkowitz CM, Shen CS, Bilir BM, Guibert E, Gumucio JJ. Different hepatocytes express the cholesterol 7 alpha-hydroxylase gene during its circadian modulation in vivo. Hepatology 21: 1658-1667 (1995).
Bernard D, Christophe A, Delanghe J, Langlois M, De Buyzere M, Comhaire F. The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox Rep. 8: 41-46 (2003).
Berr F, Holl J, Jungst D, Fischer S, Richter WO, Seifferth B, Paumgartner G. Dietary n-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease. Hepatology 16: 960-967 (1992). *
Berr F, Pratschke E, Fischer S, Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J. Clin. Invest. 90: 859-868 (1992). *
Berr F, Schreiber E, Frick U. Interrelationships of bile acid and phospholipid fatty acid species with cholesterol saturation of duodenal bile in health and gallstone disease. Hepatology 16: 71-81 (1992).
Berrougui H, Khalil A. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Rejuvenation Res. 12: 117-126 (2009).
Bersamin A, Luick BR, King IB, Stern JS, Zidenberg-Cherr S. Westernizing diets influence fat intake, red blood cell fatty acid composition, and health in remote Alaskan native communities in the Center for Alaska Native Health study. J. Am. Diet. Assoc. 108: 266-273 (2008).
Bersot T, Haffner S, Harris WS, Kellick KA, Morris CM. Hypertriglyceridemia: management of atherogenic dyslipidemia. J. Fam. Pract. 55: S1-S8 (2006).
Berthold HK, Laaksonen R, Lehtimaki T, Gylling H, Krone W, Gouni-Berthold I. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes 116: 262-267 (2008).
Bertok L. Bile acids in physico-chemical host defence. Pathophysiology 11: 139-145 (2004).
Bertolotti M, Gabbi C, Anzivino C, Carulli L, Loria P, Carulli N. Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insights from evidence on hepatic cholesterol degradation and gallstone disease in humans. Curr. Med. Chem. 15: 2271-2284 (2008).
Bertolotti M, Gabbi C, Anzivino C, Crestani M, Mitro N, Del Puppo M, Godio C, De Fabiani E, Macchioni D, Carulli L, Rossi A, Ricchi M, Loria P, Carulli N. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur. J. Clin. Invest. 37: 501-508 (2007). *
Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N. Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. Eur. J. Clin. Invest. 36: 170-175 (2006).
Bertolotti M, Zambianchi L, Carulli L, Simonini MS, Del Puppo M, Kienle MG, Loria P, Pinetti A, Carulli N. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 38: 939-946 (2003). *
Besler C, Doerries C, Giannotti G, Luscher TF, Landmesse U. Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev. Cardiovasc. Ther. 6: 1071-1082 (2008).
Besnard P, Landrier JF, Grober J, Niot I. Is the ileal bile acid-binding protein (I-BABP) gene involved in cholesterol homeostasis? Med. Sci. (Paris) 20: 73-77 (2004).
Betteridge DJ. Lipid-lowering trials in diabetes. Curr. Opin. Lipidol. 12: 619-623 (2001).
Betteridge DJ. Lipid lowering in diabetes mellitus. Curr. Opin. Lipidol. 19: 579-584 (2008).
Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J. Hepatol. 24: 343-352 (1996). *
Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1 and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J. Biol. Chem. 282: 5207-5216 (2007). *
Beyer TP, Chen Y, Porter RK, Lu D, Schmidt RJ, Mantlo NB, Konrad RJ, Cao G. Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein. Lipids 43: 611-618 (2008).
Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J. Pharmacol. Exp. Ther. 309: 861-868 (2004). *
Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK. Ligand-activated PXR interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha: functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279: 45139-45147 (2004). *
Bhat B, Esau C, Davis S, Propp S, Kinberger G, Gaus H, Freier S, Swayze EE, Bennett CF. 2'-O-Methoxyethyl/2'-fluoro modified oligonucleotides result in more potent inhibition of micro RNA-122 in vivo: a target implicated in HCV replication. Nucleic Acids Symp. Ser. (Oxf.) 52: 69 (2008).
Biasi F, Mascia C, Astegiano M, Chiarpotto E, Nano M, Vizio B, Leonarduzzi G, Poli G. Pro-oxidant and pro-apoptotic effects of cholesterol oxidation products on human colonic epithelial cells: a potential mechanism of inflammatory bowel disease progression. Free Radic. Biol. Med. 47: 1731-1741 (2009).
Biasi F, Mascia C, Poli G. TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr. 2: 233-243 (2007). *
Bickler SW, Demaio A. Western diseases: current concepts and implications for pediatric surgery research and practice. Pediatr. Surg. Int. 24: 251-255 (2008). *
Bighetti EJ, Patricio PR, Casquero AC, Berti JA, Oliveira HC. Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. Lipids Health Dis. 8: 50 (2009). *
Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 49: 637-645 (2009). *
Bilhartz LE. Cholesterol gallstone disease: the current status of nonsurgical therapy. Am. J. Med. Sci. 296: 45-56 (1988).
Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290: E716-E722 (2006). *
Bird JE, Giancarli MR, Kurihara T, Kowala MC, Valentine MT, Gitlitz PH, Pandya DG, French MH, Durham SK. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int. 57: 129-136 (2000). *
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71: 1390-1395 (2008).
Birrell MA, Catley MC, Hardaker E, Wong S, Willson TM, McCluskie K, Leonard T, Farrow SN, Collins JL, Haj-Yahia S, Belvisi MG. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J. Biol. Chem. 282: 31882-31890 (2007). *
Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, Li AC, Schulman IG. Macrophage-independent functions contribute to the anti-atherogenic activity of LXRalpha. J. Lipid Res. Mar 28 [Epub ahead of print] (2009). *
Bishop-Bailey D. FXR as a novel therapeutic target for vascular disease. Drug News Perspect. 17: 499-504 (2004).
Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. U.S.A. 101: 3668-3673 (2004). *
Bisschop PH, Bandsma RH, Stellaard F, Ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am. J. Clin. Nutr. 79: 570-576 (2004). *
Bjorkhem I. Are side-chain oxidized oxysterols regulators also in vivo? J. Lipid Res. 50: S213-S218 (2009). *
Bjorkhem I, Araya Z, Rudling M, Angelin B, Einarsson C, Wikvall K. Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1. J. Biol. Chem. 277: 26804-26807 (2002). *
Bjorkhem I, Meaney S, Heverin M, Andersson U, Axelsson M, Panzenboek U, Sattler W. Role of oxysterols and cholestenoic acids in a crosstalk between the brain and the liver. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 23 (2006). *
Blaha V, Mistr�k E. Hypolipidemic drugs and diabetes mellitus. Vnitr. Lek. 55: 357-362 (2009).
Blaner WS, O'Byrne SM, Wongsiriroj N, Kluwe J, D'Ambrosio D, Jiang H, Schwabe RF, Hillman EM, Piantedosi R, Libien J. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim. Biophys. Acta 1791: 467-473 (2009). *
Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 201: 17-32 (2008).
Blazovics A, Hagymasi K, Pronai L. Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases. Orv. Hetil. 145: 2523-2529 (2004).
Bleie O, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygard OK. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J. Intern. Med. 262: 244-253 (2007). *
Bloch AS. Low carbohydrate diets, pro: time to rethink our current strategies. Nutr. Clin. Pract. 20: 3-12 (2005).
Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, Hudes ML. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr. J. 6: 30 (2007). *
Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia 47: 104-112 (2004). *
Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82: 310-317 (1975).
Blum HE. Gene therapy for liver diseases: experimental strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 44-45 (2006). *
Boadu E, Choi HY, Lee DW, Waddington EI, Chan T, Asztalos B, Vance JE, Chan A, Castro G, Francis GA. Correction of apolipoprotein A-I-mediated lipid efflux and HDL particle formation in human Niemann-Pick type C disease fibroblasts. J. Biol. Chem. 281: 37081-37090 (2006). *
Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 967: 7-18 (2002). *
Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *
Bock J, Liebisch G, Schweimer J, Schmitz G, Rogler G. Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World J. Gastroenterol. 13: 5217-5225 (2007). *
Bodin K. Role of CYP3A4 as a cholesterol and bile acid metabolizing enzyme. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 25. June 18-19 (2004). *
Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Bjorkhem I, Diczfalusy U. Metabolism of 4 beta -hydroxycholesterol in humans. J. Biol. Chem. 277: 31534-31540 (2002). *
Bodolay E, Seres I, Szodoray P, Csipo I, Jakab Z, Vegh J, Szilagyi A, Szegedi G, Paragh G. Evaluation of paraoxonase activity in patients with mixed connective tissue disease. J. Rheumatol. 35: 237-243 (2008).
Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br. J. Pharmacol. 153 Suppl. 1: S68-S75 (2008). *
Bogdanovic M, Bulat P. Biliary function in workers occupationally exposed to aluminium dust and fumes. Arh. Hig. Rada. Toksikol. 59: 135-139 (2008).
Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J. Biol. Chem. 278: 36688-36698 (2003). *
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl. 11: 61-67 (2005). *
Bojanic DD, Tarr PT, Gale GD, Smith DJ, Bok D, Chen B, Nusinowitz S, Lovgren-Sandblom A, Bjorkhem I, Edwards PA. Differential expression and function of ABCG1 and ABCG4 during development and ageing. J. Lipid Res. 51: 169-181 (2010). *
Boland B, Beguin C, Zech F, Desager JP, Lambert M. Serum beta-carotene in anorexia nervosa patients: a case-control study. Int. J. Eat. Disord. 30: 299-305 (2001).
Bongardt F, Schopfer-Wendels A, Huth C, Heid I, Rathmann W, Martin S, Vollmert C, Holle R, Thorand B, Wichmann HE, Koenig W, Kolb H, Herder C. Genetics of type 2 diabetes: impact of interleukin-6 gene variants. Gesundheitswesen 67 Suppl. 1: 122-126 (2005).
Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; for the CAP Investigators. Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin. Ther. 30: 2298-2313 (2008).
Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int. 26: 566-571 (2006). *
Borba EF, Carvalho JF, Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin. Dev. Immunol. 13: 203-208 (2006). *
Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors. Genes Nutr. 1: 95-106 (2006). *
Borggreve SE, de Vries R, Dallinga-Thie GM, Wolffenbuttel BH, Groen AK, van Tol A, Dullaart RP. The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin:cholesterol acyltransferase activity. Biochim. Biophys. Acta 1781: 10-15 (2008). *
Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim. Biophys. Acta 1486: 128-144 (2000). *
Borthwick F, Taylor JM, Bartholomew C, Graham A. Differential regulation of the STARD1 subfamily of START lipid trafficking proteins in human macrophages. FEBS Lett. 583: 1147-1153 (2009). *
Borthwick L; on behalf of the UK Study Group. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin. Drug Investig. 15: 397-404 (1998).
Bosch T. Therapeutic apheresis - state of the art in the year 2005. Ther. Apher. Dial. 9: 459-468 (2005). *
Botes L, van der Westhuizen FH, Loots du T. Phytochemical contents and antioxidant capacities of two Aloe greatheadii var. davyana extracts. Molecules 13: 2169-2180 (2008).
Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J. 24: 2624-2633 (2005). *
Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. Arch. Dis. Child. 75: 223-227 (1996).
Bourre JM, Galea F. An important source of omega-3 fatty acids, vitamins D and E, carotenoids, iodine and selenium: a new natural multi-enriched egg. J. Nutr. Health Aging 10: 371-376 (2006).
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. Sigma receptor ligands: applications in inflammation and oncology. Curr. Opin. Investig. Drugs 5: 1158-1163 (2004).
Bouvier J, Zemski Berry KA, Hullin-Matsuda F, Makino A, Michaud S, Geloen A, Murphy RC, Kobayashi T, Lagarde M, Delton-Vandenbroucke I. Selective decrease of bis(monoacylglycero)phosphate content in macrophages by high supplementation with docosahexaenoic acid. J. Lipid Res. 50: 243-255 (2009). *
Bowden K, Ridgway ND. OSBP negatively regulates ABCA1 protein stability. J. Biol. Chem. 283: 18210-18217 (2008). *
Bowden RG, Jitomir J, Wilson RL, Gentile M. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients. J. Ren. Nutr. 19: 259-266 (2009). *
Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *
Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46: 365-371 (2007). *
Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am. J. Med. 120: S12-S17 (2007). *
Brackenridge AL, Jackson N, Jefferson W, Stolinski M, Shojaee-Moradie F, Hovorka R, Umpleby AM, Russell-Jones D. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with type 2 diabetes and normal lipids. Diabet. Med. 26: 532-539 (2009).
Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, Lusis AJ, Collins A, Hseuh WA, Collins JL, Tangirala RK, Tontonoz P. Ligand activation of LXRbeta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRalpha and apoE. J. Clin. Invest. 117: 2337-2346 (2007). *
Braeckman L, De Bacquer D, Delanghe J, Claeys L, De Backer G. Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis 143: 383-388 (1999).
Braga MF, Grace MG, Lenis J, Kennedy FP, Teplinsky AL, Roederer G, Palumbo PJ, Colin P, Leiter LA. Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. Atherosclerosis 203: 479-482 (2009).
Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J. Immunol. 183: 5917-5927 (2009).
Brailski Kh, Damianov B. Primary biliary cirrhosis. Vutr. Boles. 22: 27-37 (1983).
Bramlett KS, Yao S, Burris TP. Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. Mol. Genet. Metab. 71: 609-615 (2000). *
Branten AJ, Swinkels DW, Klasen IS, Wetzels JF. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol. Dial. Transplant. 19: 2754-2760 (2004). *
Brar P, Kwon GY, Holleran S, Bai D, Tall AR, Ramakrishnan R, Green PH. Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. Am. J. Med. 119: 786-790 (2006). *
Braun N, Wade N, Wakeland E, Major A. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr-/- mice. Lupus 17: 1070-1078 (2008). *
Bravo E, Napolitano M, Lopez-Soldado I, Valeri M, Botham KM, Stefanutti C. Hypercholesterolaemia alters the responses of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil. Eur. J. Clin. Invest. 36: 788-795 (2006). *
Bravo I, Amigo L, Cohen DE, Nervi F, Rigotti A, Francone O, Zanlungo S. Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse. Biochim. Biophys. Acta 1770: 979-988 (2007). *
Brenol CV, Monticielo OA, Xavier RM, Brenol JC. Rheumatoid arthritis and atherosclerosis. Rev. Assoc. Med. Bras. 53: 465-470 (2007).
Brewer HB Jr, Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am. J. Cardiol. 91: 3E-11E (2003). *
Briand F, Treguier M, Andre A, Grillot D, Issandou M, Ouguerram K, Sulpice T. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J. Lipid Res. Oct 27 [Epub ahead of print] (2009). *
Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, Thorpe SR, Baynes JW. Increased methionine sulfoxide content of ApoAI in type 1 diabetes. J. Lipid Res. 49: 847-855 (2008). *
Brousseau ME. Statins, super-statins and cholesterol absorption inhibitors. IDrugs 6: 458-463 (2003).
Brousseau ME. ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption. Curr. Opin. Lipidol. 14: 35-40 (2003).
Brousseau ME, Hoeg JM. Transgenic rabbits as models for atherosclerosis research. J. Lipid Res. 40: 365-375 (1999). *
Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr. Atheroscler. Rep. 4: 343-349 (2002).
Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasek-McKenna D, O'Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH Jr, Gu JZ. Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds. J. Lipid Res. 41: 433-441 (2000). *
Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515 (2004). *
Brouwers A, Langlois M, Delanghe J, Billiet J, De Buyzere M, Vercaemst R, Rietzschel E, Bernard D, Blaton V. Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism. Atherosclerosis 176: 189-195 (2004).
Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 279: 34674-34681 (2004). *
Bruemmer D, Law RE. Liver X receptors: potential novel targets in cardiovascular diseases. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 533-540 (2005).
Bruinsma KA, Taren DL. Dieting, essential fatty acid intake, and depression. Nutr. Rev. 58: 98-108 (2000).
Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin. Immunol. 119: 1-12 (2006). *
Brunham LR, Kastelein JJ, Hayden MR. ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease. JAMA 300: 1997-1998 (2008). *
Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116: 1052-1062 (2006). *
Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ. Res. 99: 672-674 (2006). *
Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13: 340-347 (2007). *
Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR. Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. PLoS Genet. 1: e83 (2005). *
Brunner J, Parhofer KG, Schwandt P, Bronisch T. Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry 35: 1-5 (2002).
Brunser O, Gotteland M, Cruchet S. Functional fermented milk products. Nestle Nutr. Workshop Ser. Pediatr. Program 60: 235-250 (2007).
Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 305: 127-160 (2006).
Bryhn M, Hansteen H, Schanche T, Aakre SE. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters. Prostaglandins Leukot. Essent. Fatty Acids 75: 19-24 (2006). *
Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bassmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm B, Holl C, Seeger M, Elsharawy A, Lu T, Egberts J, Fandrich F, Folsch UR, Krawczak M, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 39: 995-999 (2007). *
Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Gastroenterol. 97: 1138-1142 (2002). *
Buettner C, Phillips RS, Davis RB, Gardiner P, Mittleman MA. Use of dietary supplements among United States adults with coronary artery disease and atherosclerotic risks. Am. J. Cardiol. 99: 661-666 (2007). *
Buis CI, Geuken E, Visser DS, Kuipers F, Haagsma EB, Verkade HJ, Porte RJ. Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. J. Hepatol. 50: 69-79 (2009). *
Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc. Res. 83: 457-464 (2009). *
Bultel S, Helin L, Clavey V, Chinetti-Gbaguidi G, Rigamonti E, Colin M, Fruchart JC, Staels B, Lestavel S. Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler. Thromb. Vasc. Biol. 28: 2288-2295 (2008).
Buono C, Li Y, Waldo SW, Kruth HS. Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL. J. Lipid Res. 48: 2411-2418 (2007). *
Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl. Res. 150: 101-105 (2007). *
Buraczynska M, Swatowski A, Buraczynska K, Dragan M, Ksiazek A. Heat-shock protein gene polymorphisms and the risk of nephropathy in type 2 diabetes patients. Clin. Sci. (Lond.) 116: 81-86 (2009). *
Burgess BL, Parkinson PF, Racke MM, Hirsch-Reinshagen V, Fan J, Wong C, Stukas S, Theroux L, Chan JY, Donkin J, Wilkinson A, Balik D, Christie B, Poirier J, Lutjohann D, Demattos RB, Wellington CL. ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49: 1254-1267 (2008). *
Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL. Phosphatidylinositol raises HDL-C levels in humans. J. Lipid Res. 46: 350-355 (2005). *
Burke KT, Horn PS, Tso P, Heubi JE, Woollett LA. Hepatic bile acid metabolism in the neonatal hamster: expansion of the bile acid pool parallels increased Cyp7a1 expression levels. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G144-G151 (2009).
Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs 15: 1337-1351 (2006).
Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 98: 792-800 (2006). *
Burns T, Maciejewski SR, Hamilton WR, Zheng M, Mooss AN, Hilleman DE. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy 27: 633-638 (2007).
Burris TP, Eacho PI, Cao G. Genetic disorders associated with ATP binding cassette cholesterol transporters. Mol. Genet. Metab. 77: 13-20 (2002). *
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27: 1181-1195 (2005). *
Buters JT, Zysset T, Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem. Pharmacol. 46: 983-991 (1993).
Butt MS, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS. Oat: unique among the cereals. Eur. J. Nutr. 47: 68-79 (2008). *
Buysschaert M, Tomasi JP, Hermans MP. Prospective screening for biopsy proven coeliac disease, autoimmunity and malabsorption markers in Belgian subjects with type 1 diabetes. Diabet. Med. 22: 889-892 (2005). *
Byrd-Bredbenner C, Abbot JM. Differences in food supplies of U.S. households with and without overweight individuals. Appetite 52: 479-484 (2009).
Caamano JM, Pacheco A, Lanas F, Salazar LA. Single nucleotide polymorphisms in ABCG5 and ABCG8 genes in Chilean subjects with polygenic hypercholesterolemia and controls. Clin. Chem. Lab. Med. 46: 1581-1585 (2008). *
Caballeria L, Pares A, Rodes J. Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85 (1999). *
Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial. Rev. Clin. Esp. 204: 632-635 (2004).
Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, Erion MD. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 49: 407-417 (2009). *
Cabrero A, Cubero M, Llaverias G, Alegret M, Sanchez R, Laguna JC, Vazquez-Carrera M. Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages. Mol. Cell. Biochem. 275: 173-179 (2005). *
Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52: 652-657 (2003). *
Calayir E, M T, Kratzer BA, Ebner B, Panzenbock U, Stefujl J, Kostner GM. LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr. Pharm. Biotechnol. 9: 516-521 (2008).
Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17-22 (2007).
Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis 203: 18-31 (2009).
Calpe-Berdiel L, Rotllan N, Fievet C, Roig R, Blanco-Vaca F, Escola-Gil JC. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ATP-binding cassette (ABC) G5/G8. J. Lipid Res. 49: 1904-1911 (2008). *
Campana G, Pasini P, Roda A, Spampinato S. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem. Pharmacol. 69: 1755-1763 (2005). *
Campbell IW. The clinical significance of PPAR gamma agonism. Curr. Mol. Med. 5: 349-363 (2005).
Canales A, Bastida S, Librelottto J, Nus M, Sanchez-Muniz FJ, Benedi J. Platelet aggregation, eicosanoid production and thrombogenic ratio in individuals at high cardiovascular risk consuming meat enriched in walnut paste. A crossover, placebo-controlled study. Br. J. Nutr. 102: 134-141 (2009). *
Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, Santos K, Crispim D, Roisemberg I, Krolewski AS, Gross JL. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 54: 3326-3330 (2005). *
Caniato RN, Alvarenga ME, Garcia-Alcaraz MA. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust. N. Z. J. Psychiatry 40: 691-697 (2006). *
Canton RF, Peijnenburg AA, Hoogenboom RL, Piersma AH, van der Ven LT, van den Berg M, Heneweer M. Subacute effects of hexabromocyclododecane (HBCD) on hepatic gene expression profiles in rats. Toxicol. Appl. Pharmacol. 231: 267-272 (2008). *
Cantwell MM, Flynn MA, Gibney MJ. Acute postprandial effect of hydrogenated fish oil, palm oil and lard on plasma cholesterol, triacylglycerol and non-esterified fatty acid metabolism in normocholesterolaemic males. Br. J. Nutr. 95: 787-794 (2006). *
Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect. Immun. 75: 753-759 (2007). *
Cao G, Bales KR, Demattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr. Alzheimer Res. 4: 179-184 (2007).
Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC. Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. 277: 39561-39565 (2002). *
Cao G, Liang Y, Jiang XC, Eacho PI. Liver X receptors as potential therapeutic targets for multiple diseases. Drug News Perspect. 17: 35-41 (2004).
Cao WM, Murao K, Imachi H, Yu X, Dobashi H, Yoshida K, Muraoka T, Kotsuna N, Nagao S, Wong NC, Ishida T. Insulin like growth factor-I regulation of hepatic scavenger receptor class BI. Endocrinology 145: 5540-5547 (2004). *
Capell WH, Eckel RH. Severe hypertriglyceridemia with a history of treatment failure. Nat. Clin. Pract. Endocrinol. Metab. 1: 53-58 (2005). *
Capobianco E, Mart�nez N, Higa R, White V, Jawerbaum A. The effects of maternal dietary treatments with natural PPAR ligands on lipid metabolism in fetuses from control and diabetic rats. Prostaglandins Leukot. Essent. Fatty Acids 79: 191-199 (2008). *
Capristo E, Addolorato G, Mingrone G, Scarfone A, Greco AV, Gasbarrini G. Low-serum high-density lipoprotein-cholesterol concentration as a sign of celiac disease. Am. J. Gastroenterol. 95: 3331-3332 (2000). *
Cardona J, Houssin D, Gauthier F, Devictor D, Losay J, Hadchouel M, Bernard O. Liver transplantation in children with Alagille syndrome - a study of twelve cases. Transplantation 60: 339-342 (1995).
Carlson SE. Early determinants of development: a lipid perspective. Am. J. Clin. Nutr. 89: 1523S-1529S (2009).
Carmel JF, Tarnus E, Cohn JS, Bourdon E, Davignon J, Bernier L. High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes. J. Cell. Biochem. 106: 608-617 (2009). *
Carmena R, Betteridge DJ. Statins and diabetes. Semin. Vasc. Med. 4: 321-332 (2004).
Carpentier YA, Portois L, Malaisse WJ. n-3 Fatty acids and the metabolic syndrome. Am. J. Clin. Nutr. 83: 1499S-1504S (2006). *
Carrella M, Roda E. Evolving concepts in the pathophysiology of biliary lipid secretion. Ital. J. Gastroenterol. Hepatol. 31: 643-648 (1999).
Carrero JJ, Fonolla J, Marti JL, Jimenez J, Boza JJ, Lopez-Huertas E. Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. J. Nutr. 137: 384-390 (2007). *
Carroll-Portillo A, Spendier K, Pfeiffer J, Griffiths G, Li H, Lidke KA, Oliver JM, Lidke DS, Thomas JL, Wilson BS, Timlin JA. Formation of a mast cell synapse: FcvarepsilonRI membrane dynamics upon binding mobile or immobilized ligands on surfaces. J. Immunol. Dec 30 [Epub ahead of print] (2009).
Cartagena CM, Burns MP, Rebeck GW. 24S-Hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. Brain Res. Jan 3 [Epub ahead of print] (2010).
Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 50: 12-38 (2007).
Carter CJ. Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem. Int. 52: 920-934 (2008).
Carty CL, Heagerty P, Heckbert SR, Enquobahrie DA, Jarvik GP, Davis S, Tracy RP, Reiner AP. Association of genetic variation in serum amyloid-A with cardiovascular disease and interactions with IL6, IL1RN, IL1beta and TNF genes in the cardiovascular health study. J. Atheroscler. Thromb. 16: 419-430 (2009).
Carulli N, Loria P, Bertolotti M, Ponz de Leon M, Menozzi D, Medici G, Piccagli I. Effects of acute changes of bile acid pool composition on biliary lipid secretion. J. Clin. Invest. 74: 614-624 (1984). *
Carulli N, Ponz de Leon M, Podda M, Zuin M, Strata A, Frigerio G, Digrisolo A. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J. Clin. Pharmacol. 21: 436-442 (1981).
Carulli N, Ponz De Leon M, Zironi F, Pinetti A, Smerieri A, Iori R, Loria P. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J. Lipid Res. 21: 35-43 (1980). *
Carvalho JF, Pereira RM, Shoenfeld Y. Vaccination, atherosclerosis and systemic lupus erythematosus. Lupus 18: 1209-1212 (2009).
Cases Amenos A, Goicoechea Diezhandino M, de Alvaro Moreno F. Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment. Nefrologia 28 Suppl. 3: 39-48 (2008).
Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, Kimber AC, Grew JP, Farrell L, Stannard J, Napper FL, Sala-Vila A, West AL, Mathers JC, Packard C, Williams CM, Calder PC, Minihane AM. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN study. Am. J. Clin. Nutr. 88: 618-629 (2008). *
Casos K, Saiz MP, Ruiz-Sanz JI, Mitjavila MT. Atherosclerosis prevention by a fish oil-rich diet in apoE(-/-) mice is associated with a reduction of endothelial adhesion molecules. Atherosclerosis 201: 306-317 (2008).
Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Investig. 23: 639-650 (2003).
Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World J. Gastroenterol. 14: 5098-5099 (2008). *
Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell. 12: 805-816 (2003). *
Castro IA, Monteiro VC, Barroso LP, Bertolami MC. Effect of eicosapentaenoic/docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia. Nutrition 23: 127-137 (2007). *
Castro J, Amigo L, Miquel JF, Galman C, Crovari F, Raddatz A, Zanlungo S, Jalil R, Rudling M, Nervi F. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45: 1261-1266 (2007). *
Catakoglu AB, Duman BS, Kurtoglu H, Ersoz M, Sener M, Celebi H, Cagatay P, Aytekin V, Aytekin S. Common variants in the ATP-binding cassette transporter 1 gene with decreased HDL-cholesterol levels and coronary artery disease. Arch. Med. Res. 39: 735-742 (2008).
Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim. Biophys. Acta 1761: 655-666 (2006). *
Cavelier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM. Regulation and activity of the human ABCA1 gene in transgenic mice. J. Biol. Chem. 276: 18046-18051 (2001). *
Cayli S, Sati L, Seval-Celik Y, Tuncer MA, Yaymaci B, Berkman Z, Altug T, Demir R. The effects of eicosapentaenoic acid on the endothelium of the carotid artery of rabbits on a high-cholesterol diet. Histol. Histopathol. 25: 141-151 (2010).
Cazzola R, Russo-Volpe S, Miles EA, Rees D, Banerjee T, Roynette CE, Wells SJ, Goua M, Wahle KW, Calder PC, Cestaro B. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 193: 159-167 (2007).
Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 86: 245-250 (2008).
Celinska-Lowenhoff M, Undas A. Nonlipid effects of fibrates. Przegl. Lek. 61: 99-101 (2004).
Cerf E, Gasper R, Rychnovsky S, Chang XB, Buyse F, Ruysschaert JM. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem. Biophys. Res. Commun. 355: 1025-1030 (2007). *
Cerkauskiene R, Kaminskas A, Kaltenis P, Vitkus D. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome. Medicina (Kaunas) 39 Suppl. 1: 82-87 (2003).
Ceryak S, Bouscarel B, Malavolti M, Robins SJ, Caslow KL, Fromm H. Effect of ursodeoxycholic acid on hepatic LDL binding and uptake in dietary hypercholesterolemic hamsters. Atherosclerosis 153: 59-67 (2000).
Cha JY, Repa JJ. The liver X receptor and hepatic lipogenesis: the carbohydrate-response element binding protein is a target gene of LXR. J. Biol. Chem. 282: 743-751 (2007). *
Cha S, Koo I, Choi SM, Park BL, Kim KS, Kim JR, Shin HD, Kim JY. Association analyses of the INSIG2 polymorphism in the obesity and cholesterol levels of Korean populations. BMC Med. Genet. 10: 96 (2009). *
Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell. Metab. 1: 309-322 (2005). *
Chan DC, Watts GF, Barrett PH, Whitfield AJ, Van Bockxmeer FM. ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men. Arterioscler. Thromb. Vasc. Biol. 24: 2188-2191 (2004). *
Chan DC, Watts GF, Nguyen MN, Barrett PH. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am. J. Clin. Nutr. 84: 37-43 (2006). *
Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 187: 309-315 (2006).
Chang CL, Seo T, Matsuzaki M, Worgall TS, Deckelbaum RJ. n-3 Fatty acids reduce arterial LDL-cholesterol delivery and arterial lipoprotein lipase levels and lipase distribution. Arterioscler. Thromb. Vasc. Biol. 29: 555-561 (2009).
Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41: 973-983 (2007).
Chang HH, Chen CS, Lin JY. Dietary perilla oil lowers serum lipids and ovalbumin-specific IgG1, but increases total IgE levels in ovalbumin-challenged mice. Food Chem. Toxicol. Jan 15 [Epub ahead of print] (2009).
Chang HH, Chen CS, Lin JY. Dietary perilla oil lowers serum lipids and ovalbumin-specific IgG1, but increases total IgE levels in ovalbumin-challenged mice. Food Chem. Toxicol. 47: 848-854 (2009).
Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J. Lipid Res. 45: 2116-2122 (2004). *
Chang SJ, Tsai PC, Chen CJ, Lai HM, Ko YC. The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout. Rheumatology (Oxford) 46: 1662-1666 (2007). *
Chapidze G E, Kapanadze SD, Dolidze NK, Latsabidze NE, Bakhutashvili ZV. Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis. Kardiologiia 46: 11-13 (2006).
Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br. J. Nutr. 100: 1152-1157 (2008). *
Chapkin RS, Wang N, Fan YY, Lupton JR, Prior IA. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim. Biophys. Acta 1778: 466-471 (2008). *
Chapman C, Morgan LM, Murphy MC. Maternal and early dietary fatty acid intake: changes in lipid metabolism and liver enzymes in adult rats. J. Nutr. 130: 146-151 (2000). *
Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 15: S83-S89 (2009).
Charoensit P, Kawakami S, Higuchi Y, Hashida M. Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kappaB activation mediated liver injury induced by lipoplexes in mice. J. Gene Med. 10: 61-69 (2008). *
Chatterjee B, Echchgadda I, Song CS. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400: 165-191 (2005).
Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility. Am. J. Clin. Nutr. 85: 231-237 (2007). *
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870 (2001). *
Chechi K, Cheema SK. Maternal diet rich in saturated fats has deleterious effects on plasma lipids of mice. Exp. Clin. Cardol. 11: 129-135 (2006). *
Cheema SK, Agarwal-Mawal A, Murray CM, Tucker S. Lack of stimulation of cholesterol ester transfer protein by cholesterol in the presence of a diet high in monounsaturated fatty acids. J. Lipid Res. 46: 2356-2366 (2005). *
Chen BC, Kuo KK, Chen YH, Liu CH, Tsai LY, Hsu HK, Hsu C. Retinoid X receptor alpha participation in dexamethasone induced rat bile acid coenzyme A-amino acid N-acyltransferase expression in septic liver. Shock 32: 164-171 (2009).
Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *
Chen M, Li W, Wang N, Zhu Y, Wang X. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. Am. J. Physiol. Cell Physiol. 292: C1493-C1501 (2007). *
Chen S, Li Y, Li S, Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J. Gastroenterol. Hepatol. 23: 1415-1418 (2008). *
Chen S, Sorrentino R, Shimada K, Bulut Y, Doherty TM, Crother TR, Arditi M. Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J. Immunol. 181: 7186-7193 (2008). *
Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol. Ther. 2: 256-261 (2000).
Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell. Metab. 5: 73-79 (2007). *
Chen W, Chiang JY. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 313: 71-82 (2003). *
Chen W, Gluud C. Bile acids for liver transplanted patients. Cochrane Database Syst. Rev. 2: CD004384 (2004). *
Chen W, Jump DB, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/lipid rafts by docosahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 48: 18-26 (2007). *
Chen W, Owsley E, Yang Y, Stroup D, Chiang JY. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids. J. Lipid Res. 42: 1402-1412 (2001). *
Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism 57: 1516-1525 (2008). *
Chen X, Xun K, Chen L, Wang Y. TNF-alpha, a potent lipid metabolism regulator. Cell. Biochem. Funct. 27: 407-416 (2009). *
Chen Y, Jiang XY, Xu L, Li X, Cao FF, Li L, Lu M, Jin L, Wang XF. Association of ER-alpha gene polymorphism with metabolic phenotypes in Chinese Hans. Lipids 44: 719-723 (2009).
Chen Y, Thelin WR, Yang B, Milgram SL, Jacobson K. Transient anchorage of cross-linked glycosyl-phosphatidylinositol-anchored proteins depends on cholesterol, Src family kinases, caveolin, and phosphoinositides. J. Cell Biol. 175: 169-178 (2006). *
Chen Y, Veracini L, Benistant C, Jacobson K. The transmembrane protein CBP plays a role in transiently anchoring small clusters of Thy-1, a GPI-anchored protein, to the cytoskeleton. J. Cell Sci. 122: 3966-3972 (2009). *
Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch. Dermatol. 144: 1571-1575 (2008). *
Chen ZC, Shin SJ, Kuo KK, Lin KD, Yu ML, Hsiao PJ. Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance. J. Hum. Genet. 53: 757-763 (2008). *
Chen ZQ, Annilo T, Shulenin S, Dean M. Three ATP-binding cassette transporter genes, Abca14, Abca15, and Abca16, form a cluster on mouse chromosome 7F3. Mamm. Genome 15: 335-343 (2004). *
Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin. Cardiol. 21: 400-404 (2006).
Cheng D, Kim WS, Garner B. Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport 19: 1685-1689 (2008).
Cheng HH, Hu XJ, Ruan QR. Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen. Acta Pharmacol. Sin. 30: 42-53 (2009).
Cheng JB, Motola DL, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Identification and characterization of CYP2R1, a microsomal vitamin D 25-hydroxylase. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 21. June 18-19 (2004). *
Cheng JB, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi JE, Setchell KD, Russell DW. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J. Clin. Endocrinol. Metab. 88: 1833-1841 (2003). *
Cheng JF, Zapf J, Takedomi K, Fukushima C, Ogiku T, Zhang SH, Yang G, Sakurai N, Barbosa M, Jack R, Xu K. Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators. J. Med. Chem. 51: 2057-2061 (2008). *
Chernev K, Bakalov V. Clinical-dispensary finding of patients with primary biliary cirrhosis. Vutr. Boles. 24: 42-46 (1985).
Chevailler A, Saint-Andre JP, Preel JL, Boyer J, Joubaud F, Hurez D. Clinico-immunological profile of hepatic and extrahepatic diseases accompanied by anti-mitochondrial antibodies. Ann. Med. Interne. (Paris) 139: 19-23 (1988).
Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, Gonzalez S, Andrade L, Pizarro M, Accatino L. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem. J. 314: 781-786 (1996). *
Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463 (2002). *
Chiang JY. Regulation of bile acid synthesis. Front. Biosci. 3: d176-d193 (1998).
Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40: 539-551 (2004). *
Chiang JY. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G349-G356 (2003). *
Chiang JY. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin. Drug Metab. Toxicol. 5: 137-147 (2009).
Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res. Apr 3 [Epub ahead of print] (2009). *
Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262: 257-265 (2001). *
Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 275: 10918-10924 (2000). *
Chiang JYL, Li T, Jahan A. Mechanisms of bile acid inhibition of genes in bile acid synthesis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 23. June 18-19 (2004). *
Chiarla C, Giovannini I, Giuliante F, Vellone M, Ardito F, Masi A, Nuzzo G. Plasma bilirubin correlations in non-obstructive cholestasis after partial hepatectomy. Clin. Chem. Lab. Med. 46: 1598-1601 (2008). *
Chiarla C, Giovannini I, Giuliante F, Zadak Z, Vellone M, Ardito F, Clemente G, Murazio M, Nuzzo G. Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J. Crit. Care Oct 12 [Epub ahead of print] (2009).
Chiba H, Osaka T, Iwasaki N, Suzuki H, Akizawa K, Fujisawa S, Intoh S, Watanabe M, Yoshida J, Matsuno K, et al. Spurious elevation of serum high-density lipoprotein cholesterol in patients with cholestatic liver diseases. Biochem. Med. Metab. Biol. 46: 329-343 (1991).
Chinetti G, Fruchart JC, Staels B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. Biochem. Soc. Trans. 34: 1128-1131 (2006). *
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S41-S45 (2003).
Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem. Biophys. Res. Commun. 314: 151-158 (2004). *
Chinetti-Gbaguidi G, Rigamonti E, Helin L, Mutka AL, Lepore M, Fruchart JC, Clavey V, Ikonen E, Lestavel S, Staels B. Peroxisome proliferator-activated receptor-alpha controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 46: 2717-2725 (2005). *
Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195: 100-109 (2007).
Chitturi S, Farrell GC. Drug-induced cholestasis. Semin. Gastrointest. Dis. 12: 113-124 (2001).
Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, Wu MS. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin. Gastroenterol. Hepatol. 5: 221-229 (2007).
Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH Jr, Carroll MC. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U.S.A. 105: 17913-17918 (2008). *
Chiu WC, Wang YC, Chien YW, Hou YC, Hu YM, Yeh SL. Effects of dietary fish oil supplementation on cellular adhesion molecule expression and tissue myeloperoxidase activity in hypercholesterolemic mice with sepsis. J. Nutr. Biochem. 20: 254-260 (2009). *
Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, Lee MK. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced obese mice. Food Chem. Toxicol. Jan 8 [Epub ahead of print] (2010). *
Cho KH, Kim HJ, Kamanna VS, Vaziri ND. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim. Biophys. Acta 1800: 6-15 (2010). *
Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis. Diabetes 56: 1534-1543 (2007). *
Choi BG, Vilahur G, Viles-Gonzalez JF, Badimon JJ. The role of high-density lipoprotein cholesterol in atherothrombosis. Mt. Sinai J. Med. 73: 690-701 (2006). *
Choi EM. Oxidative status of DBA/1J mice with type II collagen-induced arthritis. J. Appl. Toxicol. 27: 472-481 (2007). *
Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ. In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352 (2005).
Choi JS, Bae JY, Kim DS, Li J, Kim JL, Lee YJ, Kang YH. Dietary compound quercitrin dampens VEGF induction and PPARgamma activation in oxidized LDL-exposed murine macrophages: association with scavenger receptor CD36. J. Agric. Food Chem. Nov 23 [Epub ahead of print] (2009). *
Choi M, Rolle S, Rane M, Haller H, Luft FC, Kettritz R. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 63: 96-106 (2003). *
Cholon DM, O'Neal WK, Randell SH, Riordan JR, Gentzsch M. Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. Am. J. Physiol. Lung Cell. Mol. Physiol. Dec 14 [Epub ahead of print] (2009). *
Chopra R, Sambaiah K. Effects of rice bran oil enriched with n-3 PUFA on liver and serum lipids in rats. Lipids 44: 37-46 (2009).
Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1alpha,25-Dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm. Drug Dispos. 30: 457-475 (2009). *
Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch. Immunol. Ther. Exp. (Warsz.) 57: 243-251 (2009).
Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, Redinbo MR. Structural disorder in the complex of human PXR and the macrolide antibiotic rifampicin. Mol. Endocrinol. 19: 1125-1134 (2005). *
Christenson LK, McAllister JM, Martin KO, Javitt NB, Osborne TF, Strauss JF 3rd. Oxysterol regulation of steroidogenic acute regulatory protein gene expression. Structural specificity and transcriptional and posttranscriptional actions. J. Biol. Chem. 273: 30729-30735 (1998). *
Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol. Cell. Biol. 26: 6786-6798 (2006). *
Chuang JC, Cui H, Mason BL, Mahgoub M, Bookout AL, Yu HG, Perello M, Elmquist JK, Repa JJ, Zigman JM, Lutter M. Chronic social defeat stress disrupts regulation of lipid synthesis. J. Lipid Res. Feb 2 [Epub ahead of print] (2010). *
Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein CM. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis. 66: 208-214 (2007). *
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J. Rheumatol. 34: 1849-1854 (2007).
Chuu CP, Kokontis JM, Hiipakka RA, Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 14: 543-553 (2007). *
Ciacci C, Cirillo M, Cavallaro R, Mazzacca G. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 66: 178-185 (2002).
Cigliano L, Maresca B, Salvatore A, Nino M, Monfrecola G, Ayala F, Carlucci A, Pugliese RC, Pedone C, Abrescia P. Haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting lecithin-cholesterol acyltransferase activity. J. Eur. Acad. Dermatol. Venereol. 22: 417-425 (2008). *
Cignarella A, Bellosta S, Corsini A, Bolego C. Hypolipidemic therapy for the metabolic syndrome. Pharmacol. Res. 53: 492-500 (2006). *
Cignarella A, Engel T, Eckardstein A, Kratz M, Lorkowski S, Lueken A, Assmann G, Cullen P. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis 179: 229-236 (2005).
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol. 7: 44 (2007). *
Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. Sep 25 [Epub ahead of print] (2009). *
Claessen H, Brenner H, Drath C, Arndt V. Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany. Hepatology 51: 482-490 (2010).
Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G. Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology 128: 1258-1267 (2005). *
Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 36: 653-660 (1989).
Clarke GA, Bouchard G, Paigen B, Carey MC. Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse. Gut 53: 136-142 (2004). *
Clarke R, Shipley M, Armitage J, Collins R, Harris W. Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. Br. J. Nutr. 102: 279-284 (2009). *
Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. U.S.A. 98: 2610-2615 (2001). *
Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25: 2020-2030 (2005). *
Claudel T, Sturm E, Kuipers F, Staels B. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13: 1135-1148 (2004).
Clayton PT. Inborn errors of bile acid metabolism. J. Inherit. Metab. Dis. 14: 478-496 (1991).
Clayton PT. Hereditary liver diseases: screening strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 42-43 (2006). *
Clayton PT, Mills KA, Johnson AW, Barabino A, Marazzi MG. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623-628 (1996). *
Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869-872 (2004). *
Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 26: 291-294 (1985). *
Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).
Colecchia A, Larocca A, Scaioli E, Bacchi-Reggiani ML, Di Biase AR, Azzaroli F, Gualandi R, Simoni P, Vestito A, Festi D. Natural history of small gallbladder polyps is benign: evidence from a clinical and pathogenetic study. Am. J. Gastroenterol. 104: 624-629 (2009). *
Colecchia A, Mazzella G, Sandri L, Azzaroli F, Magliuolo M, Simoni P, Bacchi-Reggiani ML, Roda E, Festi D. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J. Gastroenterol. 12: 5336-5343 (2006). *
Colin A, Reggers J, Castronovo V, Ansseau M. Lipids, depression and suicide. Encephale 29: 49-58 (2003).
Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro JM, Delerive P. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. Endocrinology 149: 5128-5135 (2008). *
Coll T, Rodriguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer X, Vazquez-Carrera M. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. Curr. Mol. Pharmacol. 2: 46-55 (2009).
Collet-Gaudillat C, Billon-Bancel A, Beressi JP. Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. Diabetes Metab. 35: 151-154 (2009).
Collins JL. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discov. Devel. 7: 692-702 (2004).
Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45: 1963-1966 (2002). *
Combarros O, Rodriguez-Rodriguez E, Mateo I, Vazquez-Higuera JL, Infante J, Berciano J, Sanchez-Juan P. APOE dependent-association of PPAR-gamma genetic variants with Alzheimer's disease risk. Neurobiol. Aging Aug 4 [Epub ahead of print] (2009).
Conchillo A, Valencia I, Puente A, Ansorena D, Astiasaran I. Functional components in fish and algae oils. Nutr. Hosp. 21: 369-373 (2006).
Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res. 152: 1-10 (2007).
Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom. Med. 69: 932-934 (2007).
Cook IT, Duniac-Dmuchowski Z, Kocarek TA, Runge-Morris M, Falany CN. 24-Hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity and inhibition of LXR activation. Drug Metab. Dispos. 37: 2069-2078 (2009). *
Cooper AD, Craig WY, Taniguchi T, Everson GT. Characteristics and regulation of bile salt synthesis and secretion by human hepatoma HepG2 cells. Hepatology 20: 1522-1531 (1994).
Corey DA, Kelley TJ. Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts. Biochim. Biophys. Acta 1772: 748-754 (2007). *
Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50: 1030-1037 (2009).
Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O'Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JR. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice. J. Nutr. Biochem. 20: 806-815 (2009). *
Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res. 549: 131-145 (2004).
Corradini SG, Elisei W, Giovannelli L, Ripani C, Della Guardia P, Corsi A, Cantafora A, Capocaccia L, Ziparo V, Stipa V, Chirletti P, Caronna R, Lomanto D, Attili AF. Impaired human gallbladder lipid absorption in cholesterol gallstone disease and its effect on cholesterol solubility in bile. Gastroenterology 118: 912-920 (2000). *
Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, Karlson EW. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol. Int. 27: 1071-1077 (2007). *
Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J. Biol. Chem. 281: 6211-6218 (2006). *
Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, Gudas LJ, Tall AR. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol. Cell. Biol. 23: 7756-7766 (2003). *
Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275: 28240-28245 (2000). *
Coutinho JM, Singaraja RR, Kang M, Arenillas DJ, Bertram LN, Bissada N, Staels B, Fruchart JC, Fievet C, Joseph-George AM, Wasserman WW, Hayden MR. Complete functional rescue of the ABCA1-/-mouse by human BAC transgenesis. J. Lipid Res. 46: 1113-1123 (2005). *
Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9: 1217-1227 (2008).
Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J. Gastroenterol. Hepatol. 21 Suppl. 3: S56-S60 (2006). *
Craig WJ. Health effects of vegan diets. Am. J. Clin. Nutr. 89: 1627S-1633S (2009). *
Crawford AR, Smith AJ, Hatch VC, Oude Elferink RP, Borst P, Crawford JM. Hepatic secretion of phospholipid vesicles in the mouse critically depends on mdr2 or MDR3 P-glycoprotein expression. Visualization by electron microscopy. J. Clin. Invest. 100: 2562-2567 (1997). *
Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech. Ageing Dev. 128: 558-565 (2007).
Crestani M, De Fabiani E, Caruso D, Mitro N, Gilardi F, Vigil Chacon AB, Patelli R, Godio C, Galli G. LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem. Soc. Trans. 32: 92-96 (2004). *
Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J. Lipid Res. 39: 2192-2200 (1998). *
Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, Dickson ER. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 15: 858-862 (1992).
Crisafulli C, Di Paola R, Mazzon E, Paterniti I, Galuppo M, Genovese T, Bramanti P, Cappellani Ddagger A, Cuzzocrea S. Liver X receptor agonist treatment reduced splanchnic ischemia and reperfusion injury. J. Leukoc. Biol. Dec 22 [Epub ahead of print] (2009). *
Cronican AA, Fitz NF, Pham T, Fogg A, Kifer B, Koldamova R, Lefterov I. Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem. Pharmacol. Jan 7 [Epub ahead of print] (2010). *
Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig. Dis. Sci. 41: 809-815 (1996).
Crosignani A, Del Puppo M, Longo M, De Fabiani E, Caruso D, Zuin M, Podda M, Javitt NB, Kienle MG. Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease. Clin. Chim. Acta 382: 82-88 (2007). *
Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, Hale B, Hames C. Prevalence and factors associated with liver enzyme abnormalities among HIV-infected. Clin. Gastroenterol. Hepatol. Oct 1 [Epub ahead of print] (2009).
Cruz-Garcia L, Minghetti M, Navarro I, Tocher DR. Molecular cloning, tissue expression and regulation of liver X receptor (LXR) transcription factors of Atlantic salmon (Salmo salar) and rainbow trout (Oncorhynchus mykiss). Comp. Biochem. Physiol. B. Biochem. Mol. Biol. Feb 4 [Epub ahead of print] (2009). *
Cui J, Heard TS, Yu J, Lo JL, Huang L, Li Y, Schaeffer JM, Wright SD. The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. J. Biol. Chem. 277: 25963-25969 (2002). *
Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278: 10214-10220 (2003). *
Cui J, Lew J-L, Zhao A, Huang L, Wright SD. The farnesoid X receptor controls gene expression in a ligand and promoter-selective fashion. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 32. June 18-19 (2004). *
Cui NQ, Zhang SK, Cui YF, Li DH, Chen C, Wu XZ. Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones. Hepatobiliary Pancreat Dis. Int. 4: 117-120 (2005). *
Cummins CL, Mangelsdorf DJ. Liver X receptors and cholesterol homoeostasis: spotlight on the adrenal gland. Biochem. Soc. Trans. 34: 1110-1113 (2006). *
Cummins CL, Volle DH, Zhang Y, McDonald JG, Sion B, Lefrancois-Martinez AM, Caira F, Veyssiere G, Mangelsdorf DJ, Lobaccaro JM. Liver X receptors regulate adrenal cholesterol balance. J. Clin. Invest. 116: 1902-1912 (2006). *
Cundiff DK, Lanou AJ, Nigg CR. Relation of omega-3 fatty acid intake to other dietary factors known to reduce coronary heart disease risk. Am. J. Cardiol. 99: 1230-1233 (2007). *
Cunnane SC, Manku MS, Horrobin DF. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Med. Hypotheses 5: 403-414 (1979).
Cuomo R, Rodino S, Rizzoli R, Simoni P, Roda E, Cantoni L, Rizzardini M, De Rosa G, Le Grazie C, Di Padova C, et al. Bile and biliary lipid secretion in rats with hexachlorobenzene-induced porphyria. Effect of S-adenosyl-L-methionine administration. J. Hepatol. 12: 87-93 (1991).
Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res. 50: S340-S345 (2009). *
Czaja AJ. Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70 (1999).
Czech C, Burns MP, Vardanian L, Augustin A, Jacobsen H, Baumann K, Rebeck GW. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J. Neurochem. 101: 929-936 (2007).
D'Acunto C, Gurioli C, Neri I. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB. J. Dermatolog. Treat. Jan 1 [Epub ahead of print] (2009).
da Silva EF, Barbaro G. New options in the treatment of lipid disorders in HIV-infected patients. Open AIDS J. 3: 31-37 (2009).
Dahlman-Wright K, Zhao C. LXR in cholesterol metabolism. J. Endocrinol. Oct 16 [Epub ahead of print] (2009). *
Dai J, Su YX, Bartell S, Le NA, Ling WH, Liang YQ, Gao L, Wu HY, Veledar E, Vaccarino V. Beneficial effects of designed dietary fatty acid compositions on lipids in triacylglycerol-rich lipoproteins among Chinese patients with type 2 diabetes mellitus. Metabolism 58: 510-518 (2009). *
Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, Li XX, Tang CK. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in ApoE-/- mice. J. Cardiovasc. Pharmacol. 51: 467-475 (2008).
Dai Y, Liang YH, Xie PY, Chen BW, Liu XG. Clinical analysis of primary biliary cirrhosis: a report of 42 cases. Beijing Da Xue Xue Bao 37: 410-414 (2005).
Dall TL, Bays H. Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy. South. Med. J. 102: 390-396 (2009).
Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT. Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women. Eur. J. Clin. Nutr. 62: 386-394 (2008). *
Daly C, Fitzgerald AP, O'Callaghan P, Collins P, Cooney MT, Graham IM; on behalf of the COMAC Group. Homocysteine increases the risk associated with hyperlipidaemia. Eur. J. Cardiovasc. Prev. Rehabil. 16: 150-155 (2009).
Damiano F, Gnoni GV, Siculella L. Functional analysis of rat liver citrate carrier promoter: differential responsiveness to polyunsaturated fatty acids. Biochem. J. 417: 561-571 (2009). *
Damsgaard CT, Frokiaer H, Andersen AD, Lauritzen L. Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men. J. Nutr. 138: 1061-1066 (2008). *
Damsgaard CT, Schack-Nielsen L, Michaelsen KF, Fruekilde MB, Hels O, Lauritzen L. Fish oil affects blood pressure and the plasma lipid profile in healthy Danish infants. J. Nutr. 136: 94-99 (2006). *
Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 6: e1000058 (2009). *
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350: 1387-1397 (2004). *
Dang H, Liu Y, Pang W, Wang N, Shyy JY, Zhu Y. Suppression of 2,3-oxidosqualene cyclase by high-fat diet contributes to liver X receptor-alpha-mediated improvement of hepatic lipid profile. J. Biol. Chem. 284: 6218-6226 (2009). *
Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM. Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet. Gynecol. 107: 106-114 (2006).
Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, Giusti V, Mace K. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 88: 309-318 (2006).
Das A, Fernandez-Zapico ME, Cao S, Yao J, Fiorucci S, Hebbel RP, Urrutia R, Shah VH. Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J. Biol. Chem. 281: 39105-39113 (2006). *
Das JB, Poulos ND, Ansari GG. Biliary lipid composition and bile acid profiles during and after enteral fast of total parenteral nutrition in the rabbit. J. Pediatr. Gastroenterol. Nutr. 22: 85-91 (1996). *
Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Patents Cardiovasc. Drug Discov. 1: 193-209 (2006).
Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 76: 251-268 (2007). *
Das UN. Do polyunsaturated fatty acids behave like an endogenous "polypill"? Med. Hypotheses 70: 430-434 (2008).
Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 7: 37 (2008). *
Dastani Z, Engert JC, Genest J, Marcil M. Genetics of high-density lipoproteins. Curr. Opin. Cardiol. 21: 329-335 (2006).
Dastani Z, Pajukanta P, Marcil M, Rudzicz N, Ruel I, Bailey SD, Lee JC, Lemire M, Faith J, Platko J, Rioux J, Hudson TJ, Gaudet D, Engert JC, Genest J. Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects. Eur. J. Hum. Genet. Oct 21 [Epub ahead of print] (2009).
Davi G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 14: 760-764 (2005).
David A, Fridlich R, Aviram I. The presence of membrane proteinase 3 in neutrophil lipid rafts and its colocalization with FcgammaRIIIb and cytochrome b558. Exp. Cell Res. 308: 156-165 (2005). *
Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf. 5: 145-156 (2006).
Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol. 99: S3-S18 (2007). *
Davies R, Schuurman A, Barker CR, Clothier B, Chernova T, Higginson FM, Judah DJ, Dinsdale D, Edwards RE, Greaves P, Gant TW, Smith AG. Hepatic gene expression in protoporphyic fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. Am. J. Pathol. 166: 1041-1053 (2005). *
Davis HR Jr, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 like 1 (NPC1L1). Atheroscler. Suppl. 9: 77-81 (2008).
Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes. Surg. 13: 865-868 (2003).
Davis RA, Attie AD. Deletion of the ileal basolateral bile acid transporter identifies the cellular sentinels that regulate the bile acid pool. Proc. Natl. Acad. Sci. U.S.A. 105: 4965-4966 (2008). *
Davis RA, Miyake JH, Hui TY, Spann NJ. Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J. Lipid Res. 43: 533-543 (2002). *
Davis W Jr, Boyd JT, Ile KE, Tew KD. Human ATP-binding cassette transporter-2 (ABCA2) positively regulates low-density lipoprotein receptor expression and negatively regulates cholesterol esterification in Chinese hamster ovary cells. Biochim. Biophys. Acta 1683: 89-100 (2004). *
Davis W, Rockway S, Kwasny M. Effect of a combined therapeutic approach of intensive lipid management, omega-3 fatty acid supplementation, and increased serum 25 (OH) vitamin D on coronary calcium scores in asymptomatic adults. Am. J. Ther. 16: 326-332 (2009).
Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278: 33920-33927 (2003). *
de Abreu DA, Eyles D, Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 34 Suppl. 1: S265-S277 (2009).
de Campo A, Toplak H, Wascher TC, Schallmoser K, Friehs A, Schmidt H, Kostner GM. Evaluation of a newly discovered LDL receptor mutation (exon 10, GAC>AAC, D271N, "FH Graz-1") in familial hypercholesterolemia - a family study. Acta Med. Austriaca 26: 20-25 (1999).
De Cosmo S, Minenna A, Zhang YY, Thompson R, Miscio G, Vedovato M, Rauseo A, Saller A, Mastroianno S, Pellegrini F, Trevisan R, Fioretto P, Doria A, Trischitta V. Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes. Am. J. Kidney Dis. 53: 273-280 (2009).
De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis� J. Biol. Chem. 276: 30708-30716 (2001). *
De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 278: 39124-39132 (2003). *
De Fabiani E, Mitro N, Godio C, Gilardi F, Caruso D, Crestani M. Bile acid signaling to the nucleus: finding new connections in the transcriptional regulation of metabolic pathways. Biochimie 86: 771-778 (2004).
de Freitas MV, de Oliveira MR, Dos Santos DF, de Cassia Mascarenhas Netto R, Fenelon SB, Penha-Silva N. Influence of the use of statin on the stability of erythrocyte membranes in multiple sclerosis. J. Membr. Biol. Feb 10 [Epub ahead of print] (2010).
De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab. Invest. 87: 792-806 (2007). *
de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, A Romijn J, Jukema JW, Havekes LM, Princen HM, Rensen PC. PXR agonism decreases plasma HDL levels in apoE3-Leiden.CETP mice. Biochim. Biophys. Acta 1791: 191-197 (2009). *
de Jong A, Plat J, Lutjohann D, Mensink RP. Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment. Br. J. Nutr. 100: 937-941 (2008).
De Luis D, Aller R, Zarzuelo S. Dietary salt in the era of anthypertensive drugs. Med. Clin. (Barc.) 127: 673-675 (2006).
de Luis DA, Aller R, Izaola O, Sagrado MG, Conde R. Influence of G308A promoter variant of tumor necrosis factor-alpha gene on insulin resistance and weight loss secondary to two hypocaloric diets: a randomized clinical trial. Arch. Med. Res. 40: 36-41 (2009).
de Luis DA, Conde R, Aller R, Izaola O, Gonzalez Sagrado M, Perez Castrillon JL, Duenas A, Romero E. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study. Eur. Rev. Med. Pharmacol. Sci. 13: 51-55 (2009).
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T. Influence of G308A polymorphism of tumor necrosis factor alpha gene on surgical results of biliopancreatic diversion. Obes. Surg. Jun 20 [Epub ahead of print] (2008). *
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T, Perez Castrillon JL. Influence of -55CT polymorphism of UCP3 gene on surgical results of biliopancreatic diversion. Obes. Surg. May 17 [Epub ahead of print] (2008).
de Luis DA, Pacheco D, Izaola O, Terroba MC, Cuellar L, Martin T. Clinical results and nutritional consequences of biliopancreatic diversion: three years of follow-up. Ann. Nutr. Metab. 53: 234-239 (2008).
de Luis DA, Sagrado MG, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T. Influence of Ala54Thr polymorphism of fatty acid-binding protein-2 on clinical results of biliopancreatic diversion. Nutrition 24: 300-304 (2008). *
de Nigris F, Williams-Ignarro S, Lerman LO, Crimi E, Botti C, Mansueto G, D'Armiento FP, De Rosa G, Sica V, Ignarro LJ, Napoli C. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc. Natl. Acad. Sci. U.S.A. 102: 4896-4901 (2005). *
de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165 (2008). *
de Roos B, Geelen A, Ross K, Rucklidge G, Reid M, Duncan G, Caslake M, Horgan G, Brouwer IA. Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. Proteomics 8: 1965-1974 (2008). *
De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior JC; and the Maxepa-HIV Group. Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acquir. Immune Defic. Syndr. 44: 278-285 (2007).
de Vogel-van den Bosch HM, Bunger M, de Groot PJ, Bosch-Vermeulen H, Hooiveld GJ, Muller M. PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression. BMC Genomics 9: 231 (2008). *
de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111: 1-66 (2008). *
de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, Rensen PC. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology 150: 2368-2375 (2009). *
Deak G, Ruzicska E, Somogyi A. Association of IgA nephropathy, hypothyroidism and hypercholesterolemia. J. Nephrol. 18: 773-776 (2005).
Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet. Genomics 17: 451-457 (2007).
Dean M. The genetics of ATP-binding cassette transporters. Methods Enzymol. 400: 409-429 (2005).
Dean M, Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33: 475-479 (2001). *
Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6: 123-142 (2005). *
Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42: 1007-1017 (2001). *
Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11: 1156-1166 (2001). *
Decarlis S, Agostoni C, Ferrante F, Scarlino S, Riva E, Giovannini M. Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. J. Inherit. Metab. Dis. Feb 15 [Epub ahead of print]] (2009). *
Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs R. D. 7: 99-110 (2006).
Dedoussis GV, Maumus S, Choumerianou DM, Skoumas J, Pitsavos C, Stefanadis C, Visvikis-Siest S. Different genes and polymorphisms affecting high-density lipoprotein cholesterol levels in Greek familial hypercholesterolemia patients. Genet. Test. 10: 192-199 (2006).
Dedoussis GV, Maumus S, Skoumas J, Choumerianou DM, Pitsavos C, Stefanadis C, Visvikis-Siest S. Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. J. Clin. Lab. Anal. 20: 98-104 (2006).
Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J. Assoc. Physicians India 54: 797-810 (2006).
Degirolamo C, Kelley KL, Wilson MD, Rudel LL. Dietary n-3 LCPUFA from fish oil but not alpha-linolenic acid-derived LCPUFA confers atheroprotection in mice. J. Lipid Res. Feb 11 [Epub ahead of print] (2010). *
del Castillo-Olivares A, Campos JA, Pandak WM, Gil G. The role of alpha1-fetoprotein transcription factor/LRH-1 in bile acid biosynthesis: a known nuclear receptor activator that can act as a suppressor of bile acid biosynthesis. J. Biol. Chem. 279: 16813-16821 (2004). *
del Castillo-Olivares A, Gil G. Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription. Nucleic Acids Res. 28: 3587-3593 (2000). *
Del Puppo M, Galli Kienle M, Crosignani A, Petroni ML, Amati B, Zuin M, Podda M. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J. Lipid Res. 42: 437-441 (2001). *
Del Puppo M, Kienle MG, Petroni ML, Crosignani A, Podda M. Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J. Lipid Res. 39: 2477-2482 (1998). *
Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 50: 6-16 (2009). *
Delerive P, Galardi CM, Bisi JE, Nicodeme E, Goodwin B. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18: 2378-2387 (2004). *
Dellavalle R, Drake A, Graber M, Heilig L, Hester E, Johnson K, McNealy K, Schilling L, Dellavalle R. Statins and fibrates for preventing melanoma. Cochrane Database Syst. Rev. 4: CD003697 (2005). *
Delva E, Jennings JM, Calkins CC, Kottke MD, Faundez V, Kowalczyk AP. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin and dynamin-independent mechanism. J. Biol. Chem. 283: 18303-18313 (2008). *
Delvecchio CJ, Bilan P, Nair P, Capone JP. LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L949-L957 (2008). *
Delvecchio CJ, Bilan P, Radford K, Stephen J, Trigatti BL, Cox G, Parameswaran K, Capone JP. Liver X receptor stimulates cholesterol efflux and inhibits expression of pro-inflammatory mediators in human airway smooth muscle cells. Mol. Endocrinol. 21: 1324-1334 (2007). *
Delvecchio CJ, Capone JP. Protein kinase C alpha modulates liver X receptor alpha transactivation. J. Endocrinol. 197: 121-130 (2008). *
Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp. Dermatol. 18: 643-649 (2009).
Demirag MD, Onen HI, Karaoguz MY, Dogan I, Karakan T, Ekmekci A, Guz G. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52: 3399-3403 (2007). *
Demonty I, Chan YM, Pelled D, Jones PJ. Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. Am. J. Clin. Nutr. 84: 1534-1542 (2006). *
Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc. Drug Rev. 25: 375-390 (2007).
Deng R, Yang D, Radke A, Yang J, Yan B. Hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over FXR-mediated antagonism. J. Pharmacol. Exp. Ther. 320: 1153-1162 (2007). *
Deng R, Yang D, Yang J, Yan B. Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor FXR but not LXR. J. Pharmacol. Exp. Ther. 317: 317-325 (2006). *
Denis M, Bissonnette R, Haidar B, Krimbou L, Bouvier M, Genest J. Expression, regulation, and activity of ABCA1 in human cell lines. Mol. Genet. Metab. 78: 265-274 (2003). *
Denke MA. Dietary fats, fatty acids, and their effects on lipoproteins. Curr. Atheroscler. Rep. 8: 466-471 (2006).
Denke MA. Diet, lifestyle, and nonstatin trials: review of time to benefit. Am. J. Cardiol. 96: 3-10 (2005). *
Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121: 140-147 (2001). *
Deo AK, Bandiera SM. Identification of human hepatic cytochrome P450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid . Drug Metab. Dispos. 36: 1983-1991 (2008). *
Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26: 1599-1607 (2004). *
Desai F, Ramanathan M, Fink CS, Wilding GE, Weinstock-Guttman B, Awad AB. Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Int. Immunopharmacol. 9: 153-157 (2009).
Desideri G, Croce G, Tucci M, Passacquale G, Broccoletti S, Valeri L, Santucci A, Ferri C. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J. Clin. Endocrinol. Metab. 88: 5341-5437 (2003). *
Desiderio S, Yoo JY. A genome-wide analysis of the acute-phase response and its regulation by Stat3beta. Ann. N. Y. Acad. Sci. 987: 280-284 (2003). *
Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 33: 2425-2432 (2006).
Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig. Dis. Sci. 49: 30-37 (2004). *
Devroey D, Velkeniers B, Duquet W, Betz W. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Int. J. Cardiol. 101: 231-235 (2005).
Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J. Inherit. Metab. Dis. 29: 431-435 (2006). *
Di Nisio M, Di Febbo C, Moretta V, Guglielmi MD, Stuppia L, Cuccurullo F, Porreca E. Effects of Toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients. Thromb. Haemost. 98: 642-646 (2007).
Diaz Encarnacion MM, Warner GM, Gray CE, Cheng J, Keryakos HK, Nath KA, Grande JP. Signaling pathways modulated by fish oil in salt-sensitive hypertension. Am. J. Physiol. Renal Physiol. 294: F1323-F1335 (2008). *
Diblasio-Smith EA, Arai M, Quinet EM, Evans MJ, Kornaga T, Basso MD, Chen L, Feingold I, Halpern AR, Liu QY, Nambi P, Savio D, Wang S, Mounts WM, Isler JA, Slager AM, Burczynski ME, Dorner AJ, Lavallie ER. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J. Transl. Med. 6: 59 (2008). *
Diczfalusy U. Analysis of cholesterol oxidation products in biological samples. J. AOAC Int. 87: 467-473 (2004).
Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, Flaring U, Bjorkbacka H. Marked up-regulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J. Lipid Res. 50: 2258-2264 (2009). *
Didilescu AC, Hanganu SC, Galie N, Greabu M, Totan A, Stratul SI, Puiu L. The role of smoking in changing essential parameters in body homeostasis. Pneumologia 58: 89-94 (2009).
Dierker T, Dreier R, Petersen A, Bordych C, Grobe K. Heparan sulfate-modulated, metalloprotease-mediated sonic hedgehog release from producing cells. J. Biol. Chem. 284: 8013-8022 (2009). *
Dierkes J, Westphal S, Luley C. Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management. Drug Saf. 26: 81-91 (2003).
Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin. Drug Saf. 3: 101-111 (2004).
Dieter MZ, Maher JM, Cheng X, Klaassen CD. Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 139: 209-218 (2004). *
Dikopoulos N, Schmid RM, Bachem M, Buttenschoen K, Adler G, Chiang JY, Weidenbach H. Bile synthesis in rat models of inflammatory bowel diseases. Eur. J. Clin. Invest. 37: 222-230 (2007). *
Dikopoulos N, Weidenbach H, Adler G, Schmid RM. Lipopolysaccharide represses cholesterol 7-alpha hydroxylase and induces binding activity to the bile acid response element II. Eur. J. Clin. Invest. 33: 58-64 (2003). *
Dimitrova-Sumkovska J, Djosic-Markovska B, Zafirova-Roganovic D, Anastasovska V. Effects of different dietary fatty acid supplements uppon lipoprotein metabolism and lipid peroxides production in hyperlipidemic rats. Prilozi. 27: 67-86 (2006).
Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 1: 193-200 (2006).
Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56: 1334-1339 (2007). *
Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F. Ursodeoxycholic acid treatment in children with Byler disease. Pediatr. Int. 41: 662-665 (1999).
Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98 (1999).
Diwakar BT, Dutta PK, Lokesh BR, Naidu KA. Bio-availability and metabolism of n-3 fatty acid rich garden cress (Lepidium sativum) seed oil in albino rats. Prostaglandins Leukot. Essent. Fatty Acids 78: 123-130 (2008). *
Dixit M, Choudhuri G, Keshri LJ, Mittal B. Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J. Gastroenterol. Hepatol. 21: 847-849 (2006). *
do Prado R, D' Almeida VM, Guerra-Shinohara E, Galdieri LC, Terreri MT, Hilario MO. Increased concentration of plasma homocysteine in children with systemic lupus erythematosus. Clin. Exp. Rheumatol. 24: 594-598 (2006).
Doggrell SA. Farnesoid X receptor agonism - a new approach to the treatment of cholesterol gallstone disease. Expert Opin. Investig. Drugs 14: 535-538 (2005).
Doggrell SA. New targets in and potential treatments for cholesterol gallstone disease. Curr. Opin. Investig. Drugs 7: 344-348 (2006).
Doggrell SA. Muraglitazar: beneficial or detrimental in the treatment of type 2 diabetes? Expert Opin. Pharmacother. 7: 1229-1233 (2006).
Doisne JM, Castaigne JG, Deruyffelaere C, Dieu-Nosjean MC, Chamot C, Alcaide-Loridan C, Charron D, Al-Daccak R. The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes. Mol. Immunol. 45: 709-718 (2008). *
Dolganiuc A, Bakis G, Kodys K, Mandrekar P, Szabo G. Acute ethanol treatment modulates Toll-like receptor-4 association with lipid rafts. Alcohol Clin. Exp. Res. 30: 76-85 (2006). *
Dolley G, Lamarche B, Despres JP, Bouchard C, Perusse L, Vohl MC. Myeloperoxidase gene sequence variations are associated with low-density-lipoprotein characteristics. J. Hum. Genet. 53: 439-446 (2008). *
Dombrecht EJ, Van Offel JF, Bridts CH, Ebo DG, Seynhaeve V, Schuerwegh AJ, Stevens WJ, De Clerck LS. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin. Exp. Rheumatol. 25: 534-539 (2007).
Dongxia L, Qi H, Lisong L, Jincheng G. Association of peroxisome proliferator-activated receptor-gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ. J. 72: 551-557 (2008). *
Dos Santos SM, Weber CC, Franke C, Muller WE, Eckert GP. Cholesterol: coupling between membrane microenvironment and ABC transporter activity. Biochem. Biophys. Res. Commun. 354: 216-221 (2007). *
Dourakis SP, Papanikolaou IS, Tzemanakis EN, Hadziyannis SJ. Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur. J. Gastroenterol. Hepatol. 14: 693-695 (2002).
Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11: 1079-1092 (2003). *
Dragsted LO, Krath B, Ravn-Haren G, Vogel UB, Vinggaard AM, Bo Jensen P, Loft S, Rasmussen SE, Sandstrom TB, Pedersen A. Biological effects of fruit and vegetables. Proc. Nutr. Soc. 65: 61-67 (2006). *
Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm. Venereol. 88: 561-565 (2008).
Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Fundam. Clin. Pharmacol. 23: 687-692 (2009).
Du HQ, Yin M, Ye HY, Shang YJ, Dai XD, Jing W, Zhang L, Xiao N, Li JF, Pan J. Expression profiles of lipid metabolism-related genes in liver of apoE(-/-)/LDLR(-/-) mice. Zhonghua Bing Li Xue Za Zhi 36: 751-755 (2007).
Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim. Biophys. Acta 1761: 281-291 (2006). *
Duane WC, Hartich LA, Bartman AE, Ho SB. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J. Lipid Res. 41: 1384-1389 (2000). *
Duane WC, Javitt NB. 27-Hydroxycholesterol: production rates in normal human subjects. J. Lipid Res. 40: 1194-1199 (1999). *
Duane WC, Javitt NB. Conversion of 7 alpha-hydroxycholesterol to bile acid in human subjects: is there an alternate pathway favoring cholic acid synthesis? J. Lab. Clin. Med. 139: 109-115 (2002). *
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
Dubrac S, Lear SR, Ananthanarayanan M, Balasubramaniyan N, Bollineni J, Shefer S, Hyogo H, Cohen DE, Blanche PJ, Krauss RM, Batta AK, Salen G, Suchy FJ, Maeda N, Erickson SK. Role of CYP27A in cholesterol and bile acid metabolism. J. Lipid Res. 46: 76-85 (2005). *
Duckworth PF, Vlahcevic ZR, Studer EJ, Gurley EC, Heuman DM, Beg ZH, Hylemon PB. Effect of hydrophobic bile acids on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and mRNA levels in the rat. J. Biol. Chem. 266: 9413-9418 (1991). *
Dueland S, Reichen J, Everson GT, Davis RA. Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem. J. 280: 373-377 (1991).
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277: 48051-48057 (2002). *
Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk 8: 187-194 (2001).
Duez H, Lefebvre B, Poulain P, Pineda Torra I, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Fruchart JC, Fievet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler. Thromb. Vasc. Biol. 25: 585-591 (2005). *
Duez H, Veen JV, Duhem C, Pourcet B, Touvier T, Fontaine C, Derudas B, Bauge E, Havinga R, Bloks VW, Wolters H, van der Sluijs FH, Vennstrom B, Kuipers F, Staels B. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 135: 689-698.e5 (2008). *
Duffy D, Rader DJ. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Curr. Opin. Cardiol. 20: 301-306 (2005).
Dullens SP, Mensink RP, Mariman EC, Plat J. Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine. Eur. J. Gastroenterol. Hepatol. 21: 642-649 (2009).
Duniec-Dmuchowski Z, Fang HL, Strom SC, Ellis E, Runge-Morris M, Kocarek T. Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2,3-oxidosqualene:lanosterol cyclase inhibition. Drug Metab. Dispos. 37: 900-908 (2009). *
Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203: 401-412 (2006). *
Duntas LH. Thyroid disease and lipids. Thyroid 12: 287-293 (2002).
Dupasquier CM, Dibrov E, Kostenuk AL, Cheung PK, Lee KG, Alexander HK, Yeganeh BK, Moghadasian MH, Pierce GN. Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am. J. Physiol. Heart Circ. Physiol. 293: H2394-H2402 (2007). *
Duraisamy Y, Lambert D, O'Neill CA, Padfield PJ. Differential incorporation of docosahexaenoic acid into distinct cholesterol-rich membrane raft domains. Biochem. Biophys. Res. Commun. 360: 885-890 (2007). *
During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J. Nutr. 135: 2305-2312 (2005). *
Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig. Dis. Sci. 52: 2368-2374 (2007). *
DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 22: 65-77 (2008). *
Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R, Forman BM. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278: 7027-7033 (2003). *
Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK, Forman BM. Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. U.S.A. 100: 833-838 (2003). *
Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottee L, Bieche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Decleves X, Duyckaerts C, Loriot MA. Xenobiotic metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. 37: 1528-1538 (2009). *
Ebbesson SO, Ebbesson LO, Swenson M, Kennish JM, Robbins DC. A successful diabetes prevention study in Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64: 409-424 (2005).
Ebbesson SO, Risica PM, Ebbesson LO, Kennish JM, Tejero ME. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64: 396-408 (2005).
Ebbesson SO, Tejero ME, Nobmann ED, Lopez-Alvarenga JC, Ebbesson L, Romenesko T, Carter EA, Resnick HE, Devereux RB, Maccluer JW, Dyke B, Laston SL, Wenger CR, Fabsitz RR, Comuzzie AG, Howard BV. Fatty acid consumption and metabolic syndrome components: the GOCADAN study. J. Cardiometab. Syndr. 2: 244-249 (2007).
Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol. 64: 321-327 (2009).
Ecker J, Liebisch G, Patsch W, Schmitz G. The conjugated linoleic acid isomer trans-9, trans-11 is a dietary occurring agonist of liver X receptor alpha. Biochem. Biophys. Res. Commun. 388: 660-666 (2009). *
Eckert GP, Vardanian L, Rebeck GW, Burns MP. Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317. Neurosci. Lett. 423: 47-52 (2007). *
Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol. Lett. 98: 13-23 (1998).
Edgel KA, Leboeuf RC, Oram JF. Tumor necrosis factor-alpha and lymphotoxin-alpha increase macrophage ABCA1 by gene expression and protein stabilization via different receptors. Atherosclerosis Oct 22 [Epub ahead of print] (2009).
Edwards CM, Otal MP, Stacpoole PW. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells. Metabolism 42: 807-813 (1993).
Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 2-12 (2002). *
Edwards PA, Kennedy MA, Mak PA. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul. Pharmacol. 38: 249-256 (2002). *
Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res. Rev. 2: 11-24 (2003).
Egert S, Kannenberg F, Somoza V, Erbersdobler HF, Wahrburg U. Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J. Nutr. 139: 861-868 (2009). *
Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc.) 34: 943-956 (1998).
Ehehalt R, Krautter M, Zorn M, Sparla R, Fullekrug J, Kulaksiz H, Stremmel W. Increased basolateral sorting of carcinoembryonic antigen in a polarized colon carcinoma cell line after cholesterol depletion: implications for treatment of inflammatory bowel disease. World J. Gastroenterol. 14: 1528-1533 (2008). *
Eilat-Adar S, Mete M, Nobmann ED, Xu J, Fabsitz RR, Ebbesson SO, Howard BV. Dietary patterns are linked to cardiovascular risk factors but not to inflammatory markers in Alaska Eskimos. J. Nutr. 139: 2322-2328 (2009).
Ek J, Hansen SP, Lajer M, Nicot C, Boesgaard TW, Pruhova S, Johansen A, Albrechtsen A, Yderstraede K, Lauenborg J, Parrizas M, Boj SF, Jorgensen T, Borch-Johnsen K, Damm P, Ferrer J, Lebl J, Pedersen O, Hansen T. A novel -192c/g mutation in the proximal P2 promoter of the hepatocyte nuclear factor-4alpha gene (HNF4A) associates with late-onset diabetes. Diabetes 55: 1869-1873 (2006). *
El Muhtaseb MS, Talwar D, Duncan A, O'Reilly DS, McKee RF, Anderson JH, Foulis A, Finlay IG. Free radical activity and lipid soluble anti-oxidant vitamin status in patients with long-term ileal pouch-anal anastomosis. Colorectal Dis. 11: 67-72 (2009). *
El-Beshbishy HA. Aqueous garlic extract attenuates hepatitis and oxidative stress induced by galactosamine/lipoploysaccharide in rats. Phytother. Res. 22: 1372-1379 (2008).
El-Mir MY, Monte MJ, Morales AI, Arevalo M, Serrano MA, Marin JJ. Effect of maternal cholestasis on biliary lipid and bile acid secretion in the infant rat. Hepatology 26: 527-536 (1997). *
El-Seraq HB, Johnson ML, Hachem C, Morgan RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136: 1601-1608 (2009). *
Elamiri A, Perwaiz S, Tuchweber B, Yousef IM. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol. Res. 48: 467-472 (2003). *
Elias E. Hepatology highlights. Hepatology 42: 1241-1242 (2005). *
Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J. Lipid Res. 49: 697-714 (2008). *
Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y, Katz M, Solomon G, Halpern Z, Gertler A. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 49: 278-286 (2009). *
Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18: 269-276 (2002).
Eliseo T, Ragona L, Catalano M, Assfalg M, Paci M, Zetta L, Molinari H, Cicero DO. Structural and dynamic determinants of ligand binding in the ternary complex of chicken liver bile acid binding protein with two bile salts revealed by NMR. Biochemistry 46: 12557-12567 (2007). *
Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thorne A, Nowak G, Ericzon BG, Bjorkhem I, Einarsson C. Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38: 930-938 (2003). *
Ellis EC. Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World J. Gastroenterol. 12: 4640-4645 (2006). *
Elta GH, Sepersky RA, Goldberg MJ, Connors CM, Miller KB, Kaplan MM. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig. Dis. Sci. 28: 971-975 (1983).
Elvevoll EO, Eilertsen KE, Brox J, Dragnes BT, Falkenberg P, Olsen JO, Kirkhus B, Lamglait A, Osterud B. Seafood diets: hypolipidemic and antiatherogenic effects of taurine and n-3 fatty acids. Atherosclerosis 200: 396-402 (2008).
Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am. J. Gastroenterol. 101: 1866-1871 (2006). *
Emerick KM, Elias ME, Melin-Aldana H, Strautnieks S, Thompson RJ, Bull LN, Knisely AS, Whitington PF, Green RM. Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion. BMC Gastroenterol. 8: 47 (2008). *
Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res. 161: 284-291 (2008).
Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, Kitade Y, Tajima K, Zhao HT, El-Kabbani O, Hara A. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch. Biochem. Biophys. 487: 1-9 (2009). *
Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler. Suppl. 7: 31-35 (2006).
Engel T, Kannenberg F, Fobker M, Nofer JR, Bode G, Lueken A, Assmann G, Seedorf U. Expression of ATP binding cassette-transporter ABCG1 prevents cell death by transporting cytotoxic 7beta-hydroxycholesterol. FEBS Lett. 581: 1673-1680 (2007). *
Englyst NA, Grimble RF, Byrne CD. Long-chain n-3 fatty acid supplementation in men increases resistance to activated protein C. Metabolism 56: 547-551 (2007). *
Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Nakamuta M. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol. Int. Jun 16 [Epub ahead of print] (2009). *
Ercan E, Tengiz I, Altuglu I, Sekuri C, Aliyev E, Ercan HE, Akin M. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol. Pol. 60: 454-458 (2004).
Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Yilmaz C. The relationship of the interleukin-6 -174 G>C gene polymorphism with cardiovascular risk factors in Turkish polycystic ovary syndrome patients. Int. J. Immunogenet. 36: 283-288 (2009). *
Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Amin R. Impact of the Pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients. PPAR Res. 2009: 874126 (2009). *
Ergen A, Isbir S, Tekeli A, Isbir T. Investigation of ABCA1 C69T and G-191C polymorphisms in coronary artery disease. In Vivo 22: 187-190 (2008).
Erickson RP, Bhattacharyya A, Hunter RJ, Heidenreich RA, Cherrington NJ. Liver disease with altered bile acid transport in Niemann-Pick C mice on a high fat, 1% cholesterol diet. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G300-G307 (2005). *
Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009 (2003). *
Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. U.S.A. 104: 15490-15495 (2007). *
Erlinger S. Drug-induced cholestasis. J. Hepatol. 26 Suppl. 1: 1-4 (1997).
Erlinger S. Cystic fibrosis: bile secretion. Br. Med. Bull. 48: 860-876 (1992).
Erlinger S. Formation of the bile. Rev. Prat. 41: 2341-2346 (1991).
Erridge C, Webb DJ, Spickett CM. 25-Hydroxycholesterol, 7beta-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Toll-like receptor 1, 2, 4 or 6 signalling in human macrophages. Free Radic. Res. 41: 260-266 (2007).
Ertam I, Alper S, Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J. Dermatolog. Treat. 17: 214-216 (2006).
Ertas FS, Hasan T, Ozdol C, Gulec S, Atmaca Y, Tulunay C, Karabulut H, Kocum HT, Dincer I, Kose KS, Erol C. Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification. Mayo Clin. Proc. 82: 944-950 (2007). *
Ertekin V, Selimoglu MA, Turkan Y, Akcay F. Serum nitric oxide levels in children with celiac disease. J. Clin. Gastroenterol. 39: 782-785 (2005).
Escobar Castro H, Garcia Novo Mf MD, Olivares P. Biliary lithiasis in childhood. Therapeutic approaches. An. Pediatr. (Barc.) 60: 170-174 (2004).
Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int. J. Cardiol. 136: 4-16 (2009).
Esterman AL, Baum H, Javitt NB, Darlington GJ. 26-Hydroxycholesterol: regulation of hydroxymethylglutaryl-CoA reductase activity in Chinese hamster ovary cell culture. J. Lipid Res. 24: 1304-1309 (1983). *
Esterman AL, Cohen BI, Javitt NB. Cholesterol metabolism: use of D2O for determination of synthesis rate in cell culture. J. Lipid Res. 26: 950-954 (1985). *
Esteve E, Villuendas G, Mallolas J, Vendrell J, Lopez-Bermejo A, Rodriguez M, Recasens M, Ricart W, San Millan JL, Escobar-Morreale H, Richart C, Fernandez-Real JM. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin. Endocrinol. (Oxf.) 65: 88-91 (2006). *
Etienne J, Beucler I, Ayrault M, Cloarec M, Polonovski J, Debray J. Abnormal lipoproteins in a case of primary biliary cirrhosis. Biomedicine 29: 33-37 (1978).
Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 32: 1044-1048 (1991). *
Evans D, Beil FU. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med. Genet. 7: 66 (2006). *
Evans J, Collins M, Jennings C, van der Merwe L, Soderstrom I, Olsson T, Levitt NS, Lambert EV, Goedecke JH. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur. J. Endocrinol. 157: 633-640 (2007). *
Evans JL, Lin JJ, Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr. Diabetes Rev. 1: 299-307 (2005).
Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez RV, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G543-G552 (2009). *
Everson GT, Daggy BP, McKinley C, Story JA. Effects of Psyllium hydrophilic mucilloid on LDL-cholesterol and bile acid synthesis in hypercholesterolemic men. J. Lipid Res. 33: 1183-1192 (1992). *
Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. J. Lipid Res. 29: 68-76 (1988). *
Everson GT, McKinley C, Kern F Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J. Clin. Invest. 87: 237-246 (1991). *
Everson GT, McKinley C, Lawson M, Johnson M, Kern F Jr. Gallbladder function in the human female: effect of the ovulatory cycle, pregnancy, and contraceptive steroids. Gastroenterology 82: 711-719 (1982).
Everson GT, Polokoff MA. HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J. Biol. Chem. 261: 2197-2201 (1986). *
Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, Shrestha R, Stegall M. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl. Surg. 5: S48-S57 (1999).
Ewerth S. On the enterohepatic circulation of bile acids in man. Acta Chir. Scand. Suppl. 513: 1-38 (1982).
Ezzidi I, Mtiraoui N, Kacem M, Chaieb M, Mahjoub T, Almawi WY. Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy. Diabetes Metab. Res. Rev. 25: 717-724 (2009).
Ezzidi I, Mtiraoui N, Kacem M, Mallat SG, Mohamed MB, Chaieb M, Mahjoub T, Almawi WY. Interleukin-10 -592C/A, -819C/T, and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes patients. Clin. Endocrinol. (Oxf.) 70: 401-407 (2009). *
Ezzidi I, Mtiraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY. Endothelial nitric oxide synthase Glu298Asp, 4b/a, and T-786C polymorphisms in type 2 diabetic retinopathy. Clin. Endocrinol. (Oxf.) 68: 542-546 (2008). *
Fabian E, Elmadfa I. Nutritional situation of the elderly in the European Union: data of the European Nutrition and Health Report (2004). Ann. Nutr. Metab. 52 Suppl. 1: 57-61 (2008).
Fabris C, Smirne C, Fangazio S, Toniutto P, Burlone M, Minisini R, Bitetto D, Falleti E, Cerutti A, Pirisi M. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatol. Res. 39: 795-804 (2009). *
Fabris C, Toniutto P, Bitetto D, Minisini R, Fornasiere E, Smirne C, Pirisi M. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation. J. Gastroenterol. 42: 543-549 (2007). *
Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, Pizzigallo E, Conti P, Vecchiet J. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J. Med. Virol. 80: 1900-1906 (2008).
Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J. Gastroenterol. 11: 2346-2350 (2005). *
Fan P, Zhang B, Kuroki S, Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme A reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ. J. 68: 1061-1066 (2004). *
Fan X, Kim HJ, Bouton D, Warner M, Gustafsson JA. Expression of liver X receptor beta is essential for formation of superficial cortical layers and migration of later-born neurons. Proc. Natl. Acad. Sci. U.S.A. 105: 13445-13450 (2008). *
Fan YY, Ly LH, Barhoumi R, McMurray DN, Chapkin RS. Dietary docosahexaenoic acid suppresses T cell protein kinase C theta lipid raft recruitment and IL-2 production. J. Immunol. 173: 6151-6160 (2004). *
Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, Runge-Morris M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67: 1257-1267 (2005). *
Farias AQ, Goncalves LL, Bittencourt PL, De Melo ES, Abrantes-Lemos CP, Porta G, Nakhle MC, Carrilho FJ, Cancado EL. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. J. Gastroenterol. Hepatol. 21: 887-893 (2006). *
Farkkila M, Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Niemela O. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int. 28: 787-797 (2008). *
Farmer JA, Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin. Endocrinol. Metab. 9: 825-847 (1995).
Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92: 794-797 (2003). *
Farooqui AA. Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist 15: 392-407 (2009).
Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: the battle of the Titans. Brain Res. Rev. 56: 443-471 (2007).
Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 21: 802-805 (2007).
Farzan SF, Singh S, Schilling NS, Robbins DJ. The adventures of sonic hedgehog in development and repair. III. Hedgehog processing and biological activity. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G844-G849 (2008). *
Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 205: 538-543 (2009).
Faulkner LE, Panagotopulos SE, Johnson JD, Woollett LA, Hui DY, Witting SR, Maiorano JN, Davidson WS. An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages. J. Lipid Res. 49: 1322-1332 (2008). *
Fayard E, Auwerx J, Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol. 14: 250-260 (2004). *
Fayard E, Schoonjans K, Auwerx J. Xol INXS: role of the liver X and the farnesol X receptors. Curr. Opin. Lipidol. 12: 113-120 (2001).
Fazle Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J. Gastroenterol. 40: 157-163 (2005). *
Feart C, Peuchant E, Letenneur L, Samieri C, Montagnier D, Fourrier-Reglat A, Barberger-Gateau P. Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am. J. Clin. Nutr. 87: 1156-1162 (2008). *
Feher J, Lengyel G. Nutrition and cardiovascular mortality. Orv. Hetil. 147: 1491-1496 (2006).
Feige JN, Auwerx J. DisSIRTing on LXR and cholesterol metabolism. Cell. Metab. 6: 343-345 (2007). *
Feingold KR. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J. Lipid Res. 48: 2531-2546 (2007). *
Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J. Lipid Res. 49: 2179-2187 (2008). *
Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ, Tsao BP. ApoE-/-Fas-/-C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis and osteopenia. J. Lipid Res. 48: 794-805 (2007). *
Fenske SA, Yesilaltay A, Pal R, Daniels K, Barker C, Quinones V, Rigotti A, Krieger M, Kocher O. Normal hepatic cell-surface localization of the high-density lipoprotein receptor, SR-BI, depends on all four PDZ domains of PDZK1. J. Biol. Chem. 284: 5797-5806 (2009). *
Fenske SA, Yesilaltay A, Pal R, Daniels K, Rigotti A, Krieger M, Kocher O. Overexpression of the PDZ1 domain of PDZK1 blocks the activity of hepatic scavenger receptor, class B, type I by altering its abundance and cellular localization. J. Biol. Chem. 283: 22097-22104 (2008). *
Fernandez A, Colell A, Caballero F, Matias N, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial S-adenosyl-L-methionine transport is insensitive to alcohol-mediated changes in membrane dynamics. Alcohol Clin. Exp. Res. 33: 1169-1180 (2009).
Fernandez A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC. Cholesterol and sphingolipids in alcohol-induced liver injury. J. Gastroenterol. Hepatol. 23 Suppl. 1: S9-S15 (2008). *
Fernandez AZ. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome. Curr. Opin. Investig. Drugs 5: 936-940 (2004).
Fernandez E, Galan AI, Moran D, Gonzalez-Buitrago JM, Munoz ME, Jimenez R. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. J. Pharmacol. Exp. Ther. 275: 442-449 (1995).
Fernandez-Checa JC. Alcohol-induced liver disease: when fat and oxidative stress meet. Ann. Hepatol. 2: 69-75 (2003). *
Fernandez-Veledo S, Nieto-Vazquez I, Rondinone CM, Lorenzo M. Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49: 3038-3048 (2006). *
Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl.) 203: 73-84 (2009).
Ferroni P, Basili S, Santilli F, Davi G. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol. Haemost. Thromb. 35: 346-354 (2006).
Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, Di Biase AR, Roda E, Simoni P, Colecchia A. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr. Clin. Pharmacol. 2: 155-177 (2007).
Fickert P, Moustafa T, Fuchsbichler A, Claudel T, Halilbasic E, Kratky D, Zatloukal K, Denk H, Trauner M. Differential effects of ursodeoxycholic acid (UDCA) and sidechain-shortened norUDCA in the treatment of fatty liver and atherosclerosis. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 54 (2008). *
Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481 (2006). *
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183 (2001). *
Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78: 551-558 (2005). *
Field FJ, Born E, Mathur SN. LXR/RXR ligand activation enhances basolateral efflux of beta-sitosterol in CaCo-2 cells. J. Lipid Res. 45: 905-913 (2004). *
Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line, Caco-2. J. Lipid Res. Jan 26 [Epub ahead of print] (2010). *
Fievet C, Staels B. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem. Pharmacol. 77: 1316-1327 (2009). *
Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R, Shneider BL, Chen F, Stoltenberg E, Spatz K, Hoda F, Cohen DE, Green RM. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J. Biol. Chem. 279: 2790-2799 (2004). *
Figge A, Matern S, Lammert F. Molecular genetics of cholesterol cholelithiasis: identification of human and murine gallstone genes. Z. Gastroenterol. 40: 425-432 (2002).
Filipovic B, Opric M, Milicic A, Paranos S. Primary biliary cirrhosis. Srp. Arh. Celok. Lek. 130: 213-216 (2002).
Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. 15: 490-516 (2009).
Filus A, Trzmiel A, Kuliczkowska-Plaksej J, Tworowska U, Jedrzejuk D, Milewicz A, Medras M. Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. Aging Male 11: 134-139 (2008).
Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour B, Sabatino G, Russo G, Castellani D, Willson TM, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor (FXR) ligand, in estrogen induced cholestasis. J. Pharmacol. Exp. Ther. 313: 604-612 (2005). *
Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30: 570-580 (2009). *
Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13: 298-309 (2007). *
Fischer Aggarwal BA, Liao M, Mosca L. Physical activity as a potential mechanism through which social support may reduce cardiovascular disease risk. J. Cardiovasc. Nurs. 23: 90-96 (2008).
Fischer S, Muller I, Zundt BZ, Jungst C, Meyer G, Jungst D. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur. J. Gastroenterol. Hepatol. 16: 305-311 (2004).
Fischler B, Papadogiannakis N, Nemeth A. Clinical aspects on neonatal cholestasis based on observations at a Swedish tertiary referral centre. Acta Paediatr. 90: 171-178 (2001).
Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 80: 271-281 (2002). *
Fitzgerald ML, Okuhira KI, Short GF 3rd, Manning JJ, Bell SA, Freeman MW. ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and apoA-I binding activities. J. Biol. Chem. 279: 48477-48485 (2004). *
Flanagan K, Modrusan Z, Cornelius J, Chavali A, Kasman I, Komuves L, Mo L, Diehl L. Intestinal epithelial cell up-regulation of LY6 molecules during colitis results in enhanced chemokine secretion. J. Immunol. 180: 3874-3881 (2008). *
Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C, Mohan R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52: 904-907 (2009). *
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43: 673-680 (2000). *
Flemming JA, Perkins KH, Luus L, Ferguson AR, Corley RB. Disruption of membrane cholesterol stimulates MyD88-dependent NF-kappaB activation in immature B cells. Cell. Immunol. 229: 68-77 (2004). *
Fletcher N, Wahlstrom D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 207: 1-24 (2005). *
Floreani A. A novel approach for prevention and dissolution of cholesterol gallstones. Liver Int. 28: 906-907 (2008). *
Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Mazzella G. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. Dig. Liver Dis. 40: 366-370 (2008).
Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Mazzella G. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment. Pharmacol. Ther. 23: 1649-1653 (2006). *
Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, Musso G, Cassader M, Bo S, Ferrara F, Caroli D, Rizzotto ER, Durazzo M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol. 103: 1959-1965 (2008). *
Flowers MT, Groen AK, Oler AT, Keller MP, Choi Y, Schueler KL, Richhards OC, Lan H, Miyazaki M, Kuipers F, Kendziorski CM, Ntambi JM, Attie AD. Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diet. J. Lipid Res. 47: 2668-2680 (2006). *
Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski CM, Ntambi JM, Attie AD. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol. Genomics 33: 361-372 (2008). *
Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, Derosa G. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm. Metab. Res. 41: 893-898 (2009).
Foley KF, Silveira MG, Hornseth JM, Lindor KD, McConnell JP. A patient with primary biliary cirrhosis and elevated LDL cholesterol. Clin. Chem. 55: 187-192 (2009). *
Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J. Clin. Rheumatol. 7: 340-345 (2001).
Fon Tacer K, Kuzman D, Seliskar M, Pompon D, Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and pro-atherogenic processes. Physiol. Genomics 31: 216-227 (2007). *
Fonolla J, Lopez-Huertas E, Machado FJ, Molina D, Alvarez I, Marmol E, Navas M, Palac�n E, Garcia-Valls MJ, Remon B, Boza JJ, Marti JL. Milk enriched with "healthy fatty acids" improves cardiovascular risk markers and nutritional status in human volunteers. Nutrition 25: 408-414 (2009). *
Font J, Ramos-Casals M, Brito-Zeron P, Nardi N, Ibanez A, Suarez B, Jimenez S, Tassies D, Garcia-Criado A, Ros E, Sentis J, Reverter JC, Lozano F. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 46: 76-80 (2007). *
Fontaine C, Rigamonti E, Nohara A, Gervois P, Teissier E, Fruchart JC, Staels B, Chinetti-Gbaguidi G. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ. Res. 101: 40-49 (2007). *
Fontaine C, Rigamonti E, Pourcet B, Duez H, Duhem C, Fruchart JC, Chinetti-Gbaguidi G, Staels B. The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. Mol. Endocrinol. 22: 1797-1811 (2008). *
Fontaine-Bisson B, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and plasma high-density lipoprotein-cholesterol concentrations in a population of young adults. J. Nutrigenet. Nutrigenomics 1: 215-223 (2008).
Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, Connelly PW, Corey PN, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations. Am. J. Clin. Nutr. 86: 768-774 (2007). *
Fontaine-Bisson B, Wolever TM, Connelly PW, Corey PN, El-Sohemy A. NF-kappaB -49Ins/Del ATTG polymorphism modifies the association between dietary polyunsaturated fatty acids and HDL-cholesterol in two distinct populations. Atherosclerosis 204: 465-470 (2009).
Forchielli ML, Bersani G, Tala S, Grossi G, Puggioli C, Masi M. The spectrum of plant and animal sterols in different oil-derived intravenous emulsions. Lipids 45: 63-71 (2010).
Ford DA, Monda JK, Brush RS, Anderson RE, Richards MJ, Fliesler SJ. Lipidomic analysis of the retina in a rat model of Smith-Lemli-Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species. J. Neurochem. 105: 1032-1047 (2008).
Forman D, Bulwer BE. Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle. Curr. Treat. Options Cardiovasc. Med. 8: 47-57 (2006).
Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am. J. Cardiol. 98: 1542-1549 (2006). *
Foschini MP, Macchia S, Losi L, Dei Tos AP, Pasquinelli G, Di Tommaso L, Del Duca S, Roncaroli F, Dal Monte PR. Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis. Virchows. Arch. 433: 267-273 (1998). *
Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, Oude Elferink RP, Housset C. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37: 184-191 (2002). *
Fourgeux C, Martine L, Bjorkhem I, Diczfalusy U, Joffre C, Acar N, Creuzot-Garcher C, Bron A, Bretillon L. Primary open angle glaucoma: association with cholesterol 24S-hydroxylase (CYP46A1) gene polymorphism and plasma 24-hydroxycholesterol levels. Invest. Ophthalmol. Vis. Sci. 50: 5712-5717 (2009). *
Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, Rhein L, Collins JL, Willson TM, Mangelsdorf DJ, Elias PM, Feingold KR. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 120: 246-255 (2003). *
Fracchia M, Jazrawi RP, Galatola G. Determination of gallbladder bile lithogenicity in patients with primary biliary cirrhosis. Ital. J. Gastroenterol. 28: 255-260 (1996).
Fracchia M, Pellegrino S, Secreto P, Pera A, Galatola G. Biliary lipid composition in idiopathic bile acid malabsorption. Gut 43: 812-816 (1998). *
Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195: 385-391 (2007).
Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti Y, Gervy MC, Deviere J, Van Gossum A. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J. Clin. Endocrinol. Metab. 90: 3510-3516 (2005). *
Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311 (2003). *
Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7: 3 (2006). *
Francke S, Manraj M, Lacquemant C, Lecoeur C, Lepretre F, Passa P, Hebe A, Corset L, Yan SL, Lahmidi S, Jankee S, Gunness TK, Ramjuttun US, Balgobin V, Dina C, Froguel P. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum. Mol. Genet. 10: 2751-2765 (2001). *
Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).
Fraunberger P, Grone E, Grone HJ, Walli AK. Simvastatin reduces endotoxin-induced NF-kappaB activation and mortality in guinea pigs despite lowering circulating LDL cholesterol. Shock 32: 159-163 (2009).
Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC. Pathophysiologic basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G1411-G1420 (2008). *
Freudenberg F, Carey MC. Hepatobiliary manifestations in inflammatory bowel disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 56-57 (2005). *
Frey T, De Maio A. Increased expression of CD14 in macrophages after inhibition of the cholesterol biosynthetic pathway by lovastatin. Mol. Med. 13: 592-604 (2007). *
Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig. Dis. Sci. 38: 1291-1296 (1993).
Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114: 1343-1353 (2004). *
Fromm H, Roat JW, Gonzalez V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Gastroenterology 85: 1257-1264 (1983).
Froy O. The relationship between nutrition and circadian rhythms in mammals. Front. Neuroendocrinol. 28: 61-71 (2007).
Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc.) 42: 39-64 (2006).
Fruchart JC, Duriez P, Staels B. Molecular mechanism of action of the fibrates. J. Soc. Biol. 193: 67-75 (1999).
Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245-257 (1999).
Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol. Res. 44: 345-352 (2001). *
Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48: 1147-1153 (2005). *
Fu JF, Fang YL, Liang L, Wang CL, Hong F, Dong GP. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J. Gastroenterol. 15: 912-918 (2009). *
Fu T, Kashireddy P, Borensztajn J. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373: 941-947 (2003). *
Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378-38387 (2001). *
Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G551-G557 (2003). *
Fuchs M, Stange EF. Cholesterol and cholestasis: a lesson from the Mdr2 (-/-) mouse. J. Hepatol. 34: 339-341 (2001). *
Fuda H, Javitt NB, Mitamura K, Ikegawa S, Strott CA. Oxysterols are substrates for cholesterol sulfotransferase. J. Lipid Res. 48: 1343-1352 (2007). *
Fuda H, Lee YC, Shimizu C, Javitt NB, Strott CA. Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J. Biol. Chem. 277: 36161-36166 (2002). *
Fujii T, Takada-Takatori Y, Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J. Pharmacol. Sci. 106: 186-192 (2008). *
Fujino T, Une M, Imanaka T, Inoue K, Nishimaki-Mogami T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. J. Lipid Res. 45: 132-138 (2004). *
Fujisawa S, Chiba H, Akizawa K, Intoh S, Watanabe M, Matsuno K, Kobayashi K. Rapid alteration in serum lipoprotein profile after bile drainage in a patient with acute bile duct obstruction: contribution of cholestasis to cholesteryl ester-dominant ApoE-rich HDL accumulation. Rinsho Byori 41: 679-684 (1993).
Fujiwara Y, Yokoyama M, Sawada R, Seyama Y, Ishii M, Tsutsumi S, Aburatani H, Hanaka S, Itakura H, Matsumoto A. Analysis of the comprehensive effects of polyunsaturated fatty acid on mRNA expression using a gene chip. J. Nutr. Sci. Vitaminol. (Tokyo) 49: 125-132 (2003).
Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T. 24S-Hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J. Neurochem. 100: 968-978 (2007). *
Fukuchi J, Song C, Dai Q, Hiipakka RA, Liao S. 5beta-Cholane activators of the farnesol X receptor. J. Steroid Biochem. Mol. Biol. 94: 311-318 (2005).
Fukuda W, Yamazaki T, Akaogi T, Hayashi H, Kusakabe T, Tsubouchi Y, Kawahito Y, Inoue M, Yoshikawa T. Malnutrition and disease progression in patients with rheumatoid arthritis. Mod. Rheumatol. 15: 104-107 (2005).
Fukuo Y, Kitami T, Nomoto T, Terashi A. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Nippon Ika Daigaku Zasshi 63: 424-430 (1996).
Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 50: 8-17 (2007). *
Furuya T, Urano T, Ikari K, Kotake S, Inoue S, Hara M, Momohara S, Kamatani N, Yamanaka H. A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis. Mod. Rheumatol. 19: 140-146 (2009). *
Furuyama S, Uehara Y, Zhang B, Baba Y, Abe S, Iwamoto T, Miura SI, Saku K. Genotypic effect of ABCG1 gene promoter -257T>G polymorphism on coronary artery disease severity in Japanese men. J. Atheroscler. Thromb. 16: 194-200 (2009). *
Gabbi C, Kim HJ, Hultenby K, Bouton D, Toresson G, Warner M, Gustafsson JA. Pancreatic exocrine insufficiency in LXRbeta(-/-) mice is associated with a reduction in aquaporin-1 expression. Proc. Natl. Acad. Sci. U.S.A. 105: 15052-15057 (2008). *
Gaby AR. Nutritional approaches to prevention and treatment of gallstones. Altern. Med. Rev. 14: 258-267 (2009). *
Gaede PH. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications. Dan. Med. Bull. 53: 258-284 (2006).
Gaiva MH, Couto RC, Oyama LM, Couto GE, Silveira VL, Ribeiro EB, Nascimento CM. Diets rich in polyunsaturated fatty acids: effect on hepatic metabolism in rats. Nutrition 19: 144-149 (2003). *
Galan AI, Munoz ME, Jimenez R. S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. J. Pharmacol. Exp. Ther. 290: 774-781 (1999). *
Gallicchio L, Kalesan B, Huang HY, Strickland P, Hoffman SC, Helzlsouer KJ. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in Washington county, Maryland. PPAR Res. 2008: 276581 (2008). *
Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129: 1445-1453 (2005). *
Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267 (2003). *
Gamerdinger M, Clement AB, Behl C. Cholesterol-like effects of selective COX inhibitors and fibrates on cellular membranes and amyloid-beta production. Mol. Pharmacol. 72: 141-151 (2007). *
Gandelman G, Aronow WS, Weiss MB. Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. Am. J. Ther. 13: 171-174 (2006).
Gao H, Zhang Z, Zhang J, Zhao N, Li Q, Bai M. Association of LT-alpha Ala252Gly gene polymorphism and the genetic predisposition of coronary heart disease in Chinese. Mol. Biol. Rep. 37: 47-50 (2010). *
Gao J, Xu Y, Yang Y, Yang Y, Zheng Z, Jiang W, Hong B, Yan X, Si S. Identification of upregulators of human ATP-binding cassette transporter A1 via high-throughput screening of a synthetic and natural compound library. J. Biomol. Screen. 13: 648-656 (2008).
Garaulet M, Corbalan MD, Madrid JA, Morales E, Baraza JC, Lee YC, Ordovas JM. CLOCK gene is implicated in weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. Int. J. Obes. (Lond.) Jan 12 [Epub ahead of print] (2010). *
Garcia AN, Muniz MT, Souza E Silva HR, da Silva HA, Athayde-Junior L. Cyp46 polymorphisms in Alzheimer's disease: a review. J. Mol. Neurosci. 39: 342-345 (2009).
Garcia MA, Margarita R, Mirta C, Hugo C, Pablo L, Estela A, de Davila MT. Alagille syndrome: cutaneous manifestations in 38 children. Pediatr. Dermatol. 22: 11-14 (2005).
Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J. The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315 (1991).
Garcia-Garcia AB, Gonzalez C, Real JT, Martin de Llano JJ, Gonzalez-Albert V, Civera M, Chaves FJ, Ascaso JF, Carmena R. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet. Genomics 15: 211-218 (2005).
Garcia-Hejl C, Vest P, Renard C, Merens-Gonthier A, Boukhira A, Thefenne-Astier H. Falsely low LDL cholesterol results and cholestasis. Clin. Chem. 52: 2125-2127 (2006). *
Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hepatocellular survival-death switch. J. Gastroenterol. Hepatol. 21 Suppl. 3: S3-S6 (2006). *
Garduno-Siciliano L, Labarrios F, Tamariz J, Moreno MG, Chamorro G, Muriel P. Effect of alpha-asarone and a derivative on lipids, bile flow and Na(+)/K(+)-ATPase in ethinyl estradiol-induced cholestasis in the rat. Fundam. Clin. Pharmacol. 21: 81-88 (2007).
Garg A, Simha V. Update on dyslipidemia. J. Clin. Endocrinol. Metab. 92: 1581-1589 (2007). *
Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, Cardona F, Soriguer F, Tinahones FJ. Inverse relation between levels of anti-oxidized-LDL antibodies and eicosapentanoic acid (EPA). Br. J. Nutr. 100: 585-589 (2008). *
Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B; The RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49: 1537-1544 (2009).
Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, Ruskeepaa AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 23: 1313-1326 (2009). *
Gautier EL, Huby T, Ouzilleau B, Doucet C, Saint-Charles F, Gremy G, Chapman MJ, Lesnik P. Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler. Thromb. Vasc. Biol. 27: 1625-1631 (2007). *
Gautier T, Tietge UJ, Boverhof R, Perton FG, Le Guern N, Masson D, Rensen PC, Havekes LM, Lagrost L, Kuipers F. Hepatic lipid accumulation in apolipoprotein CI-deficient mice is potentiated by cholesteryl ester transfer protein. J. Lipid Res. 48: 30-40 (2007). *
Gbaguidi GF, Agellon LB. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver X receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer. Nucleic Acids Res. 32: 1113-1121 (2004). *
Gbaguidi GF, Agellon LB. The atypical interaction of peroxisome proliferator-activated receptor alpha with liver X receptor alpha antagonizes the stimulatory effect of their respective ligands on the murine cholesterol 7alpha-hydroxylase gene promoter. Biochim. Biophys. Acta 1583: 229-236 (2002). *
Gehrig-Burger K, Kohout L, Gimpl G. CHAPSTEROL. A novel cholesterol-based detergent. FEBS J. 272: 800-812 (2005). *
Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc.) 42: 355-367 (2006).
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug � Arthritis Rheum. 58: 2968-2980 (2008). *
Gentili C, Tutolo G, Pianezzi A, Cancedda R, Descalzi Cancedda F. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression. Matrix Biol. 24: 35-44 (2005).
Gentzsch M, Choudhury A, Chang XB, Pagano RE, Riordan JR. Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell. Sci. 120: 447-455 (2007). *
Genvigir FD, Hirata MH, Hirata RD. ABCA1 expression and statins: inhibitory effect in peripheral blood mononuclear cells. Pharmacogenomics 10: 997-1005 (2009).
George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5: 49-59 (2008). *
Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis. 16: 39-46 (2007). *
Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15: 942-954 (2009). *
Geppert J, Kraft V, Demmelmair H, Koletzko B. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br. J. Nutr. 95: 779-786 (2006). *
Geraghty JM, Goldin RD. Liver changes associated with cholecystitis. J. Clin. Pathol. 47: 457-460 (1994). *
Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA; for the AIDS Clinical Trial Group A5186 Team. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J. Acquir. Immune Defic. Syndr. 47: 459-466 (2008). *
Gerbod-Giannone MC, Del Castillo-Olivares A, Janciauskiene S, Gil G, Hylemon PB. Suppression of cholesterol 7alpha-hydroxylase transcription and bile acid synthesis by an alpha1-antitrypsin peptide via interaction with alpha1-fetoprotein transcription factor. J. Biol. Chem. 277: 42973-42980 (2002). *
Gerbod-Giannone MC, Li Y, Holleboom A, Han S, Hsu LC, Tabas I, Tall AR. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl. Acad. Sci. U.S.A. 103: 3112-3117 (2006). *
Germann UA, Chambers TC. Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology 27: 31-60 (1998). *
Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med. 38: 3-11 (2000).
Geuken E, Visser DS, Leuvenink HG, de Jong KP, Peeters PM, Slooff MJ, Kuipers F, Porte RJ. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. Hepatology 42: 1166-1174 (2005). *
Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn. Schmiedebergs. Arch. Pharmacol. 372: 413-431 (2006). *
Geyeregger R, Shehata M, Zeyda M, Kiefer FW, Stuhlmeier KM, Porpaczy E, Zlabinger GJ, Jager U, Stulnig TM. Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes. J. Leukoc. Biol. 86: 1039-1048 (2009). *
Geyeregger R, Zeyda M, Bauer W, Kriehuber E, Saemann MD, Zlabinger GJ, Maurer D, Stulnig TM. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin bundling protein fascin. Blood 109: 4288-4295 (2007). *
Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell. Mol. Life Sci. 63: 524-539 (2006). *
Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept. 2: 4 (2004). *
Ghosh A. Obesity measures, metabolic profiles and dietary fatty acids in lean and obese postmenopausal diabetic Asian Indian women. Anthropol. Anz. 67: 83-93 (2009).
Gigliozzi A, Romeo R, Fraioli F, Cantafora A, Delle Monache M, Cardilli A, Attili AF, Scafato E, Carli L, Alvaro D. Effect of S-adenosyl-L-methionine and dilinoleoylphosphatidylcholine on liver lipid composition and ethanol hepatotoxicity in isolated perfused rat liver. Dig. Dis. Sci. 43: 2211-2222 (1998). *
Gilardi F, Viviani B, Galmozzi A, Boraso M, Bartesaghi S, Torri A, Caruso D, Crestani M, Marinovich M, De Fabiani E. Expression of sterol 27-hydroxylase in glial cells and its regulation by liver X receptor signaling. Neuroscience 164: 530-540 (2009).
Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80: 516-526 (2004). *
Gill S, Chow R, Brown AJ. Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog. Lipid Res. 47: 391-404 (2008). *
Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48: 79-106 (2008). *
Ginanni Corradini S, Arancia G, Calcabrini A, Della Guardia P, Baiocchi L, Nistri A, Giacomelli L, Angelico M. Lamellar bodies coexist with vesicles and micelles in human gallbladder bile. Ursodeoxycholic acid prevents cholesterol crystal nucleation by increasing biliary lamellae. J. Hepatol. 22 :642-657 (1995). *
Gindro T, Arrigoni A, Martinasso G, Rosina F, Perardi S, Cappello N, Benedetti P, Actis GC, Verme G, Rizzetto M. Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur. J. Gastroenterol. Hepatol. 9: 1155-1159 (1997).
Giorelli M, Livrea P, Minervini MG, Trojano M. Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients. Exp. Neurol. 204: 759-766 (2007).
Giorgi PL. Probiotics. A review. Recenti Prog. Med. 100: 40-47 (2009).
Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168: 1174-1180 (2008). *
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br. J. Dermatol. 157: 68-73 (2007). *
Glickerman DJ, Kim MH, Malik R, Lee SP. The gallbladder also secretes. Dig. Dis. Sci. 42: 489-491 (1997). *
Glueck CJ, Freiberg RA, Boppana S, Wang P. Thrombophilia, hypofibrinolysis, the eNOS T-786C polymorphism, and multifocal osteonecrosis. J. Bone Joint Surg. Am. 90: 2220-2229 (2008).
Glueck CJ, Pranikoff J, Aregawi D, Haque M, Zhu B, Tracy T, Wang P. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism 54: 1345-1349 (2005).
Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360: 1851-1861 (2009). *
Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, Looser R, Parini P, Podvinec M, Robertsson K, Gustafsson JA, Meyer UA. LXR deficiency and cholesterol feeding affect expression and phenobarbital mediated induction of cytochromes P450 in mouse liver. J. Lipid Res. 46: 1633-1642 (2005). *
Gnoni GV, Priore P, Geelen MJ, Siculella L. The mitochondrial citrate carrier: metabolic role and regulation of its activity and expression. IUBMB Life 61: 987-994 (2009).
Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 52: 725-753 (1996).
Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur. J. Hum. Genet. 11 Suppl. 2: S49-S87 (2003). *
Godsland IF, Agbaje OF, Hovorka R. Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. Am. J. Physiol. Endocrinol. Metab. 291: E167-E174 (2006). *
Godsland IF, Johnston DG. Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology. Metabolism 57: 1190-1197 (2008). *
Goke B, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab. Vasc. Dis. Res. 4: 204-213 (2007).
Goldberg RB, Sabharwal AK. Fish oil in the treatment of dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes. 15: 167-174 (2008).
Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc. Health Risk Manag. 4: 131-141 (2008).
Goldiner I, van der Velde AE, Vandenberghe KE, van Wijland MA, Halpern Z, Gilat T, Konikoff FM, Veldman RJ, Groen AK. ABCA1-dependent but ApoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs). Biochem. J. 396: 529-536 (2006). *
Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr. Med. Res. Opin. 22: 2575-2590 (2006).
Gomez M, Sanz-Gonzalez SM, Nabah YN, Lamana A, Sanchez-Madrid F, Andres V. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. Cardiovasc. Res. 81: 197-205 (2009).
Goncalves M, D'Almeida V, Guerra-Shinohara EM, Galdieri LC, Len CA, Hilario MO. Homocysteine and lipid profile in children with juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 5: 2 (2007). *
Gong H, He J, Lee JH, Mallick E, Gao X, Li S, Homanics GE, Xie W. Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. J. Biol. Chem. 284: 30113-30121 (2009). *
Gong Z, Yan S, Zhang P, Huang Y, Wang L. Effects of S-adenosylmethionine on liver methionine metabolism and steatosis with ethanol-induced liver injury in rats. Hepatol. Int. 2: 346-352 (2008). *
Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front. Biosci. 14: 4242-4256 (2009).
Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie 79: 139-144 (1997).
Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246: 2-8 (2008). *
Gonzalez MA, Roma MG, Bernal CA, Alvarez Mde L, Carrillo MC. Biliary secretory function in rats chronically intoxicated with aluminum. Toxicol. Sci. 79: 189-195 (2004). *
Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, Martin J, Redelinghuys M, Woodiwiss AJ, Norton GR, Dessein PH. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 596-603 (2008).
Goodwin B, Kliewer SA. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G926-G931 (2002). *
Goodwin B, Watson MA, Kim H, Miao J, Kemper JK, Kliewer SA. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol. Endocrinol. 17: 386-394 (2003). *
Goodwin BJ, Zuercher WJ, Collins JL. Recent advances in liver X receptor biology and chemistry. Curr. Top. Med. Chem. 8: 781-791 (2008).
Gopal DV, Pfau PR, Lucey MR. Endoscopic management of biliary complications after orthotopic liver transplantation. Curr. Treat. Options Gastroenterol. 6: 509-515 (2003).
Gordon RD, Shaw BW Jr, Iwatsuki S, Esquivel CO, Starzl TE. Indications for liver transplantation in the cyclosporine era. Surg. Clin. North Am. 66: 541-556 (1986).
Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin. Cardiol. 26: III3-III12 (2003).
Goumas GS. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? Angiology 60: 93-98 (2009).
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183: 336-341 (2005).
Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population. J. Intern. Med. 257: 272-280 (2005). *
Gouni-Berthold I, Krone W. Favorable effects of decreasing lipids in patients with diabetes mellitus. Dtsch. Med. Wochenschr. 131 Suppl. 8: S252-S254 (2006).
Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. 278: 48275-48282 (2003). *
Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum. 58: 2098-2104 (2008). *
Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354: 2552-2563 (2006). *
Grasfeder LL, Gaillard S, Hammes SR, Ilkayeva O, Newgard CB, Hochberg RB, Dwyer MA, Chang CY, McDonnell DP. Fasting-induced hepatic production of DHEA is regulated by PGC-1alpha, ERRalpha, and HNF4alpha. Mol. Endocrinol. 23: 1171-1182 (2009). *
Grattagliano I, Giudetti AM, Grattagliano V, Palmieri VO, Gnoni GV, Lapadula G, Palasciano G, Vendemiale G. Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. Eur. J. Clin. Invest. 33: 868-874 (2003). *
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412 (2003). *
Green P, Anyakoha N, Yadid G, Gispan-Herman I, Nicolaou A. Arachidonic acid-containing phosphatidylcholine species are increased in selected brain regions of a depressive animal model: implications for pathophysiology. Prostaglandins Leukot. Essent. Fatty Acids 80: 213-220 (2009). *
Greenbaum L. Hippatitis rex. Lancet 362: 2032 (2003). *
Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6: 358-370 (2006). *
Grefhorst A, Parks EJ. Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation on the liver X receptor in mice. J. Lipid Res. 50: 1374-1383 (2009). *
Gregory WL, Game FL, Farrer M, Idle JR, Laker MF, James OF. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 105: 43-50 (1994).
Gressier L, Pruvost-Balland C, Dubertret L, Viguier M. Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann. Dermatol. Venereol. 136: 50-53 (2009).
Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G. Acute hepatitis caused by a natural lipid-lowering product: when �alternative� medicine is no �alternative� at all? J. Hepatol. 50: 1273-1277 (2009).
Griel AE, Cao Y, Bagshaw DD, Cifelli AM, Holub B, Kris-Etherton PM. A macadamia nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women. J. Nutr. 138: 761-767 (2008). *
Grimes DS. Are statins analogues of vitamin D? Lancet 368: 83-86 (2006). *
Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U et al. The DNA sequence and biology of human chromosome 19. Nature 428: 529-535 (2004). *
Groen A, Kunne C, Jongsma G, van den Oever K, Mok KS, Petruzzelli M, Vrins CL, Bull L, Paulusma CC, Oude Elferink RP. Abcg5/8 independent biliary cholesterol excretion in Atp8b1-deficient mice. Gastroenterology 134: 2091-2100 (2008). *
Groen AK. The emerging role of bile acids as integrators of intermediary metabolism. J. Hepatol. 45: 337-338 (2006). *
Groen AK, Kosters A, Kunne C, Oude Elferink RPJ. The molecular mechanism of biliary lipid secretion - influence of bile salt hydrophilicity and role of Abcg5 and Abcg8. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 50. June 18-19 (2004). *
Groen AK, Oude Elferink RP. Lipid transport into bile and role in bile formation. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 131-135 (2005).
Groen AK, Oude Elferink RP, Verkade HJ, Kuipers F. The ins and outs of reverse cholesterol transport. Ann. Med. 36: 135-145 (2004).
Grossfield A, Feller SE, Pitman MC. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc. Natl. Acad. Sci. U.S.A. 103: 4888-4893 (2006). *
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24: e149-e161 (2004). *
Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA. Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia. Dtsch. Med. Wochenschr. 122: 1516-1520 (1997).
Grunhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, Mosteanu O, Sauerbruch T, Lammert F. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 46: 793-801 (2007). *
Grunhage F, Lammert F. Pathogenesis of gallstones: a genetic perspective. Best Pract. Res. Clin. Gastroenterol. 20: 997-1015 (2006).
Guan JZ, Tamasawa N, Brunham LR, Matsui J, Murakami H, Suda T, Ochiai S, Tsutsui M, Kudou K, Satoh K, Hayden MR. A case of Tangier disease with a novel mutation in the C-terminal region of ATP-binding cassette transporter A1. Am. J. Med. Genet. 130A: 398-401 (2004). *
Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, Yamashita M, Suda T. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. J. Atheroscler. Thromb. 15: 20-25 (2008). *
Guan M, Zhang J, Chen Y, Liu W, Kong N, Zou H. High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China. Scand. J. Rheumatol. Mar 20 [Epub ahead of print] (2009). *
Guaraldi G, Ventura P, Garlassi E, Orlando G, Squillace N, Nardini G, Stentarelli C, Zona S, Marchini S, Moriondo V, Tebas P. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease. HIV Med. 10: 28-34 (2009).
Guarino MP, Carotti S, Morini S, Perrone G, Behar J, Altomare A, Alloni R, Caviglia R, Emerenziani S, Rabitti C, Cicala M. Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut 57: 1740-1741 (2008).
Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 56: 815-820 (2007). *
Guebre-Egziabher F, Rabasa-Lhoret R, Bonnet F, Bastard JP, Desage M, Skilton MR, Vidal H, Laville M. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects. Eur. J. Clin. Nutr. 62: 1287-1293 (2008). *
Gueguen Y, Souidi M, Baudelin C, Dudoignon N, Grison S, Dublineau I, Marquette C, Voisin P, Gourmelon P, Aigueperse J. Short-term hepatic effects of depleted uranium on xenobiotic and bile acid metabolizing cytochrome P450 enzymes in the rat. Arch. Toxicol. 80: 187-195 (2006). *
Guerreiro CS, Cravo ML, Brito M, Vidal PM, Fidalgo PO, Leitao CN. The D1822V APC polymorphism interacts with fat, calcium, and fiber intakes in modulating the risk of colorectal cancer in Portuguese persons. Am. J. Clin. Nutr. 85: 1592-1597 (2007). *
Guirado S, Conejo-Mir J, Munoz M, Wite J, Fernandez-Freire L, Ortiz J. Sitosterol xanthomatosis. J. Eur. Acad. Dermatol. Venereol. 21: 100-103 (2007). *
Guisasola MC, Dul�n E, Almendral J, Garcia-Barreno P. Reduction of heat shock protein antibody levels by statin therapy. Lipids 44: 317-324 (2009).
Guldutuna S, Deisinger B, Weiss A, Freisleben HJ, Zimmer G, Sipos P, Leuschner U. Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim. Biophys. Acta 1326: 265-274 (1997). *
Guldutuna S, Zimmer G, Leuschner M, Bhatti S, Elze A, Deisinger B, Hofmann M, Leuschner U. The effect of bile salts and calcium on isolated rat liver mitochondria. Biochim. Biophys. Acta 1453: 396-406 (1999). *
Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am. J. Gastroenterol. 103: 3005-3010 (2008). *
Gunn IR, Maxwell FK, Gaffney D, McMahon AD, Packard CJ. Haemochromatosis gene mutations and risk of coronary heart disease: a west of Scotland coronary prevention study (WOSCOPS) substudy. Heart 90: 304-306 (2004). *
Gunnarsdottir I, Tomasson H, Kiely M, Martinez JA, Bandarra NM, Morais MG, Thorsdottir I. Inclusion of fish or fish oil in weight-loss diets for young adults: effects on blood lipids. Int. J. Obes. (Lond.) 32: 1105-1112 (2008). *
Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 49: 497-500 (2002).
Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071 (2003). *
Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761: 1401-1409 (2006). *
Guo L, Fang H, Collins J, Fan XH, Dial S, Wong A, Mehta K, Blann E, Shi L, Tong W, Dragan YP. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics 7: S18 (2006). *
Guo L, Hu WR, Lian JH, Ji W, Deng T, Qian M, Gong BQ. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. Eur. J. Pharmacol. 551: 80-86 (2006). *
Gupta DS, Kaul D, Kanwar AJ, Parsad D. Psoriasis: crucial role of LXR-alpha RNomics. Genes Immun. Oct 1 [Epub ahead of print] (2009). *
Gupta R, Dixon KM, Deo SS, Holliday CJ, Slater M, Halliday GM, Reeve VE, Mason RS. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J. Invest. Dermatol. 127: 707-715 (2007). *
Gupta S, Pandak WM, Hylemon PB. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 293: 338-343 (2002). *
Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J. Biol. Chem. 276: 15816-15822 (2001). *
Gupta S, Todd Stravitz R, Pandak WM, Muller M, Reno Vlahcevic Z, Hylemon PB. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 32: 341-347 (2000). *
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 19: 854-858 (2004). *
Gurantz D, Hofmann AF. Influence of bile acid structure on bile flow and biliary lipid secretion in the hamster. Am. J. Physiol. 247: G736-G748 (1984).
Guruvayoorappan C, Sudha G. Phytopharmacological evaluation of Byesukar for hypoglycaemic activity and its effect on lipid profile and hepatic enzymes of glucose metabolism in diabetic rats. Ann. Hepatol. 7: 358-363 (2008).
Gustafsson JA. Steroids and the scientist. Mol. Endocrinol. 19: 1412-1417 (2005). *
Gustafsson U, Benthin L, Granstrom L, Groen AK, Sahlin S, Einarsson C. Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery. Hepatology 41: 1322-1328 (2005). *
Gutierrez A, Ratliff EP, Andres AM, Huang X, McKeehan WL, Davis RA. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. Arterioscler. Thromb. Vasc. Biol. 26: 301-306 (2006).
Gutierrez Macia MM, Mateo Garc�a MG, Vidal Marsal F, Domingo Pedrol P. Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis. Enferm. Infecc. Microbiol. Clin. 26 Suppl. 6: 18-23 (2008).
Gylling H, Farkkila M, Vuoristo M, Miettinen TA. Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. Hepatology 21: 89-95 (1995).
Gylling H, Hallikainen M, Nissinen MJ, Miettinen TA. The effect of a very high daily plant stanol ester intake on serum lipids, carotenoids, and fat-soluble vitamins. Clin. Nutr. Aug 25 [Epub ahead of print] (2009).
Gylling H, Hallikainen M, Pihlajamaki J, Agren J, Laakso M, Rajaratnam RA, Rauramaa R, Miettinen TA. Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J. Lipid Res. 45: 1660-1665 (2004). *
Gylling H, Vuoristo M, Farkkila M, Miettinen TA. The metabolism of cholestanol in primary biliary cirrhosis. J. Hepatol. 24: 444-451 (1996). *
Haberbosch W. Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective? Herz. 32: 51-57 (2007).
Haberbosch W, Unkelbach K, Schuster D, Gardemann A, Tillmanns H, Holschermann H. CD14 promoter polymorphism (- 159C-->t) is not associated with myocardial infarction or coronary artery disease in patients with assumed high genetic risk. Thorac. Cardiovasc. Surg. 57: 386-390 (2009).
Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am. J. Gastroenterol. 104: 1241-1248 (2009). *
Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 66: 1949-1969 (2006).
Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, Lambert D, Visvikis S. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum. Genet. 13: 109-117 (2005). *
Hager EJ, Tse HM, Piganelli JD, Gupta M, Baetscher M, Tse TE, Pappu AS, Steiner RD, Hoffmann GF, Gibson KM. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J. Inherit. Metab. Dis. 30: 888-895 (2007). *
Haikal Z, Play B, Landrier JF, Giraud A, Ghiringhelli O, Lairon D, Jourdheuil-Rahmani D. NPC1L1 and SR-BI are involved in intestinal cholesterol absorption from small-size lipid donors. Lipids 43: 401-408 (2008).
Halder I, Muldoon MF, Ferrell RE, Manuck SB. Serotonin receptor 2A (HTR2A) gene polymorphisms are associated with blood pressure, central adiposity, and the metabolic syndrome. Metab. Syndr. Relat. Disord. 5: 323-330 (2007).
Hall EA, Ren S, Hylemon PB, Redford K, del Castillo A, Gil G, Pandak WM. Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia. Lipids 40: 1237-1244 (2005).
Hall EA, Ren S, Hylemon PB, Rodriguez-Agudo D, Redford K, Marques D, Kang D, Gil G, Pandak WM. Detection of the steroidogenic acute regulatory protein, StAR, in human liver cells. Biochim. Biophys. Acta 1733: 111-119 (2005). *
Hall MG, Quignodon L, Desvergne B. Peroxisome proliferator-activated receptor beta/delta in the brain: facts and hypothesis. PPAR Res. 2008: 780452 (2008). *
Halpern Z, Moshkowitz M, Laufer H, Peled Y, Gilat T. Effect of phospholipids and their molecular species on cholesterol solubility and nucleation in human and model biles. Gut 34: 110-115 (1993). *
Hamada T, Egashira N, Nishizono S, Tomoyori H, Nakagiri H, Imaizumi K, Ikeda I. Lymphatic absorption and deposition of various plant sterols in stroke-prone spontaneously hypertensive rats, a strain having a mutation in ATP binding cassette transporter G5. Lipids 42: 241-248 (2007).
Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. Metabolism 56: 1345-1349 (2007). *
Hamai H, Keyserman F, Quittell LM, Worgall TS. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J. Lipid Res. 50: 1101-1108 (2009). *
Hamelet J, Demuth K, Paul JL, Delabar JM, Janel N. Hyperhomocysteinemia due to cystathionine beta synthase deficiency induces dysregulation of genes involved in hepatic lipid homeostasis in mice. J. Hepatol. 46: 151-159 (2007). *
Hamelet J, Seltzer V, Petit E, Noll C, Andreau K, Delabar JM, Janel N. Cystathionine beta synthase deficiency induces catalase-mediated hydrogen peroxide detoxification in mice liver. Biochim. Biophys. Acta 1782: 482-488 (2008). *
Hamlat N, Forcheron F, Neggazi S, Del Carmine P, Feugier P, Bricca G, Aouichat-Bouguerra S, Beylot M. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance. Cardiovasc. Diabetol. 8: 64 (2009). *
Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 33: 213-219 (2007). *
Han J, Zhou X, He W, Huang Z, Gotto AM Jr, Hajjar DP. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression: a new SREBP1 dependent mechanism. J. Biol. Chem. 283: 2129-2138 (2008). *
Han KC, Kim JH, Kim KH, Kim EE, Seo JH, Yang EG. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay. Anal. Biochem. Nov 11 [Epub ahead of print] (2009). *
Han S, Chiang JY. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos. 37: 469-478 (2009). *
Han SH, Lee OY, Eun CS, Roh BJ, Sohn W, Baeg SS, Yoon BC, Choi HS. A case of protein-losing enteropathy associated with small bowel villous atrophy. Korean J. Gastroenterol. 49: 31-36 (2007).
Han X, Kitamoto S, Lian Q, Boisvert WA. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J. Biol. Chem. 284: 32950-32958 (2009). *
Hanada K. Sphingolipids in infectious diseases. Jpn. J. Infect. Dis. 58: 131-148 (2005).
Hand NJ, Master ZR, Le Lay J, Friedman JR. Hepatic function is preserved in the absence of mature microRNAs. Hepatology 49: 618-626 (2009). *
Handelsman B, Bonorris G, Marks JW, Schoenfield LJ. Enrichment of bile with tauroursodeoxycholic acid and biliary cholesterol saturation in hamsters. Am. J. Physiol. 243: G424-G427 (1982).
Handschin C, Gnerre C, Fraser DJ, Martinez-Jimenez C, Jover R, Meyer UA. Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch. Biochem. Biophys. 434: 75-85 (2005). *
Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433: 387-396 (2005). *
Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55: 649-673 (2003). *
Handschin C, Podvinec M, Amherd R, Looser R, Ourlin JC, Meyer UA. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J. Biol. Chem. 277: 29561-29567 (2002). *
Handschin C, Podvinec M, Looser R, Amherd R, Meyer UA. Multiple enhancer units mediate drug induction of CYP2H1 by xenobiotic-sensing orphan nuclear receptor chicken xenobiotic receptor. Mol. Pharmacol. 60: 681-689 (2001). *
Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, Williams ML, Feingold KR. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J. Clin. Invest. 100: 705-712 (1997). *
Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X-receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46: 2595-2604 (2005). *
Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drugs 9: 247-255 (2008).
Hanson RF, Szczepanik-VanLeeuwen P, Williams GC, Grabowski G, Sharp HL. Defects of bile acid synthesis in Zellweger's syndrome. Science 203: 1107-1108 (1979). *
Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2: 423-430 (2005).
Harada LM, Amigo L, Cazita PM, Salerno AG, Rigotti AA, Quintao EC, Oliveira HC. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 191: 313-318 (2007).
Harada LM, Carrilho AJ, Oliveira HC, Nakandakare ER, Quintao EC. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol. Clin. Exp. Pharmacol. Physiol. 33: 1209-1215 (2006). *
Hardison WG, Grundy SM. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology 87: 130-135 (1984).
Hardison WG, Grundy SM. Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology 84: 617-620 (1983).
Harris WS. Does treatment with eicosapentaenoic acid prevent major coronary events in patients with hypercholesterolemia? Nat. Clin. Pract. Cardiovasc. Med. 4: 532-533 (2007).
Harroun TA, Katsaras J, Wassall SR. Cholesterol is found to reside in the center of a polyunsaturated lipid membrane. Biochemistry 47: 7090-7096 (2008). *
Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res. 4: 84-88 (2007).
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage - a three-year study of patients from one gastroenterological department. Med. Sci. Monit. 8: CR292-CR296 (2002). *
Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid Res. 50: 1090-1100 (2009). *
Hartman HB, Lai K, Evans MJ. Loss of small heterodimer partner expression in the liver protects against dyslipidemia. J. Lipid Res. 50: 193-203 (2009). *
Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr. Opin. Lipidol. 20: 30-38 (2009).
Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50: 1593-1602 (2007). *
Hartweg J, Perera R, Montori V, Dinneen S, Neil H, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 1: CD003205 (2008). *
Hascalovici JR, Song W, Vaya J, Khatib S, Fuhrman B, Aviram M, Schipper HM. Impact of heme oxygenase-1 on cholesterol synthesis, cholesterol efflux and oxysterol formation in cultured astroglia. J. Neurochem. 108: 72-81 (2009).
Hasebe A, Pennock ND, Mu HH, Chan FV, Taylor ML, Cole BC. A microbial TLR2 agonist imparts macrophage-activating ability to apolipoprotein A-1. J. Immunol. 177: 4826-4832 (2006). *
Hashimoto K, Cohen RN, Yamada M, Markan KR, Monden T, Satoh T, Mori M, Wondisford FE. Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model. J. Biol. Chem. 281: 295-302 (2006). *
Hashimoto K, Matsumoto S, Yamada M, Satoh T, Mori M. Liver X receptor alpha gene expression is positively regulated by thyroid hormone. Endocrinology 148: 4667-4675 (2007). *
Hashimoto M, Hossain S, Shido O. Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity. Mol. Cell. Biochem. 293: 1-8 (2006). *
Hashimoto M, Hossain S, Shimada T, Shido O. Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin. Exp. Pharmacol. Physiol. 33: 934-939 (2006). *
Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M. Over-produced IL-6 decreases blood lipid levels via up-regulation of VLDLR. Ann. Rheum. Dis. May 10 [Epub ahead of print] (2009).
Hassan AS, Bunick D, Lund LA, Bottje WG. Glutathione and bile acid synthesis. Effect of GSH content of HepG2 cells on the activity and mRNA levels of cholesterol 7 alpha-hydroxylase. Biochem. Pharmacol. 44: 1475-1477 (1992).
Hassanali Z, Ametaj B, Field CJ, Proctor SD, Vine DF. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obes. Metab. Nov 16 [Epub ahead of print] (2009).
Hattori H, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N. A561C polymorphism of E-selectin is associated with ischemic cerebrovascular disease in the Japanese population without diabetes mellitus and hypercholesterolemia. Brain Res. 1108: 221-223 (2006).
Hauenschild A, Bretzel RG, Schnell-Kretschmer H, Kloer HU, Hardt PD, Ewald N. Successful treatment of severe hypertriglyceridemia with a formula diet rich in omega-3 fatty acids and medium-chain triglycerides. Ann. Nutr. Metab. 56: 170-175 (2010).
Haugaard SB, Vaag A, Mu H, Madsbad S. Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention. Lipids Health Dis. 8: 34 (2009). *
Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr. Opin. Cardiol. 24: 473-482 (2009).
Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21: 1393-1403 (2001). *
He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98: 192-199 (2006). *
He X, Lu Y, Saha N, Yang H, Heng CK. Acyl-CoA: cholesterol acyltransferase-2 gene polymorphisms and their association with plasma lipids and coronary artery disease risks. Hum. Genet. 118: 393-403 (2005). *
Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: 1149-1156 (1994).
Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656-660 (1976).
Hedenborg G, Jonsson G, Norman A, Wisen O. Bile constituents in ascitic fluid. Scand. J. Clin. Lab. Invest. 48: 543-552 (1988).
Hegele RA, Cao H. Single nucleotide polymorphisms of RXRA encoding retinoid X receptor alpha. J. Hum. Genet. 46: 423-425 (2001). *
Hegele RA, Robinson JF. ABC transporters and sterol absorption. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 31-37 (2005).
Heid IM, Vollmert C, Kronenberg F, Huth C, Ankerst DP, Luchner A, Hinney A, Bronner G, Wichmann HE, Illig T, Doring A, Hebebrand J. Association of the MC4R V103I polymorphism with the metabolic syndrome: the KORA study. Obesity (Silver Spring) 16: 369-376 (2008). *
Heigl F, Hettich R, Lotz N, Reeg H, Eder B, Steckholzer-Kroth K, Browatzki M, Harre K, Arendt R. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center). Atheroscler. Suppl. 10: 137-141 (2009).
Heimer S, Langmann T, Moehle C, Mauerer R, Dean M, Beil FU, von Bergmann K, Schmitz G. Mutations in the human ATP-binding cassette transporters ABCG5 and ABCG8 in sitosterolemia. Hum. Mutat. 20: 151 (2002). *
Heliovaara MK, Remitz A, Reitamo S, Teppo AM, Karonen SL, Ebeling P. 13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 56: 786-791 (2007). *
Helland IB, Saugstad OD, Saarem K, Van Houwelingen AC, Nylander G, Drevon CA. Supplementation of n-3 fatty acids during pregnancy and lactation reduces maternal plasma lipid levels and provides DHA to the infants. J. Matern. Fetal Neonatal Med. 19: 397-406 (2006).
Henderson CJ, Wolf CR. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Intervent. 3: 331-343 (2003). *
Heneghan HM, Sultan S. Homocysteine, the cholesterol of the 21st century. Impact of hyperhomocysteinemia on patency and amputation-free survival after intervention for critical limb ischemia. J. Endovasc. Ther. 15: 399-407 (2008).
Henkel AS, Elias MS, Green RM. Homocysteine supplementation attenuates the unfolded protein response in a murine nutritional model of steatohepatitis. J. Biol. Chem. 284: 31807-31816 (2009). *
Henningsson S, Hakansson A, Westberg L, Baghaei F, Rosmond R, Holm G, Ekman A, Nissbrandt H, Eriksson E. Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women. Obesity (Silver Spring) 14: 1868-1873 (2006). *
Herath KB, Jayasuriya H, Guan Z, Schulman M, Ruby C, Sharma N, Macnaul K, Menke JG, Kodali S, Galgoci A, Wang J, Singh SB. Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents. J. Nat. Prod. 68: 1437-1440 (2005). *
Hernandez-Morante JJ, Larque E, Lujan JA, Zamora S, Garaulet M. n-6 From different sources protect from metabolic alterations to obese patients: a factor analysis. Obesity (Silver Spring) 17: 452-459 (2009). *
Hernandez-Nazara A, Curiel-Lopez F, Martinez-Lopez E, Hernandez-Nazara Z, Panduro A. Genetic predisposition of cholesterol gallstone disease. Ann. Hepatol. 5: 140-149 (2006). *
Hernandez-Trujillo Y, Rodriguez-Esparragon F, Macias-Reyes A, Caballero-Hidalgo A, Rodriguez-Perez JC. Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. Cardiovasc. Diabetol. 7: 3 (2008).
Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, Reijngoud DJ, Muller M, Stellaard F, Groen AK, Kuipers F. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptoralpha-controlled metabolic pathways in mice. Hepatology Oct 23 [Epub ahead of print] (2009). *
Herron KL, Lofgren IE, Adiconis X, Ordovas JM, Fernandez ML. Associations between plasma lipid parameters and APOC3 and APOA4 genotypes in a healthy population are independent of dietary cholesterol intake. Atherosclerosis 184: 113-120 (2006).
Herron KL, McGrane MM, Waters D, Lofgren IE, Clark RM, Ordovas JM, Fernandez ML. The ABCG5 polymorphism contributes to individual responses to dietary cholesterol and carotenoids in eggs. J. Nutr. 136: 1161-1165 (2006). *
Herszenyi L, Szalay L, Schaff Z, Gergely P, Feher J. Ursodeoxycholic acid therapy in biliary cirrhosis. Orv. Hetil. 134: 2085-2089 (1993).
Hertel JK, Johansson S, Raeder H, Midthjell K, Lyssenko V, Groop L, Molven A, Njolstad PR. Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study). Diabetologia 51: 971-977 (2008). *
Herzum I, Giehl C, Soufi M, Junclas H, Wahl HG. Interference in a homogeneous assay for low-density lipoprotein cholesterol by lipoprotein X. Clin. Chem. Lab. Med. 45: 667-671 (2007). *
Hessvik NP, Boekschoten MV, Baltzersen MA, Kersten S, Xu X, Andersen H, Rustan A, Thoresen H. Liver X receptor beta (LXRbeta) is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux. Am. J. Physiol. Endocrinol. Metab. Dec 8 [Epub ahead of print] (2009). *
Hettema ME, Zhang D, de Leeuw K, Stienstra Y, Smit AJ, Kallenberg CG, Bootsma H. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res. Ther. 10: R49 (2008). *
Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin. Liver Dis. 27: 282-294 (2007).
Heuman DM, Hylemon PB, Vlahcevic ZR. Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. J. Lipid Res. 30: 1161-1171 (1989). *
Heuman DM, Vlahcevic ZR, Bailey ML, Hylemon PB. Regulation of bile acid synthesis. II. Effect of bile acid feeding on enzymes regulating hepatic cholesterol and bile acid synthesis in the rat. Hepatology 8: 892-897 (1988).
Heuman DM, Vlahcevic ZR, Pandak WM, Hylemon PB, Kim YS, Lillienau J, Hofmann AF. Effect of cholylsarcosine on hepatic cholesterol and bile acid synthesis and bile secretion in rats. Gastroenterology 103: 1641-1648 (1992).
Heverin M, Meaney S, Brafman A, Shafir M, Olin M, Shafaati M, von Bahr S, Larsson L, Lovgren-Sandblom A, Diczfalusy U, Parini P, Feinstein E, Bjorkhem I. Studies on the cholesterol-free mouse: strong activation of LXR-regulated hepatic genes when replacing cholesterol with desmosterol. Arterioscler. Thromb. Vasc. Biol. 27: 2191-2197 (2007).
Heynekamp JJ, Hunsaker LA, Vander Jagt TA, Royer RE, Deck LM, Vander Jagt DL. Isocoumarin-based inhibitors of pancreatic cholesterol esterase. Bioorg. Med. Chem. 16: 5285-5294 (2008). *
Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38: 1122-1129 (2008). *
Higuchi T, Shirai N, Suzuki H. Reduction in plasma glucose after lipid changes in mice fed fish oil, docosahexaenoic acid, and eicosapentaenoic acid diets. Ann. Nutr. Metab. 50: 147-154 (2006).
Higuchi T, Shirai N, Suzuki H, Kawashima M, Tamura Y. Effects of yogurt supplemented with fish oil on plasma lipid and glucose concentrations, and liver lipid contents in mice. Int. J. Vitam. Nutr. Res. 78: 129-138 (2008).
Hill AM, Buckley JD, Murphy KJ, Saint DA, Morris AM, Howe PR. Combined effects of omega-3 supplementation and regular exercise on body composition and cardiovascular risk factors. Asia Pac. J. Clin. Nutr. 14: S57 (2005).
Hill AM, Fleming JA, Kris-Etherton PM. The role of diet and nutritional supplements in preventing and treating cardiovascular disease. Curr. Opin. Cardiol. 24: 433-441 (2009).
Hingorani M, Nischal KK, Davies A, Bentley C, Vivian A, Baker AJ, Mieli-Vergani G, Bird AC, Aclimandos WA. Ocular abnormalities in Alagille syndrome. Ophthalmology 106: 330-227 (1999).
Hinrichs JW, Klappe K, van Riezen M, Kok JW. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains. J. Lipid Res. 46: 2367-2376 (2005). *
Hirako S, Kim HJ, Arai T, Chiba H, Matsumoto A. Effect of concomitantly used fish oil and cholesterol on lipid metabolism. J. Nutr. Biochem. May 14 [Epub ahead of print] (2009). *
Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, Sakai N, Hirano K, Kawata S, Tarui S. Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology 18: 103-110 (1993).
Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J. Am. Coll. Cardiol. 42: 1429-1437 (2003). *
Hiratsuka S, Koizumi K, Ooba T, Yokogoshi H. Effects of dietary docosahexaenoic acid connecting phospholipids on the learning ability and fatty acid composition of the brain. J. Nutr. Sci. Vitaminol. (Tokyo) 55: 374-380 (2009). *
Hirayama T, Honda A, Matsuzaki Y, Miyazaki T, Ikegami T, Doy M, Xu G, Lea M, Salen G. Hypercholesterolemia in rats with hepatomas: increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol. Hepatology 44: 602-611 (2006). *
Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, Miyazaki T, Matsuzaki Y. Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol. Res. 39: 149-156 (2009). *
Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279: 45685-45692 (2004). *
Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279: 41197-41207 (2004). *
Hirschhorn JN. Genetic approaches to studying common diseases and complex traits. Pediatr. Res. 57: 74R-77R (2005). *
Hisadome T, Nakama T, Itoh H, Furusawa T. Physical-chemical properties of chenodeoxycholic acid and ursodeoxycholic acid. Gastroenterol. Jpn. 15: 257-263 (1980).
Hisaka S, Kato Y, Kitamoto N, Yoshida A, Kubushiro Y, Naito M, Osawa T. Chemical and immunochemical identification of propanoyl-lysine derived from oxidized n-3 polyunsaturated fatty acid. Free Radic. Biol. Med. 46: 1463-1471 (2009).
Hitoshi S. Lipid synthetic transcription factor, SREBP. Nippon Rinsho 63: 897-907 (2005).
Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, Taskinen MR. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 50: 2067-2075 (2007). *
Ho CH, Kuo BI, Kong CW, Chau WK, Hsu HC, Gau JP, Yu YB. Influence of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, B vitamins and other factors on plasma homocysteine and risk of thromboembolic disease in Chinese. J. Chin. Med. Assoc. 68: 560-565 (2005).
Hoashi S, Hinenoya T, Tanaka A, Ohsaki H, Sasazaki S, Taniguchi M, Oyama K, Mukai F, Mannen H. Association between fatty acid compositions and genotypes of FABP4 and LXR-alpha in Japanese Black cattle. BMC Genet. 9: 84 (2008). *
Hobbs HH, Cohen JC. ABCG5 and ABCG8 play major role in defense against sterol accumulation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 55. June 18-19 (2004). *
Hoda F, Green RM. Hepatic canalicular membrane transport of bile salt in C57L/J and AKR/J mice: implications for cholesterol gallstone formation. J. Membr. Biol. 196: 9-14 (2003). *
Hodoglugil U, Tanyolac S, Williamson DW, Huang Y, Mahley RW. Apolipoprotein A5: potential modulator of plasma triglyceride levels in Turks. J. Lipid Res. 47: 144-153 (2006). *
Hoe HS, Cooper MJ, Burns MP, Lewis PA, van der Brug M, Chakraborty G, Cartagena CM, Pak DT, Cookson MR, Rebeck GW. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J. Neurosci. 27: 10895-10905 (2007).
Hoekstra M, Lammers B, Out R, Li Z, Van Eck M, Van Berkel TJ. Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol. Pharm. 6: 182-189 (2009). *
Hoekstra M, Out R, Kar Kruijt J, Van Eck M, Van Berkel TJ. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells. J. Hepatol. 42: 400-407 (2005). *
Hoekstra M, Ye D, Hildebrand RB, Zhao Y, Lammers B, Stitzinger M, Kuiper J, Van Berkel TJ, Van Eck M. Scavenger receptor BI-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. J. Lipid Res. 50: 1039-1046 (2009). *
Hofman M, Princen H, Zwinderman A, Jukema J. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clin. Sci. (Lond.) 108: 539-545 (2005).
Hofman MK, Weggemans RM, Zock PL, Schouten EG, Katan MB, Princen HM. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J. Nutr. 134: 2200-2204 (2004). *
Hofmann AF. Primary and secondary prevention of gallstone disease: implications for patient management and research priorities. Am. J. Surg. 165: 541-548 (1993).
Hofmann AF. Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol. 27: 106-113 (1995).
Hofmann AF. Progress in idiopathic bile acid malabsorption. Gut 43: 738-739 (1998). *
Hofmann AF. Medical dissolution of gallstones by oral bile acid therapy. Am. J. Surg. 158: 198-204 (1989).
Hofmann AF. Current concepts of biliary secretion. Dig. Dis. Sci. 34: 16S-20S (1989).
Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand. J. Gastroenterol. Suppl. 204: 1-15 (1994).
Hofmann AF. Bile acid secretion, bile flow and biliary lipid secretion in humans. Hepatology 12: 17S-22S (1990).
Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14: 24-29 (1999). *
Hofmann AF. Bile acids, cholesterol, gallstone calcification, and the enterohepatic circulation of bilirubin. Gastroenterology 116: 1276-1277 (1999). *
Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159: 2647-2658 (1999). *
Hofmann AF. Nonsurgical treatment of gallstone disease. Annu. Rev. Med. 41: 401-415 (1990). *
Hofmann AF. Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man [J Clin Invest 1968;47:1043-1052]. J. Hepatol. 41: 195-200 (2004). *
Hofmann AF. Helicobacter and cholesterol gallstones: do findings in the mouse apply to man? Gastroenterology 128: 1126-1129 (2005). *
Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front. Biosci. 14: 2584-2598 (2009).
Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49: 1403-1418 (2009). *
Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, Schteingart CD, Olinga P, Groothuis GM. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42: 1391-1398 (2005). *
Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65: 2461-2483 (2008). *
Hofmann AF, Schteingart CD, Lillienau J. Biological and medical aspects of active ileal transport of bile acids. Ann. Med. 23: 169-175 (1991).
Hogenboom S, Romeijn GJ, Houten SM, Baes M, Wanders RJ, Waterham HR. Peroxisome deficiency does not result in deficiency of enzymes involved in cholesterol biosynthesis. Adv. Exp. Med. Biol. 544: 329-330 (2003).
Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22: 1-8 (1999). *
Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80: 1678S-1688S (2004). *
Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv. Exp. Med. Biol. 624: 1-15 (2008). *
Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. J. Bone Miner. Res. 22 Suppl. 2: V28-V33 (2007). *
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; on behalf of the AFORRD study group. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52: 50-59 (2009). *
Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang da Y, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17: 1581-1591 (2003). *
Holub BJ. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostaglandins Leukot. Essent. Fatty Acids 81: 199-204 (2009). *
Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd. Belg. 70: 193-219 (2008).
Holzapfel J, Heun R, Lutjohann D, Jessen F, Maier W, Kolsch H. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. Neurosci. Lett. 408: 57-61 (2006). *
Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ. Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Eur. J. Hum. Genet. 16: 14-17 (2008). *
Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18: 461-467 (2008).
Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40: 933-941 (2004). *
Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO. LXRalpha enhances lipid synthesis in SZ95 sebocytes. J. Invest. Dermatol. 128: 1266-1272 (2008). *
Hong SH, Rhyne J, Zeller K, Miller M. ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis 164: 245-250 (2002).
Honjo Y, Sasaki S, Kobayashi Y, Misawa H, Nakamura H. 1,25-Dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J. Endocrinol. 188: 635-643 (2006). *
Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J. Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue. Clin. Nutr. 27: 764-772 (2008).
Hoogerwerf WA, Soloway RD. Gallstones. Curr. Opin. Gastroenterol. 15: 442 (1999).
Hooijmans CR, Blom HJ, Oppenraaij-Emmerzaal D, Ritskes-Hoitinga M, Kiliaan AJ. S-Adenosylmethionine and S-adenosylhomocysteine levels in the aging brain of APP/PS1 Alzheimer mice. Neurol. Sci. 30: 439-445 (2009).
Hooijmans CR, Kiliaan AJ. Fatty acids, lipid metabolism and Alzheimer pathology. Eur. J. Pharmacol. 585: 176-196 (2008). *
Hooiveld GJ, Vos TA, Scheffer GL, Van Goor H, Koning H, Bloks V, Loot AE, Meijer DK, Jansen PL, Kuipers F, Muller M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117: 678-687 (1999). *
Horton JD, Shimomura I, Ikemoto S, Bashmakov Y, Hammer RE. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278: 36652-36660 (2003). *
Horvath B, Szapary L, Debreceni L, Feher G, Kenyeres P, Fulop A, Battyani I, Toth K. Effect of Sclerovit on endothelial dysfunction, hemorheological parameters, platelet aggregation, plasma concentration of homocysteine and progression of atherosclerosis in patients with vascular diseases. Clin. Hemorheol. Microcirc. 42: 19-28 (2009).
Hosl M, Berneburg M. Vitamin D and the skin. Hautarzt. 59: 737-744 (2008).
Hosoyamada T. Clinical studies of pediatric malabsorption syndromes. Fukuoka Igaku Zasshi 97: 322-350 (2006).
Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J. Cardiovasc. Pharmacol. 51: 258-266 (2008).
Hotoleanu C, Porojan-Iuga M, Rusu ML, Andercou A. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis. Rom. J. Intern. Med. 45: 159-164 (2007).
Hou CT. New bioactive fatty acids. Asia Pac. J. Clin. Nutr. 17 Suppl. 1: 192-195 (2008).
Houten S, Auwerx J. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36: 482-491 (2004).
Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 25: 1419-1425 (2006). *
Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ. Inherited disorders of HDL metabolism and atherosclerosis. Curr. Opin. Lipidol. 16: 139-145 (2005).
Hovland A, Hardersen R, Sexton J, Mollnes TE, Lappegard KT. Different inflammatory responses induced by three LDL-lowering apheresis columns. J. Clin. Apher. 24: 247-253 (2009).
Howard BV, Comuzzie A, Devereux RB, Ebbesson SO, Fabsitz RR, Howard WJ, Laston S, Maccluer JW, Silverman A, Umans JG, Wang H, Weissman NJ, Wenger CR. Cardiovascular disease prevalence and its relation to risk factors in Alaska Eskimos. Nutr. Metab. Cardiovasc. Dis. Oct 1 [Epub ahead of print] (2009).
Howard WR, Pospisil JA, Njolito E, Noonan DJ. Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol. Appl. Pharmacol. 163: 195-202 (2000). *
Howarth AG, Jiang Y, Pannirselvam M, Wiehler WB, Berger JP, Severson DL, Anderson TJ, Triggle CR. A non-thiazolidinedione PPARgamma agonist reverses endothelial dysfunction in diabetic (db/db -/-) mice. J. Pharmacol. Exp. Ther. 316: 364-370 (2006). *
Hoy SM, Keating GM. Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 69: 1077-1105 (2009).
Hozoji M, Munehira Y, Ikeda Y, Makishima M, Matsuo M, Kioka N, Ueda K. Direct interaction of nuclear liver X receptor-beta with ABCA1 modulates cholesterol efflux. J. Biol. Chem. 283: 30057-30063 (2008). *
Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Karlik T. Changes in lipid metabolism in patients in the active phase of Crohn's disease. Vnitr. Lek. 53: 1035-1039 (2007).
Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Karlik T, Martinek A, Mendlova A. Cholesterol metabolism in active Crohn's disease. Wien. Klin. Wochenschr. 121: 270-275 (2009). *
Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Ticha A, Karlik T. Lipid metabolism in active Crohn's disease: pre-results. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 150: 363-366 (2006).
Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker CL, Brubaker PL, Drucker DJ, Adeli K. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 137: 997-1005.e4 (2009). *
Hsu JC, Su TC, Chen MF, Liau CS, Lee YT. Xanthoma striatum palmare in a patient with primary biliary cirrhosis and hypercholesterolemia. J. Gastroenterol. Hepatol. 20: 1799-1800 (2005). *
Hsun-Wei Huang T, Peng G, Qian Li G, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol. Appl. Pharmacol. 210: 225-235 (2006). *
Hu B, Collini M, Unwalla R, Miller C, Singhaus R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V, Chen L, Resmini C, Liu QY, Feingold I, Huselton C, Azam F, Farnegardh M, Enroth C, Bonn T, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J. Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis. J. Med. Chem. 49: 6151-6154 (2006). *
Hu C, Jia W, Fang Q, Zhang R, Wang C, Lu J, Xiang K. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet. Med. 23: 1307-1312 (2006). *
Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem. 281: 39831-39838 (2006). *
Hu X, Li S, Wu J, Xia C, Lala DS. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17: 1019-1026 (2003). *
Hu YW, Ma X, Li XX, Liu XH, Xiao J, Mo ZC, Xiang J, Liao DF, Tang CK. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 204: e35-e43 (2009).
Hu YW, Wang Q, Ma X, Li XX, Liu XH, Xiao J, Liao DF, Xiang J, Tang CK. TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J. Atheroscler. Thromb. Jan 7 [Epub ahead of print] (2010). *
Huang JC, Hoogwerf RJ. Cholesterol guidelines update: more aggressive therapy for higher-risk patients. Cleve. Clin. J. Med. 72: 253-262 (2005). *
Huang Q, Wang TH, Lu WS, Mu PW, Yang YF, Liang WW, Li CX, Lin GP. Estrogen receptor alpha gene polymorphism associated with type 2 diabetes mellitus and the serum lipid concentration in Chinese women in Guangzhou. Chin. Med. J. (Engl.) 119: 1794-1801 (2006). *
Huang TH, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br. J. Pharmacol. 145: 767-774 (2005). *
Huang TH, Razmovski-Naumovski V, Salam NK, Duke RK, Tran VH, Duke CC, Roufogalis BD. A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem. Pharmacol. 70: 1298-1308 (2005). *
Huang X, Yang C, Jin C, Luo Y, Wang F, McKeehan WL. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol. Carcinog. 48: 553-562 (2009). *
Huang XS, Zhao SP, Hu M, Luo YP. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med. Hypotheses 69: 136-140 (2007).
Huang Y, Zheng Y. The probiotic Lactobacillus acidophilus reduces cholesterol absorption through the down-regulation of Niemann-Pick C1-like 1 in Caco-2 cells. Br. J. Nutr. Oct 9 [Epub ahead of print] (2009). *
Hubacek JA, Berge KE, Stefkova J, Pitha J, Skodova Z, Lanska V, Poledne R. Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels. Physiol. Res. 53: 395-401 (2004). *
Hubacek JA, Lanska V, Skodova Z, Adamkova V, Poledne R. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur. J. Hum. Genet. 16: 135-138 (2008). *
Hubbert ML, Zhang Y, Lee FY, Edwards PA. Regulation of hepatic Insig-2 by the farnesoid X-receptor. Mol. Endocrinol. 21: 1359-1369 (2007). *
Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290: 35-43 (2002). *
Hui DY, Howles PN. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin. Cell. Dev. Biol. 16: 183-192 (2005). *
Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, Peeters PM, Sauer PJ, Verkade HJ. Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl. 10: 872-880 (2004). *
Humaloja K, Roine RP, Vuoristo M, Farkkila M, Hockerstedt K, Salaspuro M. Serum dolichols in chronic cholestatic liver diseases. J. Hepatol. 31: 1014-1019 (1999). *
Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann. Hum. Genet. 66: 343-352 (2002). *
Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43: 943-949 (2006). *
Hunt M, O'Byrne J, Solaas K, Frode Kase B, Alexson SEH. New insights into bile acid amidation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 24. June 18-19 (2004). *
Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gafvels M, Einarsson C, Alexson SE. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 275: 28947-28953 (2000). *
Hunter DJ, Kraft P. Drinking from the fire hose - statistical issues in genomewide association studies. N. Engl. J. Med. 357: 436-439 (2007). *
Huq MD, Tsai NP, Gupta P, Wei LN. Regulation of retinal dehydrogenases and retinoic acid synthesis by cholesterol metabolites. EMBO J. 25: 3203-3213 (2006). *
Hussaini SH, Pereira SP, Murphy GM, Kennedy C, Wass JA, Besser GM, Dowling RH. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid. Gut 36: 126-132 (1995). *
Hussainzada N, Claro Da Silva T, Swaan PW. The cytosolic half of helix III forms the substrate exit route during permeation events of the sodium/bile acid cotransporter ASBT. Biochemistry 48: 8528-8539 (2009). *
Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J. Gastroenterol. 13: 361-368 (2007). *
Hutchins GF, Gollan JL. Recent developments in the pathophysiology of cholestasis. Clin. Liver Dis. 8: 1-26 (2004).
Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention. MedGenMed. 7: 18 (2005). *
Huuskonen J, Vishnu M, Chau P, Fielding PE, Fielding CJ. Liver X receptor inhibits the synthesis and secretion of apolipoprotein A1 by human liver-derived cells. Biochemistry 45: 15068-15074 (2006). *
Huuskonen J, Vishnu M, Pullinger CR, Fielding PE, Fielding CJ. Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor. Biochemistry 43: 1626-1632 (2004). *
Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223 (1993).
Hylemon PB, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Pandak WM, Dent P. Conjugated bile acids promote activation of the ERK 1/2 and AKT pathways via a pertussis toxin-sensitive GI-dependent mechanism in primary rodent and human hepatocytes. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 24 (2006). *
Hylemon PB, Gupta S, Dent P. Regulation of bile acid biosynthesis by cell signaling pathways. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 29. June 18-19 (2004). *
Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J. Lipid Res. 50: 1509-1520 (2009). *
Hyogo H, Tazuma S, Cohen DE. Cholesterol gallstones. Curr. Opin. Gastroenterol. 18: 366-371 (2002).
Ichikawa H, Imano M, Takeyama Y, Shiozaki H, Ohyanagi H. Involvement of osteopontin as a core protein in cholesterol gallstone formation. J. Hepatobiliary Pancreat. Surg. 16: 197-203 (2009). *
Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol. Endocrinol. 17: 1255-1267 (2003). *
Igarashi M, Gao F, Kim HW, Ma K, Bell JM, Rapoport SI. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. Biochim. Biophys. Acta 1791: 132-139 (2009). *
Igarashi M, Hirata A, Yamaguchi H, Jimbu Y, Tominaga M. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J. Atheroscler. Thromb. 15: 34-40 (2008).
Igarashi M, Ma K, Gao F, Kim HW, Greenstein D, Rapoport SI, Rao JS. Brain lipid concentrations in bipolar disorder. J. Psychiatr. Res. Sep 18 [Epub ahead of print] (2009).
Igimi H, Asakawa S, Watanabe D, Shimura H. Liquid crystal formation in ursodeoxycholate-rich human gallbladder bile. Gastroenterol. Jpn. 18: 93-97 (1983).
Igimi H, Carey MC. Cholesterol gallstone dissolution in bile: dissolution kinetics of crystalline (anhydrate and monohydrate) cholesterol with chenodeoxycholate, ursodeoxycholate, and their glycine and taurine conjugates. J. Lipid Res. 22: 254-270 (1981). *
Iguchi Y, Kihira K, Nishimaki-Mogami T, Une M. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids 75: 95-100 (2010).
Iguchi Y, Yamaguchi M, Sato H, Kihira K, Nishimaki-Mogami T, Une M. Bile alcohols function as the ligands of membrane-type bile acid-activated G protein-coupled receptor. J. Lipid Res. Dec 18 [Epub ahead of print] (2009). *
Ii H, Yokoyama N, Yoshida S, Tsutsumi K, Hatakeyama S, Sato T, Ishihara K, Akiba S. Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A(2)-knockout mice. PLoS One 4: e8089 (2009). *
Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 136: 1234-1241 (2009). *
Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y, Tomoyori H, Imaizumi K, Suzuki K. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARalpha, promotes energy consumption and reduces visceral fat deposition in rats. Biochim. Biophys. Acta 1760: 800-807 (2006). *
Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, Tanaka N. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A(2) expression in HepG2 cells. Hepatology 41: 896-905 (2005). *
Ilan Y, Shouval D. Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687 (1992).
Ile KE, Davis W, Boyd JT, Soulika AM, Tew KD. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim. Biophys. Acta 1678: 22-32 (2004). *
Ilhan N, Kahraman N, Seckin D, Ilhan N, Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell. Biochem. Funct. 25: 527-532 (2007). *
Illingworth DR. An overview of lipid-lowering drugs. Drugs 36 Suppl. 3: 63-71 (1988).
Imamura A, Takahashi R, Murakami R, Kataoka H, Cheng XW, Numaguchi Y, Murohara T, Okumura K. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. Eur. J. Endocrinol. 158: 189-195 (2008). *
Imayama I, Ichiki T, Patton D, Inanaga K, Miyazaki R, Ohtsubo H, Tian Q, Yano K, Sunagawa K. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 51: 1631-1636 (2008).
Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2: 217-225 (2005). *
Inamoto Y, Teramoto T, Shirai K, Tsukamoto H, Sanda T, Miyamura K, Yamamori I, Hirabayashi N, Kodera Y. Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation. Int. J. Hematol. 82: 362-366 (2005).
Infante J, Rodr�guez-Rodriguez E, Mateo I, Llorca J, Vazquez-Higuera JL, Berciano J, Combarros O. Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol. Aging Jun 30 [Epub ahead of print] (2008).
Innocenti F, Hepp J, Humeres R, Sanhueza E, Zapata R, Rios H, Suarez L, Sandoval R, Rius M, Zamboni M. Rapid steroid taper and neoral monotherapy in liver transplantation in Chile: a step in the right direction? Transplant Proc. 36: 1675-1676 (2004). *
Inokuchi A, Hinoshita E, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem. 276: 46822-46829 (2001). *
Inoue I. Lipid metabolism and magnesium. Clin. Calcium 15: 1827-1838 (2005).
Inoue I. Hyperlipidemia and peroxisome proliferator-activated receptor (PPAR) - regulation of the PPARalpha gene by CLOCK: BMAL1. Nippon Rinsho 63: 643-656 (2005).
Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun. 290: 131-139 (2002). *
Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, Ohta Y, Onji M, Muto Y, Moriwaki H. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 15: 70-77 (1995).
Inoue Y, Inoue J, Lambert G, Yim SH, Gonzalez FJ. Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis. J. Biol. Chem. 279: 44740-44748 (2004). *
Inoue Y, Yu AM, Inoue J, Gonzalez FJ. Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J. Biol. Chem. 279: 2480-2489 (2004). *
Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Bjorkhem I, Gonzalez FJ. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J. Lipid Res. 47: 215-227 (2006). *
Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 50: 175-184 (2009).
Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs 21: 90-119 (1981).
Isharwal S, Misra A, Wasir JS, Nigam P. Diet and insulin resistance: a review and Asian Indian perspective. Indian J. Med. Res. 129: 485-499 (2009).
Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *
Ishida H, Kuruta Y, Gotoh O, Yamashita C, Yoshida Y, Noshiro M. Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B). J. Biochem. 126: 19-25 (1999).
Ishida H, Yamashita C, Kuruta Y, Yoshida Y, Noshiro M. Insulin is a dominant suppressor of sterol 12 alpha-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. J. Biochem. 127: 57-64 (2000).
Ishimoto K, Tachibana K, Sumitomo M, Omote S, Hanano I, Yamasaki D, Watanabe Y, Tanaka T, Hamakubo T, Sakai J, Kodama T, Doi T. Identification of human low-density lipoprotein receptor as a novel target gene regulated by liver X receptor alpha. FEBS Lett. 580: 4929-4933 (2006). *
Islam KK, Knight BL, Frayn KN, Patel DD, Gibbons GF. Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue. Biochim. Biophys. Acta 1734: 259-268 (2005). *
Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, Eliadou E, Kaminski A, Szymczak M, Drewniak T, Revillon Y. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr. Transplant. 3: 219-224 (1999).
Ismair MG, Hausler S, Stuermer CA, Guyot C, Meier PJ, Roth J, Stieger B. ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 49: 1673-1682 (2009).
Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, Kagata Y, Miyazaki K, Kusuhara M, Okazaki M, Matsubara O, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist deteriorates fatty-liver and cholesterol metabolism in hypercholesterolemic mice. J. Biol. Chem. 280: 7002-7009 (2005). *
Ito K, Hoekstra D, van Ijzendoorn SC. Cholesterol but not association with detergent resistant membranes is necessary for the transport function of MRP2/ABCC2. FEBS Lett. 582: 4153-4157 (2008). *
Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87 (2007). *
Ito T. Physiological function of ABCG1. Drug News Perspect. 16: 490-492 (2003).
Itoh S, Kono M, Akimoto T. Psoriasis treated with ursodeoxycholic acid: three case reports. Clin. Exp. Dermatol. 32: 398-400 (2007). *
Iuliano L, Monticolo R, Straface G, Zullo S, Galli F, Boaz M, Quattrucci S. Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am. J. Clin. Nutr. 90: 477-484 (2009). *
Ivanisevic M, Vujovic S, Drezgic M. Effects of estro-progestagens on lipid and hormonal profiles in women with premature primary ovarian failure. Med. Pregl. 58: 296-300 (2005).
Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest. 119: 2143-2159 (2009). *
Iwaki T, Hirabayashi N, Miyazawa N, Takeuchi Y, Ishizaki K, Sakakura H, Kasai H, Maeda M, Araki T. The choleretic effects of N-acetylglucosaminides, major urinary metabolites of ursodeoxycholic acid, in bile fistula rats. Eur. J. Pharmacol. 363: 41-48 (1998).
Iwamura K. Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones. Tokai. J. Exp. Clin. Med. 7: 671-683 (1982).
Iwano S, Nukaya M, Saito T, Asanuma F, Kamataki T. A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem. Biophys. Res. Commun. 335: 220-226 (2005). *
Iwayanagi Y, Takada T, Suzuki H. HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1. Pharm. Res. 25: 1134-1141 (2008). *
Izzat NN, Overturf M, Weisbrodt NW, Loose DS. Bile acid transport in hypercholesterolemic resistant rabbits. J. Physiol. Pharmacol. 60: 79-84 (2009). *
Jackson KG, Bateman PA, Yaqoob P, Williams CM. Impact of saturated, polyunsaturated and monounsaturated fatty acid-rich micelles on lipoprotein synthesis and secretion in Caco-2 cells. Lipids Nov 8 [Epub ahead of print] (2009).
Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res. Ther. 8: R81 (2006). *
Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am. J. Clin. Nutr. 87: 1981S-1990S (2008).
Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin. Ther. 29: 763-777 (2007).
Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. (Greenwich) 8: 35-41 (2006).
Jacquemin E. Progressive familial intrahepatic cholestasis and hereditary anomalies of hepatocellular metabolism of bile acids. Arch. Pediatr. 5: 45-53 (1998).
Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin. Liver Dis. 21: 551-562 (2001). *
Jacquemin E, Setchell KD, O'Connell NC, Estrada A, Maggiore G, Schmitz J, Hadchouel M, Bernard O. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J. Pediatr. 125: 379-384 (1994).
Jaffe JR, Nag SS, Landsman PB, Alexander CM. Reassessment of cardiovascular risk in diabetes. Curr. Opin. Lipidol. 17: 644-652 (2006).
Jahan A, Chiang JY. Cytokine regulation of human sterol 12alpha-hydroxylase (CYP8B1) gene. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G685-G695 (2005). *
Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, Jones EA, Brewer HB Jr. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 89: 1266-1278 (1985).
Jahovic N, Gedik N, Ercan F, Sirvanci S, Yuksel M, Sener G, Alican I. Effects of statins on experimental colitis in normocholesterolemic rats. Scand. J. Gastroenterol. 41: 954-962 (2006). *
Jain R. Biliary sludge: when should it not be ignored? Curr. Treat. Options Gastroenterol. 7: 105-109 (2004).
Jakel H, Fruchart-Najib J, Fruchart JC. Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis. Drug News Perspect. 19: 91-97 (2006).
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann. Med. 38: 2-10 (2006).
Jakobsen CH, St�rvold GL, Bremseth H, Follestad T, Sand K, Mack M, Olsen KS, Lundemo AG, Iversen JG, Krokan HE, Sch�nberg SM. DHA induces ER stress and growth arrest in human colon cancer cells - associations with cholesterol and calcium homeostasis. J. Lipid Res. 49: 2089-2100 (2008). *
Jakobsson T, Venteclef N, Toresson G, Damdimopoulos AE, Ehrlund A, Lou X, Sanyal S, Steffensen KR, Gustafsson JA, Treuter E. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol. Cell 34: 510-518 (2009). *
Jalving M, Koornstra JJ, Jong S, Vries EG, Kleibeuker JH. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment. Pharmacol. Ther. 21: 321-339 (2005). *
Jamroz-Wisniewska A, Wojcicka G, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy. Hig. Med. Dosw. (Online) 61: 760-785 (2007). *
Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. U.S.A. 96: 266-271 (1999). *
Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383: 728-731 (1996). *
Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, Defesche JC, Kastelein JJ. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 25: 1475-1481 (2005). *
Jansen GR. Effect of delta(22)-5beta-taurocholenic acid on hepatic cholesterol and fatty acid in gold thioglucose obese mice fed low- or high-fat diets. J. Nutr. Biochem. 10: 638-643 (1999).
Jansen H. Hepatic lipase: friend or foe and under what circumstances? Curr. Atheroscler. Rep. 6: 343-347 (2004).
Jansen PL. Genetics of cholestasis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 37-40 (2006). *
Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *
Jansen PL, van der Lelie H. Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin's disease. Neth. J. Med. 44: 99-102 (1994).
Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 59: 483-99 (2007). *
Jatwa R, Parmar HS, Panda S, Kar A. Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice. Basic Clin. Pharmacol. Toxicol. 101: 177-180 (2007).
Javitt NB. 26-Hydroxycholesterol: synthesis, metabolism, and biologic activities. J. Lipid Res. 31: 1527-1533 (1990). *
Javitt NB. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 4: 161-168 (1990). *
Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J. 8: 1308-1311 (1994). *
Javitt NB. Oxysteroids: a new class of steroids with autocrine and paracrine functions. Trends Endocrinol. Metab. 15: 393-397 (2004). *
Javitt NB. Oxysterols: novel biologic roles for the 21st century. Steroids 73: 149-157 (2008).
Javitt NB. Oxysterols: functional significance in fetal development and the maintenance of normal retinal function. Curr. Opin. Lipidol. 18: 283-288 (2007).
Javitt NB. Cholic acid synthesis from 27-hydroxycholesterol in humans. Gastroenterology 115: 509 (1998).
Javitt NB. Biologic role(s) of the 25(R),26-hydroxycholesterol metabolic pathway. Biochim. Biophys. Acta 1529: 136-141 (2000). *
Javitt NB. Cholesterol, hydroxycholesterols, and bile acids. Biochem. Biophys. Res. Commun. 292: 1147-1153 (2002). *
Javitt NB. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J. Lipid Res. 43: 665-670 (2002). *
Javitt NB. Cholesterol homeostasis: role of the LDL receptor. FASEB J. 9: 1378-1381 (1995). *
Javitt NB. Metabolite regulation of cholesterol synthesis. Hosp. Pract. (Off. Ed). 20: 109-112, 116-117, 120-121 (1985).
Javitt NB, Budai K. Cholesterol and bile acid synthesis in Hep G2 cells. Metabolic effects of 26- and 7 alpha-hydroxycholesterol. Biochem. J. 262: 989-992 (1989). *
Javitt NB, Javitt JI. Cholesterol and bile acid synthesis: utilization of D2O for metabolic studies. Biomed. Environ. Mass Spectrom. 18: 624-628 (1989).
Javitt NB, Lee YC, Shimizu C, Fuda H, Strott CA. Cholesterol and hydroxycholesterol sulfotransferases: identification, distinction from dehydroepiandrosterone sulfotransferase, and differential tissue expression. Endocrinology 142: 2978-2984 (2001). *
Javitt NB, Pfeffer R, Kok E, Burstein S, Cohen BI, Budai K. Bile acid synthesis in cell culture. J. Biol. Chem. 264: 10384-10387 (1989). *
Jayalakshmi K, Sonkar K, Behari A, Kapoor VK, Sinha N. Solid state (13)C NMR analysis of human gallstones from cancer and benign gall bladder diseases. Solid State Nucl. Magn. Reson. 36: 60-65 (2009).
Jean-Louis S, Akare S, Ali MA, Mash EA Jr, Meuillet E, Martinez JD. Deoxycholic acid induces intracellular signaling through membrane perturbations. J. Biol. Chem. 281: 14948-14960 (2006). *
Jeannesson E, Siest G, Bastien B, Albertini L, Aslanidis C, Schmitz G, Visvikis-Siest S. Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the Stanislas Cohort. Clin. Chim. Acta 403: 198-202 (2009). *
Jefcoate CR. Liver X receptor opens a new gateway to StAR and to steroid hormones. J. Clin. Invest. 116: 1832-1835 (2006). *
Jeffrey GP, Muller DP, Burroughs AK, Matthews S, Kemp C, Epstein O, Metcalfe TA, Southam E, Tazir-Melboucy M, Thomas PK, et al. Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease. J. Hepatol. 4: 307-317 (1987).
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27: 2422-2428 (2004). *
Jelinek DF, Andersson S, Slaughter CA, Russell DW. Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J. Biol. Chem. 265: 8190-8197 (1990). *
Jenkins DJ, Kendall CW. Resistant starches. Curr. Opin. Gastroenterol. 16: 178-183 (2000).
Jensen JM, Proksch E. The skin's barrier. G. Ital. Dermatol. Venereol. 144: 689-700 (2009).
Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 17: 247-257 (2006).
Jetten AM. Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr. Drug Targets Inflamm. Allergy 3: 395-412 (2004).
Ji C, Shinohara M, Kuhlenkamp J, Chan C, Kaplowitz N. Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology 46: 1586-1596 (2007). *
Ji Z, Zhang D, Li L, Shen X, Deng X, Dong L, Wu M, Liu Y. The hepatotoxicity of multi-walled carbon nanotubes in mice. Nanotechnology 20: 445101(2009).
Jia D, Otsuki M. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas 26: 286-291 (2003).
Jia M, Xue N, Cao Z, Liu H. Effects of dietary different ratios of n-3 to n-6 polyunsaturated fatty acids influence lipid metabolism and appetite of rats. Wei Sheng Yan Jiu 38: 175-178 (2009).
Jia XW, Tian YP, Wang Y, Deng XX, Dong ZN. Correlation of polymorphism in IL-6 gene promoter with BMI, inflammatory factors, and pathogenesis and progression of CHD. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15: 1270-1275 (2007).
Jiang D, Fang D, Kelley TJ, Burgess JD. Electrochemical analysis of cell plasma membrane cholesterol at the airway surface of mouse trachea. Anal. Chem. 80: 1235-1239 (2008). *
Jiang J, He M. Clinical features of primary biliary cirrhosis and treatment of it by integrated traditional Chinese and western medicine. Zhong Xi Yi Jie He Xue Bao 1: 99-102 (2003).
Jiang W, Miyamoto T, Kakizawa T, Nishio SI, Oiwa A, Takeda T, Suzuki S, Hashizume K. Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem. Biophys. Res. Commun. 351: 176-184 (2006). *
Jiang YD, Xiong JT, Cao J, Li GZ, Wang SR. Effects of peroxisome proliferators activated receptors on caveolin-1 expression in foam cells. Zhonghua Xin Xue Guan Bing Za Zhi 35: 661-665 (2007).
Jiang YD, Yen CJ, Chou WL, Kuo SS, Lee KC, Chiu KC, Chuang LM. Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in type 2 diabetic subjects. Diabet. Med. 22: 1690-1695 (2005).
Jiang YJ, Kim P, Elias PM, Feingold KR. LXR and PPAR activators stimulate cholesterol sulfotransferase (SULT2B1b) in human keratinocytes. J. Lipid Res. 46: 2657-2666 (2005). *
Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J. Lipid Res. 47: 2248-2258 (2006). *
Jiang ZY, Parini P, Eggertsen G, Davis MA, Hu H, Suo GJ, Zhang SD, Rudel LL, Han TQ, Einarsson C. Increased expression of LXRalpha , ABCG5, ABCG8 and SRBI in the liver from normolipidemic nonobese Chinese gallstone patients. J. Lipid Res. 49: 464-472 (2008). *
Jin S, Mathis AS, Rosenblatt J, Minko T, Friedman GS, Gioia K, Serur DS, Knipp GT. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation. Transplantation 77: 497-504 (2004).
Jin X, Lok E, Caldwell D, Mueller R, Kapal K, Liston V, Kubow S, Chan HM, Mehta R. Dietary fats altered nephrotoxicity profile of methylmercury in rats. J. Appl. Toxicol. 29: 126-140 (2009). *
Jirsa M, Cebecauerova D, Budisova L, Chuzhanova N, Hrebicek M, Dvorakova L, Vitek L, Brodanova M, Hulek P, Taimr P. Indel in the FIC1/ATP8B1 gene - a novel rare type of mutation associated with benign recurrent intrahepatic cholestasis. Hepatol. Res. 30: 1-3 (2004).
Johnson LE, Elias MS, Bolick DT, Skaflen MD, Green RM, Hedrick CC. The G protein-coupled receptor G2A: involvement in hepatic lipid metabolism and gallstone formation in mice. Hepatology 48: 1138-1148 (2008). *
Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPAR-gamma activity after administration of poloxamer 407 to mice. Can. J. Physiol. Pharmacol. 86: 643-649 (2008).
Jones GT, van Rij AM, Cole J, Williams MJ, Bateman EH, Marcovina SM, Deng M, McCormick SP. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin. Chem. 53: 679-685 (2007). *
Jones KS, Alimov AP, Rilo HL, Jandacek RP, Woollett LA, Penberthy WT. A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development. Nutr. Metab. (Lond.) 5: 23 (2008). *
Jones MD PH. Treatment of dyslipidemias. Endocr. Pract. 2: 30-36 (1996).
Jones PJ, Demonty I, Chan YM, Herzog Y, Pelled D. Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects. Lipids Health Dis. 6: 28 (2007). *
Jones PJ, Varady KA. Are functional foods redefining nutritional requirements? Appl. Physiol. Nutr. Metab. 33: 118-123 (2008). *
Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14: 27-39 (2000). *
Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, Lamers CH, Masclee AA. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 52: 109-115 (2003). *
Jonkers IJ, Smelt AH, Princen HM, Kuipers F, Romijn JA, Boverhof R, Masclee AA, Stellaard F. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J. Nutr. 136: 987-991 (2006). *
Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J. Clin. Gastroenterol. 20: 215-219 (1995).
Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'Connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119: 299-309 (2004). *
Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277: 11019-11025 (2002). *
Jover R, Moya M, Gomez-Lechon MJ. Transcriptional regulation of cytochrome P450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr. Drug. Metab. 10: 508-519 (2009).
Jump DB. Dietary polyunsaturated fatty acid regulation of hepatic gene transcription. Scand. J. Nutr. 46: 59-67 (2002). *
Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13: 155-164 (2002).
Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27: 137-144 (2007). *
Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277: 30559-30566 (2002). *
Jung D, Inagaki T, Dawson PA, Kliewer SA, Mangelsdorf DJ, Moschetta A. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48: 2693-2700 (2007). *
Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37: 622-631 (2003). *
Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122: 1954-1966 (2002). *
Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, Kim SM, Lee SY, Ahn SM, Kim YK, Kim HJ, Kim DJ, Lee KW. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J. Nutr. Biochem. 19: 371-375 (2008). *
Jung UJ, Torrejon C, Tighe AP, Deckelbaum RJ. n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am. J. Clin. Nutr. 87: 2003S-2009S (2008). *
Junge G, Neuhaus R, Schewior L, Klupp J, Guckelberger O, Langrehr JM, Tullius S, Neuhaus P. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant. Proc. 37: 1695-1696 (2005). *
Jungst C, Kullak-Ublick GA, Jungst D. Microlithiasis and sludge. Best Pract. Res. Clin. Gastroenterol. 20: 1053-1062 (2006).
Jungst C, Sreejayan N, Zundt B, Muller I, Spelsberg FW, Huttl TP, Kullak-Ublick GA, del Pozo R, Jungst D, von Ritter C. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. Eur. J. Clin. Invest. 38: 634-639 (2008). *
Juran BD, Lazaridis KN. Is the FXR the fix for cholesterol gallstone disease? Hepatology 42: 218-221 (2005). *
Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 14: 192-196 (2005). *
Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol. 177: 7416-7422 (2006). *
Juzyszyn Z, Kurzawski M, Lener A, Modrzejewski A, Pawlik A, Drozdzik M. Cholesterol 7alpha-hydrolase (CYP7A1) c.-278A>C promoter polymorphism in gallstone disease patients. Genet. Test. 12: 97-100 (2008).
Kaaja RJ, Kontula KK, Raiha A, Laatikainen T. Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand. J. Gastroenterol. 29: 178-181 (1994).
Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulange A, Vidal H, Slama G, Clement K, Guerre-Millo M, Rizkalla SW. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am. J. Clin. Nutr. 86: 1670-1679 (2007). *
Kaeding J, Bouchaert E, Belanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Belanger A, Barbier O. Activators of the farnesoid X-receptor negatively regulate androgen glucuronidation in human prostate cancer LNCaP cells. Biochem. J. 410: 245-253 (2008). *
Kagalwalla AF, Al Amir AR, Khalifa A, Sylven M, Al Ajaji S, Kagalwalla YA. Progressive familial intrahepatic cholestasis (Byler's disease) in Arab children. Ann. Trop. Paediatr. 15: 321-327 (1995).
Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S. Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin. Appl. Thromb. Hemost. 7: 153-157 (2001).
Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 45: 653-656 (2004). *
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93: 104-107 (2004). *
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. 93: 1046-1050 (2004). *
Kakimoto H, Kawata S, Imai Y, Inada M, Matsuzawa Y, Tarui S. Changes in lipid composition of erythrocyte membranes with administration of S-adenosyl-L-methionine in chronic liver disease. Gastroenterol. Jpn. 27: 508-513 (1992).
Kakko S, Kelloniemi J, von Rohr P, Hoeschele I, Tamminen M, Brousseau ME, Kesaniemi YA, Savolainen MJ. ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease. Atherosclerosis 166: 285-290 (2003).
Kakumu S. Is mortality from liver disease associated with normal serum aminotransferase concentrations? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3 (2004). *
Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ. LXRs regulate the balance between fat storage and oxidation. Cell. Metab. 1: 231-244 (2005). *
Kalaany NY, Mangelsdorf DJ. LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68: 159-191 (2006). *
Kalab M, Krechler T. The effect of the heptoprotective agent LIV 52 on liver damage. Cas. Lek. Cesk. 136: 758-760 (1997).
Kalantar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial. Int. 10: 315-325 (2006). *
Kalischuk LD, Inglis GD, Buret AG. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog. 1: 2 (2009). *
Kamath BM, Schwarz KB, Hadzic N. Alagille syndrome and liver transplantation. J. Pediatr. Gastroenterol. Nutr. 50: 11-15 (2010).
Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J. Gastroenterol. Hepatol. 20: 1429-1434 (2005). *
Kamisako T, Ogawa H. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J. Gastroenterol. Hepatol. 19: 879-883 (2004). *
Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abcg5 and abcg8 expressions in the rats: effects of diosgenin and ethinyl estradiol. Hepatol. Res. 26: 348-352 (2003).
Kamisako T, Ogawa H. Effect of obstructive jaundice on the regulation of hepatic cholesterol metabolism in the rat. Disappearance of abcg5 and abcg8 mRNA after bile duct ligation. Hepatol. Res. 25: 99-104 (2003).
Kamisako T, Ogawa H, Yamamoto K. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 22: 1832-1837 (2007). *
Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann. Surg. 239: 510-517 (2004). *
Kanayama T, Arito M, So K, Hachimura S, Inoue J, Sato R. Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J. Biol. Chem. 282: 10290-10298 (2007). *
Kanazawa Y, Koizumi M, Hirakawa H, Endo K, Yoshida S, Miyakawa T, Konno Y, Goto Y, Goto J, Nambara T. The effect of ursodeoxycholic acid on biliary bile acid composition in patients with cholesterol gallstone. Tohoku. J. Exp. Med. 136: 235-249 (1982). *
Kanchanapoo J, Rao MC, Sophasan S, Suksamrarn A, Piyachaturawat P. Inhibitory effects of choleretic hydroxyacetophenones on ileal bile acid transport in rats. Life Sci. 78: 1630-1636 (2006). *
Kanda T, Yokosuka O, Kojima H, Imazeki F, Nagao K, Tatsuno I, Saito Y, Saisho H. Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman. World J. Gastroenterol. 10: 2607-2608 (2004). *
Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, Kronfeld-Schor N, Cohen HY. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell Dec 28 [Epub ahead of print] (2009).
Kang HW, Kim D, Kim HJ, Kim CH, Kim YS, Park MJ, Kim JS, Cho SH, Sung MW, Jung HC, Lee HS, Song IS. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am. J. Gastroenterol. 105: 178-187 (2010). *
Kang Q, Chen A. Curcumin inhibits SREBP-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 150: 5384-5394 (2009). *
Kang X, Zhong W, Liu J, Song Z, McClain CJ, Kang YJ, Zhou Z. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology 50: 1241-1250 (2009).
Kannenberg F, Ellinghaus P, Assmann G, Seedorf U. Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J. Biol. Chem. 274: 35455-35460 (1999). *
Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J. Bezafibrate induced rhabdomyolysis. Ann. Rheum. Dis. 51: 536-538 (1992). *
Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA. A prospective trial of colchicine for primary biliary cirrhosis. N. Engl. J. Med. 315: 1448-1454 (1986).
Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 101: 1332-1338 (1991).
Kaplan R, Gan X, Menke JG, Wright SD, Cai TQ. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J. Lipid Res. 43: 952-959 (2002). *
Kaplowitz N. Hepatology highlights. Hepatology 39: 271-272 (2004). *
Kapoor P, Ansari MN, Bhandari U. Modulatory effect of curcumin on methionine-induced hyperlipidemia and hyperhomocysteinemia in albino rats. Indian J. Exp. Biol. 46: 534-540 (2008).
Karakas M, Koenig W. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs 12: 585-592 (2009).
Karkucak M, Capkin E, Alver A, Akyuz A, Kiris A, Ak E, Topbas M, Tosun M. The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Clin. Rheumatol. Dec 14 [Epub ahead of print] (2009). *
Karlaganis G, Bremmelgaard A, Karlaganis V, Sjovall J. Precursor of 27-nor-5 beta-cholestane-3 alpha, 7 alpha, 12 alpha, 24,25-pentol in man. J. Steroid Biochem. 18: 725-729 (1983).
Karten B, Campenot RB, Vance DE, Vance JE. Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J. Biol. Chem. 281: 4049-4057 (2006). *
Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J. Pharmacol. Sci. 108: 40-48 (2008). *
Kase ET, Thoresen GH, Westerlund S, H�jlund K, Rustan AC, Gaster M. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50: 2171-2180 (2007). *
Kassab A, Ajmi T, Issaoui M, Chaeib L, Miled A, Hammami M. Homocysteine enhances LDL fatty acid peroxidation, promoting microalbuminuria in type 2 diabetes. Ann. Clin. Biochem. 45: 476-480 (2008).
Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41: 56-65 (2009). *
Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol. 49: 643-649 (2009). *
Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. Eur. J. Pharm. Sci. 15: 1-9 (2002). *
Kawasaki M, Yagasaki K, Miura Y, Funabiki R. Comparison of the changes in lipid metabolism between hepatoma-bearing and lipopolysaccharide-treated rats. Biosci. Biotechnol. Biochem. 68: 72-78 (2004). *
Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res. Clin. Pract. 59: 181-189 (2003).
Kazawa T, Kawasaki T, Sakamoto A, Imamura M, Ohashi R, Jiang S, Tanaka T, Iwanari H, Hamakubo T, Sakai J, Kodama T, Naito M. Expression of liver X receptor alpha and lipid metabolism in granulocyte-macrophage colony-stimulating factor-induced human monocyte-derived macrophage. Pathol. Int. 59: 152-160 (2009). *
Kedzia A, Krysiak R, Madej A, Okopien B. Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report. Pol. Arch. Med. Wewn. 117: 473-476 (2007).
Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc. Diabetol. 4: 13 (2005). *
Keech AC, The Field Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study ISRCTN64783481. Cardiovasc. Diabetol. 3: 9 (2004). *
Keizman D, Goldiner I, Leikin-Frenkel A, Konikoff FM. Innovations in the medical treatment of gallstones and fatty liver: FABACs (fatty acid bile acid conjugates). Harefuah. 147: 344-349, 373, 372 (2008).
Kelley DS, Siegel D, Vemuri M, Chung GH, Mackey BE. Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men. J. Nutr. 138: 30-35 (2008). *
Kemper JK, Kim H, Miao J, Bhalla S, Bae Y. Role of an mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP. Mol. Cell. Biol. 24: 7707-7719 (2004). *
Kendall CW, Emam A, Augustin LS, Jenkins DJ. Resistant starches and health. J. AOAC Int. 87: 769-774 (2004).
Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, Defronzo RA. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin � Diabetes Care 29: 1016-1023 (2006). *
Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell. Metab. 1: 121-131 (2005). *
Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, Edwards PA. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276: 39438-39447 (2001). *
Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig. Dis. Sci. 31: 705-711 (1986).
Kerkeni M, Addad F, Chauffert M, Myara A, Gerhardt M, Chevenne D, Trivin F, Farhat MB, Miled A, Maaroufi K. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann. Clin. Biochem. 43: 200-206 (2006).
Kern F Jr, Everson GT. Contraceptive steroids increase cholesterol in bile: mechanisms of action. J. Lipid Res. 28: 828-839 (1987). *
Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Braverman DZ, Szczepanik-Van Leeuwen P, Klein PD. Biliary lipids, bile acids, and gallbladder function in the human female: effects of contraceptive steroids. J. Lab. Clin. Med. 99: 798-805 (1982).
Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Erfling W, Braverman DZ, Szczepanik-van Leeuwen P, Klein PD. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J. Clin. Invest. 68: 1229-1242 (1981). *
Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res. 2008: 132960 (2008). *
Kesaniemi YA, Miettinen TA, Salaspuro MP. Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes. Gut 22: 579-584 (1981). *
Kesaniemi YA, Salaspuro MP, Vuoristo M, Miettinen TA. Biliary lipid secretion in chronic cholestatic liver disease. Gut 23: 931-938 (1982). *
Kevresan S, Kuhajda K, Kandrac J, Fawcett JP, Mikov M. Biosynthesis of bile acids in mammalian liver. Eur. J. Drug Metab. Pharmacokinet. 31: 145-156 (2006).
Key TJ, Appleby PN, Rosell MS. Health effects of vegetarian and vegan diets. Proc. Nutr. Soc. 65: 35-41 (2006). *
Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, Rao P, Pande G, Lakshmi Narusu M, Khaja MN, Pramila R, Habeeb A, Habibullah CM. Management of hyperbilirubinemia in biliary atresia by hepatic progenitor cell transplantation through hepatic artery: a case report. Transplant. Proc. 40: 1153-1155 (2008). *
Khan MA, Gallo RM, Renukaradhya GJ, Du W, Gervay-Hague J, Brutkiewicz RR. Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation. J. Immunol. 182: 4744-4750 (2009).
Khandelwal S, Demonty I, Jeemon P, Lakshmy R, Mukherjee R, Gupta R, Snehi U, Niveditha D, Singh Y, van der Knaap HC, Passi SJ, Prabhakaran D, Reddy KS. Independent and interactive effects of plant sterols and fish oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidaemic Indian adults. Br. J. Nutr. 102: 722-732 (2009). *
Khanna AK. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. J. Biomed. Sci. 16: 66 (2009). *
Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196 (2004). *
Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 44: 1728-1736 (2003). *
Kilpelainen T, Lakka T, Laaksonen D, Mager U, Salopuro T, Kubaszek A, Todorova B, Laukkanen O, Lindstrom J, Eriksson J, Hamalainen H, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M. Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome. Metabolism 57: 428-436 (2008). *
Kim EJ, Yoo YG, Yang WK, Lim YS, Na TY, Lee IK, Lee MO. Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia signaling. Arterioscler. Thromb. Vasc. Biol. 28: 1796-1802 (2008).
Kim GH, Park K, Yeom SY, Lee KJ, Kim G, Ko J, Rhee DK, Kim YH, Lee HK, Kim HW, Oh GT, Lee KU, Lee JW, Kim SW. Characterization of ASC-2 as an anti-atherogenic transcriptional coactivator of liver X receptors in macrophages. Mol. Endocrinol. 23: 966-974 (2009). *
Kim HJ, Fan X, Gabbi C, Yakimchuk K, Parini P, Warner M, Gustafsson JA. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc. Natl. Acad. Sci. U.S.A. 105: 2094-2099 (2008). *
Kim HJ, Lee KT, Park YB, Jeon SM, Choi MS. Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6J-Lep(ob/ob) mice. Mol. Nutr. Food Res. 52: 965-973 (2008). *
Kim HJ, Miyazaki M, Ntambi JM. Dietary cholesterol opposes PUFA-mediated repression of the stearoyl-CoA desaturase-1 gene by SREBP-1 independent mechanism. J. Lipid Res. 43: 1750-1757 (2002). *
Kim JY, Kim HJ, Kim KT, Park YY, Seong HA, Park KC, Lee IK, Ha H, Shong M, Park SC, Choi HS. Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its DNA binding. Mol. Endocrinol. 18: 2880-2894 (2004). *
Kim KH, Yoon JM, Choi AH, Kim WS, Lee GY, Kim JB. Liver X receptor ligands suppress ubiquitination and degradation of LXRalpha by displacing BARD1/BRCA1. Mol. Endocrinol. 23: 466-474 (2009). *
Kim KM, Choi JY, Yoo SE, Park MY, Lee BS, Ko YH, Sung SH, Shin HM, Park JE. HMCO5, herbal extract, inhibits NF-kappaB expression in lipopolysaccharide treated macrophages and reduces atherosclerotic lesions in cholesterol fed mice. J. Ethnopharmacol. 114: 316-324 (2007). *
Kim MH, Lee HS, Park HJ, Kim WY. Risk factors associated with metabolic syndrome in Korean elderly. Ann. Nutr. Metab. 51: 533-540 (2008). *
Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Eur. J. Pharmacol. 595: 119-125 (2008). *
Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute phase response. Am. J. Physiol. Endocrinol. Metab. 287: E731-E738 (2004). *
Kim ND, Im EO, Choi YH, Yoo YH. Synthetic bile acids: novel mediators of apoptosis. J. Biochem. Mol. Biol. 35: 134-141 (2002). *
Kim S, Sohn I, Ahn JI, Lee KH, Lee YS, Lee YS. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 340: 99-109 (2004). *
Kim SY, Jo DS, Hwang PH, Park JH, Park SK, Yi HK, Lee DY. Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus. Metabolism 55: 366-370 (2006). *
Kim TH, Baek JI, Hong JM, Choi SJ, Lee HJ, Cho HJ, Park EK, Kim UK, Kim SY. Significant association of SREBP-2 genetic polymorphisms with avascular necrosis in the Korean population. BMC Med. Genet. 9: 94 (2008). *
Kim WK, Meliton V, Tetradis S, Weinmaster G, Hahn TJ, Carlson M, Nelson SF, Parhami F. Osteogenic oxysterol, 20(S)-hydroxycholesterol, induces Notch target gene expression in bone marrow stromal cells. J. Bone Miner. Res. Oct 19 [Epub ahead of print] (2009). *
Kim WS, Fitzgerald ML, Kang K, Okuhira KI, Bell SA, Manning JJ, Koehn SL, Lu N, Moore KJ, Freeman MW. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 280: 3989-3995 (2005). *
Kimura M, Okuno E, Inada J, Ohyama H, Kido R. Purification and characterization of amino-acid N-choloyltransferase from human liver. Hoppe Seylers Z. Physiol. Chem. 364: 637-645 (1983).
Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98: 1303-1310 (2007). *
Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6: 12 (2007). *
Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 33: 921-923 (2006).
Kis E, Ioja E, Nagy T, Szente L, Heredi-Szabo K, Krajcsi P. Effect of membrane cholesterol on BSEP/Bsep activity - species specificity studies for substrates and inhibitors. Drug Metab. Dispos. 37: 1878-1886 (2009). *
Kis E, Rajnai Z, Ioja E, Heredi Szabo K, Nagy T, Mehn D, Krajcsi P. Mouse Bsep ATPase assay: a nonradioactive tool for assessment of the cholestatic potential of drugs. J. Biomol. Screen. 14: 10-15 (2009).
Kitayama K, Nakai D, Kono K, van der Hoop AG, Kurata H, de Wit EC, Cohen LH, Inaba T, Kohama T. Novel non-systemic inhibitor of ileal apical Na(+)-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur. J. Pharmacol. 539: 89-98 (2006). *
Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid Res. 44: 2339-2348 (2003). *
Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24: 239-247 (2007). *
Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14: 523-525 (2004).
Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003). *
Kiyosawa N, Ito K, Niino N, Sakuma K, Kanbori M, Yamoto T, Manabe S, Matsunuma N. Effect of serum cholesterol on the mRNA content of amyloid precursor protein in rat livers. Toxicol. Lett. 150: 157-166 (2004). *
Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101: 186-196 (2008). *
Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 8: R200 (2007). *
Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S. NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis. Hepatology 43: 126-133 (2005). *
Klett EL, Lu K, Kosters A, Vink E, Lee MH, Altenburg M, Shefer S, Batta AK, Yu H, Chen J, Klein R, Looije N, Oude Elferink RP, Groen AK, Maeda N, Salen G, Patel SB. A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med. 2: 5 (2004). *
Klett EL, Patel SB. Biomedicine. Will the real cholesterol transporter please stand up. Science 303: 1149-1150 (2004). *
Kliewer SA. Cholesterol detoxification by the nuclear pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 102: 2675-2676 (2005). *
Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res. 54: 345-367 (1999).
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774 (1992). *
Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 56: 239-263 (2001). *
Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. U.S.A. 97: 817-822 (2000). *
Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin. Transplant. 18: 642-646 (2004). *
Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF. A role for PPAR-alpha in the control of SREBP activity and lipid synthesis in the liver. Biochem. J. 389: 413-421 (2005). *
Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res. 44: 2049-2058 (2003). *
Ko JS, Choi BS, Seo JK, Shin JY, Chae JH, Kang GH, Lee R, Ki CS, Kim JW. A novel DHCR7 mutation in a Smith-Lemli-Opitz syndrome infant presenting with neonatal cholestasis. J. Korean Med. Sci. 25: 159-162 (2010). *
Kobayashi M, Lee H, Nakayama J, Fukuda M. Carbohydrate-dependent defense mechanisms against Helicobacter pylori infection. Curr. Drug Metab. 10: 29-40 (2009). *
Kocarek TA, Shenoy SD, Mercer-Haines NA, Runge-Morris M. Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes. J. Pharmacol. Toxicol. Methods 47: 177-187 (2002). *
Kocerha J, Prucha MS, Kroll KJ, Steinhilber D, Denslow N. Regulation of steroidogenic acute regulatory protein transcription in largemouth bass by orphan nuclear receptor signaling pathways. Endocrinology 151: 341-349 (2010). *
Kocher O, Pal R, Roberts M, Cirovic C, Gilchrist A. Targeted disruption of the PDZK1 gene by homologous recombination. Mol. Cell. Biol. 23: 1175-1180 (2003). *
Kocher O, Yesilaltay A, Cirovic C, Pal R, Rigotti A, Krieger M. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J. Biol. Chem. 278: 52820-52825 (2003). *
Kocher O, Yesilaltay A, Shen CH, Zhang S, Daniels K, Pal R, Chen J, Krieger M. Influence of PDZK1 on lipoprotein metabolism and atherosclerosis. Biochim. Biophys. Acta 1782: 310-316 (2008). *
Koeijvoets KC, Mooijaart SP, Dallinga-Thie GM, Defesche JC, Steyerberg EW, Westendorp RG, Kastelein JJ, Martin van Hagen P, Sijbrands EJ. Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. Eur. Heart J. 30: 618-623 (2009).
Koeijvoets KC, van der Net JB, Dallinga-Thie GM, Steyerberg EW, Mensink RP, Kastelein JJ, Sijbrands EJ, Plat J. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis 204: 453-458 (2009).
Koeijvoets KC, van Rossum EF, Dallinga-Thie GM, Steyerberg EW, Defesche JC, Kastelein JJ, Lamberts SW, Sijbrands EJ. A functional polymorphism in the glucocorticoid receptor gene and its relation to cardiovascular disease risk in familial hypercholesterolemia. J. Clin. Endocrinol. Metab. 91: 4131-4136 (2006). *
Koga S, Miyata Y, Ibayashi H. Plasma lipoproteins and apoproteins in primary biliary cirrhosis. Hepatology 5: 286-292 (1985).
Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, Ahn TH, Shin EK, Jeong EM. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int. J. Cardiol. 97: 239-244 (2004).
Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int. J. Cardiol. 124: 149-159 (2008).
Kohno H, Sakai T, Saito S, Okano K, Kitahara K. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Exp. Eye Res. 84: 569-576 (2007). *
Kohro T, Yamazaki T. Eicosapentaenoic acid (EPA) in reducing secondary cardiovascular events in hypercholesterolemic Japanese patients. Circ. J. 73: 1197-1198 (2009). *
Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33: 145-150 (2005).
Koizumi A, Mizukami H, Inoue M. pX gene causes hypercholesterolemia in hypercholesterolemia-resistant BALB/c mice. Biol. Pharm. Bull. 28: 1731-1735 (2005). *
Kojima S, Toyota Y, Shiba M, Tsushima M, Matsuoka H, Yamamoto A. Different apheresis methods in the treatment of hypercholesterolemia in primary biliary cirrhosis: a case report. Artif. Organs 19: 938-941 (1995).
Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547 (2003). *
Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, Shan B, Schwarz M, Kuipers F. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. 278: 41930-41937 (2003). *
Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124: 160-171 (2003). *
Kolanczyk M, Kuhnisch J, Kossler N, Osswald M, Stumpp S, Thurisch B, Kornak U, Mundlos S. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Med. 6: 21 (2008). *
Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 278: 13244-13256 (2003). *
Koletzko B, Decsi T. Metabolic aspects of trans fatty acids. Clin. Nutr. 16: 229-237 (1997).
Kolovou G, Anagnostopoulou K, Kostakou P, Marvaki C, Mihas C, Mikhailidis DP, Cokkinos DV. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin. Chem. Lab. Med. 45: 1190-1198 (2007). *
Kolovou G, Damaskos D, Anagnostopoulou K, Cokkinos DV. Apolipoprotein E gene polymorphism and gender. Ann. Clin. Lab. Sci. 39: 120-133 (2009).
Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J. 81: 358-366 (2005). *
Kolsch H, Lutjohann D, Jessen F, Popp J, Hentschel F, Kelemen P, Friedrichs S, Maier W, Heun R. RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. J. Cell. Mol. Med. Jun 9 [Epub ahead of print] (2008). *
Kolsch H, Lutjohann D, Jessen F, Von Bergmann K, Schmitz S, Urbach H, Maier W, Heun R. Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. Int. J. Mol. Med. 17: 791-794 (2006). *
Komatsu A, Node K. Effects of PPARgamma agonist on dyslipidemia and atherosclerosis. Nippon Rinsho 68: 294-298 (2010).
Komori H, Arai H, Kashima T, Huby T, Kita T, Ueda Y. Coexpression of CLA-1 and human PDZK1 in murine liver modulates HDL cholesterol metabolism. Arterioscler. Thromb. Vasc. Biol. 28: 1298-1303 (2008).
Komuves LG, Schmuth M, Fowler AJ, Elias PM, Hanley K, Man MQ, Moser AH, Lobaccaro JM, Williams ML, Mangelsdorf DJ, Feingold KR. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J. Invest. Dermatol. 118: 25-34 (2002). *
Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328: 116-122 (2009). *
Kong FM, Sui CY, Li YJ, Guo KJ, Guo RX. Hepatobiliary membrane transporters involving in the formation of cholesterol calculus. Hepatobiliary Pancreat. Dis. Int. 5: 286-289 (2006). *
Konig B, Spielmann J, Haase K, Brandsch C, Kluge H, Stangl GI, Eder K. Effects of fish oil and conjugated linoleic acids on expression of target genes of PPARalpha and sterol regulatory element-binding proteins in the liver of laying hens. Br. J. Nutr. 100: 355-363 (2008). *
Konikoff FM. Gallstones - approach to medical management. MedGenMed. 5: 8 (2003). *
Konikoff FM, Leikin-Frenkel A, Goldiner I, Michowitz M, Brezowski E, Harats D, Gilat T. Biliary and systemic effects of fatty acid bile acid conjugates. Eur. J. Gastroenterol. Hepatol. 15: 649-655 (2003).
Kooner JS, Chambers JC, Aguilar-Salinas CA, Hinds DA, Hyde CL, Warnes GR, Gomez Perez FJ, Frazer KA, Elliott P, Scott J, Milos PM, Cox DR, Thompson JF. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet. 40: 149-151 (2008). *
Koopen NR, Wolters H, Voshol P, Stieger B, Vonk RJ, Meier PJ, Kuipers F, Hagenbuch B. Decreased Na+-dependent taurocholate uptake and low expression of the sinusoidal Na+-taurocholate cotransporting protein (Ntcp) in livers of mdr2 P-glycoprotein-deficient mice. J. Hepatol. 30: 14-21 (1999). *
Korach-Andre M, Parini P, Larsson L, Arner A, Steffensen KR, Gustafsson JA. Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice. Am. J. Physiol. Endocrinol. Metab. Aug 18 [Epub ahead of print] (2009). *
Korkin AL. Assessment of bile lithogenicity and litholysis efficiency of biliary microlites in patients with opisthorchosis in effective period of praziquantel and ursodeoxycholic acid therapy. Vopr. Pitan. 78: 63-66 (2009).
Korolenko TA, Savchenko NG, Yuz'ko JV, Alexeenko TV, Sorochinskaya NV. Activity of lysosomal enzymes in the bile and serum of mice with intrahepatic cholestasis. Bull. Exp. Biol. Med. 145: 560-563 (2008).
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44: 467-494 (2005).
Kostara C, Papathanasiou A, Cung MT, Elisaf M, Goudevenos J, Bairaktari E. Evaluation of established coronary heart disease on the basis of HDL and non-HDL NMR lipid profiling. J. Proteome Res. Dec 20 [Epub ahead of print] (2009). *
Kosters A, Frijters RJ, Kunne C, Vink E, Schneiders MS, Schaap FG, Nibbering CP, Patel SB, Groen AK. Diosgenin-induced biliary cholesterol secretion in mice requires Abcg8. Hepatology 41: 141-150 (2005). *
Kosters A, Frijters RJ, Schaap FG, Vink E, Plosch T, Ottenhoff R, Jirsa M, De Cuyper IM, Kuipers F, Groen AK. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J. Hepatol. 38: 710-716 (2003). *
Kosters A, Jirsa M, Groen AK. Genetic background of cholesterol gallstone disease. Biochim. Biophys. Acta 1637: 1-19 (2003). *
Kosters A, Kunne C, Looije N, Patel SB, Oude Elferink RP, Groen AK. The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice. J. Lipid Res. 47: 1959-1966 (2006). *
Kotokorpi P, Venteclef N, Ellis E, Gustafsson JA, Mode A. The human ADFP gene is a direct liver-X-receptor (LXR) target gene and differentially regulated by synthetic LXR ligands. Mol. Pharmacol. 77: 79-86 (2010). *
Koubaa N, Hammami S, Nakbi A, Ben Hamda K, Mahjoub S, Kosaka T, Hammami M. Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behcet's disease patients. Clin. Chem. Lab. Med. 46: 187-192 (2008). *
Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Hamda KB, Farhat MB, Miled A, Hammami M. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin. Biochem. 42: 771-776 (2009). *
Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, Vardas E, Vrentzos G, Ganotakis E, Mouzas IA, Gravanis A, Emmanouel D, Kouroumalis EA. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig. Dis. Sci. 45: 2347-2351 (2000). *
Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 283-288 (2009).
Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Mendez-Sanchez N, Uribe M, Bock HH, Schirin-Sokhan R, Stumvoll M, Mossner J, Lammert F, Wittenburg H. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans? J. Hepatol. 48: 116-124 (2008). *
Kovacs P, Kurtz U, Wittenburg H. Hepatic insulin resistance ties cholesterol gallstone formation and the metabolic syndrome. Ann. Hepatol. 7: 262-264 (2008). *
Kovacs WJ, Shackelford JE, Tape KN, Richards MJ, Faust PL, Fliesler SJ, Krisans SK. Disturbed cholesterol homeostasis in a peroxisome-deficient PEX2 knockout mouse model. Mol. Cell Biol. 24: 1-13 (2004). *
Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am. J. Med. 108: 481-486 (2000). *
Kowdley KV. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin. Liver Dis. 2: 373-389, x (1998).
Kozarek RA. Pancreaticobiliary biofilm: is cholesterol the answer? Gut 54: 326-328 (2005). *
Krahenbuhl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 15: 1160-1166 (1992).
Kralova Lesna I, Suchanek P, Kovar J, Stavek P, Poledne R. Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport. J. Lipid Res. 49: 2414-2418 (2008). *
Kramer JA, LeDeaux J, Butteiger D, Young T, Crankshaw C, Harlow H, Kier L, Bhat BG. Transcription profiling in rat liver in response to dietary docosahexaenoic acid implicates stearoyl-coenzyme a desaturase as a nutritional target for lipid lowering. J. Nutr. 133: 57-66 (2003). *
Kramer W, Girbig F, Corsiero D, Pfenninger A. Molecular elucidation of intestinal cholesterol absorption. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 54. June 18-19 (2004). *
Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13: 997-1016 (2006).
Krapivner S, Chernogubova E, Ericsson M, Ahlbeck-Glader C, Hamsten A, van 't Hooft FM. Human evidence for the involvement of insulin-induced gene 1 in the regulation of plasma glucose concentration. Diabetologia 50: 94-102 (2007). *
Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-deficient mice without inducing liver steatosis and hypertriglyceridemia. J. Lipid Res. 50: 312-326 (2009). *
Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J. Clin. Immunol. 25: 582-591 (2005). *
Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter W, Schulthess G. TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp. Clin. Endocrinol. Diabetes 115: 322-326 (2007).
Krisans SK, Thompson SL, Pena LA, Kok E, Javitt NB. Bile acid synthesis in rat liver peroxisomes: metabolism of 26-hydroxycholesterol to 3 beta-hydroxy-5-cholenoic acid. J. Lipid Res. 26: 1324-1332 (1985). *
Kruit JK, Groen AK, van Berkel TJ, Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol. 12: 6429-6439 (2006). *
Kruit JK, Plosch T, Havinga R, Boverhof R, Groot PH, Groen AK, Kuipers F. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128: 147-156 (2005). *
Krupkova M, Janku M, Liska F, Sedova L, Kazdova L, Krenova D, Kren V, Seda O. Pharmacogenetic model of retinoic acid-induced dyslipidemia and insulin resistance. Pharmacogenomics 10: 1915-1927 (2009).
Kryczka W, Grieb P. Clinical pharmacology of ursodeoxycholic acid (UDCA). Postepy. Hig. Med. Dosw. 48: 53-68 (1994).
Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *
Kubota K, Itho M, Kishi H, Igarashi S, Minegishi T. Primary hypothyroidism presenting as multiple ovarian cysts in an adult woman: a case report. Gynecol. Endocrinol. 24: 586-589 (2008).
Kucerka N, Marquardt D, Harroun TA, Nieh MP, Wassall SR, Katsaras J. The functional significance of lipid diversity: orientation of cholesterol in bilayers is determined by lipid species. J. Am. Chem. Soc. 131: 16358-16359 (2009). *
Kudo T, Kawashima M, Tamagawa T, Shibata S. Clock mutation facilitates accumulation of cholesterol in the liver of mice fed a cholesterol and/or cholic acid diet. Am. J. Physiol. Endocrinol. Metab. 294: E120-E130 (2008). *
Kuhajda K, Kevresan S, Kandrac J, Fawcett JP, Mikov M. Chemical and metabolic transformations of selected bile acids. Eur. J. Drug Metab. Pharmacokinet. 31: 179-235 (2006).
Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. 18: 289-297 (2007).
Kuipers I, van der Harst P, Kuipers F, van Genne L, Goris M, Lehtonen JY, van Veldhuisen DJ, van Gilst WH, de Boer RA. Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system. Lab. Invest. Feb 1 [Epub ahead of print] (2010). *
Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am. J. Gastroenterol. 96: 3110-3116 (2001). *
Kuliczkowska J, Filus A, Trzmiel A, Tworowska U, Demissie M, Jedrzejuk D, Milewicz A. PPAR-gamma2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw. Endokrynol. Pol. 59: 312-315 (2008).
Kullak-Ublick GA. Regulation of hepatic and intestinal bile acid transport by FXR controlled signaling pathways. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 51-52 (2006). *
Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342 (2004). *
Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburaki J, Kameda H, Suwa A, Hagiyama H, Hirohata S, Makino H, Hashimoto H. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J. Rheumatol. 32: 863-869 (2005).
Kumar N, Wang H, Liu D, Collins S. Liver X receptor is a regulator of orphan nuclear receptor NOR-1 gene transcription in adipocytes. Int. J. Obes. (Lond.) 33: 519-524 (2009). *
Kuniyasu H, Luo Y, Fujii K, Sasahira T, Moriwaka Y, Tatsumoto N, Sasaki T, Yamashita Y, Ohmori H. CD10 enhances metastasis of colorectal cancer by abrogating the antitumoral effect of methionine-enkephalin in the liver. Gut Oct 13 [Epub ahead of print] (2009).
Kurian KC, Rai P, Sankaran S, Jacob B, Chiong J, Miller AB. The effect of statins in heart failure: beyond its cholesterol-lowering effect. J. Card. Fail. 12: 473-478 (2006).
Kurihara T, Akimoto M, Abe K, Hashimoto H, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I. Inhibitory effect of ursodeoxycholic acid on the progression of chronic hepatic disorders with special reference to increases in blood flow. Clin. Ther. 15: 866-874 (1993).
Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I, Suzuki Y, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 15: 890-898 (1993).
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *
Kurt M, Onal IK, Parlak E, Shorbagi A, Kekilli M, Ibis M, Hayran M, Sasmaz N. Do metabolic alterations serve as biochemical markers in the diagnosis of malignant biliary obstruction? An observational study. Eur. J. Gastroenterol. Hepatol. 22: 58-60 (2010).
Kurtovic J, Riordan S. Clinical aspects of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 31-32. October 15-16 (2003). *
Kurzawski M, Juzyszyn Z, Modrzejewski A, Pawlik A, Wiatr M, Czerny B, Adamcewicz R, Drozdzik M. Apolipoprotein B (APOB) gene polymorphism in patients with gallbladder disease. Arch. Med. Res. 38: 360-363 (2007).
Kushida A, Tamura H. Retinoic acids induce neurosteroid biosynthesis in human glial GI-1 cells via the induction of steroidogenic genes. J. Biochem. 146: 917-923 (2009). *
Kusunoki S, Kaida KI, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: new aspects of research. Biochim. Biophys. Acta 1780: 441-444 (2008). *
Kutz K, Schulte A. Effect of ursodeoxycholic acid on bile supersaturated with cholesterol in patients pretreated with clofibrate. Z. Gastroenterol. 19: 231-236 (1981).
Kuzuya M, Ando F, Iguchi A, Shimokata H. Glutathione peroxidase 1 Pro198Leu variant contributes to the metabolic syndrome in men in a large Japanese cohort. Am. J. Clin. Nutr. 87: 1939-1944 (2008). *
Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res. Clin. Pract. 77 Suppl. 1: S228-S232 (2007).
Kyoko U, Seiji U, Shinichi I, Masakazu T, Shinji K, Tohru F, Masunori M. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 291: H2522-H2532 (2006). *
Kyriakou T, Pontefract DE, Viturro E, Hodgkinson CP, Laxton RC, Bogari N, Cooper G, Davies M, Giblett J, Day IN, Simpson IA, Albrecht C, Ye S. Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients. Hum. Mol. Genet. 16: 1412-1422 (2007). *
Labori KJ, Bjornbeth BA, Hvattum E, Lyberg T, Raeder MG. Intravenous bilirubin, dibromosulfophthalein, and bromosulfophthalein infusions uncouple biliary phospholipid and cholesterol secretion from bile acid secretion by inhibiting hepatic phosphoglycoprotein-3 activity in pigs. Scand. J. Gastroenterol. 35: 873-882 (2000). *
Lacaille F. Bile acids and their therapeutic use in children. Arch. Pediatr. 2: 1200-1208 (1995).
Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23: 2182-2191 (2003). *
Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell Biol. 21: 7558-7568 (2001). *
Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. U.S.A. 98: 507-512 (2001). *
Lagogianni I, Papapanagiotou A, Piperi C, Kalofoutis C, Troupis G, Zachari A, Kalofoutis A. Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus. Clin. Biochem. 38: 286-290 (2005). *
Lai K, Harnish DC, Evans MJ. Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner. J. Biol. Chem. 278: 36418-36429 (2003). *
Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295-1302 (2006). *
Laios E, Glynou K. Allelic drop-out in the LDLR gene affects mutation detection in familial hypercholesterolemia. Clin. Biochem. 41: 38-40 (2008). *
Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM. The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp. Mol. Pathol. 82: 280-283 (2007). *
Lala DS, Syka PM, Lazarchik SB, Mangelsdorf DJ, Parker KL, Heyman RA. Activation of the orphan nuclear receptor steroidogenic factor 1 by oxysterols. Proc. Natl. Acad. Sci. U.S.A. 94: 4895-4900 (1997). *
Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fievet C, Staels B, Tailleux A. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler. Thromb. Vasc. Biol. 29: 1488-1495 (2009).
Lalloyerc F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 26: 2731-2737 (2006).
Lally S, Owens D, Tomkin GH. The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes. Atherosclerosis 193: 343-351 (2007).
Lam CK, Chen J, Cao Y, Yang L, Wong YM, Yeung SY, Yao X, Huang Y, Chen ZY. Conjugated and non-conjugated octadecaenoic acids affect differently intestinal acyl coenzyme A: cholesterol acyltransferase activity. Atherosclerosis 198: 85-93 (2008).
Lam NV, Chen W, Suruga K, Nishimura N, Goda T, Yokogoshi H. Enhancing effect of taurine on CYP7A1 mRNA expression in Hep G2 cells. Amino Acids 30: 43-48 (2006). *
Lam RS, Shaw AR, Duszyk M. Membrane cholesterol content modulates activation of BK channels in colonic epithelia. Biochim. Biophys. Acta 1667: 241-248 (2004). *
Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278: 2563-2570 (2003). *
Lamberts SW, Uitterlinden AG. Genetic testing in clinical practice. Annu. Rev. Med. 60: 431-442 (2009). *
Lambou-Gianoukos S, Heller SJ. Lithogenesis and bile metabolism. Surg. Clin. North Am. 88: 1175-1194 (2008).
Lambrinoudaki I, Kaparos G, Rizos D, Galapi F, Alexandrou A, Sergentanis TN, Creatsa M, Christodoulakos G, Kouskouni E, Botsis D. Apolipoprotein E and paraoxonase 1 polymorphisms are associated with lower serum thyroid hormones in postmenopausal women. Clin. Endocrinol. (Oxf.) 71: 284-290 (2009). *
Lamireau T, Bouchard G, Yousef IM, Clouzeau-Girard H, Rosenbaum J, Desmouliere A, Tuchweber B. Dietary lecithin protects against cholestatic liver disease in cholic acid-fed Abcb4- deficient mice. Pediatr. Res. 61: 185-190 (2007). *
Lammert F, Carey MC, Paigen B. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. Gastroenterology 120: 221-238 (2001). *
Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).
Lammert F, Matern S. Evidence-based prevention of cholecystolithiasis. Dtsch. Med. Wochenschr. 129: 1548-1550 (2004).
Lammert F, Matern S. The genetic background of cholesterol gallstone formation: an inventory of human lithogenic genes. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 163-170 (2005).
Lammert F, Sauerbruch T. Genetics of gallstone disease. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 16-18 (2006). *
Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39: 117-128 (2004). *
Lammert F, Wasmuth HE, Mendez-Sanchez N, Rahbar-Tabrizi N, Schirin-Sokhan R, King-Martinez AC, Marschall HU, Wittenburg H, Uribe M, Matern S. Common haplotypes of the ABCG5/G8 genes encoding the hepatocanalicular cholesterol transporter are associated with cholecystolithiasis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 56. June 18-19 (2004). *
Lampasona V, Petrone A, Tiberti C, Capizzi M, Spoletini M, di Pietro S, Sondini M, Bonicchio S, Giorgino F, Bonifacio E, Bosi E, Bozzetti R; for the NIRAD Study Group. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: NIRAD 4. Diabetes Care Oct 6 [Epub ahead of print] (2009).
Lan Y, Liu J, Cheng H, Zou SL, Gan XL. Expressions of SHP and CYP7A1 in pregnant rats with intrahepatic cholestasis. Zhonghua Gan Zang Bing Za Zhi 16: 453-456 (2008).
Landis MS, Patel HV, Capone JP. Oxysterol activators of liver X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and secretion of tumor necrosis factor-alpha from human monocytes. J. Biol. Chem. 277: 4713-4721 (2002). *
Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates the human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G476-G485 (2006). *
Landrier JF, Gouranton E, Reboul E, Cardinault N, El Yazidi C, Malezet-Desmoulins C, Andr� M, Nowicki M, Souidi M, Borel P. Vitamin E decreases endogenous cholesterol synthesis and apo-AI-mediated cholesterol secretion in Caco-2 cells. J. Nutr. Biochem. Feb 8 [Epub ahead of print] (2010). *
Landrier JF, Grober J, Demydchuk J, Besnard P. FXRE can function as an LXRE in the promoter of human ileal bile acid-binding protein (I-BABP) gene. FEBS Lett. 553: 299-303 (2003). *
Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is PPARalpha-dependent. J. Biol. Chem. 279: 45512-45518 (2004). *
Landrier JF, Thomas C, Grober J, Zaghini I, Petit V, Poirier H, Niot I, Besnard P. The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors. Biochim. Biophys. Acta 1735: 41-49 (2005). *
Lange Y, Ye J, Steck TL. How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids. Proc. Natl. Acad. Sci. U.S.A. 101: 11664-11667 (2004). *
Langheim S, Yu L, von Bergmann K, Lutjohann D, Xu F, Hobbs HH, Cohen JC. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J. Lipid Res. 46: 1732-1738 (2005). *
Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF, Schaffer JE, Ory DS. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc. Natl. Acad. Sci. U.S.A. 103: 13807-13812 (2006). *
Langmann T, Liebisch G, Moehle C, Schifferer R, Dayoub R, Heiduczek S, Grandl M, Dada A, Schmitz G. Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim. Biophys. Acta 1740: 155-161 (2005). *
Langmann T, Porsch-Ozcurumez M, Unkelbach U, Klucken J, Schmitz G. Genomic organization and characterization of the promoter of the human ATP-binding cassette transporter-G1 (ABCG1) gene. Biochim. Biophys. Acta 1494: 175-180 (2000). *
Lanzarotto F, Panarotto B, Sorbara R, Panteghini M, Pagani F, Sosta S, Lanzini A. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. Gut 44: 552-556 (1999). *
Lapidus A, Akerlund JE, Einarss on C. Gallbladder bile composition in patients with Crohn 's disease. World J. Gastroenterol. 12: 70-74 (2006). *
Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm. Bowel Dis. 4: 89-94 (1998). *
Lara LF, Levy MJ. Idiopathic recurrent acute pancreatitis. MedGenMed. 6: 10 (2004). *
Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler. Thromb. Vasc. Biol. 29: 1930-1936 (2009).
Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, Lefevre M, Rood JC, Williamson DA, Ravussin E. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16: 1355-1362 (2008). *
LaRusso NF, Thistle JL. Ursodeoxycholic acid ingestion after ileal resection. Effect on biliary bile acid and lipid composition. Dig. Dis. Sci. 26: 705-709 (1981).
Lau P, Fitzsimmons R, Raichur S, Wang SC, Lechtken A, Muscat GE. The orphan nuclear receptor, RORalpha, regulates gene expression that controls lipid metabolism: staggerer (sg/sg) mice are resistant to diet induced obesity. J. Biol. Chem. 283: 18411-18421 (2008). *
Lauretani F, Semba RD, Bandinelli S, Miller ER 3rd, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L. Plasma polyunsaturated fatty acids and the decline of renal function. Clin. Chem. 54: 475-481 (2008). *
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23: 1464-1467 (1996). *
Lavery DJ, Schibler U. Circadian transcription of the cholesterol 7 alpha hydroxylase gene may involve the liver-enriched bZIP protein DBP. Genes Dev. 7: 1871-1884 (1993). *
Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand Black/White F1 mice. J. Immunol. 173: 7641-7646 (2004). *
Lazaridis KN, LaRusso NF. Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220 (2003). *
Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 98: 1666-1677 (2007). *
Le Goff W, Settle M, Greene DJ, Morton RE, Smith JD. Reevaluation of the role of the multidrug resistant P-glycoprotein in cellular cholesterol homeostasis. J. Lipid Res. 47: 51-58 (2006). *
Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, Martin P, Pineau T, Bournot P. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. Biochim. Biophys. Acta 1683: 49-58 (2004). *
Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B, Sasso GL, Moschetta A, Schibler U. REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol. 7: e1000181 (2009). *
Leaf DA, Hatcher L. The effect of lean fish consumption on triglyceride levels. Phys. Sportsmed. 37: 37-43 (2009).
Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6: 663-672 (2004). *
Leblond F, Seidah NG, Precourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G805-G815 (2009). *
Lebovitz HE. Insulin resistance - a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 8: 237-249 (2006).
Lecerf JM. Fatty acids and cardiovascular disease. Nutr. Rev. 67: 273-283 (2009). *
Leckel K, Blaheta RA, Markus BH. State of hepatocyte transplantation: a risk or a chance? Zentralbl. Chir. 128: 283-290 (2003).
Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496 (2008). *
Lee C, Martin KO, Javitt NB. Bile acid synthesis: 7 alpha-hydroxylation of intermediates in the sterol 27-hydroxylase metabolic pathway. J. Lipid Res. 37: 1356-1362 (1996). *
Lee DD, Stojadinovic O, Krzyzanowska A, Vouthounis C, Blumenberg M, Tomic-Canic M. Retinoid-responsive transcriptional changes in epidermal keratinocytes. J. Cell Physiol. 220: 427-439 (2009).
Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31: 572-580 (2006). *
Lee H, Hubbert ML, Osborne TF, Woodford K, Zerangue N, Edwards PA. Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha. J. Biol. Chem. 282: 21653-21661 (2007). *
Lee H, Kang R, Hahn Y, Yang Y, Kim SS, Cho SH, Chung SI, Yoon Y. Antiobesity effect of baicalin involves the modulations of proadipogenic and antiadipogenic regulators of the adipogenesis pathway. Phytother. Res. 23: 1615-1623 (2009).
Lee J, Choi HS. Reverse cholesterol transport in cultured gallbladder epithelial cells. Korean J. Gastroenterol. 43: 145-152 (2004).
Lee J, Hong EM, Byun HW, Choi MH, Jang HJ, Eun CS, Kae SH, Choi HS. The effect of PPARalpha and PPARgamma ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells. Dig. Dis. Sci. 53: 1707-1715 (2008). *
Lee J, Hong EM, Koh DH, Choi MH, Jang HJ, Kae SH, Choi HS. HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells. Dig. Dis. Sci. Feb 19 [Epub ahead of print] (2009). *
Lee J, Scheri RC, Zhang Y, Curtis LR. Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice. Toxicol. Appl. Pharmacol. 233: 193-202 (2008). *
Lee J, Shirk A, Oram JF, Lee SP, Kuver R. Polarized cholesterol and phospholipid efflux in cultured gall-bladder epithelial cells: evidence for an ABCA1-mediated pathway. Biochem. J. 364: 475-484 (2002). *
Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann. Clin. Lab. Sci. 38: 361-367 (2008).
Lee KH, Choi EM. Effect of pine pollen extract on experimental chronic arthritis. Phytother. Res. 23: 651-657 (2009).
Lee L, Alloosh M, Saxena R, Van Alstine W, Watkins BA, Klaunig JE, Sturek M, Chalasani N. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology 50: 56-67 (2009). *
Lee S. Gallstones: how do we translate an old story into future therapy? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3 (2004). *
Lee SJ, Choi MG, Kim DS, Kim TW. Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients. Metabolism 55: 1-7 (2006). *
Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, Hsiao SH, Pan CC, Kou YR, Hsu YP, Ho LT. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci. 84: 97-104 (2009). *
Lee YH, Alberta JA, Gonzalez FJ, Waxman DJ. Multiple, functional DBP sites on the promoter of the cholesterol 7 alpha-hydroxylase P450 gene, CYP7. Proposed role in diurnal regulation of liver gene expression. J. Biol. Chem. 269: 14681-14689 (1994). *
Lee YK, Moore DD. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J. Biol. Chem. 277: 2463-2467 (2002). *
Lee YK, Moore DD. Liver receptor homolog-1, an emerging metabolic modulator. Front. Biosci. 13: 5950-5958 (2008).
Lee YK, Schmidt DR, Cummins CL, Choi M, Peng L, Zhang Y, Goodwin B, Hammer RE, Mangelsdorf DJ, Kliewer SA. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol. Endocrinol. 22: 1345-1356 (2008). *
Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147-191 (2009). *
Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).
Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R. Expression profiling in APP23 mouse brain: inhibition of A-beta amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodegener. 2: 20 (2007).
Legrand P, Schmitt B, Mourot J, Catheline D, Chesneau G, Mireaux M, Kerhoas N, Weill P. The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese humans. Lipids Dec 14 [Epub ahead of print] (2009).
Leheska JM, Thompson LD, Howe JC, Hentges E, Boyce J, Brooks JC, Shriver B, Hoover L, Miller MF. Effects of conventional and grass feeding systems on the nutrient composition of beef. J. Anim. Sci. 86: 3575-3585 (2008).
Lehmann B. Role of the vitamin D3 pathway in healthy and diseased skin - facts, contradictions and hypotheses. Exp. Dermatol. 18: 97-108 (2009).
Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272: 3137-3140 (1997). *
Lehrke M, Lebherz C, Millington SC, Guan HP, Millar J, Rader DJ, Wilson JM, Lazar MA. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. Cell. Metab. 1: 297-308 (2005). *
Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br. J. Pharmacol. 151: 450-456 (2007). *
Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, Bernheim J, Konikoff FM, Gilat T. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur. J. Gastroenterol. Hepatol. 20: 1205-1213 (2008).
Leiss O, Meyer-Krahmer K, von Bergmann K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. J. Lipid Res. 27: 213-223 (1986).
Leitzmann C. Vegetarian diets: what are the advantages? Forum Nutr. 57: 147-156 (2005).
Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly-Y M, Storlien L, et al. Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol. 4: e369 (2006). *
Lemaire G, Benod C, Nahoum V, Pillon A, Boussioux AM, Guichou JF, Subra G, Pascussi JM, Bourguet W, Chavanieux A, Balaguer P. Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol. Pharmacol. 72: 572-581 (2007). *
Lemberg A, Schreier L, Romay S, Fernandez MA, Rosello D, Gonzales S, Perazzo JC, Filinger EJ, Tomaro ML. Involvement of serum apolipoprotein AI and B100 and lecithin cholesterol acyl transferase in alcoholic cirrhotics. Ann. Hepatol. 6: 227-232 (2007). *
Lemos ET, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Silva GC, Teixeira N, Silva AS, Carvalho L, Teixeira F, Das UN. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition 25: 330-339 (2009). *
Leo MA, Kim C, Lowe N, Lieber CS. Interaction of ethanol with beta-carotene: delayed blood clearance and enhanced hepatotoxicity. Hepatology 15: 883-891 (1992).
Lepage G, Paradis K, Lacaille F, Senechal L, Ronco N, Champagne J, Lenaerts C, Roy CC, Rasquin-Weber A. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J. Pediatr. 130: 52-58 (1997). *
Lepercq P, Hermier D, David O, Michelin R, Gibard C, Beguet F, Relano P, Cayuela C, Juste C. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br. J. Nutr. 93: 457-469 (2005). *
Leung JK, Cases S, Vu TH. P311 functions in an alternative pathway of lipid accumulation that is induced by retinoic acid. J. Cell Sci. 121: 2751-2758 (2008). *
Leuschner M, Leuschner U, Lazarovici D, Kurtz W, Hellstern A. Dissolution of gall stones with an ursodeoxycholic acid menthol preparation: a controlled prospective double blind trial. Gut 29: 428-432 (1988). *
Leuschner U. Drug therapy of gallstone disease. Schweiz. Rundsch. Med. Prax. 81: 905-906 (1992).
Leuschner U. Oral bile acid treatment of biliary cholesterol stones. Recenti Prog. Med. 83: 392-399 (1992).
Leuschner U, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Ital. J. Gastroenterol. 27: 376-377 (1995).
Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig. Dis. Sci. 30: 642-649 (1985).
Leuschner U, Reber E, Erb W. Treatment of patients with gallstones with chenodeoxycholic acid. Dtsch. Med. Wochenschr. 102: 156-160 (1977).
Leuschner U, Schneider M, Korte L. The influence of chenodeoxycholic acid and ursodeoxycholic acid on the hepatic structure of the rat. Z. Gastroenterol. 17: 244-255 (1979).
Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135-142 (2005). *
Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition and pathophysiology. Antioxid. Redox Signal. Nov 4 [Epub ahead of print] (2009).
Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).
Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *
Levy E. The metabolic syndrome: can nutrition influence rebellious organs? Bull. Acad. Natl. Med. 193: 1271-1278 (2009).
Levy E, Brunet S, Alvarez F, Seidman E, Bouchard G, Escobar E, Martin S. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. Life Sci. 80: 1472-1483 (2007). *
Levy E, Lalonde G, Delvin E, Elchebly M, Precourt LP, Seidah NG, Spahis S, Rabasa-Lhoret R, Ziv E. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology Feb 3 [Epub ahead of print] (2010).
Levy E, Spahis S, Sinnett D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 18: 310-318 (2007).
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G; LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77: 1632-1638 (2004).
Levy J, Budai K, Javitt NB. Bile acid synthesis in HepG2 cells: effect of cyclosporin. J. Lipid Res. 35: 1795-1800 (1994). *
Levy O, Elsbach P. Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr. Infect. Dis. Rep. 3: 407-412 (2001).
Lew JL, Zhao A, Yu J, Huang L, De Pedro N, Pelaez F, Wright SD, Cui J. The farnesoid X receptor (FXR) controls gene expression in a ligand- and promoter- selective fashion. J. Biol. Chem. 279: 8856-8861 (2004). *
Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr. Opin. Cardiol. 21: 345-352 (2006).
Lewis NR, Sanders DS, Logan RF, Fleming KM, Hubbard RB, West J. Cholesterol profile in people with newly diagnosed coeliac disease: a comparison with the general population and changes following treatment. Br. J. Nutr. 102: 509-513 (2009). *
Lewis SJ. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. Am. J. Med. 122: S38-S50 (2009). *
Lewkowicz P, Banasik M, Glowacka E, Lewkowicz N, Tchorzewski H. Effect of high doses of shark liver oil supplementation on T cell polarization and peripheral blood polymorphonuclear cell function. Pol. Merkuriusz. Lek. 18: 686-692 (2005).
Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114: 1564-1576 (2004). *
Li AC, Glass CK. PPAR and LXR-dependent pathways controlling lipid metabolism and development of atherosclerosis. J. Lipid Res. 45: 2161-2173 (2004). *
Li C, Xu M, Gu Q. ATP binding cassette transporter G1 gene expression is reduced in type 2 diabetic patients. Endocr. J. 56: 313 (2009). *
Li CP, Tong MJ, Hwang SJ, Luo JC, Co RL, Tsay SH, Chang FY, Lee SD. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J. Gastroenterol. Hepatol. 15: 95-98 (2000). *
Li D, Wu Y, Zhang AZ, Wahlqvist ML. Omega-3 PUFA status in type 2 diabetes mellitus patients, a case-control study. Asia Pac. J. Clin. Nutr. 14: S101 (2005).
Li F, Tan W, Kang Z, Wong CW. Tocotrienol enriched palm oil prevents atherosclerosis through modulating the activities of peroxisome proliferators-activated receptors. Atherosclerosis Jan 25 [Epub ahead of print] (2010).
Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J. Pharmacol. Exp. Ther. 318: 956-965 (2006). *
Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, Salen G. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7alpha-hydroxylase. Metabolism 53: 927-932 (2004). *
Li J, Scherl A, Medina F, Frank PG, Kitsis RN, Tanowitz HB, Sotgia F, Lisanti MP. Impaired phagocytosis in caveolin-1 deficient macrophages. Cell Cycle 4: 1599-1607 (2005). *
Li J, Wilson A, Gao X, Kuruba R, Liu Y, Poloyac S, Pitt B, Xie W, Li S. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J. Pharmacol. Exp. Ther. 331: 234-243 (2009). *
Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, Li S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 77: 169-177 (2008). *
Li J, Zhang JZ, Zou CP, Fang BJ, Liang XQ. Shengqing Capsule down-regulates estrogen and progesterone receptors in epithelial tissue of gallbladder in guinea pigs with gallstone. Zhong Xi Yi Jie He Xue Bao 6: 1040-1044 (2008).
Li JQ, Li MY, Dai YX, Liu YM, Zheng J, Liu WB. Serum adiponectin and free fatty acid profile in essential hypertensive patients with or without metabolic syndrome. Zhonghua Xin Xue Guan Bing Za Zhi 36: 232-235 (2008).
Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin. Cardiol. 29: 300-304 (2006).
Li L, Xu X, Lu F, Zhao N. Effects of ursodeoxycholic acid on intrahepatic cholestasis in rats. Chin. Med. J. (Engl.) 116: 1099-1103 (2003).
Li LL, Kang XL, Ran XJ, Wang Y, Wang CH, Huang L, Ren J, Luo X, Mao XM. Associations between 45T/G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 34: 1287-1290 (2007). *
Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, Mao XM. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects. Clin. Exp. Pharmacol Physiol. 35: 187-191 (2008).
Li P, Kim SW, Li X, Datta S, Pond WG, Wu G. Dietary supplementation with cholesterol and docosahexaenoic acid affects concentrations of amino acids in tissues of young pigs. Amino Acids 37: 709-716 (2009). *
Li S, Zhang ZW, Guan YF. On the bile acid receptor FXR. Sheng Li Ke Xue Jin Zhan 34: 314-318 (2003).
Li SY, Chang CQ, Ma FY, Yu CL. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet. Biomed. Environ. Sci. 22: 122-129 (2009).
Li T, Chanda D, Zhang Y, Choi HS, Chiang JY. Glucose stimulates cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription in human hepatocytes. J. Lipid Res. Oct 28 [Epub ahead of print] (2009). *
Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 48: 373-384 (2007). *
Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G74-G84 (2005). *
Li T, Chiang JY. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009: 501739 (2009). *
Li T, Chiang JY. A novel role of transforming growth factor beta1 in transcriptional repression of human cholesterol 7alpha-hydroxylase gene. Gastroenterology 133: 1660-1669 (2007). *
Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-Jun pathway in human liver cells. Hepatology 43: 1202-1210 (2006). *
Li T, Kong X, Owsley E, Ellis E, Strom S, Chiang JY. Insulin regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element binding protein 1c. J. Biol. Chem. 281: 28745-28754 (2006). *
Li T, Ma H, Chiang JY. TGFbeta1, TNFalpha, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. J. Lipid Res. 49: 1981-1989 (2008). *
Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28: 91-106 (2007). *
Li X, Zhou Z, Huang G, Su H, Yan X, Yang L. Metabolic syndrome in adult-onset latent autoimmune diabetes. Metab. Syndr. Relat. Disord. 3: 174-180 (2005).
Li Y, Bolten C, Bhat BG, Woodring-Dietz J, Li S, Prayaga SK, Xia C, Lala DS. Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol. Endocrinol. 16: 506-514 (2002). *
Li Y, Choi M, Suino K, Kovach A, Daugherty J, Kliewer SA, Xu HE. Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. Proc. Natl. Acad. Sci. U.S.A. 102: 9505-9510 (2005). *
Li Y, Fisher E, Klapper M, Boeing H, Pfeiffer A, Hampe J, Schreiber S, Burwinkel B, Schrezenmeir J, Doring F. Association between functional FABP2 promoter haplotype and type 2 diabetes. Horm. Metab. Res. 38: 300-307 (2006).
Li Y, Mezei O, Shay NF. Human and murine hepatic sterol-12-alpha-hydroxylase and other xenobiotic metabolism mRNA are upregulated by soy isoflavones. J. Nutr. 137: 1705-1712 (2007). *
Li Z, Zhang Q, Peng X, Wu Y, Xia Y, Liu X. The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes Obes. Metab. 10: 794-802 (2008). *
Li-Hawkins J, Gafvels M, Olin M, Lund EG, Andersson U, Schuster G, Bjorkhem I, Russell DW, Eggertsen G. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Invest. 110: 1191-1200 (2002). *
Li-Hawkins J, Lund EG, Bronson AD, Russell DW. Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275: 16543-16549 (2000). *
Li-Hawkins J, Lund EG, Turley SD, Russell DW. Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 275: 16536-16542 (2000). *
Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276: 49066-49076 (2001). *
Liang XM, Otani H, Zhou Q, Tone Y, Fujii R, Mune M, Yukawa S, Akizawa T. Various dietary protein intakes and progression of renal failure in spontaneously hypercholesterolemic Imai rats. Nephron. Exp. Nephrol. 105: e98-e107 (2007).
Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 88: 623-634 (2004). *
Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).
Liao H, Langmann T, Schmitz G, Zhu Y. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22: 127-132 (2002). *
Liao YF, Chen LL, Zeng TS, Zheng J, Li HQ. Association of the +33371 A/G polymorphism in adiponectin receptor 2 gene with type 2 diabetes in the Chinese population. J. Endocrinol. Invest. 30: 860-864 (2007).
Lichti-Kaiser K, Xu C, Staudinger JL. Cyclic AMP-dependent protein kinase signaling modulates pregnane X receptor activity in a species-specific manner. J. Biol. Chem. 284: 6639-6649 (2009). *
Liddle C, Goodwin B. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin. Liver Dis. 22: 115-122 (2002).
Lilja HE, Suviolahti E, Soro-Paavonen A, Hiekkalinna T, Day A, Lange K, Sobel E, Taskinen MR, Peltonen L, Perola M, Pajukanta P. Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia. J. Lipid Res. 45: 1876-1884 (2004). *
Lillienau J, Hagey LR, Borgstrom B. Hepatic and ileal transport and effect on biliary secretion of norursocholic acid and its conjugates in rats. Am. J. Physiol. 261: G1057-G1064 (1991).
Lim A, Manley K, Roberts M, Fraenkel M. Fish oil for kidney transplant recipients. Cochrane Database Syst. Rev. 2: CD005282 (2007). *
Lim C, Bijvelds M, Nigg A, Schoonderwoerd K, Houtsmuller A, de Jonge H, Tilly B. Cholesterol depletion and genistein as tools to promote F508delCFTR retention at the plasma membrane. Cell. Physiol. Biochem. 20: 473-482 (2007). *
Lim GH, Roslani AC, Pang B, Bih-Shiou CT. Cholesterol atheroembolism of the colon can mimic the endoscopic features of pseudomembranous colitis. Surg. Laparosc. Endosc. Percutan. Tech. 18: 616-618 (2008).
Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, Jawan B, Chen CL. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl. 11: 1258-1264 (2005). *
Lin CC, Yin MC, Liu WH. Alleviative effects of S-allyl cysteine and S-ethyl cysteine on MCD diet-induced hepatotoxicity in mice. Food Chem. Toxicol. 46: 3401-3406 (2008). *
Lin DC. Probiotics as functional foods. Nutr. Clin. Pract. 18: 497-506 (2003). *
Lindegaard ML, Wassif CA, Vaisman B, Amar M, Wasmuth EV, Shamburek R, Nielsen LB, Remaley AT, Porter FD. Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome. Hum. Mol. Genet. 17: 3806-3813 (2008).
Linden D, William-Olsson L, Ahnmark A, Ekroos K, Hallberg C, Sjogren HP, Becker B, Svensson L, Clapham JC, Oscarsson J, Schreyer S. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J. 20: 434-443 (2006). *
Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K. Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J. Lipid Res. 43: 1072-1077 (2002). *
Lindholm D, Bornhauser BC, Korhonen L. Mylip makes an Idol turn into regulation of LDL receptor. Cell. Mol. Life Sci. 66: 3399-3402 (2009). *
Lindi V, Schwab U, Louheranta A, Vessby B, Hermansen K, Tapsell L, Riccardi G, Rivellese AA, Laakso M, Uusitupa MI; KANWU Study Group. The G-250A polymorphism in the hepatic lipase gene promoter is associated with changes in hepatic lipase activity and LDL cholesterol: the KANWU study. Nutr. Metab. Cardiovasc. Dis. 18: 88-95 (2008).
Lindner MA. A fish oil diet inhibits colon cancer in mice. Nutr. Cancer 15: 1-11 (1991).
Lindqvist HM, Sandberg AS, Fagerberg B, Hulthe J. Plasma phospholipid EPA and DHA in relation to atherosclerosis in 61-year-old men. Atherosclerosis 205: 574-578 (2009).
Lindshield BL, King JL, Wyss A, Goralczyk R, Lu CH, Ford NA, Erdman JW Jr. Lycopene biodistribution is altered in 15,15'-carotenoid monooxygenase knockout mice. J. Nutr. 138: 2367-2371 (2008). *
Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 327: 46-50 (2010). *
Liou YA, King DJ, Zibrik D, Innis SM. Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J. Nutr. 137: 945-952 (2007). *
Lipozencic J. The 1st world congress on gender-specific medicine men, women and medicine a new view of the biology of sex/gender differences and aging. Acta Dermatovenerol. Croat. 14: 132-134 (2006).
Lirussi F, Vaja S, Murphy GM, Dowling RH. Cholestasis of total parenteral nutrition: bile acid and bile lipid metabolism in parenterally nourished rats. Gastroenterology 96: 493-502 (1989).
Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem. Sci. 25: 530-534 (2000). *
Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10: 728-733 (2004). *
Liu HL, Lin YG, Wu J, Sun H, Gong ZC, Hu PC, Yin JY, Zhang W, Wang D, Zhou HH, Liu ZQ. Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes. Eur. J. Clin. Pharmacol. 64: 663-671 (2008). *
Liu HR, Tao L, Gao E, Qu Y, Lau WB, Lopez BL, Christopher TA, Koch W, Yue TL, Ma XL. Rosiglitazone inhibits hypercholesterolemia-induced myeloperoxidase upregulation - a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc. Res. 81: 344-352 (2009). *
Liu JJ, Glickman JN, Masyuk AI, LaRusso NF. Cholangiocyte bile salt transporters in cholesterol gallstone-susceptible and resistant inbred mouse strains. J. Gastroenterol. Hepatol. 23: 1596-1602 (2008). *
Liu JP. New functions of cholesterol binding proteins. Mol. Cell. Endocrinol. 303: 1-6 (2009).
Liu R, Iqbal J, Yeaong C, Wang DQ, Hussain MM, Jiang XC. Phospholipid transfer protein-deficient mice absorb less cholesterol. Arterioscler. Thromb. Vasc. Biol. 27: 2014-2021 (2007). *
Liu SP, Li YS, Chen YJ, Chiang EP, Li AF, Lee YH, Tsai TF, Hsiao M, Hwang SF, Chen YM. Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver. Hepatology 46: 1413-1425 (2007). *
Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J. Autoimmun. 25: 258-263 (2005).
Liu XH, Tang CK. The research progress of ATP binding cassette transporter G1. Sheng Li Ke Xue Jin Zhan 40: 229-233 (2009).
Liu Y, Havinga R, van der Leij FR, Boverhof R, Sauer PJ, Kuipers F, Stellaard F. Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. Pediatr. Res. 63: 375-381 (2008). *
Liu Y, Yu H, Zhang Y, Zhao Y. TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med. Hypotheses 70: 314-316 (2008).
Ljungberg A, Linden D, Ameen C, Bergstrom G, Oscarsson J. Importance of PPARalpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism. Growth Horm. IGF Res. 17: 154-164 (2007).
Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol. 7: 73-89 (2006).
Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, Getz GS, Fu YX. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316: 285-288 (2007). *
Lo Sasso G, Celli N, Caboni M, Murzilli S, Salvatore L, Morgano A, Vacca M, Pagliani T, Parini P, Moschetta A. Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. Hepatology Nov 13 [Epub ahead of print] (2009). *
Lo Sasso G, Petruzzelli M, Moschetta A. A translational view on the biliary lipid secretory network. Biochim. Biophys. Acta 1781: 79-96 (2008). *
Lobaccaro JM, Repa JJ, Lu TT, Caira F, Henry-Berger J, Volle DH, Mangelsdorf DJ. Regulation of lipid metabolism by the orphan nuclear receptors. Ann. Endocrinol. (Paris) 62: 239-247 (2001).
Lobo GP, Hessel S, Eichinger A, Noy N, Moise AR, Wyss A, Palczewski K, von Lintig J. ISX is a retinoic acid-sensitive gatekeeper that controls intestinal beta,beta-carotene absorption and vitamin A production. FASEB J. Jan 8 [Epub ahead of print] (2010). *
Lockman AR, Tribastone AD, Knight KV, Franko JP. Treatment of cholesterol abnormalities. Am. Fam. Physician 71: 1137-1142 (2006). *
Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Adult heart block is associated with disease activity in primary Sjogren's syndrome. Scand. J. Rheumatol. 34: 383-386 (2005). *
Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Serum lipid levels in Sjogren's syndrome. Rheumatology (Oxford) 45: 481-484 (2006). *
Loginov AS, Matiushin BN, Tkachev VD, Iakimchuk GN. A new approach to the diagnosis of cholestasis by the activity of copper-containing enzymes. Ter. Arkh. 65: 34-36 (1993).
Loginov AS, Reshetniak VI, Petrakov AV. The treatment of primary biliary liver cirrhosis with rifampicin. Ter. Arkh. 65: 57-62 (1993).
Loguercio C, Federico A, Masarone M, Torella R, Blanco CD, Persico M. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. Am. J. Gastroenterol. 103: 3159-3166 (2008). *
London RM, George J. Pathogenesis of NASH: animal models. Clin. Liver Dis.11: 55-74 (2007).
Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, Podda M. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51: 265-269 (2002). *
Longo M, Crosignani A, Podda M. Hyperlipidemia in chronic cholestatic liver disease. Curr. Treat. Options Gastroenterol. 4: 111-114 (2001).
Look MP, Reichel C, von Falkenhausen M, Hahn C, Stockinger K, von Bergmann K, Rao GS, Spengler U, Sauerbruch T. Vitamin E status in patients with liver cirrhosis: normal or deficient? Metabolism 48: 86-91 (1999).
Loomba R, Bettencourt R, Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment. Pharmacol. Ther. 30: 1137-1149 (2009). *
Lopez D, McLean MP. Estrogen regulation of the scavenger receptor class B gene: anti-atherogenic or steroidogenic, is there a priority? Mol. Cell. Endocrinol. 247: 22-33 (2006).
Lopez LR, Hurley BL, Simpson DF, Matsuura E. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 1051: 97-103 (2005). *
Lopez P, Gutierrez C, Suarez A. IFNalpha treatment generates antigen-presenting cellsinsensitive to atorvastatin inhibition of MHC-II expression. Clin. Immunol. 129: 350-359 (2008). *
Lopez-Huertas E. Health effects of oleic acid and long chain omega-3 fatty acids (EPA and DHA) enriched milks. A review of intervention studies. Pharmacol. Res. Nov 5 [Epub ahead of print] (2009). *
Lorkowski S, Kratz M, Wenner C, Schmidt R, Weitkamp B, Fobker M, Reinhardt J, Rauterberg J, Galinski EA, Cullen P. Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8) in Tangier disease. Biochem. Biophys. Res. Commun. 283: 821-830 (2001). *
Lorkowski S, Rust S, Engel T, Jung E, Tegelkamp K, Galinski EA, Assmann G, Cullen P. Genomic sequence and structure of the human ABCG1 (ABC8) gene. Biochem. Biophys. Res. Commun. 280: 121-131 (2001). *
Lourida ES, Georgiadis AN, Papavasiliou EC, Papathanasiou AI, Drosos AA, Tselepis AD. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized LDL and decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res. Ther. 9: R19 (2007). *
Lovas K, Rost TH, Skorve J, Ulvik RJ, Gudbrandsen OA, Bohov P, Wensaas AJ, Rustan AC, Berge RK, Husebye ES. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes Obes. Metab. 11: 304-314 (2009). *
Love JD, Gooch JT, Benko S, Li C, Nagy L, Chatterjee VK, Evans RM, Schwabe JW. The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12. J. Biol. Chem. 277: 11385-11391 (2002). *
Love MW, Dawson PA. New insights into bile acid transport. Curr. Opin. Lipidol. 9: 225-229 (1998).
Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol. Belg. 70: 381-388 (2007).
Lozano A, Vildosola H, Takano J, Vargas G, Uribe R, Moreno C. Clinical and immunological profile in 22 patients with primary biliary cirrhosis. Rev. Gastroenterol. Peru. 20: 14-24 (2000).
Lozanoska-Ochser B, Barone F, Pitzalis C, Peakman M. Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells. Diabetes 55: 1004-1010 (2006). *
Lu H, Sun J, Sun L, Shu X, Xu Y, Xie D. Polymorphism of human leptin receptor gene is associated with type 2 diabetic patients complicated with non-alcoholic fatty liver disease in China. J. Gastroenterol. Hepatol. 24: 228-232 (2009). *
Lu J, Wu DM, Zheng YL, Sun DX, Hu B, Shan Q, Zhang ZF, Fan SH. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF-mediated inflammatory pathway. Brain Behav. Immun. 23: 193-203 (2009).
Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer HB Jr, Salen G, Dean M, Srivastava A, Patel SB. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am. J. Hum. Genet. 69: 278-290 (2001). *
Lu R, Ito JI, Iwamoto N, Nishimaki-Mogami T, Yokoyama S. Fibroblast growth factor-1 induces expression of LXRalpha and production of 25-hydroxycholesterol to up-regulate apolipoprotein E gene transcription in rat astrocytes. J. Lipid Res. 50: 1156-1164 (2009). *
Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6: 507-515 (2000). *
Lu Y, Dolle ME, Imholz S, van 't Slot R, Verschuren WM, Wijmenga C, Feskens EJ, Boer JM. Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations. J. Lipid Res. 49: 2582-2589 (2008). *
Luley C. Lipometabolic disorder - cholesterol and triglycerides. Clin. Res. Cardiol. 95 Suppl. 6: vi17-vi22 (2006).
Lund E, Boberg KM, Bystrom S, Olund J, Carlstrom K, Bjorkhem I. Formation of novel C21-bile acids from cholesterol in the rat. Structure identification of the major di- and trihydroxylated species. J. Biol. Chem. 266: 4929-4937 (1991). *
Lund EG, Peterson LB, Adams AD, Lam MH, Burton CA, Chin J, Guo Q, Huang S, Latham M, Lopez JC, Menke JG, Milot DP, Mitnaul LJ, Rex-Rabe SE, Rosa RL, Tian JY, Wright SD, Sparrow CP. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem. Pharmacol. 71: 453-463 (2006). *
Lundasen T, Andersson EM, Schreyer S, Ostlund-Lindqvist AM, Angelin B, Rudling M. Ileal bile acid transport inhibition lowers plasma glucose and lipid levels in ob/ob mice. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 45 (2006). *
Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260: 530-536 (2006). *
Lundell K, Wikvall K. Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9: 323-331 (2008).
Lundin EA, Zhang JX, Lairon D, Tidehag P, Aman P, Adlercreutz H, Hallmans G. Effects of meal frequency and high-fibre rye-bread diet on glucose and lipid metabolism and ileal excretion of energy and sterols in ileostomy subjects. Eur. J. Clin. Nutr. 58: 1410-1419 (2004). *
Lundquist JT, Harnish DC, Kim CY, Mehlmann JF, Unwalla RJ, Phipps KM, Crawley ML, Commons T, Green DM, Xu W, Hum WT, Eta JE, Feingold I, Patel V, Evans MJ, Lai K, Borges-Marcucci L, Mahaney PE, Wrobel JE. Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J. Med. Chem. Jan 22 [Epub ahead of print] (2010). *
Luoma PV. Cytochrome P450 - physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Ann. Med. 39: 359-370 (2007).
Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 185: 33-42 (2006).
Lutjohann D, Hahn C, Prange W, Sudhop T, Axelson M, Sauerbruch T, von Bergmann K, Reichel C. Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. Int. J. Clin. Pharmacol. Ther. 42: 307-313 (2004).
Lv S, Fan R, Du Y, Hou M, Tang Z, Ling W, Zhu H. Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice. Eur. J. Nutr. 48: 205-212 (2009).
Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch. Dis. Child. 75: 67-70 (1996). *
Lyons MA, Wittenburg H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 131: 1943-1970 (2006). *
Lyons MA, Wittenburg H. Susceptibility to cholesterol gallstone formation: evidence that LITH genes also encode immune-related factors. Biochim. Biophys. Acta 1761: 1133-1147 (2006). *
Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48: 770-781 (2008). *
Ma SW, Benzie IF, Yeung VT. Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism. Transl. Res. 152: 134-142 (2008). *
Ma X, Hu YW, Mo ZC, Li XX, Liu XH, Xiao J, Yin WD, Liao DF, Tang CK. NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. Cardiovasc. Drugs Ther. 23: 199-206 (2009).
Ma Y, Xu L, Rodriguez-Agudo D, Li X, Heuman DM, Hylemon PB, Pandak WM, Ren S. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am. J. Physiol. Endocrinol. Metab. 295: E1369-E1379 (2008). *
Mabley JG, Wallace R, Pacher P, Murphy K, Szabo C. Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int. J. Mol. Med. 19: 947-952 (2007). *
Maccio DR, Calfa G, Roth GA. Oral testosterone in male rats and the development of experimental autoimmune encephalomyelitis. Neuroimmunomodulation 12: 246-254 (2005).
MacDonald AC, Williams CN. Studies of bile lipids and bile acids of wild North American black bears in Nova Scotia, showing a high content of ursodeoxycholic acid. J. Surg. Res. 38: 173-179 (1985).
MacDonald IA, Williams CN, Sutherland JD, MacDonald AC. Estimation of ursodeoxycholic acid in human and bear biles using Clostridium absonum 7 beta-hydroxysteroid dehydrogenase. Anal. Biochem. 135: 349-354 (1983).
Mace S, Cousin E, Ricard S, Genin E, Spanakis E, Lafargue-Soubigou C, Genin B, Fournel R, Roche S, Haussy G, Massey F, Soubigou S, Brefort G, Benoit P, Brice A, Campion D, Hollis M, Pradier L, Benavides J, Deleuze JF. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol. Dis. 18: 119-125 (2005).
Macias RI, Jimenez S, Serrano MA, Monte MJ, Marin JJ. Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sci. 79: 1014-1019 (2006). *
Macias RI, Serrano MA, Monte MJ, Jimenez S, Hernandez B, Marin JJ. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis. J. Pharmacol. Exp. Ther. 312: 751-758 (2005). *
Mack JT, Beljanski V, Tew KD, Townsend DM. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. Biomed. Pharmacother. 60: 587-592 (2006).
Mack JT, Townsend DM, Beljanski V, Tew KD. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr. Drug Metab. 8: 47-57 (2007).
Madden J, Carrero JJ, Brunner A, Dastur N, Shearman CP, Calder PC, Grimble RF. Polymorphisms in the CD36 gene modulate the ability of fish oil supplements to lower fasting plasma triacyl glycerol and raise HDL cholesterol concentrations in healthy middle-aged men. Prostaglandins Leukot. Essent. Fatty Acids 78: 327-335 (2008). *
Madsen L, Petersen RK, Steffensen KR, Pedersen LM, Hallenborg P, Ma T, Froyland L, D�skeland SO, Gustafsson JA, Kristiansen K. Activation of liver X receptors prevents statin-induced death of 3T3-L1 preadipocytes. J. Biol. Chem. 283: 22723-22736 (2008). *
Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85: 275-291 (1999).
Magadmi ME, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM, Durrington PN, Laing I, Bruce IN. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J. Rheumatol. 33: 50-56 (2006). *
Magae J, Tsuruga M, Maruyama A, Furukawa C, Kojima S, Shimizu H, Ando K. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes. J. Antibiot. (Tokyo) 62: 365-369 (2009).
Magdeldin S, Elewa Y, Ikeda T, Ikei J, Zhang Y, Xu B, Nameta M, Fujinaka H, Yoshida Y, Yaoita E, Yamamoto T. Dietary supplementation with arachidonic acid but not eicosapentaenoic or docosahexaenoic acids alter lipids metabolism in C57BL/6J mice. Gen. Physiol. Biophys. 28: 266-275 (2009).
Mahadevan U, Sandborn WJ. Evolving medical therapies for Crohn's disease. Curr. Gastroenterol. Rep. 3: 471-476 (2001).
Mahmutefendic H, Blagojevic G, Kucic N, Lucin P. Constitutive internalization of murine MHC class I molecules. J. Cell. Physiol. 210: 445-455 (2006). *
Mailhot G, Ravid Z, Barchi S, Moreau A, Rabasa-Lhoret R, Levy E. CFTR knockdown stimulates lipid synthesis and transport in intestinal Caco-2/15 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G1239-G1249 (2009). *
Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54: 2817-2829 (2006). *
Mainous AG 3rd, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. Ann. Fam. Med. 2: 133-138 (2004). *
Maitra U, Parks JS, Li L. Innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1 mediated down-regulation of RARalpha and NFATc2. Mol. Cell Biol. 29: 5989-5997 (2009). *
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV. Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am. J. Clin. Nutr. Jan 20 [Epub ahead of print] (2010). *
Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am. J. Cardiol. 102: 429-433 (2008).
Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr. Pharm. Des. 15: 290-303 (2009).
Makino I, Nakagawa S. Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid. J. Lipid Res. 19: 723-728 (1978). *
Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 97: 177-183 (2005). *
Makishima M. Regulation of cholesterol homeostasis by nuclear receptors. Seikagaku 76: 509-516 (2004).
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365 (1999). *
Makni M, Fetoui H, Gargouri NK, Garoui EM, Jaber H, Makni J, Boudawara T, Zeghal N. Hypolipidemic and hepatoprotective effects of flax and pumpkin seed mixture rich in omega-3 and omega-6 fatty acids in hypercholesterolemic rats. Food Chem. Toxicol. 46: 3714-3720 (2008). *
Makowski P, Pikula S. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394 (1997).
Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol. 33: 2458-2463 (2006).
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am. J. Gastroenterol. Jan 12 [Epub ahead of print] (2010). *
Malandrino N, Capristo E, Farnetti S, Leggio L, Abenavoli L, Addolorato G, Gasbarrini G. Metabolic and nutritional features in adult celiac patients. Dig. Dis. 26: 128-133 (2008).
Malerod L, Sporstol M, Juvet LK, Mousavi SA, Gjoen T, Berg T, Roos N, Eskild W. Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH-1. Biochem. Biophys. Res. Commun. 336: 1096-1105 (2005). *
Malesci D, Valentini G, La Montagna G. Metabolic syndrome in inflammatory rheumatic diseases. Reumatismo 58: 169-176 (2006).
Malinowski JM, Metka K. Elevation of low-density lipoprotein cholesterol concentration with over-the-counter fish oil supplementation. Ann. Pharmacother. 41: 1296-1300 (2007).
Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 54: 614-621 (2006).
Malyszko J, Malyszko JS, Mysliwiec M. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. Transplant. Proc. 41: 3056-3059 (2009). *
Mamianetti A, Garrido D, Carducci CN, Vescina MC. Fecal bile acid excretion profile in gallstone patients. Medicina (B. Aires) 59: 269-273 (1999).
Mamoon A, Ventura-Holman T, Maher JF, Subauste JS. Retinoic acid responsive genes in the murine hepatocyte cell line AML 12. Gene 408: 95-103 (2008). *
Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J. Invest. Dermatol. 126: 386-392 (2006). *
Mandeville WH, Arbeeny C. Bile acid sequestrants: their use in combination with other lipid-lowering agents. IDrugs 2: 237-242 (1999).
Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. Ann. N. Y. Acad. Sci. 1179: 179-198 (2009). *
Manes S, del Real G, Martinez-A C. Pathogens: raft hijackers. Nat. Rev. Immunol. 3: 557-568 (2003).
Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42: 181-188 (2001).
Manson ME, Corey DA, White NM, Kelley TJ. cAMP-mediated regulation of cholesterol accumulation in cystic fibrosis and Niemann-Pick type C cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L809-L819 (2008). *
Mantaring M, Rhyne J, Ho Hong S, Miller M. Genotypic variation in ATP-binding cassette transporter-1 (ABCA1) as contributors to the high and low high-density lipoprotein-cholesterol (HDL-C) phenotype. Transl. Res. 149: 205-210 (2007). *
Marai I, Shoenfeld Y. The beneficial effects of statins in autoimmune disease therapy. Drug News Perspect. 20: 165-169 (2007).
Marasini B, Pipia C, DeValle G, Crosignani A, Petroni L, Cugno M, Zeni S, Bruno S, Bassani C. Vascular impairment in patients with primary biliary cirrhosis. Int. J. Microcirc. Clin. Exp. 15: 75-79 (1995).
Marcil M, Vu H, Cui W, Dastani Z, Engert JC, Gaudet D, Castro-Cabezas M, Sniderman AD, Genest Jr J, Cianflone K. Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemia. Arterioscler. Thromb. Vasc. Biol. 26: 1619-1625 (2006). *
Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin. Cardiol. 32: 365-372 (2009).
Marin JJG, Romero MR, Vallejo M, Perez MJ, Briz O. Emerging interest in bile acid transporters in pathophysiology and pharmacology. Med. Hypotheses Res. 2: 425-448 (2005). *
Marino JP Jr, Kallander LS, Ma C, Oh HJ, Lee D, Gaitanopoulos DE, Krawiec JA, Parks DJ, Webb CL, Ziegler K, Jaye M, Thompson SK. The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages. Bioorg. Med. Chem. Lett. 19: 5617-5621 (2009). *
Marouf R, Mojiminiyi O, Qurtom M, Abdella N, Al Wazzan H, Al Humood S, Al Mazeedy M. Plasma homocysteine and hematological factors in patients with venous thromboembolic diseases in Kuwait. Acta Haematol. 117: 98-105 (2006).
Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41: 514-520 (2000). *
Marrink SJ, Vries AH, Harroun TA, Katsaras J, Wassall SR. Cholesterol shows preference for the interior of polyunsaturated lipid membranes. J. Am. Chem. Soc. 130: 10-11 (2008).
Marschall HU, Busch N. CSE (cholesterol-synthesis enzyme) inhibitors in the treatment of hypercholesterolemia in primary biliary cirrhosis. Dtsch. Med. Wochenschr. 125: 100-101 (2000).
Marschall HU, Einarsson C. Gallstone disease. J. Intern. Med. 261: 529-542 (2007). *
Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *
Marschall HU, Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Diczfalusy U, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Comprehensive study of the effects of rifampicin and ursodeoxycholic acid on genes and proteins involved in regulation, transport and detoxification of biliary compounds in gallstone patients. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 47. June 18-19 (2004). *
Martin B, Solanas-Barca M, Garcia-Otin AL, Pamp�n S, Cofan M, Ros E, Rodriguez-Rey JC, Pocov� M, Civeira F. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutr. Metab. Cardiovasc. Dis. Sep 10 [Epub ahead of print] (2009).
Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein (L-FABP) gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G36-G48 (2006). *
Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560 (2005). *
Martin GG, Atshaves BP, McIntosh AL, Payne HR, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice. Mol. Cell. Biochem. 324: 101-115 (2009). *
Martin HJ, Maser E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem. Biol. Interact. 178: 145-150 (2009). *
Martin JM, Beshears J, Milkman KL, Bazerman MH, Sutherland LA. Modeling expert opinions on food healthfulness: a nutrition metric. J. Am. Diet. Assoc. 109: 1088-1091 (2009). *
Martin KO, Budai K, Javitt NB. Cholesterol and 27-hydroxycholesterol 7 alpha-hydroxylation: evidence for two different enzymes. J. Lipid Res. 34: 581-588 (1993). *
Martin KO, Reiss AB, Lathe R, Javitt NB. 7 alpha-Hydroxylation of 27-hydroxycholesterol: biologic role in the regulation of cholesterol synthesis. J. Lipid Res. 38: 1053-1058 (1997). *
Martin MT, Brennan R, Hu W, Ayanoglu E, Lau C, Ren H, Wood CR, Corton JC, Kavlock RJ, Dix DJ. Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. Toxicol. Sci. 97: 595-613 (2007). *
Martin SC, Viljoen A. The value of a specialist lipid clinic. Int. J. Clin. Pract. 62: 961-966 (2008).
Martin V, Fabelo N, Santpere G, Puig B, Marin R, Ferrer I, Diaz M. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J. Alzheimers Dis. 19: 489-502 (2010).
Mart�n V, Fabelo N, Santpere G, Puig B, Mar�n R, Ferrer I, D�az M. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J. Alzheimers Dis. Oct 8 [Epub ahead of print] (2009).
Martinez LO, Jacquet S, Terce F, Collet X, Perret B, Barbaras R. New insight on the molecular mechanisms of high-density lipoprotein cellular interactions. Cell. Mol. Life Sci. 61: 2343-2360 (2004). *
Martinez N, Capobianco E, White V, Pustovrh M, Higa R, Jawerbaum A. Peroxisome proliferator-activated receptor alpha activation regulates lipid metabolism in the feto-placental unit from diabetic rats. Reproduction 136: 95-103 (2008). *
Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide Arberas MV, Rueda Gutierrez M, Aguirre Errasti C. Plasma homocysteine levels in systemic lupus erythematosus. Med. Clin. (Barc.) 120: 681-685 (2003).
Martinez-Calatrava MJ, Martinez-Larrad MT, Zabena C, Gonzalez-Sanchez JL, Fernandez-Perez C, Serrano-Rios M. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes. Metab. 9: 134-135 (2007). *
Martini C, Pallottini V, De Marinis E, Marino M, Cavallini G, Donati A, Straniero S, Trentalance A. Omega-3 as well as caloric restriction prevent the age-related modifications of cholesterol metabolism. Mech. Ageing Dev. 129: 722-727 (2008).
Martins F, Suzan AJ, Cerutti SM, Arcari DP, Ribeiro ML, Bastos DH, Carvalho PD. Consumption of mate tea (Ilex paraguariensis) decreases the oxidation of unsaturated fatty acids in mouse liver. Br. J. Nutr. 101: 519-524 (2009). *
Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G, Pinon-Esteban P, Campo-Perez R, Castro-Beiras A. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant. Proc. 37: 4071-4073 (2005). *
Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21: 1769-1780 (2007). *
Mas E, Danjoux M, Garcia V, Carpentier S, Segui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One 4: e7929 (2009). *
Mas MR, Comert B, Mas N, Yamanel L, Ozotuk H, Tasci I, Jazrawi RP. Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. World J. Gastroenterol. 13: 4336-4339 (2007). *
Mascitelli L, Pezzetta F, Goldstein MR. Low cholesterol and mental disorders in children and adolescents with celiac disease. Psychosomatics 50: 300-301 (2009).
Masclee AA, Vu MK. Gallbladder motility in inflammatory bowel diseases. Dig. Liver Dis. 35 Suppl. 3: S35-S38 (2003).
Mascrez B, Ghyselinck NB, Watanabe M, Annicotte JS, Chambon P, Auwerx J, Mark M. Ligand-dependent contribution of RXRbeta to cholesterol homeostasis in Sertoli cells. EMBO Rep. 5: 285-290 (2004). *
Masson D, Lagrost L, Athias A, Gambert P, Brimer-Cline C, Lan L, Schuetz JD, Schuetz EG, Assem M. Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 25: 2164-2169 (2005). *
Masson D, Qatanani M, Sberna AL, Xiao R, Pais de Barros JP, Grober J, Deckert V, Athias A, Gambert P, Lagrost L, Moore DD, Assem M. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J. Lipid Res. 49: 1682-1691 (2008). *
Mataki C, Magnier BC, Houten SM, Annicotte JS, Argmann C, Thomas C, Overmars H, Kulik W, Metzger D, Auwerx J, Schoonjans K. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol. Cell Biol. 27: 8330-8339 (2007). *
Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine Dec 18 [Epub ahead of print] (2009).
Mathis AS, Jin S, Friedman GS, Peng F, Carl SM, Knipp GT. The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. J. Pharm. Sci. 96: 209-222 (2007). *
Mathur A, Al-Azzawi HH, Lu D, Yancey KW, Swartz-Basile DA, Nakeeb A, Pitt HA. Steatocholecystitis: the influence of obesity and dietary carbohydrates. J. Surg. Res. 147: 290-297 (2008). *
Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA. Nonalcoholic fatty pancreas disease. HPB (Oxford) 9: 312-318 (2007). *
Mathur SN, Watt KR, Field FJ. Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid. J. Lipid Res. 48: 395-404 (2007). *
Matic M, Mahns A, Tsoli M, Corradin A, Polly P, Robertson GR. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int. J. Biochem. Cell. Biol. 39: 478-483 (2007). *
Maton PN, Ellis HJ, Higgins MJ, Dowling RH. Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids. Eur. J. Clin. Invest. 10: 325-332 (1980).
Maton PN, Murphy GM, Dowling RH. Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action. Lancet 2: 1297-1301 (1977).
Matsumoto S, Hashimoto K, Yamada M, Satoh T, Hirato J, Mori M. Liver X receptor-alpha positively regulates proopiomelanocortin (POMC) gene expression at the transcriptional level in the pituitary. Mol. Endocrinol. 23: 47-60 (2009). *
Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii KI, Ishigami M, Nishida M, Hirano KI, Kihara S, Hori M, Shimomura I, Yamashita S. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem. Biophys. Res. Commun. 358: 1091-1095 (2007). *
Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116: 1435-1442 (2006). *
Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern. Med. 46: 771-774 (2007). *
Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; The JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ. J. 73: 1283-1290 (2009). *
Matsuzaki Y, Bouscarel B, Ikegami T, Honda A, Doy M, Ceryak S, Fukushima S, Yoshida S, Shoda J, Tanaka N. Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver. Biochim. Biophys. Acta 1588: 139-148 (2002). *
Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46: 1392-1403 (2007). *
Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARG gene variant on obesity characteristics in Brazil. Braz. J. Med. Biol. Res. 40: 927-932 (2007). *
Mauldin JP, Nagelin MH, Wojcik AJ, Srinivasan S, Skaflen MD, Ayers CR, McNamara CA, Hedrick CC. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation 117: 2785-2792 (2008). *
Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology 136: 425-440 (2009). *
Maurer KJ, Ihrig MM, Rogers AB, Ng V, Bouchard G, Leonard MR, Carey MC, Fox JG. Identification of cholelithogenic enterohepatic Helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology 128: 1023-1033 (2005). *
Maurer KJ, Rao VP, Ge Z, Rogers AB, Oura TJ, Carey MC, Fox JG. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 133: 1304-1315 (2007). *
Mavrommatis Y, Ross K, Rucklidge G, Reid M, Duncan G, Gordon MJ, Thies F, Sneddon A, de Roos B. Intervention with fish oil, but not with docosahexaenoic acid, results in lower levels of hepatic soluble epoxide hydrolase with time in apoE knockout mice. Br. J. Nutr. 103: 16-24 (2010). *
Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 438: 612-621 (2005). *
Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr. Opin. Lipidol. 16: 167-172 (2005).
Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44: 2109-2119 (2003). *
Mayer C, Gruber HJ, Landl EM, Pailer S, Scharnagl H, Truschnig-Wilders M, M�rz W. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int. J. Clin. Pharmacol. Ther. 45: 319-327 (2007).
Mayer Jr O, Simon J, Holubec L, Pikner R, Trefil L. Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates. Physiol. Res. 55: 475-481 (2006). *
Mayoral R, Valverde AM, Llorente Izquierdo C, Gonzalez-Rodr�guez A, Bosca L, Martin-Sanz P. Impairment of TGF-beta signaling in caveolin-1 deficient hepatocytes: role in liver regeneration. J. Biol. Chem. Dec 5 [Epub ahead of print] (2009). *
Mayr M, Mayr U, Chung YL, Yin X, Griffiths JR, Xu Q. Vascular proteomics: linking proteomic and metabolomic changes. Proteomics 4: 3751-3761 (2004). *
Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, Sollier CB, Roussi J, Drouet L; for the FITENAT Study Group. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul. Fibrinolysis Aug 27 [Epub ahead of print] (2009).
Mazzella G, Fusaroli P, Pezzoli A, Azzaroli F, Mazzeo C, Zambonin L, Simoni P, Festi D, Roda E. Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. Dig. Dis. Sci. 44: 2478-2483 (1999). *
Mazzone A, Tietz P, Jefferson J, Pagano R, LaRusso NF. Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. Hepatology 43: 287-296 (2006). *
Mbongo-Kama E, Harnois F, Mennecier D, Leclercq E, Burnat P, Ceppa F. MDR3 mutations associated with intrahepatic and gallbladder cholesterol cholelithiasis: an update. Ann. Hepatol. 6: 143-149 (2007). *
McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65: 2719-2740 (2005).
McCulloch MI, Burger H, Spearman CW, Cooke L, Goddard E, Gajjar P, Numanoglu A, Rode H, Kahn D, Millar AJ. Nephrotoxic effects of immunosuppressant therapy in pediatric liver transplant recipients. Transplant. Proc. 37: 1220-1223 (2005). *
McEwan IJ, Lavery D, Fischer K, Watt K. Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nucl. Recept. Signal. 5: e001 (2007). *
McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr. Atheroscler. Rep. 11: 470-476 (2009).
McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27: 715-728 (2007).
McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am. J. Health Syst. Pharm. 64: 595-605 (2007).
McMaster A, Ray D. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp. Physiol. 92: 299-309 (2007). *
Meaney S, Bjorkhem I. On the role of oxysterols in regulation of cholesterol homeostasis by nuclear receptors. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 26. June 18-19 (2004). *
Mei CL, Chen ZJ, Liao YH, Wang YF, Peng HY, Chen Y. Interleukin-10 inhibits the down-regulation of ATP binding cassette transporter A1 by tumour necrosis factor-alpha in THP-1 macrophage-derived foam cells. Cell Biol. Int. 31: 1456-1461 (2007). *
Mei CL, He P, Cheng B, Liu W, Wang YF, Wan JJ. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways. Cell Biol. Int. 33: 301-308 (2009). *
Meier PJ, Stieger B. Bile salt transporters. Annu. Rev. Physiol. 64: 635-661 (2002). *
Meier-Abt PJ. Transport and metabolic functions. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper�s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 21-22. October 20 - 21 (2003). *
Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D'Agostino RB Sr, Cupples LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N. Engl. J. Med. 359: 2208-2219 (2008). *
Mella JG, Schirin-Sokhan R, Rigotti A, Pimentel F, Villarroel L, Wasmuth HE, Sauerbruch T, Nervi F, Lammert F, Miquel JF. Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high-risk populations. J. Lipid Res. 48: 1378-1385 (2007). *
Mellado M, Rodriguez-Frade JM, Manes S, Martinez-A C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol. 19: 397-421 (2001). *
Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res. Rev. 57: 410-420 (2008).
Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A, Brodehl J. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am. J. Gastroenterol. 95: 3522-3528 (2000). *
Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response: potential role of hepatocyte nuclear factor-1. J. Biol. Chem. 276: 30118-30126 (2001). *
Mencarelli A, Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med. Dec 11 [Epub ahead of print] (2009).
Mencarelli A, Renga B, Palladino G, Distrutti E, Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochem. Pharmacol. 78: 1214-1223 (2009). *
Mendez-Gonzalez J, Suren-Castillo S, Calpe-Berdiel L, Rotllan N, Vazquez-Carrera M, Escola-Gil JC, Blanco-Vaca F. Disodium ascorbyl phytostanol phosphate (FM-VP4), a modified phytostanol, is a highly active hypocholesterolaemic agent that affects the enterohepatic circulation of both cholesterol and bile acids in mice. Br. J. Nutr. 103: 153-160 (2010). *
Mendez-Sanchez N, Brink MA, Paigen B, Carey MC. Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology 115: 722-732 (1998). *
Mendez-Sanchez N, Gonzalez V, Aguayo P, Sanchez JM, Tanimoto MA, Elizondo J, Uribe M. Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight. J. Nutr. 131: 2300-2303 (2001). *
Mendez-Sanchez N, King-Mart�nez AC, Ramos MH, Pichardo-Bahena R, Uribe M. The Amerindian's genes in the Mexican population are associated with development of gallstone disease. Am. J. Gastroenterol. 99: 2166-2170 (2004). *
Mendez-Sanchez N, Panduro A, Murguia D, Rincon AR, Uribe M. Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann. Hepatol. 1: 85-89 (2002). *
Menke JG, Macnaul KL, Hayes NS, Baffic J, Chao YS, Elbrecht A, Kelly LJ, Lam MH, Schmidt A, Sahoo S, Wang J, Wright SD, Xin P, Zhou G, Moller DE, Sparrow CP. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology 143: 2548-2558 (2002). *
Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am. J. Med. Sci. 330: 295-302 (2005).
Menzel S. Genetic and molecular analyses of complex metabolic disorders: genetic linkage. Ann. N. Y. Acad. Sci. 967: 249-257 (2002). *
Merabishvili N, Kamladze S, Sulaberidze G. Peculiarities of lipid metabolism during pregnancy. Georgian Med. News 138: 86-89 (2006).
Merabishvili N, Kamladze S, Sulaberidze G. Peculiarities of lipid metabolism in pregnant patients with chronic cholecystitis. Georgian Med. News 141: 14-17 (2006).
Merris M, Wang T, Soteropoulos P, Lenard J. Differential gene expression of Caenorhabditis elegans on unmethylated and 4alpha-methyl sterols. J. Lipid Res. 48: 1159-1166 (2007). *
Meyer BJ, Hammervold T, Rustan AC, Howe PR. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids 42: 109-115 (2007).
Meyer-Hermann M, Figge MT, Straub RH. Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis: a systems biology approach. Arthritis Rheum. 60: 2585-2594 (2009). *
Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha dependent and independent mechanisms. Physiol. Genomics 26: 8-14 (2006). *
Mezey E. Metabolic effects of alcohol. Fed. Proc. 44: 134-138 (1985).
Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, Willson TM, Khorasanizadeh S, Rastinejad F. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 11: 1093-1100 (2003). *
Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, Billheimer J, Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45: 1410-1417 (2004). *
Miao J, Fang S, Lee J, Comstock C, Knudsen KE, Kemper JK. Functional specificity of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol. Cell. Biol. 29: 6170-6181 (2009). *
Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis 204: 476-482 (2009).
Micallef MA, Garg ML. Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia. J. Nutr. Biochem. 20: 927-939 (2009). *
Micallef MA, Garg ML. The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women. J. Nutr. 138: 1086-1090 (2008). *
Michael LF, Schkeryantz JM, Burris TP. The pharmacology of LXR. Mini. Rev. Med. Chem. 5: 729-740 (2005).
Michel V, Bakovic M. Lipid rafts in health and disease. Biol. Cell 99: 129-140 (2007).
Miele L, Vallone S, Cefalo C, Torre GL, Stasi CD, Vecchio FM, D'Agostino M, Gabrieli ML, Vero V, Biolato M, Pompili M, Gasbarrini G, Rapaccini G, Amerio P, Simone CD, Grieco A. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 51: 778-786 (2009).
Mieli-Vergani G, Vergani D. Liver transplantation in metabolic liver diseases. J. Gastroenterol. Hepatol. 19: S396-S397 (2004). *
Miettinen TA, Farkkila M, Vuoristo M, Karvonen AL, Leino R, Lehtola J, Friman C, Seppala K, Tuominen J. Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. Hepatology 21: 1261-1268 (1995).
Miettinen TA, Klett EL, Gylling H, Isoniemi H, Patel SB. Liver transplantation in a patient with sitosterolemia and cirrhosis. Gastroenterology 130: 542-547 (2006). *
Miettinen TE, Tarpila S, Gylling H. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones. Hepatology 25: 514-518 (1997). *
Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 98: 564-571 (2006). *
Mikhailidis DP, Fonseca V, Barradas MA, Hutton RA, Jeremy JY, Epstein O, McIntyre N, Dandona P. Platelet aggregation and thromboxane A2 release in primary biliary cirrhosis and effect of D-penicillamine treatment. Prostaglandins Leukot. Essent. Fatty Acids 31: 131-138 (1988).
Mikov M, Fawcett JP, Kuhajda K, Kevresan S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur. J. Drug Metab. Pharmacokinet. 31: 237-251 (2006).
Milewicz A, Tworowska-Bardzinska U, Dunajska K, Jedrzejuk D, Lwow F. Relationship of PPARgamma2 polymorphism with obesity and metabolic syndrome in postmenopausal Polish women. Exp. Clin. Endocrinol. Diabetes 117: 628-632 (2009).
Millar JS, Duffy D, Gadi R, Bloedon LT, Dunbar RL, Wolfe ML, Movva R, Shah A, Fuki IV, McCoy M, Harris CJ, Wang MD, Howey DC, Rader DJ. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 29: 140-146 (2009).
Millatt LJ, Bocher V, Fruchart JC, Staels B. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim. Biophys. Acta 1631: 107-118 (2003). *
Miller A, Crumbley C, Prufer K. The N-terminal nuclear localization sequences of liver X receptors alpha and beta bind to importin alpha and are essential for both nuclear import and transactivating functions. Int. J. Biochem. Cell. Biol. 41: 834-843 (2009). *
Miller C, Florman S, Kim-Schluger L, Lento P, De La Garza J, Wu J, Xie B, Zhang W, Bottone E, Zhang D, Schwartz M. Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl. 10: 1315-1319 (2004). *
Miller JP. Dyslipoproteinaemia of liver disease. Baillieres Clin. Endocrinol. Metab. 4: 807-832 (1990).
Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102: 657-667 (2009).
Miller WL. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim. Biophys. Acta 1771: 663-676 (2007). *
Mills PR, Rooney PJ, Watkinson G, MacSween RN. Hypercholesterolaemic arthropathy in primary biliary cirrhosis. Ann. Rheum. Dis. 38: 179-180 (1979). *
Milte CM, Coates AM, Buckley JD, Hill AM, Howe PR. Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels. Br. J. Nutr. 99: 1083-1088 (2008). *
Minder EI, Karlaganis G, Paumgartner G. Radioimmunological determination of serum 3 beta-hydroxy-5-cholenoic acid in normal subjects and patients with liver disease. J. Lipid Res. 20: 986-993 (1979). *
Mindrescu C, Gupta RP, Hermance EV, DeVoe MC, Soma VR, Coppola JT, Staniloae CS. Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia. Vasc. Health Risk Manag. 4: 1439-1447 (2008).
Mingrone G, Altomonte L, Ghirlanda G, Greco AV. Comparative effects of chenodeoxycholic acid and ursodeoxycholic acid on lipid synthesis in rat liver. Exp. Pathol. 20: 193-196 (1981).
Mitamura T. Alterations of high density lipoproteins in experimental intrahepatic cholestasis in the rat induced by administration of alpha-naphthylisothiocyanate. J. Biochem. 95: 29-36 (1984).
Mitro N, Mak PA, Vargas L, Godio C, Hampton E, Molteni V, Kreusch A, Saez E. The nuclear receptor LXR is a glucose sensor. Nature 445: 219-223 (2007). *
Miwa K, Inazu A, Kawashiri M, Nohara A, Higashikata T, Kobayashi J, Koizumi J, Nakajima K, Nakano T, Niimi M, Mabuchi H, Yamagishi M. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin. Chim. Acta 402: 19-24 (2009). *
Miwa K, Inazu A, Kobayashi J, Higashikata T, Nohara A, Kawashiri M, Katsuda S, Takata M, Koizumi J, Mabuchi H. ATP-binding cassette transporter G8 M429V polymorphism as a novel genetic marker of higher cholesterol absorption in hypercholesterolemic Japanese subjects. Clin. Sci. (Lond.) 109: 183-188 (2005). *
Miyachi H. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands. Curr. Med. Chem. 14: 2335-2343 (2007).
Miyake Y, Sasaki S, Arakawa M, Tanaka K, Murakami K, Ohya Y. Fatty acid intake and asthma symptoms in Japanese children: The Ryukyus Child Health Study. Clin. Exp. Allergy 38: 1644-1650 (2008). *
Miyake Y, Sasaki S, Tanaka K, Ohfuji S, Hirota Y. Maternal fat consumption during pregnancy and risk of wheeze and eczema in Japanese infants aged 16-24 months: The Osaka Maternal and Child Health Study. Thorax 64: 815-821 (2009).
Miyake Y, Sasaki S, Tanaka K, Ohya Y, Matsunaga I, Yoshida T, Hirota Y, Oda H. Relationship between dietary fat and fish intake and the prevalence of atopic eczema in pregnant Japanese females: baseline data from the Osaka Maternal and Child Health Study. Asia Pac. J. Clin. Nutr. 17: 612-619 (2008).
Miyata M, Matsuda Y, Nomoto M, Takamatsu Y, Sato N, Hamatsu M, Dawson PA, Gonzalez FJ, Yamazoe Y. Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorption. Drug Metab. Dispos. 37: 338-344 (2009). *
Miyata M, Takamatsu Y, Kuribayashi H, Yamazoe Y. Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal FGF15 expression. J. Pharmacol. Exp. Ther. 331: 1079-1085 (2009). *
Miyazaki Y, Defronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes. Metab. 10: 1204-1211 (2008). *
Mizoguchi Y, Sakagami Y, Miyajima K, Yamamoto S, Morisawa S. Experimental immunological intrahepatic cholestasis model. Gastroenterol. Jpn. 23: 18-22 (1988).
Mizuno K, Hoshino M, Hayakawa T, Yamada H, Nakazawa T, Inagaki T, Takeuchi T, Kunimatsu M. Uncoupling of biliary lipid from bile acid secretion by formyl-methionyl-leucyl-phenylalanine in the rat. Hepatology 24: 1224-1229 (1996). *
Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S, Takahashi K. Genuine functions of P-glycoprotein (ABCB1). Curr. Drug Metab. 9: 167-174 (2008).
Moan J, Porojnicu AC. The photobiology of vitamin D, a topic of renewed focus. Tidsskr. Nor. Laegeforen 126: 1048-1052 (2006).
Modica S, Bellafante E, Moschetta A. Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. Front. Biosci. 14: 4719-4745 (2009).
Modica S, Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett. 580: 5492-5499 (2006). *
Modok S, Heyward C, Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid and cholesterol rich environment. J. Lipid Res. 45: 1910-1918 (2004). *
Mohan R, Heyman RA. Orphan nuclear receptor modulators. Curr. Top. Med. Chem. 3: 1637-1647 (2003).
Mohler ER 3rd. Therapy insight: peripheral arterial disease and diabetes - from pathogenesis to treatment guidelines. Nat. Clin. Pract. Cardiovasc. Med. 4: 151-162 (2007).
Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 52: 2774-2782 (2005). *
Moleda P, Majkowska L, Safranow K, Adler G, Goracy I. Relationship between I/D polymorphism of angiotensin I converting enzyme gene and microvascular complications in type 2 diabetic patients. Przegl. Lek. 64: 134-139 (2007).
Molina H, Azocar L, Ananthanarayanan M, Arrese M, Miquel JF. Localization of the sodium-taurocholate cotransporting polypeptide in membrane rafts and modulation of its activity by cholesterol in vitro. Biochim. Biophys. Acta 1778: 1283-1291 (2008). *
Mollsten A, Jorsal A, Lajer M, Vionnet N, Tarnow L. The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia Oct 16 [Epub ahead of print] (2009). *
Molteni V, Li X, Nabakka J, Liang F, Wityak J, Koder A, Vargas L, Romeo R, Mitro N, Mak PA, Seidel HM, Haslam JA, Chow D, Tuntland T, Spalding TA, Brock A, Bradley M, Castrillo A, Tontonoz P, Saez E. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J. Med. Chem. 50: 4255-4259 (2007). *
Molvarec A, Nagy B, Kovacs M, Walentin S, Imreh E, Rigo J Jr, Szalay J, Fust G, Prohaszka Z, Karadi I. Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms. Clin. Chim. Acta 380: 157-164 (2007). *
Mong JL, Ng MC, Guldan GS, Tam CH, Lee HM, Ma RC, So WY, Wong GW, Kong AP, Chan JC, Waye MM. Associations of insulin-like growth factor binding protein-3 gene polymorphisms with IGF-I activity and lipid parameters in adolescents. Int. J. Obes. (Lond.) 33: 1446-1453 (2009).
Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33: 539-576 (1987).
Montagnana M, Fava C, Nilsson PM, Engstrom G, Hedblad B, Lippi G, Minuz P, Berglund G, Melander O. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals. Diabet. Med. 25: 902-908 (2008). *
Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, Ruiz P, Manten E, Safdar K, O'Brien C, Tzakis AG. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78: 264-268 (2004).
Montanaro MA, Gonzalez MS, Bernasconi AM, Brenner RR. Role of liver X receptor, insulin and peroxisome proliferator activated receptor alpha on in vivo desaturase modulation of unsaturated fatty acid biosynthesis. Lipids 42: 197-210 (2007).
Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15: 804-816 (2009). *
Montet JC. Ursodeoxycholic acid. Physical properties and hepatoprotective activity. Pathol. Biol. (Paris) 39: 621-624 (1991).
Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, Kliewer SA. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnane X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol. Rev. 58: 742-759 (2006). *
Moore JT, Goodwin B, Willson TM, Kliewer SA. Nuclear receptor regulation of genes involved in bile acid metabolism. Crit. Rev. Eukaryot. Gene Expr. 12: 119-135 (2002).
Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic renal failure. Am. J. Nephrol. 30: 147-154 (2009).
Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 20: 1437-1441 (1994).
Morales JR, Ballesteros I, Deniz JM, Hurtado O, Vivancos J, Nombela F, Lizasoain I, Castrillo A, Moro MA. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 118: 1450-1459 (2008). *
Morello F, Saglio E, Noghero A, Schiavone D, Williams TA, Verhovez A, Bussolino F, Veglio F, Mulatero P. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis 207: 38-44 (2009).
Moreno M, Molina H, Amigo L, Zanlungo S, Arrese M, Rigotti A, Miquel JF. Hepatic overexpression of caveolins increases bile salt secretion in mice. Hepatology 38: 1477-1488 (2003). *
Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J. Am. Coll. Cardiol. 44: 2293-2300 (2004).
Morgado N, Rigotti A, Valenzuela A. Comparative effect of fish oil feeding and other dietary fatty acids on plasma lipoproteins, biliary lipids, and hepatic expression of proteins involved in reverse cholesterol transport in the rat. Ann. Nutr. Metab. 49: 397-406 (2005). *
Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr. Atheroscler. Rep. 6: 461-467 (2004).
Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J. Hypertens. 27: 1863-1872 (2009).
Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 56: 1714-1718 (2007). *
Morita SY, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H, Matsuo M, Ueda K. Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology 46: 188-199 (2007). *
Morozova RP, Pasichna EP, Donchenko HV, Kastrykina TF, Silonov SB, Palyvoda OM, Delemenchuk NV. Lipids and caplain in guinea pigs tissues in the process of development of experimental autoimmune encephalomyelitis. Ukr. Biokhim. Zh. 79: 104-111 (2007).
Morris PJ. Physical activity recommendations for children and adolescents with chronic disease. Curr. Sports Med. Rep. 7: 353-358 (2008).
Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, Puffenberger E, Bull L, Knisely AS. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 119: 188-195 (2000). *
Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm. Bowel Dis. 15: 1399-1409 (2009). *
Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10: 1352-1358 (2004). *
Moschetta A, Kliewer SA. Weaving betaKlotho into bile acid metabolism. J. Clin. Invest. 115: 2075-2077 (2005). *
Moschetta A, Xu F, Hagey LR, van Berge Henegouwen GP, van Erpecum KJ, Brouwers JF, Cohen JC, Bierman M, Hobbs HH, Steinbach JH, Hofmann AF. A phylogenetic survey of biliary lipids in vertebrates. J. Lipid Res. 46: 2221-2232 (2005). *
Moser AJ, Gangopadhyay A, Bradbury NA, Peters KW, Frizzell RA, Bridges RJ. Electrogenic bicarbonate secretion by prairie dog gallbladder. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1683-G1694 (2007). *
Mossner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Muller N, Fallgatter AJ, Riederer P. Consensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression. World J. Biol. Psychiatry 8: 141-74 (2007).
Motawi TM, Hashem RM, Rashed LA, El-Razek SM. Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats. J. Pharm. Pharmacol. 61: 1339-1346 (2009).
Motoshima K, Noguchi-Yachide T, Sugita K, Hashimoto Y, Ishikawa M. Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists. Bioorg. Med. Chem. 17: 5001-5014 (2009). *
Motoyama KR, Curb JD, Kadowaki T, El-Saed A, Abbott RD, Okamura T, Evans RW, Nakamura Y, Sutton-Tyrrell K, Rodriquez BL, Kadota A, Edmundowicz D, Willcox BJ, Choo J, Katsumi N, Otake T, Kadowaki S, Kuller LH, Ueshima H, Sekikawa A. Association of serum n-6 and n-3 polyunsaturated fatty acids with lipids in 3 populations of middle-aged men. Am. J. Clin. Nutr. 90: 49-55 (2009). *
Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *
Moudiou T, Galli-Tsinopoulou A, Nousia-Arvanitakis S. Effect of exocrine pancreatic function on resting energy expenditure in cystic fibrosis. Acta Paediatr. 96: 1521-1525 (2007).
Mouzat K, Prod'homme M, Volle DH, Sion B, Dechelotte P, Gauthier K, Vanacker JM, Lobaccaro JM. Oxysterol nuclear receptor LXRbeta regulates cholesterol homeostasis and contractile function in mouse uterus. J. Biol. Chem. 282: 4693-4701 (2007). *
Mowat AP. Orthotopic liver transplantation in liver-based metabolic disorders. Eur. J. Pediatr. 151 Suppl. 1: S32-S38 (1992).
Moyad MA. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol. Nurs. 24: 49-52 (2004).
Moyad MA, Merrick GS. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: part III - a rapid review of FDA-approved cholesterol-lowering agents. Urol. Nurs. 26: 330-332 (2006).
Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur. J. Clin. Nutr. 63 Suppl. 2: S22-S33 (2009). *
Mtiraoui N, Ezzidi I, Kacem M, Ben Hadj Mohamed M, Chaieb M, Haj Jilani AB, Mahjoub T, Almawi WY. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes Metab. Res. Rev. 25: 57-63 (2009). *
Mueller AM, Pedre X, Stempfl T, Kleiter I, Couillard-Despres S, Aigner L, Giegerich G, Steinbrecher A. Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis. J. Neuroinflammation 5: 20 (2008).
Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O'Malley KM, Zhang L, Li J, Shi Y, Kennedy LJ, Blanar M, Cheng PT, Tino J, Srivastava R. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J. Pharmacol. Exp. Ther. 327: 716-726 (2008). *
Mulas MF, Demuro G, Mulas C, Putzolu M, Cavallini G, Donati A, Bergamini E, Dessi S. Dietary restriction counteracts age-related changes in cholesterol metabolism in the rat. Mech. Ageing Dev. 126: 648-654 (2005).
Muller O, Schalla C, Scheibner J, Stange EF, Fuchs M. Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice. Biochem. J. 361: 673-679 (2002). *
Munetsuna E, Hojo Y, Hattori M, Ishii H, Kawato S, Ishida A, Kominami SA, Yamazaki T. Retinoic acid stimulates 17beta-estradiol and testosterone synthesis in rat hippocampal slice cultures. Endocrinology 150: 4260-4269 (2009). *
Munoz S, Rivas-Santiago B, Enciso JA. Mycobacterium tuberculosis entry into mast cells through cholesterol-rich membrane microdomains. Scand. J. Immunol. 70: 256-263 (2009). *
Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, Tedde A, Desogus A, Muntoni S. Serum lipoproteins and cancer. Nutr. Metab. Cardiovasc. Dis. 19: 218-225 (2009).
Murakami K, Miyake Y, Sasaki S, Tanaka K, Ohya Y, Hirota Y; Osaka Maternal and Child Health Study Group. Education, but not occupation or household income, is positively related to favorable dietary intake patterns in pregnant Japanese women: the Osaka Maternal and Child Health Study. Nutr. Res. 29: 164-172 (2009). *
Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123: 634-641 (2005). *
Murthy S, Born E, Mathur SN, Field FJ. Liver-X-receptor-mediated increase in ATP-binding cassette transporter A1 expression is attenuated by fatty acids in CaCo-2 cells: effect on cholesterol efflux to high-density lipoprotein. Biochem. J. 377: 545-552 (2004). *
Murthy S, Born E, Mathur SN, Field FJ. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J. Lipid Res. 43: 1054-1064 (2002). *
Murthy S, Tong H, Hohl RJ. Regulation of fatty acid synthesis by farnesyl pyrophosphate. J. Biol. Chem. 280: 41793-41804 (2005). *
Muscat GE, Dressel U. Cardiovascular disease and PPARdelta: targeting the risk factors. Curr. Opin. Investig. Drugs 6: 887-894 (2005).
Musial K, Szprynger K, Szczepanska M, Zwolinska D. Heat shock proteins in children and young adults on chronic hemodialysis. Pediatr. Nephrol. 24: 2029-2034 (2009).
Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, Ardizzoni A. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. Br. J. Haematol. 145: 84-86 (2009). *
Mutch DM, Klocke B, Morrison P, Murray CA, Henderson CJ, Seifert M, Williamson G. The disruption of hepatic cytochrome P450 reductase alters mouse lipid metabolism. J. Proteome Res. 6: 3976-3984 (2007). *
Mutoh M, Niho N, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol. Chem. 387: 381-385 (2006).
Myerson M, Ngai C, Jones J, Holleran S, Ramakrishnan R, Berglund L, Ginsberg HN. Treatment with high dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J. Lipid Res. 46: 2735-2744 (2005). *
Myint PK, Welch AA, Bingham SA, Luben RN, Wareham NJ, Day NE, Khaw KT. Habitual fish consumption and risk of incident stroke: the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study. Public Health Nutr. 9: 882-888 (2006).
Nachimuthu S, Raggi P. Novel agents to manage dyslipidemias and impact atherosclerosis. Cardiovasc. Hematol. Disord. Drug Targets 6: 209-217 (2006).
Nagano M, Kuroki S, Mizuta A, Furukawa M, Noshiro M, Chijiiwa K, Tanaka M. Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats. Steroids 69: 701-709 (2004).
Nagasaka H, Miida T, Hirano KI, Ota A, Murayama K, Yorifuji T, Kobayashi K, Takatani T, Tsukahara H, Hui SP, Takayanagi M, Chiba H. Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome. Atherosclerosis 198: 434-440 (2008).
Nagasaka H, Okano Y, Tsukahara H, Shigematsu Y, Momoi T, Yorifuji J, Miida T, Ohura T, Kobayashi K, Saheki T, Hirano K, Takayanagi M, Yorifuji T. Sustaining hypercitrullinemia, hypercholesterolemia and augmented oxidative stress in Japanese children with aspartate/glutamate carrier isoform 2-citrin-deficiency even during the silent period. Mol. Genet. Metab. 97: 21-26 (2009). *
Nagasaka H, Yorifuji T, Egawa H, Yanai H, Fujisawa T, Kosugiyama K, Matsui A, Hasegawa M, Okada T, Takayanagi M, Chiba H, Kobayashi K. Evaluation of risk for atherosclerosis in Alagille syndrome and progressive familial intrahepatic cholestasis: two congenital cholestatic diseases with different lipoprotein metabolisms. J. Pediatr. 146: 329-335 (2005). *
Nagasaka H, Yorifuji T, Hirano K, Ota A, Toyama-Nakagawa Y, Takatani T, Tsukahara H, Kobayashi K, Takayanagi M, Inomata Y, Uemoto S, Miida T. Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis. Metabolism 58: 48-54 (2009). *
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 536: 182-191 (2006). *
Nagassaki S, Herculano RD, Graeff CF, Tanus-Santos JE. eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur. J. Clin. Pharmacol. 65: 385-392 (2009).
Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113: 90-97 (2006).
Naiki Y, Sorrentino R, Wong MH, Michelsen KS, Shimada K, Chen S, Yilmaz A, Slepenkin A, Schroder NW, Crother TR, Bulut Y, Doherty TM, Bradley M, Shaposhnik Z, Peterson EM, Tontonoz P, Shah PK, Arditi M. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J. Immunol. 181: 7176-7185 (2008). *
Naito H, Kamijima M, Yamanoshita O, Nakahara A, Katoh T, Tanaka N, Aoyama T, Gonzalez FJ, Nakajima T. Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism. J. Occup. Health 49: 353-362 (2007). *
Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ, Nakajima T. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet. Genomics 16: 569-577 (2006).
Nakagaki M, Danzinger RG, Hofmann AF, DiPietro RA. Biliary secretion and hepatic metabolism of taurine-conjugated 7 alpha-hydroxy and 7 beta-hydroxy bile acids in the dog. Defective hepatic transport and bile hyposecretion. Gastroenterology 87: 647-659 (1984).
Nakagawa S, Makino I, Ishizaki T, Dohi I. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 2: 367-369 (1977).
Nakahara M, Fujii H, Maloney PR, Shimizu M, Sato R. Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J. Biol. Chem. 277: 37229-37234 (2002). *
Nakajima A, Doki K, Homma M, Sagae T, Saito R, Ito S, Sumida T, Kohda Y. Investigation of glucocorticoid-induced side effects in patients with autoimmune diseases. Yakugaku Zasshi 129: 445-450 (2009). *
Nakajima K. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome. Curr. Clin. Pharmacol. Feb 16 [Epub ahead of print] (2010).
Nakajima M, Shimizu H, Miyazaki A, Watanabe S, Kitami N, Sato N. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis? J. Gastroenterol. 34: 607-612 (1999). *
Nakajima T, Tanaka N, Sugiyama E, Kamijo Y, Hara A, Hu R, Li G, Li Y, Nakamura K, Gonzalez FJ, Aoyama T. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. Biochem. Pharmacol. 76: 108-119 (2008). *
Nakamoto K, Wang S, Jenison RD, Guo GL, Klaassen CD, Wan YJ, Zhong XB. Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet. 7: 29 (2006). *
Nakamura K, Kennedy MA, Baldan A, Bojanic DD, Lyons K, Edwards PA. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J. Biol. Chem. 279: 45980-45989 (2004). *
Nakamura T, Ito Y, Yanagiba Y, Ramdhan DH, Kono Y, Naito H, Hayashi Y, Li Y, Aoyama T, Gonzalez FJ, Nakajima T. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha. Toxicology 265: 27-33 (2009). *
Nakamura T, Shibata N, Nishimoto-Shibata T, Feng D, Ikemoto M, Motojima K, Iso-O N, Tsukamoto K, Tsujimoto M, Arai H. Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1. Proc. Natl. Acad. Sci. U.S.A. 102: 13404-13409 (2005). *
Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int. J. Clin. Pharmacol. Ther. 48: 22-28 (2010).
Nakanishi S, Yamane K, Ohishi W, Nakashima R, Yoneda M, Nojima H, Watanabe H, Kohno N. Manganese superoxide dismutase Ala16Val polymorphism is associated with the development of type 2 diabetes in Japanese-Americans. Diabetes Res. Clin. Pract. 81: 381-385 (2008).
Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M, Toda G. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol. Res. 22: 250-260 (2002).
Nakanuma Y, Nakamura Y, Hoso M, Ohta G. Atrophy and ductopenia of the right hepatic lobe in a patient with choledocholithiasis. Acta Pathol. Jpn. 36: 1719-1726 (1986).
Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, Ishikawa T. Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab. Pharmacokinet. 21: 437-457 (2006). *
Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am. J. Pathol. 174: 2007-2014 (2009). *
Nakaya K, Ayaori M, Hisada T, Sawada S, Tanaka N, Iwamoto N, Ogura M, Yakushiji E, Kusuhara M, Nakamura H, Ohsuzu F. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. J. Atheroscler. Thromb. 14: 133-141 (2007).
Nakayama F. Oral cholelitholysis - cheno versus urso: Japanese experience. Dig. Dis. Sci. 25: 129-134 (1980).
Nakhjavani M, Esfahanian F, Jahanshahi A, Esteghamati A, Nikzamir AR, Rashidi A, Zahraei M. The relationship between the insertion/deletion polymorphism of the ACE gene and hypertension in Iranian patients with type 2 diabetes. Nephrol. Dial. Transplant. 22: 2549-2553 (2007). *
Nakken KE, Labori KJ, Rodningen OK, Nakken S, Berge KE, Eiklid K, Raeder MG. ABCB4 sequence variations in young adults with cholesterol gallstone disease. Liver Int. 29: 743-747 (2009). *
Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am. J. Cardiol. 98: S34-S38 (2006). *
Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia. J. Biol. Chem. 279: 52961-52969 (2004). *
Namgaladze D, Morbitzer D, von Knethen A, Brune B. Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. Nov 30 [Epub ahead of print] (2009).
Nanda N, Bobby Z, Hamide A. Oxidative stress and protein glycation in primary hypothyroidism. Male/female difference. Clin. Exp. Med. 8: 101-108 (2008). *
Narins SC, Ramakrishnan R, Park EH, Smith PR, Meyers WC, Abedin MZ. Gallbladder Na/H exchange activity is up-regulated prior to cholesterol crystal formation. Eur. J. Clin. Invest. 35: 514-522 (2005).
Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J. Pediatr. Gastroenterol. Nutr. 26: 49-55 (1998). *
Narushima K, Takada T, Yamanashi Y, Suzuki H. Niemann-Pick C1-like 1 mediates alpha-tocopherol transport. Mol. Pharmacol. 74: 42-49 (2008). *
Nascimento FA, Barbosa-da-Silva S, Fernandes-Santos C, Mandarim-de-Lacerda CA, Aguila MB. Adipose tissue, liver and pancreas structural alterations in C57BL/6 mice fed high-fat-high-sucrose diet supplemented with fish oil (n-3 fatty acid rich oil). Exp. Toxicol. Pathol. Jan 29 [Epub ahead of print] (2009).
Nasr SH, Markowitz GS, Reddy BS, Maesaka J, Swidler MA, D'Agati VD. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int. 69: 772-775 (2006).
Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens. Res. 30: 541-548 (2007).
Neffati S, Charfeddine B, Smach MA, Othmen LB, Ltaief A, Brahem I, Dridi H, Limem K. Hypocholesterolemia and celiac disease: about one case. Ann. Biol. Clin. (Paris) 67: 359-361 (2009).
Nehlin JO, Mogensen JP, Petterson I, Jeppesen L, Fleckner J, Wulff EM, Sauerberg P. Selective PPAR agonists for the treatment of type 2 diabetes. Ann. N. Y. Acad. Sci. 1067: 448-453 (2006). *
Nemoto N, Suzuki S, Kikuchi H, Okabe H, Sassa S, Sakamoto S. Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. In Vivo 23: 685-689 (2009).
Nervi F, Miquel JF, Alvarez M, Ferreccio C, Garcia-Zattera MJ, Gonzalez R, Perez-Ayuso RM, Rigotti A, Villarroel L. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J. Hepatol. 45: 299-305 (2006). *
Nervi F, Zanlungo S, Rigotti A. A new twist in the cholesterol metabolism-based enterohepatic connection. Gastroenterology 135: 705-706 (2008). *
Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, de Boo T, Van der Meer JW, Kastelein JJ, Stalenhorf AF. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 34: 94-99 (2004).
Neufeld EB, Stonik JA, Demosky SJ Jr, Knapper CL, Combs CA, Cooney A, Comly M, Dwyer N, Blanchette-Mackie J, Remaley AT, Santamarina-Fojo S, Brewer HB Jr. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J. Biol. Chem. 279: 15571-15578 (2004). *
Neuhaus O, Hartung HP. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev. Neurother. 7: 547-556 (2007).
Newberry EP, Kennedy SM, Xie Y, Luo J, Davidson NO. Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. Mol. Cell. Biochem. 326: 79-86 (2009). *
Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell. Signal. 20: 2180-2197 (2008). *
Nguyen DH, Taub D. Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5. Blood 99: 4298-4306 (2002). *
Nguyen DH, Taub D. CXCR4 function requires membrane cholesterol: implications for HIV infection. J. Immunol. 168: 4121-4126 (2002). *
Nguyen DH, Taub DD. Inhibition of chemokine receptor function by membrane cholesterol oxidation. Exp. Cell. Res. 291: 36-45 (2003). *
Ni HX, Yu NJ, Yang XH. The study of ginsenoside on PPARgamma expression of mononuclear macrophage in type 2 diabetes. Mol. Biol. Rep. Oct 10 [Epub ahead of print] (2009). *
Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Clin. Ther. 28: 243-250 (2006). *
Nicolaou KC, Evans RM, Roecker AJ, Hughes R, Downes M, Pfefferkorn JA. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 1: 908-920 (2003).
Niculescu LS, Vladica M, Sima AV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem. Biophys. Res. Commun. Nov 19 [Epub ahead of print] (2009). *
Nieland TJ, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T, Krieger M. Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J. Lipid Res. 45: 1256-1265 (2004). *
Nielsen AA, Nielsen JN, Gronbaek H, Eivindson M, Vind I, Munkholm P, Brandslund I, Hey H. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone. Digestion 75: 10-16 (2007). *
Niemeier A, Kovacs WJ, Strobl W, Stangl H. Atherogenic diet leads to posttranslational down-regulation of murine hepatocyte SR-BI expression. Atherosclerosis 202: 169-175 (2009).
Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics 16: 565-568 (2006).
Nies LK, Cymbala AA, Kasten SL, Lamprecht DG, Olson KL. Complementary and alternative therapies for the management of dyslipidemia. Ann. Pharmacother. 40: 1984-1992 (2006).
Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr. Pharm. Des. 7: 231-259 (2001). *
Nigam A, Frasure-Smith N, Lesperance F, Julien P. Relationship between n-3 and n-6 plasma fatty acid levels and insulin resistance in coronary patients with and without metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 19: 264-270 (2009).
Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc. Natl. Acad. Sci. U.S.A. 102: 2970-2974 (2005). *
Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 63: 6090-6095 (2003). *
Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimaki T, Kahonen M, Reunanen A, Jula A, Moilanen L, Kesaniemi YA, Nieminen MS, Hurme M. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand. J. Clin. Lab. Invest. 68: 767-770 (2008). *
Nikkila K. Liver transplantation restores low serum levels of very low density and high density lipoproteins in end-stage primary biliary cirrhosis. Ann. Med. 24: 129-136 (1992).
Nikkila K, Hockerstedt K, Miettinen TA. Serum and hepatic cholestanol, squalene and noncholesterol sterols in man: a study on liver transplantation. Hepatology 15: 863-870 (1992).
Nikkila K, Hockerstedt K, Miettinen TA. Liver transplantation modifies serum cholestanol, cholesterol precursor and plant sterol levels. Clin. Chim. Acta 208: 205-218 (1992).
Nikkila K, Miettinen TA. Serum cholesterol precursors, cholestanol, and plant sterols in primary biliary cirrhosis. Scand. J. Gastroenterol. 23: 967-972 (1988).
Nikkila K, Miettinen TA, Hockerstedt KV, Isoniemi H. Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl. Int. 18: 221-225 (2005). *
Nikkila K, Nissinen MJ, Gylling H, Isoniemi H, Miettinen TA. Serum sterols in patients with primary biliary cirrhosis and acute liver failure before and after liver transplantation. J. Hepatol. 49: 936-945 (2008). *
Nilsell K, Angelin B, Leijd B, Einarsson K. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 85: 1248-1256 (1983).
Nilsson A, Duan RD. Absorption and lipoprotein transport of sphingomyelin. J. Lipid Res. 47: 154-171 (2006). *
Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J. Intern. Med. 263: 464-478 (2008). *
Nilsson SE, Read S, Berg S, Johansson B. Heritabilities for fifteen routine biochemical values: findings in 215 Swedish twin pairs 82 years of age or older. Scand. J. Clin. Lab. Invest. 69: 562-569 (2009).
Ninomiya R, Matsuoka K, Moroi Y. Micelle formation of sodium chenodeoxycholate and solubilization into the micelles: comparison with other unconjugated bile salts. Biochim. Biophys. Acta 1634: 116-125 (2003). *
Ninomiya Y, Yasuda T, Kawamoto M, Yuge O, Okazaki Y. Liver X receptor ligands inhibit the lipopolysaccharide-induced expression of microsomal prostaglandin E synthase-1 and diminish prostaglandin E(2) production in murine peritoneal macrophages. J. Steroid Biochem. Mol. Biol. 103: 44-50 (2007).
Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr. J. 55: 213-216 (2008). *
Nishimaki-Mogami T, Kawahara Y, Tamehiro N, Yoshida T, Inoue K, Ohno Y, Nagao T, Une M. 5alpha-Bile alcohols function as farnesoid X receptor antagonists. Biochem. Biophys. Res. Commun. 339: 386-391 (2006). *
Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira KI, Sai K, Kagechika H, Shudo K, Abe-Dohmae S, Yokoyama S, Ohno Y, Inoue K, Sawada JI. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem. Pharmacol. 76: 1006-1013 (2008). *
Nishimaki-Mogami T, Une M, Fujino T, Sato Y, Tamehiro N, Kawahara Y, Shudo K, Inoue K. Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor. J. Lipid Res. 45 1538-1545 (2004). *
Nishimoto T, Pellizzon MA, Aihara M, Stylianou IM, Billheimer JT, Rothblat G, Rader DJ. Fish oil promotes macrophage reverse cholesterol transport in mice. Arterioscler. Thromb. Vasc. Biol. 29: 1502-1508 (2009).
Nishioka T, Having R, Tazuma S, Stellaard F, Kuipers F, Verkade HJ. Administration of phosphatidylcholine-cholesterol liposomes partially reconstitutes fat absorption in chronically bile-diverted rats. Biochim. Biophys. Acta 1636: 90-98 (2004).
Nitta M, Ku S, Brown C, Okamoto AY, Shan B. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proc. Natl. Acad. Sci. U.S.A. 96: 6660-6665 (1999). *
Niu N, Zhu X, Liu Y, Du T, Wang X, Chen D, Sun B, Gu HF, Liu Y. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes Metab. Res. Rev. 23: 21-25 (2006).
Niva S, Weill P, Loewenbach R. Egg fortification with n-3 polyunsaturated fatty acids (PUFA): nutritional benefits versus high n-6 PUFA western diets, and consumer acceptance. Isr. Med. Assoc. J. 10: 262-265 (2008). *
No authors listed. Clinical and functional changes in the biliary tract in patients with psoriasis concurrent with chronic opisthorchiasis. Med. Parazitol. (Mosk.) 4: 21-24 (2009).
No authors listed. Comparative assessment of bile and blood cholesterol, pigment, and protein metabolic parameters in patients with cholelithiasis in the presence and absence of opisthorchiasis. Ter. Arkh. 81: 49-52 (2009).
No authors listed. New policosanol product combines natural cholesterol lowering with omega-3 fatty acids to lower CV risk. Cardiovasc. J. S. Afr. 17: 92 (2006).
No authors listed. My friend is taking fish oil plus red yeast rice capsules, and his cholesterol has dropped from 245 to 180. Can I take this product instead of a statin? Heart Advis. 11: 8 (2008).
Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48: 119-128 (2008). *
Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44: 458-465 (2006). *
Noble CA, Kushner RF. An update on low-carbohydrate, high-protein diets. Curr. Opin. Gastroenterol. 22: 153-159 (2006).
Nofer JR, Remaley AT, Feuerborn R, Wolinska I, Engel T, von Eckardstein A, Assmann G. Apolipoprotein A-I (APO A-I) activates CDC42 signaling through ABCA1 transporter. J. Lipid Res. 47: 794-803 (2006). *
Noh YH, Lee SM, Kim EJ, Kim DY, Lee H, Lee JH, Lee JH, Park SY, Koo JH, Wang JH, Lim IJ, Choi SB. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Diabetes Metab. Res. Rev. 24: 384-391 (2008).
Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsuchida M, Takata M, Katsuda S, Miwa K, Inazu A, Kuipers F, Kobayashi J, Koizumi J, Yamagishi M, Mabuchi H. High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 27: 923-928 (2007).
Nohara A, Mabuchi H. Nuclear receptor regulation of cholesterol metabolism. Nippon Rinsho 59 Suppl. 2: 468-471 (2001).
Nomiyama T, Bruemmer D. Liver X receptors as therapeutic targets in metabolism and atherosclerosis. Curr. Atheroscler. Rep. 10: 88-95 (2008).
Nomoto M, Miyata M, Shimada M, Yoshinari K, Gonzalez FJ, Shibasaki S, Kurosawa T, Shindo Y, Yamazoe Y. ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Eur. J. Pharmacol. 574: 192-200 (2007). *
Norata GD, Catapano AL. Lipid lowering activity of drugs affecting cholesterol absorption. Nutr. Metab. Cardiovasc. Dis. 14: 42-51 (2004).
Norata GD, Ongari M, Uboldi P, Pellegatta F, Catapano AL. Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells. Int. J. Mol. Med. 16: 717-722 (2005).
Norioka M, Suzuki M, Ryomoto K, Ikebuchi M, Harano Y. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects. J. Atheroscler. Thromb. 7: 198-202 (2000).
Norlin M. Expression of key enzymes in bile acid biosynthesis during development: CYP7B1-mediated activities show tissue-specific differences. J. Lipid Res. 43: 721-731 (2002). *
Norlin M, Chiang JY. Transcriptional regulation of human oxysterol 7alpha-hydroxylase by sterol response element binding protein. Biochem. Biophys. Res. Commun. 316: 158-164 (2004). *
Norlin M, Toll A, Bjorkhem I, Wikvall K. 24-Hydroxycholesterol is a substrate for hepatic cholesterol 7alpha-hydroxylase (CYP7A). J. Lipid Res. 41: 1629-1639 (2000). *
Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med. 7: 199-218 (2007).
Northfield TC, Hofmann AF. Biliary lipid output during three meals and an overnight fast. I. Relationship to bile acid pool size and cholesterol saturation of bile in gallstone and control subjects. Gut 16: 1-11 (1975). *
Northfield TC, LaRusso NF, Hofmann AF, Thistle JL. Biliary lipid output during three meals and an overnight fast. II. Effect of chenodeoxycholic acid treatment in gallstone subjects. Gut 16: 12-17 (1975). *
Noshiro H, Chijiiwa K, Makino I, Nakano K, Hirota I. Deoxycholic acid in gall bladder bile does not account for the shortened nucleation time in patients with cholesterol gall stones. Gut 36: 121-125 (1995). *
Noshiro M, Kawamoto T, Furukawa M, Fujimoto K, Yoshida Y, Sasabe E, Tsutsumi S, Hamada T, Honma S, Honma K, Kato Y. Rhythmic expression of DEC1 and DEC2 in peripheral tissues: DEC2 is a potent suppressor for hepatic cytochrome P450s opposing DBP. Genes Cells 9: 317-329 (2004). *
Noshiro M, Usui E, Kawamoto T, Kubo H, Fujimoto K, Furukawa M, Honma S, Makishima M, Honma K, Kato Y. Multiple mechanisms regulate circadian expression of the gene for cholesterol 7alpha-hydroxylase (Cyp7a), a key enzyme in hepatic bile acid biosynthesis. J. Biol. Rhythms 22: 299-311 (2007).
Novikov DK, Kosykh VA, Repin VS. The inhibition of bile acid synthesis in cultured rabbit hepatocytes by bezafibrate. Izv. Akad. Nauk. Ser. Biol. 4: 630-634 (1993).
Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, Kirikoshi H, Inamori M, Kubota K, Saito S, Mizoue T, Masaki N, Nagashima Y, Terauchi Y, Nakajima A. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 51: 548-556 (2009).
Nozawa H. Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem. Biophys. Res. Commun. 336: 754-761 (2005). *
Nunez L, Amigo L, Mingrone G, Rigotti A, Puglielli L, Raddatz A, Pimentel F, Greco AV, Gonzalez S, Garrido J, et al. Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis. Gut 37: 422-426 (1995). *
Nunomura S, Endo K, Makishima M, Ra C. Oxysterol represses high-affinity IgE receptor-stimulated mast cell activation in liver X receptor-dependent and -independent manners. FEBS Lett. Feb 4 [Epub ahead of print] (2010). *
Nurmohamed MT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc. Health Risk Manag. 3: 845-852 (2007).
Nutting DF, Kumar NS, Siddiqi SA, Mansbach CM. Nutrient absorption. Curr. Opin. Gastroenterol. 18: 168-175 (2002).
Nyalala JO, Wang J, Dang A, Faas FH, Smith WG. Hypertriglyceridemia and hypercholesterolemia: effects of drug treatment on fatty acid composition of plasma lipids and membranes. Prostaglandins Leukot. Essent. Fatty Acids 78: 271-280 (2008). *
O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14: 838-847 (1991).
O'Leary DP. Biliary cholesterol transport and the nucleation defect in cholesterol gallstone formation. J. Hepatol. 22: 239-246 (1995). *
Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett. 583: 1215-1225 (2009). *
Oda S, Sugai T, Ohta H. Preparation of methyl ursodeoxycholate via microbial reduction of methyl 7-ketolithocholate in an anaerobic interface bioreactor. J. Biosci. Bioeng. 91: 202-207 (2001). *
Oda Y, Uchida Y, Moradian S, Crumrine D, Elias PM, Bikle DD. Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation. J. Invest. Dermatol. 129: 1367-1378 (2009). *
Odermarsky M, Nilson A, Sjoblad S, Liuba P. Atherogenic vascular and lipid phenotypes in young type 1 diabetics are associated with diabetes high risk HLA. Am. J. Physiol. Heart Circ. Physiol. 293: H3175-H3179 (2007). *
Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J. Clin. Invest. 99: 1880-1887 (1997). *
Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br. J. Clin. Pharmacol. 64: 496-509 (2007). *
Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, Bruemmer D. Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ. Res. 96: e59-e67 (2005). *
Ogihara T, Chuang JC, Vestermark GL, Garmey JC, Ketchum RJ, Huang X, Brayman KL, Thorner MO, Repa JJ, Mirmira RG, Evans-Molina C. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/FFA cycling. J. Biol. Chem. Dec 14 [Epub ahead of print] (2009). *
Ogundare M, Theofilopoulos S, Lockhart A, Hall LJ, Arenas E, Sjovall J, Brenton AG, Wang Y, Griffiths WJ. Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain? J. Biol. Chem. Dec 7 [Epub ahead of print] (2009). *
Ogura T, Takada H, Okuno M, Kitade H, Matsuura T, Kwon M, Arita S, Hamazaki K, Itomura M, Hamazaki T. Fatty acid composition of plasma, erythrocytes and adipose: their correlations and effects of age and sex. Lipids Jan 22 [Epub ahead of print] (2010).
Oh RC, Lanier JB. Management of hypertriglyceridemia. Am. Fam. Physician 75: 1365-1371 (2007). *
Ohama T, Hirano K, Zhang Z, Aoki R, Tsujii K, Nakagawa-Toyama Y, Tsukamoto K, Ikegami C, Matsuyama A, Ishigami M, Sakai N, Hiraoka H, Ueda K, Yamashita S, Matsuzawa Y. Dominant expression of ATP-binding cassette transporter-1 on basolateral surface of Caco-2 cells stimulated by LXR/RXR ligands. Biochem. Biophys. Res. Commun. 296: 625-630 (2002). *
Ohira H, Takiguchi J, Rai T, Shishido S, Sato Y. Two cases of primary biliary cirrhosis complicated with syringomyelia. Am. J. Gastroenterol. 98: 224-226 (2003). *
Ohman M, Akerfeldt T, Nilsson I, Rosen C, Hansson LO, Carlsson M, Larsson A. Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acids. Ups. J. Med. Sci. 113: 315-324 (2008).
Ohnesorg T, Keller B, de Angelis MH, Adamski J. Transcriptional regulation of human and murine 17beta-hydroxysteroid dehydrogenase type-7 confers its participation in cholesterol biosynthesis. J. Mol. Endocrinol. 37: 185-197 (2006). *
Ohno M. Functional analysis of nuclear receptor FXR controlling metabolism of cholesterol. Yakugaku Zasshi 128: 343-355 (2008). *
Ohta Y, Kongo-Nishimura M, Imai Y, Kitagawa A. Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment. J. Pineal Res. 42: 159-165 (2007). *
Ohta Y, Kongo-Nishimura M, Imai Y, Matsura T, Kitagawa A, Yamada K. alpha-Tocopherol protects against alpha-naphthylisothiocyanate-induced hepatotoxicity in rats less effectively than melatonin. Chem. Biol. Interact. 161: 115-124 (2006). *
Ohtsuka T. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Arch. Dermatol. Res. 300: 545-550 (2008). *
Oikari S, Ahtialansaari T, Heinonen MV, Mauriala T, Auriola S, Kiehne K, Folsch UR, Janne J, Alhonen L, Herzig KH. Downregulation of PPARs and SREBP by acyl-CoA-binding protein overexpression in transgenic rats. Pflugers Arch. 456: 369-377 (2008). *
Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; for the JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 206: 535-539 (2009).
Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, Fujiu K, Maemura K, Kubota N, Kadowaki T, Nagai R. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nat. Med. 14: 656-666 (2008). *
Okada T, Noguchi R, Hosokawa M, Fukunaga K, Nishiyama T, Zaima N, Hirata T, Miyashita K. Effects of trans and conjugated LC n-3 polyunsaturated fatty acids on lipid composition and abdominal fat weight in rats. J. Food Sci. 73: H201-H206 (2008). *
Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, Kamatani N, Yamanaka H. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 34: 964-968 (2007).
Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr. J. 54: 431-435 (2007). *
Oki K, Yamane K, Kamei N, Asao T, Awaya T, Kohno N. The single nucleotide polymorphism upstream of insulin-induced gene 2 (INSIG2) is associated with the prevalence of hypercholesterolaemia, but not with obesity, in Japanese American women. Br. J. Nutr. 101: 322-327 (2009). *
Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur. J. Gastroenterol. Hepatol. 8: 685-691 (1996).
Okopien B, Haberka M, Madej A, Belowski D, Labuzek K, Krysiak R, Zielinski M, Basiak M, Herman ZS. Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol. Rep. 58: 729-735 (2006). *
Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23: 563-572 (2006).
Okuno T, Seto Y, Okanoue T, Takino T. Chronic active hepatitis with histological features of primary biliary cirrhosis. Dig. Dis. Sci. 32: 775-779 (1987).
Okuyama H, Ichikawa Y, Sun Y, Hamazaki T, Lands WE. Cancers common in the USA are stimulated by omega 6 fatty acids and large amounts of animal fats, but suppressed by omega 3 fatty acids and cholesterol. World Rev. Nutr. Diet. 96: 143-149 (2007).
Olano-Martin E, Abraham EC, Gill-Garrison R, Valdes AM, Grimaldi K, Tang F, Jackson KG, Williams CM, Minihane AM. Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender. J. Lipid Res. 49: 945-953 (2008). *
Olano-Martin E, Anil E, Caslake MJ, Packard CJ, Bedford D, Stewart G, Peiris D, Williams CM, Minihane AM. Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis Aug 21 [Epub ahead of print] (2009).
Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 69: 609-632 (2009).
Oliva L, Beauge F, Choquart D, Montet AM, Guitaoui M, Montet JC. Ursodeoxycholate alleviates alcoholic fatty liver damage in rats. Alcohol Clin. Exp. Res. 22: 1538-1543 (1998). *
Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98: 5306-5311 (2001). *
Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, Bernardi D, Ramonda R, Plebani M, Punzi L. Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin. Exp. Rheumatol. 27: 79-83 (2009).
Olofsson PS, Soderstrom LA, Wagsater D, Sheikine Y, Ocaya P, Lang F, Rabu C, Chen L, Rudling M, Aukrust P, Hedin U, Paulsson-Berne G, Sirsjo A, Hansson GK. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117: 1292-1301 (2008). *
Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to aging - role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun. Ageing 4: 1 (2007). *
Ondeyka JG, Jayasuriya H, Herath KB, Guan Z, Schulman M, Collado J, Dombrowski AW, Kwon SS, McCallum C, Sharma N, MacNaul K, Hayes N, Menke JG, Singh SB. Steroidal and triterpenoidal fungal metabolites as ligands of liver X receptors. J. Antibiot. (Tokyo) 58: 559-565 (2005). *
Ong HT, Cheah JS. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics. Chin. Med. J. (Engl.) 121: 1588-1594 (2008). *
Ontsouka CE, Burgener IA, Mani O, Albrecht C. Polyunsaturated fatty acid-enriched diets used for the treatment of canine chronic enteropathies decrease the abundance of selected genes of cholesterol homeostasis. Domest. Anim. Endocrinol. 38: 32-37 (2010). *
Onuki Y, Hagiwara C, Sugibayashi K, Takayama K. Specific effect of polyunsaturated fatty acids on the cholesterol-poor membrane domain in a model membrane. Chem. Pharm. Bull. (Tokyo) 56: 1103-1109 (2008). *
Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin. Sci. (Lond.) 114: 611-624 (2008). *
Oosterveer MH, van Dijk TH, Grefhorst A, Bloks VW, Havinga R, Kuipers F, Reijngoud DJ. Lxra deficiency hampers the hepatic adaptive response to fasting in mice. J. Biol. Chem. 283: 25437-25445 (2008). *
Oosterveer MH, van Dijk TH, Tietge UJ, Boer T, Havinga R, Stellaard F, Groen AK, Kuipers F, Reijngoud DJ. High fat feeding induces hepatic fatty acid elongation in mice. PLoS One 4: e6066 (2009). *
Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular cisease. Circ. Res. 99: 1031-1043 (2006). *
Oram JF, Vaughan AM, Stocker R. ATP-binding cassette transporter A1 mediates cellular secretion of alpha-tocopherol. J. Biol. Chem. 276: 39898-39902 (2001). *
Ordovas JM. Genotype-phenotype associations: modulation by diet and obesity. Obesity (Silver Spring) 16 Suppl. 3: S40-S46 (2008).
Oregon-Romero E, Vazquez-Del Mercado M, Navarro-Hernandez RE, Torres-Carrillo N, Martinez-Bonilla G, Estrada-Garcia I, Rangel-Villalobos H, Munoz-Valle JF. Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels and clinical features. Rheumatol. Int. 27: 53-59 (2006). *
Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y; The JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circ. J. Feb 9 [Epub ahead of print] (2010). *
Orlacchio A, Bruce IN, Rahman P, Kawarai T, Bernardi G, St George-Hyslop PH, Gladman DD, Urowitz MB. The apolipoprotein E2 isoform is associated with accelerated onset of coronary artery disease in systemic lupus erythematosus. Med. Sci. Monit. 14: CR233-CR237 (2008). *
Ortiz DF, St Pierre MV, Abdulmessih A, Arias IM. A yeast ATP-binding cassette-type protein mediating ATP-dependent bile acid transport. J. Biol. Chem. 272: 15358-15365 (1997). *
Ory DS. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ. Res. 95: 660-670 (2004). *
Osmancevic A, Landin-Wilhelmsen K, Larko O, Mellstrom D, Wennberg AM, Hulthen L, Krogstad AL. UVB therapy increases 25(OH) vitamin D syntheses in postmenopausal women with psoriasis. Photodermatol. Photoimmunol. Photomed. 23: 172-178 (2007).
Ostlund RE. Cholesterol absorption. Curr. Opin. Gastroenterol. 18: 254-258 (2002).
Ostlund RE Jr. Phytosterols and cholesterol metabolism. Curr. Opin. Lipidol. 15: 37-41 (2004).
Ostlund RE Jr. Phytosterols in human nutrition. Annu. Rev. Nutr. 22: 533-549 (2002). *
Ostuni MA, Tumilasci OR, Peranzi G, Cardoso EM, Contreras LN, Arregger AL, Papadopoulos V, Lacapere JJ. Effect of translocator protein (18-kDa) ligand binding on neurotransmitter-induced saliva secretion in rat submandibular glands. Biol. Cell 100: 427-439 (2008). *
Otte K, Kranz H, Kober I, Thompson P, Hoefer M, Haubold B, Remmel B, Voss H, Kaiser C, Albers M, Cheruvallath Z, Jackson D, Casari G, Koegl M, Paabo S, Mous J, Kremoser C, Deuschle U. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell Biol. 23: 864-872 (2003). *
Ou X, Dai X, Long Z, Tang Y, Cao D, Hao X, Hu Y, Li X, Tang C. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression. Sci. China C. Life Sci. 51: 418-429 (2008).
Oude Elferink RP, Groen AK. The mechanism of biliary lipid secretion and its defects. Gastroenterol. Clin. North Am. 28: 59-74, vi (1999).
Oude Elferink RP, Ottenhoff R, Fricker G, Seward DJ, Ballatori N, Boyer J. Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G762-G768 (2004). *
Oude Elferink RP, Ottenhoff R, van Wijland M, Frijters CM, van Nieuwkerk C, Groen AK. Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein. J. Lipid Res. 37: 1065-1075 (1996). *
Oude Elferink RP, Ottenhoff R, van Wijland M, Smit JJ, Schinkel AH, Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J. Clin. Invest. 95: 31-38 (1995). *
Oudshoorn JH, Lecluse AL, van den Berg R, Vaes WH, van der Laag J, Houwen RH. Decreased coenzyme Q10 concentration in plasma of children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 43: 646-650 (2006). *
Ouellet V, Weisnagel SJ, Marois J, Bergeron J, Julien P, Gougeon R, Tchernof A, Holub BJ, Jacques H. Dietary cod protein reduces plasma C-reactive protein in insulin-resistant men and women. J. Nutr. 138: 2386-2391 (2008). *
Ouguerram K, Maugeais C, Gardette J, Magot T, Krempf M. Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects. Br. J. Nutr. 96: 100-106 (2006). *
Ouimet M, Wang MD, Cadotte N, Ho K, Marcel YL. Epoxycholesterol impairs cholesteryl ester hydrolysis in macrophage foam cells, resulting in decreased cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 28: 1144-1450 (2008).
Ourlin JC, Lasserre F, Pineau T, Fabre JM, Sa-Cunha A, Maurel P, Vilarem MJ, Pascussi JM. The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol. Endocrinol. 17: 1693-1703 (2003). *
Ouvrier A, Cadet R, Lobaccaro JM, Drevet JR, Saez F. LXR regulate cholesterol homeostasis in the proximal mouse epididymis. Folia Histochem. Cytobiol. 47: S75-S79 (2009). *
Ouvrier A, Cadet R, Vernet P, Lallier B, Chardigny JM, Lobaccaro JM, Drevet JR, Saez F. LXR and ABCA1 control cholesterol homeostasis in the proximal mouse epididymis in a cell specific manner. J. Lipid Res. 50: 1766-1775 (2009). *
Overgaard J, Porsgaard T, Guo Z, Lauritzen L, Mu H. Postprandial lipid responses of butter blend containing fish oil in a single-meal study in humans. Mol. Nutr. Food Res. 52: 1140-1146 (2008). *
Owen JS, Brown DJ, Harry DS, McIntyre N, Beaven GH, Isenberg H, Gratzer WB. Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins. J. Clin. Invest. 76: 2275-2285 (1985). *
Owen JS, Goodall H, Mistry P, Harry DS, Day RC, McIntyre N. Abnormal high density lipoproteins from patients with liver disease regulate cholesterol metabolism in cultured human skin fibroblasts. J. Lipid Res. 25: 919-931 (1984). *
Owsley E, Chiang JY. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem. Biophys. Res. Commun. 304: 191-195 (2003). *
Ozsait B, Komurcu Bayrak E, Poda M, Can G, Hergenc G, Onat A, Humphries SE, Erginel Unaltuna N. CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu. Kardiyol. Derg. 8: 324-330 (2008).
Oztekin D, Aydal I, Oztekin O, Okcu S, Borekci R, Tinar S. Predicting fetal asphyxia in intrahepatic cholestasis of pregnancy. Arch. Gynecol. Obstet. 280: 975-979 (2009).
Pachikian BD, Neyrinck AM, Cani PD, Portois L, Deldicque L, De Backer FC, Sohet FM, Bindels LB, Malaisse WJ, Francaux M, Carpentier YA, Delzenne NM. Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol. 8: 21 (2008). *
Pac�n M. Severe hyperlipidemia, secondary to hypothyroidism due to atrophic thyroiditis in a girl. Arch. Argent. Pediatr. 107: 53-56 (2009).
Pageaux GP, Calmus Y, Boillot O, Ducerf C, Vanlemmens C, Boudjema K, Samuel D. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl. 10: 1454-1460 (2004). *
Pagotto U, Vanuzzo D, Vicennati V, Pasquali R. Pharmacological therapy of obesity. G. Ital. Cardiol. (Rome) 9: 83S-93S (2008).
Paintlia AS, Paintlia MK, Singh AK, Singh I. Inhibition of Rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol. Pharmacol. 73: 1381-1393 (2008). *
Pajukanta P. Do DNA sequence variants in ABCA1 contribute to HDL cholesterol levels in the general population? J. Clin. Invest. 114: 1244-1247 (2004). *
Pal M, Pillarisetti S. HDL elevators and mimetics - emerging therapies for atherosclerosis. Cardiovasc. Hematol. Agents Med. Chem. 5: 55-66 (2007).
Palikhe A, Sinisalo J, Seppanen M, Valtonen V, Nieminen MS, Lokki ML. Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease. Tissue Antigens 69: 47-55 (2007). *
Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. Am. J. Med. 83: 37-43 (1987).
Pamuk ON, Unlu E, Cakir N. Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. J. Rheumatol. 33: 2447-2452 (2006).
Pandak WM, Bohdan P, Franklund C, Mallonee DH, Eggertsen G, Bjorkhem I, Gil G, Vlahcevic ZR, Hylemon PB. Expression of sterol 12alpha-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. Gastroenterology 120: 1801-1809 (2001). *
Pandak WM, Hylemon PB, Ren S, Marques D, Gil G, Redford K, Mallonee D, Vlahcevic ZR. Regulation of oxysterol 7alpha-hydroxylase (CYP7B1) in primary cultures of rat hepatocytes. Hepatology 35: 1400-1408 (2002). *
Pandey SN, Dixit M, Choudhuri G, Mittal B. Lipoprotein receptor associated protein (LRPAP1) insertion/deletion polymorphism: association with gallbladder cancer susceptibility. Int. J. Gastrointest. Cancer 37: 124-128 (2006).
Pandey SN, Srivastava A, Dixit M, Choudhuri G, Mittal B. Haplotype analysis of signal peptide (insertion/deletion) and XbaI polymorphisms of the APOB gene in gallbladder cancer. Liver Int. 27: 1008-1015 (2007). *
Pang CP, Baum L, Lam DS. Hunting for disease genes in multi-functional diseases. Clin. Chem. Lab. Med. 38: 819-825 (2000).
Panini SR, Everson GT, Spencer TA. Effects of specific inhibition of sterol biosynthesis on the uptake and utilization of low density lipoprotein cholesterol by HepG2 cells. J. Lipid Res. 32: 1657-1665 (1991). *
Papi G, Uberti ED, Betterle C, Carani C, Pearce EN, Braverman LE, Roti E. Subclinical hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 14: 197-208 (2007).
Paragh G, Harangi M, Mark L. New trends in lipidology: the increasing role of HDL-cholesterol. Orv. Hetil. 149: 1395-1404 (2008).
Pare JF, Malenfant D, Courtemanche C, Jacob-Wagner M, Roy S, Allard D, Belanger L. The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis, and regulated by a DR4 element. J. Biol. Chem. 279: 21206-21216 (2004). *
Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, Berenguer J, Rodriguez-Martinez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J. Hepatol. 32: 561-566 (2000). *
Park JH, Kim JH, Kim WH, Kim DS, Park TS, Baek HS. Association of the endothelial nitric oxide synthase (ecNOS) gene polymorphism with carotid atherosclerosis in type 2 diabetes. Diabetes Res. Clin. Pract. 72: 322-327 (2006).
Park S, Park Y. Effects of dietary fish oil and trans fat on rat aorta histopathology and cardiovascular risk markers. Nutr. Res. Pract. 3: 102-107 (2009).
Park SE, Kang ES, Kim DH, Kim SK, Lee JH, Ahn CW, Lee HC, Cha BS. Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with type 2 diabetes treated with rosiglitazone. Diabet. Med. 26: 577-581 (2009). *
Park SS, Choi H, Kim SJ, Kim OJ, Chae KS, Kim E. FXRalpha down-regulates LXRalpha signaling at the CETP promoter via a common element. Mol. Cells 26: 409-414 (2008).
Park Y, Harris WS. Dose-response of n-3 polyunsaturated fatty acids on lipid profile and tolerability in mildly hypertriglyceridemic subjects. J. Med. Food 12: 803-808 (2009).
Park YJ, Qatanani M, Chua SS, Larey JL, Johnson SA, Watanabe M, Moore DD, Lee YK. Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis. Hepatology 47: 1578-1586 (2008). *
Park YM, Province MA, Gao X, Feitosa M, Wu J, Ma D, Rao D, Kraja AT. Longitudinal trends in the association of metabolic syndrome with 550 k single-nucleotide polymorphisms in the Framingham Heart Study. BMC Proc. 3 Suppl. 7: S116 (2009). *
Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368 (1999). *
Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel JF, Desreumaux P, Peyrin-Biroulet L. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm. Bowel Dis. 15: 1476-1484 (2009).
Parquet M, Rey C, Groussard M, Infante R. Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat. Biochim. Biophys. Acta 665: 299-305 (1981).
Parra-Rojas I, Ruiz-Madrigal B, Martinez-Lopez E, Panduro A. Influence of the -308 TNF-alpha and -174 IL-6 polymorphisms on lipid profile in Mexican subjects. Hereditas 143: 167-172 (2006). *
Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet. Genomics 18: 921-926 (2008).
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16: 873-879 (2006).
Pascual I, Larrayoz IM, Campos MM, Rodriguez IR. Methionine sulfoxide reductase b2 is highly expressed in the retina and protects retinal pigmented epithelium cells from oxidative damage. Exp. Eye Res. Dec 18 [Epub ahead of print] (2009). *
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ, Maurel P. Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34: 633-664 (2004).
Pasquali M, Mandanici G, Conte C, Muci ML, Mazzaferro S. Understanding the different functions of vitamin D. G. Ital. Nefrol. 26 Suppl. 46: 53-57 (2009).
Patade A, Devareddy L, Lucas EA, Korlagunta K, Daggy BP, Arjmandi BH. Flaxseed reduces total and LDL cholesterol concentrations in Native American postmenopausal women. J. Womens Health (Larchmt.) 17: 355-366 (2008).
Patel B, Schutte R, Sporns P, Doyle J, Jewel L, Fedorak RN. Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. Inflamm. Bowel Dis. 8: 340-346 (2002). *
Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 56: 792-798 (2007). *
Patel DD, Knight BL, Soutar AK, Gibbons GF, Wade DP. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochem. J. 351: 747-753 (2000). *
Patel DD, Knight BL, Wiggins D, Humphreys SM, Gibbons GF. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J. Lipid Res. 42: 328-337 (2001). *
Patel NV, Forman BM. Linking lipids, Alzheimer's and LXRs? Nucl. Recept. Signal. 2: e001 (2004). *
Patel SD, Taylor HC. Intrahepatic cholestasis during nicotinic acid therapy. Cleve. Clin. J. Med. 61: 70-75 (1994).
Patenaude A, Rodriguez-Leyva D, Edel AL, Dibrov E, Dupasquier CM, Austria JA, Richard MN, Chahine MN, Malcolmson LJ, Pierce GN. Bioavailability of alpha-linolenic acid from flaxseed diets as a function of the age of the subject. Eur. J. Clin. Nutr. 63: 1123-1129 (2009). *
Paterson CR, Moody JP, Pennington CR. Skin content of 7-dehydrocholesterol in patients with malabsorption. Nutrition 13: 771-773 (1997). *
Patt CH, Yoo HY, Dibadj K, Flynn J, Thuluvath PJ. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig. Dis. Sci. 48: 797-801 (2003). *
Patterson AD, Slanar O, Krausz KK, Li F, Hofer CC, Perl�k F, Gonzalez FJ, Idle JR. Human urinary metabolomic profile of PPAR induced fatty acid oxidation. J. Proteome Res. 8: 4293-4300 (2009). *
Paulusma CC, Dewaart DR, Kunne C, Mok KS, Oude Elferink RP. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J. Biol. Chem. 284: 9947-9954 (2009). *
Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, de Waart DR, Hoek FJ, Vreeling H, Hoeben KA, van Marle J, Pawlikowska L, Bull LN, Hofmann AF, Knisely AS, Oude Elferink RP. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 44: 195-204 (2006). *
Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ. Res. 98: 361-369 (2006). *
Paumgartner G. Biliary physiology and disease: reflections of a physician scientist. Hepatology [In Press] (2009). *
Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand. J. Gastroenterol. Suppl. 204: 27-31 (1994).
Pausch J, Gatzen M. Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins? Internist (Berl.) 47: 1239-1244 (2006).
Pazzi P, Gamberini S, Buldrini P, Gullini S. Biliary sludge: the sluggish gallbladder. Dig. Liver Dis. 35 Suppl. 3: S39-S45 (2003).
Pearlman BJ, Bonorris GG, Phillips MJ, Chung A, Vimadalal S, Marks JW, Schoenfield LJ. Cholesterol gallstone formation and prevention by chenodeoxycholic and ursodeoxycholic acids. A new hamster model. Gastroenterology 77: 634-641 (1979).
Pearlman BJ, Marks JW, Bonorris GG, Schoenfield LJ. Gallstone dissolution - a progress report. Clin. Gastroenterol. 8: 123-140 (1979).
Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8: 571-575 (1998).
Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693-704 (1998). *
Peffer RC, Moggs JG, Pastoor T, Currie RA, Wright J, Milburn G, Waechter F, Rusyn I. Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor. Toxicol. Sci. 99: 315-325 (2007). *
Pei WD, Zhang YH, Sun YH, Gu YC, Wang YF, Zhang CY, Zhang J, Liu LS, Hui RT, Liu YQ, Yang YJ. Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia. Circ. J. 70: 1606-1610 (2006). *
Pejic RN, Lee DT. Hypertriglyceridemia. J. Am. Board Fam. Med. 19: 310-316 (2006). *
Pejnovic N, Vratimos A, Lee SH, Popadic D, Takeda K, Akira S, Chan WL. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol. Immunol. 47: 37-45 (2009). *
Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, Fiorucci S, Clerici C, Gioiello A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem. 47: 4559-4569 (2004). *
Pelton PD, Patel M, Demarest KT. Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr. Top. Med. Chem. 5: 265-282 (2005).
Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, Cotichini R, Stroffolini T, Mele A. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 41: 1151-1159 (2005). *
Peng D, Hiipakka R, Dai Q, Guo J, Reardon C, Getz G, Liao S. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J. Pharmacol. Exp. Ther. 327: 332-342 (2008). *
Peng D, Hiipakka RA, Xie JT, Reardon CA, Getz GS, Liao S. Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice. Atherosclerosis Jul 8 [Epub ahead of print] (2009).
Perales J, Angel Lasuncion M, Cano A, Martin-Scapa MA, Maties M, Herrera E. Changes in the lipid profile in chronic hepatopathies. Med. Clin. (Barc.) 102: 364-368 (1994).
Perales MS, Alejandre J, Palomino-Morales RJ, Torres C, Linares A. Influence of cholesterol and fish oil dietary intake on nitric oxide-induced apoptosis in vascular smooth muscle cells. Nitric Oxide Dec 26 [Epub ahead of print] (2009).
Perales S, Alejandre MJ, Palomino-Morales R, Torres C, Iglesias J, Linares A. Effect of oxysterol-induced apoptosis of vascular smooth muscle cells on experimental hypercholesterolemia. J. Biomed. Biotechnol. 2009: 456208 (2009). *
Perassolo MS, Almeida JC, Steemburgo T, Dall'Alba V, de Mello VD, Zelmanovitz T, de Azevedo MJ, Gross JL. Endothelial dysfunction and serum fatty acid composition in patients with type 2 diabetes mellitus. Metabolism 57: 1167-1172 (2008). *
Pereira S, Saboya C, Chaves G, Ramalho A. Class III obesity and its relationship with the nutritional status of vitamin A in pre- and postoperative gastric bypass. Obes. Surg. 19: 738-744 (2009).
Pereira SP, Bain IM, Kumar D, Dowling RH. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment. Pharmacol. Ther. 17: 923-933 (2003). *
Peretti N, Delvin E, Sinnett D, Marcil V, Garofalo C, Levy E. Asymmetrical regulation of scavenger receptor class B type I by apical and basolateral stimuli using Caco-2 cells. J. Cell. Biochem. 100: 421-433 (2007). *
Perez-Aguilar F, Benlloch S, Berenguer M. Study of patients referred for elevated ferritin levels and/or transferrin saturation: significance of non-alcoholic fatty liver disease. Gastroenterol. Hepatol. 27: 508-514 (2004).
Perez-Echarri N, Perez-Matute P, Marcos-Gomez B, Marti A, Martinez JA, Moreno-Aliaga MJ. Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats. J. Nutr. Biochem. 20: 705-714 (2009). *
Perez-Guisado J, Munoz-Serrano A, Alonso-Moraga A. Spanish ketogenic Mediterranean diet: a healthy cardiovascular diet for weight loss. Nutr. J. 7: 30 (2008). *
Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobreglio G. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur. J. Endocrinol. 143: 497-503 (2000). *
Persson J, Nilsson J, Lindholm MW. Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells. BMC Immunol. 9: 70 (2008). *
Pertovaara M, Kahonen M, Juonala M, Laitinen T, Taittonen L, Lehtimaki T, Viikari JS, Raitakari OT, Hurme M. Autoimmunity and atherosclerosis: the presence of antinuclear antibodies is associated with decreased carotid elasticity in young women. The Cardiovascular Risk in Young Finns Study. Rheumatology (Oxford) 48: 1553-1556 (2009).
Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, Sobajic SS, Djuricic I, Maletic R, Ristic-Medic DK. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton) 12: 331-336 (2007). *
Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J. Biol. Chem. 272: 27307-27312 (1997). *
Peters MJ, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW, Dijkmans BA, Voskuyl AE. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J. Rheumatol. 35: 1495-1499 (2008).
Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT. Changes in lipid profile during infliximab treatment and corticosteroid therapy in rheumatoid arthritis. Ann. Rheum. Dis. 66: 958-961 (2007). *
Peters MJ, Watt PH, Cherry L, Welsh P, Henninger E, Dijkmans BA, McInnes IB, Nurmohamed MT, Sattar N. Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Ann. Rheum. Dis. Jul 28 [Epub ahead of print] (2009).
Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50: 2858-2868 (2004). *
Pewzner-Jung Y, Park H, Laviad EL, Silva LC, Lahiri S, Stiban J, Erez-Roman R, Brugger B, Sachsenheimer T, Wieland F, Prieto M, Merrill AH Jr, Futerman AH. A critical role for ceramide synthase 2 in liver homeostasis: I. Alterations in lipid metabolic pathways. J. Biol. Chem. Jan 28 [Epub ahead of print] (2010). *
Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 96: 2745-2750 (2001). *
Pianese P, Salvia G, Campanozzi A, D'Apolito O, Dello Russo A, Pettoello-Mantovani M, Corso G. Sterol profiling in red blood cell membranes and plasma of newborns receiving total parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 47: 645-651 (2008). *
Piazza F, Montagnani M, Russo C, Azzaroli F, Aldini R, Roda E, Roda A. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Dig. Liver Dis. 32: 318-328 (2000).
Piehler A, Kaminski WE, Wenzel JJ, Langmann T, Schmitz G. Molecular structure of a novel cholesterol-responsive A subclass ABC transporter, ABCA9. Biochem. Biophys. Res. Commun. 295: 408-416 (2002). *
Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J. Inherit. Metab. Dis. Dec 27 [Epub ahead of print] (2008). *
Pietrzak A, Kadzielewski J, Janowski K, Rolinski J, Krasowska D, Chodorowska G, Paszkowski T, Kapec E, Jastrzebska I, Tabarkiewicz J, Lotti T. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int. J. Dermatol. 48: 379-387 (2009). *
Pikuleva I, Javitt NB. Novel sterols synthesized via the CYP27A1 metabolic pathway. Arch. Biochem. Biophys. 420: 35-39 (2003). *
Pincon JA, Chatelain P, Mallet-Guy Y, Bouvier R, de Parscau L, Francois R. Byler's disease. Ultrastructural study. Apropos of a case in an infant. Pediatrie. 39: 279-288 (1984).
Pineda Torra I, Freedman LP, Garabedian MJ. Identification of DRIP205 as a coactivator for the farnesoid X receptor. J. Biol. Chem. 279: 36184-36191 (2004). *
Pins JJ, Keenan JM. Dietary and nutraceutical options for managing the hypertriglyceridemic patient. Prog. Cardiovasc. Nurs. 21: 89-93 (2006).
Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, Gardner-Medwin J, Hiller L, Martin U, Townend J, Bacon PA, Gordon C. Impaired endothelial function in systemic lupus erythematosus. Lupus 16: 84-88 (2007). *
Piperno A, Vergani A, Salvioni A, Trombini P, Vigano M, Riva A, Zoppo A, Boari G, Mancia G. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int. 24: 471-476 (2004). *
Piraino G, Cook JA, O'Connor M, Hake PW, Burroughs TJ, Teti D, Zingarelli B. Synergistic effect of peroxisome proliferator-activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages. Shock 26: 146-153 (2006). *
Pisciotta L, Cortese C, Gnasso A, Liberatoscioli L, Pastore A, Mannucci L, Irace C, Federici G, Bertolini S. Serum homocysteine, methylenetetrahydrofolate reductase gene polymorphism and cardiovascular disease in heterozygous familial hypercholesterolemia. Atherosclerosis 179: 333-338 (2005).
Piscopo S. The Mediterranean diet as a nutrition education, health promotion and disease prevention tool. Public Health Nutr. 12: 1648-1655 (2009).
Pishva H, Mahboob SA, Mehdipour P, Eshraghian MR, Mohammadi-Asl J, Hosseini S, Karimi F. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects. Nutrition Jan 15 [Epub ahead of print] (2010). *
Pitchumoni CS, Rubin A, Das K. Pancreatitis in inflammatory bowel diseases. J. Clin. Gastroenterol. Jan 15 [Epub ahead of print] (2010).
Pizato N, Bonatto S, Yamazaki RK, Aikawa J, Nogata C, Mund RC, Nunes EA, Piconcelli M, Naliwaiko K, Curi R, Calder PC, Fernandes LC. Ratio of n-6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats. Nutr. Cancer 53: 194-201 (2005). *
Plans-Rubio P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. Pharmacoeconomics 13: 623-643 (1998).
Plat J, Nichols JA, Mensink RP. Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J. Lipid Res. 46: 2468-2476 (2005). *
Plewa R, Luczak M, Burchardt P, Bolewski A, Wierzchowiecki J, Siminiak T. Monogenic hypercholesterolaemias - an evaluation of apolipoprotein B100 and LDL receptor gene polymorphisms. Kardiol. Pol. 64: 127-133 (2006).
Plosch T, Bloks VW, Terasawa Y, Berdy S, Siegler K, Van Der Sluijs F, Kema IP, Groen AK, Shan B, Kuipers F, Schwarz M, Schwartz M. Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. Gastroenterology 126: 290-300 (2004). *
Plosch T, Kok T, Bloks VW, Smit MJ, Havinga R, Chimini G, Groen AK, Kuipers F. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J. Biol. Chem. 277: 33870-33877 (2002). *
Plosch T, Kosters A, Groen AK, Kuipers F. The ABC of hepatic and intestinal cholesterol transport. Handb. Exp. Pharmacol. 170: 465-482 (2005).
Plosch T, van der Veen JN, Havinga R, Huijkman NC, Bloks VW, Kuipers F. Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G414-G423 (2006). *
Plosch T, van Straten EM, Kuipers F. Cholesterol transport by the placenta: placental liver X receptor activity as a modulator of fetal cholesterol metabolism? Placenta 28: 604-610 (2007).
Podymova SD, Nadinskaia MIu. Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome. Klin. Med. (Mosk.) 76: 45-48 (1998).
Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322: 1702-1705 (2008). *
Polokoff MA, Everson GT. Hepatocyte-hepatoma cell hybrids. Characterization and demonstration of bile acid synthesis. J. Biol. Chem. 261: 4085-4089 (1986). *
Pomeroy S, Worsley A. The relevance of the Heart Foundation of Australia's dietary recommendations for adult Australians: a comparison of views of general practitioners, cardiologists and dietitians. Asia Pac. J. Clin. Nutr. 17: 290-296 (2008).
Ponugoti B, Fang S, Kemper JK. Functional interaction of hepatic nuclear factor-4 and peroxisome proliferator-activated receptor-gamma coactivator 1alpha in CYP7A1 regulation is inhibited by a key lipogenic activator, sterol regulatory element-binding protein-1c. Mol. Endocrinol. 21: 2698-2712 (2007). *
Pooler PA, Duane WC. Effects of bile acid administration on bile acid synthesis and its circadian rhythm in man. Hepatology 8: 1140-1146 (1988).
Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689-692 (2000). *
Pooya S, Jalali MD, Jazayery AD, Saedisomeolia A, Eshraghian MR, Toorang F. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr. Metab. Cardiovasc. Dis. Jun 18 [Epub ahead of print] (2009).
Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66: 1503-1507 (2007). *
Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF. Anti-inflammatory therapy with TNFalpha inhibitors improves HDL-cholesterol anti-oxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68: 868-872 (2009).
Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS. Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 40: 3485-3492 (2009).
Popruk S, Tungtrongchitr R, Petmitr S, Pongpaew P, Harnroongroj T, Pooudong S, Phonrat B, Yamborisut U, Chongviriyaphan N, Tungtrongchitr A. Leptin, soluble leptin receptor, lipid profiles, and LEPR gene polymorphisms in Thai children and adolescents. Int. J. Vitam. Nutr. Res. 78: 9-15 (2008).
Porchay I, Pean F, Bellili N, Royer B, Cogneau J, Chesnier MC, Caradec A, Tichet J, Balkau B, Marre M, Fumeron F. ABCA1 single nucleotide polymorphisms on high-density lipoprotein-cholesterol and overweight: the D.E.S.I.R. Study. Obesity (Silver Spring) 14: 1874-1879 (2006). *
Porchay-Balderelli I, Pean F, Bellili N, Jaziri R, Marre M, Fumeron F; for the DIABHYCAR Study Group. The CETP TaqIB polymorphism is associated with the risk of sudden death in type 2 diabetic patients. Diabetes Care 30: 2863-2867 (2007). *
Porsch-Ozcurumez M, Langmann T, Heimerl S, Borsukova H, Kaminski WE, Drobnik W, Honer C, Schumacher C, Schmitz G. The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J. Biol. Chem. 276: 12427-12433 (2001). *
Portincasa P, Di Ciaula A, vanBerge-Henegouwen GP. Smooth muscle function and dysfunction in gallbladder disease. Curr. Gastroenterol. Rep. 6: 151-162 (2004).
Portincasa P, Di Ciaula A, Wang HH, Moschetta A, Wang DQ. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr. Med. Chem. 16: 1531-1542 (2009).
Portincasa P, Di Ciaula A, Wang HH, Palasciano G, van Erpecum KJ, Moschetta A, Wang DQ. Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology 47: 2112-2126 (2008). *
Portincasa P, Moschetta A, Palasciano G. From lipid secretion to cholesterol crystallization in bile. Relevance in cholesterol gallstone disease. Ann. Hepatol. 1: 121-128 (2002). *
Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *
Posokhova EN, Khoshchenko OM, Chasovskikh MI, Pivovarova EN, Dushkin MI. Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors. Biochemistry (Mosc.) 73: 296-304 (2008).
Post SM, de Wit EC, Princen HM. Cafestol, the cholesterol-raising factor in boiled coffee, suppresses bile acid synthesis by downregulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase in rat hepatocytes. Arterioscler. Thromb. Vasc. Biol. 17: 3064-3070 (1997).
Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21: 1840-1845 (2001). *
Post SM, Groenendijk M, van der Hoogt CC, Fievet C, Luc G, Hoekstra M, Princen HM, Staels B, Rensen PC. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 26: 2724-2730 (2006).
Post SM, Twisk J, van der Fits L, de Wit EC, Hoekman MF, Mager WH, Princen HM. Lipoprotein cholesterol uptake mediates up-regulation of bile-acid synthesis by increasing cholesterol 7alpha-hydroxylase but not sterol 27-hydroxylase gene expression in cultured rat hepatocytes. Biochem. J. 341: 339-346 (1999). *
Potaczek DP, Undas A, Celinska-Lowenhoff M, Szczeklik A. The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects. Cardiovasc. Drugs Ther. 20: 229-232 (2006). *
Potaczek DP, Undas A, Celinska-Lowenhoff M, Szczeklik A. Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood Coagul. Fibrinolysis 17: 35-38 (2006).
Poupon R. Molecular mechanisms of bile formation and cholestatic diseases. Bull. Acad. Natl. Med. 187: 1261-1274 (2003).
Poupon R. Cholestasis and cholestatic liver diseases. Gastroenterol. Clin. Biol. 33: 778-788 (2009).
Poupon R, Chignard N, Rosmorduc O, Barbu V, Housset C. Biliary function and its regulation. Med. Sci. (Paris) 20: 1096-1099 (2004).
Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554 (1991).
Poupon RE, Eschwege E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J. Hepatol. 11: 16-21 (1990).
Poupon RE, Ouguerram K, Chretien Y, Verneau C, Eschwege E, Magot T, Poupon R. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 17: 577-582 (1993).
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352: 2184-2192 (2005). *
Pradhan SB, Dali S. Relation between gallbladder neoplasm and Helicobacter hepaticus infection. Kathmandu Univ. Med. J. (KUMJ) 2: 331-335 (2004).
Prakash S, Martoni C. Toward a new generation of therapeutics: artificial cell targeted delivery of live cells for therapy. Appl. Biochem. Biotechnol. 128: 1-22 (2006).
Pramfalk C, Karlsson E, Groop L, Rudel LL, Angelin B, Eriksson M, Parini P. Control of ACAT2 liver expression by HNF4alpha: lesson from MODY1 patients. Arterioscler. Thromb. Vasc. Biol. 29: 1235-1241 (2009).
Preisig R, Halter F, Bircher J. New aspects in the treatment of cholecysto-and choledolithiasis. Schweiz. Med. Wochenschr. 111: 297-302 (1981).
Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. (Oxf.) 70: 815-828 (2009). *
Prieur X, Lesnik P, Moreau M, Rodr�guez JC, Doucet C, Chapman MJ, Huby T. Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice. Biochim. Biophys. Acta 1791: 764-771 (2009). *
Prieur X, Roszer T, Ricote M. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim. Biophys. Acta Sep 28 [Epub ahead of print] (2009). *
Priore Oliva C, Carubbi F, Schaap FG, Bertolini S, Calandra S. Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J. Intern. Med. 263: 450-458 (2008). *
Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W, Baralle FE, Dallinga-Thie GM, Geisel J, Keller C, Menys VC, Schmitz G. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 175: 269-279 (2004).
Prociuk MA, Edel AL, Richard MN, Gavel NT, Ander BP, Dupasquier CM, Pierce GN. Cholesterol-induced stimulation of platelet aggregation is prevented by a hempseed-enriched diet. Can. J. Physiol. Pharmacol. 86: 153-159 (2008).
Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55: 2502-2509 (2006). *
Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp. Dermatol. 17: 1063-1072 (2008).
Propst A, Propst T, Lechleitner M, Hoppichler F, Kathrein H, Vogel W, Judmaier G, Knapp E, Braunsteiner H. Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig. Dis. Sci. 38: 379-380 (1993).
Prufer K, Boudreaux J. Nuclear localization of liver X receptor alpha and beta is differentially regulated. J. Cell. Biochem. 100: 69-85 (2007). *
Prufer K, Hernandez C, Gilbreath M. Mutations in the AF-2 region abolish ligand-induced intranuclear immobilization of the liver X receptor alpha. Exp. Cell Res. 314: 2652-2660 (2008). *
Pu D, Guan YF. Advances on pregnane X receptor. Sheng Li Ke Xue Jin Zhan 38: 318-322 (2007).
Puddu GM, Cravero E, Arnone G, Muscari A, Puddu P. Molecular aspects of atherogenesis: new insights and unsolved questions. J. Biomed. Sci. 12: 839-853 (2005). *
Puiggros C, Sanchez J, Chacon P, Sab�n P, Rossello J, Bou R, Planas M. Evolution of lipid profile, liver function, and pattern of plasma fatty acids according to the type of lipid emulsion administered in parenteral nutrition in the early postoperative period after digestive surgery. JPEN J. Parenter. Enteral Nutr. 33: 501-512 (2009). *
Puskas LG, Kitajka K. Nutrigenomic approaches to study the effects of n-3 PUFA diet in the central nervous system. Nutr. Health 18: 227-232 (2006).
Puskas LG, Menesi D, Feher LZ, Kitajka K. High-throughput functional genomic methods to analyze the effects of dietary lipids. Curr. Pharm. Biotechnol. 7: 525-539 (2006).
Pyrzak B, Wisniewska A, Rymkiewicz-Kluczynska B. The influence of polymorphism the Gly972Arg variant insulin receptor substrate-1 (IRS-1) gene, and G-308A TNF-a gene on obesity and insulin resistance in children with obesity. Endokrynol. Diabetol. Chor. Przemiany. Materii. Wieku. Rozw. 12: 175-178 (2006).
Pyrzak B, Wisniewska A, Rymkiewicz-Kluczynska B. Tumor necrosis factor alpha (TNF-a) gene G-308A polymorphism relationschip to insulin resistance and lipid abnormalities in children with obesity. Endokrynol. Diabetol. Chor. Przemiany. Materii. Wieku. Rozw. 12: 171-174 (2006).
Pytrus T, Iwanczak B, Smigiel R, Ryzko J, Socha P, Iwanczak F. Ascites and extreme lipid abnormalities as initial symptoms of cystic fibrosis in a 5-years-old girl - case report. Pol. Merkur. Lekarski. 27: 388-392 (2009).
Qin B, Polansky MM, Harry D, Anderson RA. Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats. Mol. Nutr. Food Res. Jan 28 [Epub ahead of print] (2010). *
Qin P, Borges-Marcucci LA, Evans MJ, Harnish DC. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G267-G273 (2005). *
Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 27: 2428-2434 (2007).
Qiu G, Hill JS. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J. Cardiovasc. Pharmacol. 51: 388-395 (2008).
Quaye IK, Ababio G, Amoah AG. Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. J. Atheroscler. Thromb. 13: 90-94 (2006). *
Quinet EM, Basso MD, Halpern AR, Yates DW, Sheffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W, Hartman HB, Evans MJ, Gardell SJ, Diblasio-Smith E, Mounts WM, Lavallie ER, Wrobel J, Nambi P, Vlasuk GP. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res. 50: 2358-2370 (2009). *
Quinet EM, Savio DA, Halpern AR, Chen L, Miller CP, Nambi P. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J. Lipid Res. 45: 1929-1942 (2004). *
Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GS, Gustafsson JA, Basso MD, Nambi P. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting. Mol. Pharmacol. 70: 1340-1349 (2006). *
Quinn CM, Jessup W, Wong J, Kritharides L, Brown AJ. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPAR-gamma ligands. Biochem. J. 385: 823-830 (2005). *
Racine R, Grandcolas L, Grison S, Gourmelon P, Gueguen Y, Veyssiere G, Souidi M. Molecular modifications of cholesterol metabolism in the liver and the brain after chronic contamination with cesium 137. Food Chem. Toxicol. 47: 1642-1647 (2009). *
Racine R, Gueguen Y, Gourmelon P, Veyssiere G, Souidi M. Modifications of the expression of genes involved in cerebral cholesterol metabolism in the rat following chronic ingestion of depleted uranium. J. Mol. Neurosci. 38: 159-165 (2009).
Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol. 100: S15-S19 (2007). *
Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. Role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50: S189-S194 (2009). *
Raedsch R, Plachky J, Wolf N, Simonis G. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. Eur. J. Drug Metab. Pharmacokinet. 20: 113-118 (1995).
Raedsch R, Stiehl A, Gotz R, Walker S, Kommerell B. Kinetics of cholesterol gallstone dissolution by glycocheno-, glyco-ursodeoxycholic acid, and mixtures of both in vitro. Z. Gastroenterol. 19: 159-163 (1981).
Raedsch R, Stiehl A, Walker S, Scherrmann JM, Kommerell B. Combined ursodeoxycholic acid plus colchicine - treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study. Z. Gastroenterol. 30 Suppl. 1: 55-57 (1992).
Rafique S, Guardascione M, Osman E, Burroughs AK, Owen JS. Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-L-methionine. Clin. Sci. (Lond.) 83: 353-356 (1992).
Raggers RJ, Pomorski T, Holthuis JC, Kalin N, van Meer G. Lipid traffic: the ABC of transbilayer movement. Traffic 1: 226-234 (2000).
Rahier JF, Rahier J, Leclercq I, Geubel AP. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol. Belg. 71: 318-320 (2008).
Rahman T, Taha AY, Jun Song B, Orr SK, Liu Z, Chen CT, Bazinet RP. The very low density lipoprotein receptor is not necessary for maintaining brain polyunsaturated fatty acid concentrations. Prostaglandins Leukot. Essent. Fatty Acids Jan 25 [Epub ahead of print] (2010). *
Raicht RF, Cohen BI, Sarwal A, Takahashi M. Ursodeoxycholic acid. Effects on sterol metabolism in rats. Biochim. Biophys. Acta 531: 1-8 (1978).
Rajab MA, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig. Dis. Sci. Oct 1 [Epub ahead of print] (2009). *
Rajan N, Carmichael AJ, Bramble MG, Hudson M. Cutaneous xanthomatosis: a novel presentation of hypercholesterolaemia in primary sclerosing cholangitis. Br. J. Dermatol. 155: 223-225 (2006). *
Rajanikant GK, Zemke D, Kassab M, Majid A. The therapeutic potential of statins in neurological disorders. Curr. Med. Chem. 14: 103-112 (2007).
Rajaram S, Haddad EH, Mejia A, Sabate J. Walnuts and fatty fish influence different serum lipid fractions in normal to mildly hyperlipidemic individuals: a randomized controlled study. Am. J. Clin. Nutr. 89: 1657S-1663S (2009). *
Rakic B, Sagan SM, Noestheden M, Belanger S, Nan X, Evans CL, Xie XS, Pezacki JP. Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. Chem. Biol. 13: 23-30 (2006). *
Rallis E, Anyfantakis V. Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy. Skinmed. 7: 101-102 (2008). *
Rambjor GS, Walen AI, Windsor SL, Harris WS. Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids 31: S45-S49 (1996).
Ramel A, Pumberger C, Martinez AJ, Kiely M, Bandarra NM, Thorsdottir I. Cardiovascular risk factors in young, overweight, and obese European adults and associations with physical activity and omega-3 index. Nutr. Res. 29: 305-312 (2009). *
Ramirez MI, Karaoglu D, Haro D, Barillas C, Bashirzadeh R, Gil G. Cholesterol and bile acids regulate cholesterol 7 alpha-hydroxylase expression at the transcriptional level in culture and in transgenic mice. Mol. Cell. Biol. 14: 2809-2821 (1994). *
Ramos-Casals M, Brito-Zeron P, Siso A, Vargas A, Ros E, Bove A, Belenguer R, Plaza J, Benavent J, Font J. High prevalence of serum metabolic alterations in primary Sjogren's syndrome: influence on clinical and immunological expression. J. Rheumatol. 34: 754-761 (2007).
Ranalletta M, Wang N, Han S, Yvan-Charvet L, Welch C, Tall AR. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 26: 2308-2315 (2006).
Ranieri R. Effect of omega-3 fatty acids on the lipid structure of HIV positive patients on antiretroviral therapy: personal observation of 20 subjects. Infez. Med. 15: 237-241 (2007).
Ranjith N, Pegoraro RJ, Naidoo DP, Shanmugam R, Rom L. Genetic variants associated with insulin resistance and metabolic syndrome in young Asian Indians with myocardial infarction. Metab. Syndr. Relat. Disord. 6: 209-214 (2008).
Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokic E. Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern. Med. 46: 945-951 (2007). *
Ratliff EP, Gutierrez A, Davis RA. Transgenic expression of CYP7a1 in LDL receptor deficient mice blocks diet-induced hypercholesterolemia. J. Lipid Res. 47: 1513-1520 (2006). *
Ratner RE, Parikh S, Tou C; On Behalf Of The Gallant 9 Study Group. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diab. Vasc. Dis. Res. 4: 214-221 (2007).
Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2657-2662 (2000). *
Ravingerova T, Adameova A, Kelly T, Antonopoulou E, Pancza D, Ondrejcakova M, Khandelwal VK, Carnicka S, Lazou A. Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins. Can. J. Physiol. Pharmacol. 87: 1028-1036 (2009).
Re S, Zanoletti M, Emanuele E. Aggressive dogs are characterized by low omega-3 polyunsaturated fatty acid status. Vet. Res. Commun. 32: 225-230 (2008).
Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur. Heart J. 14 Suppl. K: 125-129 (1993).
Real JT, Martinez-Hervas S, Garcia-Garcia AB, Chaves FJ, Civera M, Ascaso JF, Carmena R. Association of C677T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia. J. Atheroscler. Thromb. Jan 9 [Epub ahead of print] (2010).
Rebe C, Raveneau M, Chevriaux A, Lakomy D, Sberna AL, Costa A, Bessede G, Athias A, Steinmetz E, Lobaccaro JM, Alves G, Menicacci A, Vachenc S, Solary E, Gambert P, Masson D. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ. Res. 105: 393-401 (2009).
Rebecchi IM, Rodrigues AC, Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Soares SA, Bertolami MC, Falud AA, Bernik MM, Dorea EL, Dagli ML, Avanzo JL, Hirata RD. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem. Pharmacol. 77: 66-75 (2009). *
Rebeck GW. Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J. Mol. Neurosci. 23: 219-224 (2004).
Recinos A 3rd, Carr BK, Bartos DB, Boldogh I, Carmical JR, Belalcazar LM, Brasier AR. Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. Physiol. Genomics 19: 131-142 (2004). *
Reddy SK, Austin SL, Spencer-Manzon M, Koeberl DD, Clary BM, Desai DM, Smith AD, Kishnani PS. Liver transplantation for glycogen storage disease type Ia. J. Hepatol. 51: 483-490 (2009).
Redeen S, Ryberg A, Petersson F, Eriksson O, Nagga K, Borch K. Homocysteine levels in chronic gastritis and other conditions: relations to incident cardiovascular disease and dementia. Dig. Dis. Sci. Mar 7 [Epub ahead of print] (2009). *
Redgrave TG. Chylomicrons in disease - future challenges. Invited keynote address. Atheroscler. Suppl. 9: 3-6 (2008).
Redinger RN. The coming of age of our understanding of the enterohepatic circulation of bile salts. Am. J. Surg. 185: 168-172 (2003). *
Redinger RN. The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: bile salts as ligands for nuclear hormone receptors. Can. J. Gastroenterol. 17: 265-271 (2003). *
Redinger RN. Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis. J. Lab. Clin. Med. 142: 7-20 (2003). *
Reggiani A, Dizioli P, Quattrocchi D, Quinzani M, Marelli A, Bodini P. Intrahepatic cholestasis: clinical and nosological classification. Critical survey of personal experience. Minerva Gastroenterol. Dietol. 43: 71-81 (1997).
Regoly-Merei A, Ferencz A, Frenkl R, Gergely A, Zajkas G, Antal M. Effect of fat and retinol loading on serum triglyceride and retinol levels in patients with ulcerative colitis. Nahrung. 35: 21-26 (1991).
Reichel C, Meier-Abt PJ. Cholestatic liver diseases. Ther. Umsch. 54: 639-644 (1997).
Reichen J. Gallstones - natural history and conservative management. Ther. Umsch. 60: 109-112 (2003).
Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 121: 710-723 (2001). *
Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut 40: 754-760 (1997). *
Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. Aug 14 [Epub ahead of print] (2009).
Reinke Y, Zimmer KP, Naim HY. Toxic peptides in Frazer's fraction interact with the actin cytoskeleton and affect the targeting and function of intestinal proteins. Exp. Cell Res. 315: 3442-3452 (2009).
Reiss AB, Awadallah NW, Malhotra S, Montesinos MC, Chan ES, Javitt NB, Cronstein BN. Immune complexes and IFN-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J. Lipid Res. 42: 1913-1922 (2001). *
Reiss AB, Martin KO, Javitt NB, Martin DW, Grossi EA, Galloway AC. Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J. Lipid Res. 35: 1026-1030 (1994). *
Reiss AB, Martin KO, Rojer DE, Iyer S, Grossi EA, Galloway AC, Javitt NB. Sterol 27-hydroxylase: expression in human arterial endothelium. J. Lipid Res. 38: 1254-1260 (1997). *
Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, Shah N, Cronstein BN, Chan ES, Carsons SE. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp. Biol. Med. (Maywood) 234: 354-360 (2009). *
Ren S, Hylemon P, Zhang ZP, Rodriguez-Agudo D, Marques D, Li X, Zhou H, Gil G, Pandak W. Identification of a novel sulfonated oxysterol, 5-cholesten-3beta , 25-diol 3-sulfonate, in hepatocyte nuclei and mitochondria. J. Lipid Res. 47: 1081-1090 (2006). *
Ren S, Hylemon PB, Li X, Zhang ZP, Rodriguez-Agudo D, Zhou H, Gil G, Erickson S, Pandak WM. Discovery of a novel oxysterol, 5-cholesten-3B, 25-diol 3-sulfonate, in nuclei and mitochondria following overexpression of the gene encoding StarD1. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 25 (2006). *
Ren S, Hylemon PB, Marques D, Gurley E, Bodhan P, Hall E, Redford K, Gil G, Pandak WM. Overexpression of cholesterol transporter StAR increases in vivo rates of bile acid synthesis in the rat and mouse. Hepatology 40: 910-917 (2004). *
Ren S, Hylemon PB, Marques D, Hall EA, Redford K, Gil G, Pandak WM. Effect of increasing the expression of intracellular cholesterol transporters (StAR, MLN64, and SCP-2) on bile acid synthesis. J. Lipid Res. 45: 2123-2131 (2004). *
Ren S, Marques D, Redford K, Hylemon PB, Gil G, Vlahcevic ZR, Pandak WM. Regulation of oxysterol 7alpha-hydroxylase (CYP7B1) in the rat. Metabolism 52: 636-642 (2003). *
Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta Jan 6 [Epub ahead of print] (2010). *
Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277: 18793-18800 (2002). *
Repa JJ, Buhman KK, Farese RV Jr, Dietschy JM, Turley SD. ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis. Hepatology 40: 1088-1097 (2004). *
Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, Dietschy JM. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J. Neurosci. 27: 14470-14480 (2007).
Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14: 2819-2830 (2000). *
Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16: 459-481 (2000). *
Repa JJ, Mangelsdorf DJ. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10: 557-563 (1999).
Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289: 1524-1529 (2000). *
Reschly EJ, Ai N, Ekins S, Welsh WJ, Hagey LR, Hofmann AF, Krasowski MD. Evolution of the bile salt nuclear receptor FXR in vertebrates. J. Lipid Res. 49: 1577-1587 (2008). *
Reschly EJ, Ai N, Welsh WJ, Ekins S, Hagey LR, Krasowski MD. Ligand specificity and evolution of liver X receptors. J. Steroid Biochem. Mol. Biol. 110: 83-94 (2008).
Reyes H. Phylogenetic vision of bile acids. Rev. Med. Chil. 122: 944-950 (1994).
Reynier MO, Montet JC, Gerolami A, Marteau C, Crotte C, Montet AM, Mathieu S. Comparative effects of cholic, chenodeoxycholic, and ursodeoxycholic acids on micellar solubilization and intestinal absorption of cholesterol. J. Lipid Res. 22: 467-473 (1981). *
Reynolds WF, Kumar AP, Piedrafita FJ. The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands. Biochem. Biophys. Res. Commun. 349: 846-854 (2006). *
Rezen T, Tamasi V, Lovgren Sandblom A, Bjorkhem I, Meyer UA, Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse liver. BMC Genomics 10: 384 (2009). *
Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch. Med. Res. 37: 86-94 (2006).
Rho YH, Oeser A, Chung CP, Milne GL, Stein CM. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch. Drug. Inf. 2: 34-40 (2009).
Rhodes B, Nash EF, Tullis E, Pencharz PB, Brotherwood M, Dupuis A, Stephenson A. Prevalence of dyslipidemia in adults with cystic fibrosis. J. Cyst. Fibros. Oct 27 [Epub ahead of print] (2009).
Ribas V, Palomer X, Roglans N, Rotllan N, Fievet C, Tailleux A, Julve J, Laguna JC, Blanco-Vaca F, Escola-Gil JC. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochim. Biophys. Acta 1737: 130-137 (2005). *
Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O'Neal WK. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE 4: e5806 (2009). *
Ribot J, Felipe F, Bonet ML, Palou A. Changes of adiposity in response to vitamin A status correlate with changes of PPAR gamma 2 expression. Obes. Res. 9: 500-509 (2001). *
Riccardi L, Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296: H272-H281 (2009). *
Ricci P, Hofmann AF, Hagey LR, Jorgensen RA, Rolland Dickson E, Lindor KD. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig. Dis. Sci. 43: 1292-1295 (1998). *
Riccioni G, Bucciarelli T, D'Orazio N, Palumbo N, di Ilio E, Corradi F, Pennelli A, Bazzano LA. Plasma antioxidants and asymptomatic carotid atherosclerotic disease. Ann. Nutr. Metab. 53: 86-90 (2008).
Riccioni G, D'Orazio N, Palumbo N, Bucciarelli V, Ilio ED, Bazzano LA, Bucciarelli T. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease In Manfredonia study. Eur. J. Cardiovasc. Prev. Rehabil. 16: 351-357 (2009).
Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Muller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol. Endocrinol. 21: 1603-1616 (2007). *
Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J. Nutr. Biochem. 16: 321-330 (2005). *
Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24: 230-239 (2004). *
Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34: 621-628 (2007). *
Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18,245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2: 26-33 (2009).
Ridlon JM, Kang DJ, Hylemon PB. Isolation and characterization of a bile acid inducible 7alpha-dehydroxylating operon in Clostridium hylemonae TN271. Anaerobe May 21 [Epub ahead of print] (2009). *
Riendeau V, Garenc C. Effect of 27-hydroxycholesterol on survival and death of human macrophages and vascular smooth muscle cells. Free Radic. Res. 43: 1019-1028 (2009).
Riestra P, Lopez-Simon L, Ortega H, Gorgojo L, Martin-Moreno JM, Schoppen S, de Oya M, Garces C. Fat intake influences the effect of the hepatic lipase C-514T polymorphism on HDL-cholesterol levels in children. Exp. Biol. Med. (Maywood) 234: 744-749 (2009). *
Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 28: 1050-1059 (2008).
Rigamonti E, Helin L, Lestavel S, Mutka AL, Lepore M, Fontaine C, Bouhlel MA, Bultel S, Fruchart JC, Ikonen E, Clavey V, Staels B, Chinetti-Gbaguidi G. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 97: 682-689 (2005). *
Rihmer Z, Purebl G, Faludi G, Halmy L. Association of obesity and depression. Neuropsychopharmacol. Hung. 10: 183-189 (2008).
Riikola A, Sipila K, Kahonen M, Jula A, Nieminen MS, Moilanen L, Kesaniemi YA, Lehtimaki T, Hulkkonen J. Interleukin-6 promoter polymorphism and cardiovascular risk factors: the Health 2000 Survey. Atherosclerosis 207: 466-470 (2009).
Rimkunas VM, Graham MJ, Crooke RM, Liscum L. TNF-alpha plays a role in hepatocyte apoptosis in Niemann Pick type C liver disease. J. Lipid Res. 50: 327-333 (2009). *
Ringseis R, Eder K. Effects of dietary fat and oxidized cholesterol on gene expression in rat liver as assessed by cDNA expression array analysis. Eur. J. Nutr. 44: 231-241 (2005). *
Ringseis R, Eder K. Influence of conjugated linoleic acids on functional properties of vascular cells. Br. J. Nutr. 102: 1099-1116 (2009). *
Rios FJ, Jancar S, Melo IB, Ketelhuth DF, Gidlund M. Role of PPAR-gamma in the modulation of CD36 and FcgammaRII induced by LDL with low and high degrees of oxidation during the differentiation of the monocytic THP-1 cell line. Cell Physiol. Biochem. 22: 549-556 (2008). *
Ripolles Piquer B, Nazih H, Bourreille A, Segain JP, Huvelin JM, Galmiche JP, Bard JM. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 55: 980-988 (2006). *
Risch N, Tang H, Katzenstein H, Ekstein J. Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am. J. Hum. Genet. 72: 812-822 (2003). *
Rise P, Ghezzi S, Manzoni C, Colombo C, Galli C. The in vitro effects of cigarette smoke on fatty acid metabolism are partially counteracted by simvastatin. Prostaglandins Leukot. Essent. Fatty Acids 80: 71-75 (2009). *
Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress and increases fatty acid oxidation in moderately obese men. Diabetes 57: 332-339 (2008). *
Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J. Hepatol. 36: 454-458 (2002). *
Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J. Cardiovasc. Pharmacol. Ther. 7: 219-226 (2002).
Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S. The methyl transferase PRMT1 functions as co-activator of farnesoid X feceptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol. Pharmacol. 68: 551-558 (2005). *
Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 289-303 (2005).
Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp. Clin. Endocrinol. Diabetes 115: 477-482 (2007).
Robertson KM, Schuster GU, Steffensen KR, Hovatta O, Meaney S, Hultenby K, Johansson LC, Svechnikov K, Soder O, Gustafsson JA. The liver X receptor beta is essential for maintaining cholesterol homeostasis in the testis. Endocrinology 146: 2519-2530 (2005). *
Robichaud JC, Francis GA, Vance DE. A role for hepatic scavenger receptor class B, type I in decreasing high density lipoprotein levels in mice that lack phosphatidylethanolamine N-methyltransferase. J. Biol. Chem. 283: 35496-35506 (2008). *
Robinson JG. Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res. 2008: 891425 (2008). *
Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am. J. Cardiol. 98: S39-S49 (2006). *
Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, Gaudet D, Vohl MC. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 49: 482-489 (2004). *
Robitaille J, Gaudet D, Perusse L, Vohl MC. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. Int. J. Obes. (Lond.) 31: 411-417 (2007).
Robitaille J, Houde A, Lemieux S, Gaudet D, Perusse L, Vohl MC. The lipoprotein/lipid profile is modulated by a gene-diet interaction effect between polymorphisms in the liver X receptor-alpha and dietary cholesterol intake in French-Canadians. Br. J. Nutr. 97: 11-18 (2007). *
Roda A, Grigolo B, Roda E, Simoni P, Pellicciari R, Natalini B, Fini A, Labate AM. Quantitative relationship between bile acid structure and biliary lipid secretion in rats. J. Pharm. Sci. 77: 596-605 (1988).
Roda A, Roda E, Festi D, Sama C, Mazzella G, Aldini R, Barbara L. A radioimmunoassay of primary bile acid conjugates in human serum. Ric. Clin. Lab. 7: 163-178 (1977).
Roda E, Aldini R, Mazzella G, Roda A, Sama C, Festi D, Barbara L. Enterohepatic circulation of bile acids after cholecystectomy. Gut 19: 640-649 (1978). *
Roda E, Bazzoli F, Labate AM, Mazzella G, Roda A, Sama C, Festi D, Aldini R, Taroni F, Barbara L. Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. Hepatology 2: 804-810 (1982).
Roda E, Cipolla A, Salzetta A, Marchetto S, Pezzoli A, Accogli E, Novelli V, Polimeni C, Cerre C, Mazzella G. Influence of ursodeoxycholic acid on biliary lipids. Scand. J. Gastroenterol. Suppl. 204: 16-18 (1994).
Roda E, Mazzella G, Bazzoli F, Villanova N, Minutello A, Simoni P, Ronchi M, Poggi C, Festi D, Aldini R, et al. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis. Dig. Dis. Sci. 34 (Suppl.): 52S-58S (1989).
Roda E, Roda A, Sama C, Festi D, Mazzella G, Aldini R, Barbara L. Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients. Dig. Dis. Sci. 24: 123-128 (1979).
Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, Wietlisbach V, Riesen WF, Walther T, Medinger L, Nicod P, Desvergne B, Mooser V. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann. Intern. Med. 136: 582-589 (2002). *
Rodriguez-Acebes S, de la Cueva P, Fernandez-Hernando C, Ferruelo AJ, Lasuncion MA, Rawson RB, Martinez-Botas J, Gomez-Coronado D. Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-delta24-reductase deficient cell line. Biochem. J. 420: 305-315 (2009). *
Rodriguez-Agudo D, Ren S, Wong E, Marques D, Redford K, Gil G, Hylemon P, Pandak WM. Intracellular cholesterol transporter StarD4 binds free cholesterol and increases cholesterol ester formation. J. Lipid Res. 49: 1409-1419 (2008). *
Rodriguez-Rodriguez E, Mateo I, Llorca J, Sanchez-Quintana C, Infante J, Garcia-Gorostiaga I, Sanchez-Juan P, Berciano J, Combarros O. Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144: 964-968 (2007).
Roediger WE. Intestinal mycoplasma in Crohn's disease. Novartis Found. Symp. 263: 85-93 (2004).
Roediger WE. A new hypothesis for the aetiology of Crohn's disease - evidence from lipid metabolism and intestinal tuberculosis. Postgrad. Med. J. 67: 666-671 (1991). *
Roelandt T, Giddelo C, Heughebaert C, Denecker G, Hupe M, Crumrine D, Kusuma A, Haftek M, Roseeuw D, Declercq W, Feingold KR, Elias PM, Hachem JP. The "caveolae brake hypothesis" and the epidermal barrier. J. Invest. Dermatol. 129: 927-936 (2009). *
Rog T, Pasenkiewicz-Gierula M, Vattulainen I, Karttunen M. Ordering effects of cholesterol and its analogues. Biochim. Biophys. Acta 1788: 97-121 (2009). *
Roglans N, Bellido A, Rodriguez C, Cabrero A, Novell F, Ros E, Zambon D, Laguna JC. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin. Pharmacol. Ther. 72: 692-701 (2002). *
Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59: 855-861 (2004). *
Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int. J. Technol. Assess. Health Care 22: 327-337 (2006).
Romanato G, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, Zambon S, Basato S, Zanoni S, Filosa T, Pilon F, Manzato E. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment. Pharmacol. Ther. 29: 298-307 (2009). *
Romanato G, Scarpa M, Ruffolo C, Marin R, Zambon S, Zanoni S, Basato S, Filosa T, Pilon F, Angriman I, Manzato E. Lipid and phospholipid profile after bowel resection for Crohn's disease. Int. J. Colorectal Dis. 23: 931-938 (2008). *
Romanowicz L, Bankowski E. Lipid compounds of the umbilical cord artery and their alterations in preeclampsia. Atherosclerosis 204: e44-e51 (2009).
Romics L, Nemesanszky E, Szalay F, Csaszar A, Tresch J, Karadi I. Lipoprotein(a) concentration and phenotypes in primary biliary cirrhosis. Clin. Chim. Acta 255: 165-171 (1996). *
Ronis MJ, Chen Y, Badeaux J, Badger TM. Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J. Nutr. 139: 1431-1438 (2009).
Roosbeek S, Peelman F, Verhee A, Labeur C, Caster H, Lensink MF, Cirulli C, Grooten J, Cochet C, Vandekerckhove J, Amoresano A, Chimini G, Tavernier J, Rosseneu M. Phosphorylation by protein kinase CK2 modulates the activity of the ATP-binding cassette A1 (ABCA1) transporter. J. Biol. Chem. 279: 37779-37788 (2004). *
Ros E, Mataix J. Fatty acid composition of nuts - implications for cardiovascular health. Br. J. Nutr. 96 Suppl. 2: S29-S35 (2006).
Rosenblat M, Volkova N, Roqueta-Rivera M, Nakamura MT, Aviram M. Increased macrophage cholesterol biosynthesis and decreased cellular paraoxonase 2 (PON2) expression in Delta6-desaturase knockout (6-DS KO) mice: beneficial effects of arachidonic acid. Atherosclerosis Dec 1 [Epub ahead of print] (2009).
Rosenson RS. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am. J. Cardiol. 99: 96-104 (2007). *
Rosenson RS. Management of non-high-density lipoprotein abnormalities. Atherosclerosis 207: 328-335 (2009).
Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev. Cardiovasc. Ther. 6: 1319-1330 (2008).
Rosenthal RL. Effectiveness of altering serum cholesterol levels without drugs. Proc. Bayl. Univ. Med. Cent. 13: 351-355 (2000).
Rosman-Urbach M, Niv Y, Birk Y, Morgenstern S, Schwartz B. Relationship between nutritional habits adopted by ulcerative colitis relevant to cancer development patients at clinical remission stages and molecular-genetic parameters. Br. J. Nutr. 95: 188-195 (2006). *
Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazouilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1220-1222 (2004). *
Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120: 1459-1467 (2001). *
Rossi M, Vajro P, Iorio R, Battagliese A, Brunetti-Pierri N, Corso G, Di Rocco M, Ferrari P, Rivasi F, Vecchione R, Andria G, Parenti G. Characterization of liver involvement in defects of cholesterol biosynthesis: long-term follow-up and review. Am. J. Med. Genet. 132A: 144-151 (2005). *
Roth A, Looser R, Kaufmann M, Meyer UA. Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharmacogenet. Genomics 18: 325-337 (2008).
Roy S, Hyogo H, Yadav SK, Wu MK, Jelicks LA, Locker JD, Frank PG, Lisanti MP, Silver DL, Cohen DE. A biphasic response of hepatobiliary cholesterol metabolism to dietary fat at the onset of obesity in the mouse. Hepatology 41: 887-895 (2005). *
Roy-Chowdhury N, Lu Y, Jiang J, Lee SW, Guha C, Roy-Chowdhury J. Comparison of gene therapy strategies for treatment of liver diseases. J. Gastroenterol. Hepatol. 19: S295-S301 (2004). *
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. Regulation of lipoprotein trafficking in the kidney: role of inflammatory mediators and transcription factors. Biochem. Soc. Trans. 32: 88-91 (2004). *
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J. Am. Soc. Nephrol. 14: 593-600 (2003). *
Rubic T, Lorenz RL. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc. Res. 69: 527-535 (2006). *
Rubin DC. Nutrient absorption. Curr. Opin. Gastroenterol. 20: 65-69 (2004).
Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann. Intern. Med. 121: 207-218 (1994). *
Rudkowska I, Jones PJ. Polymorphisms in ABCG5/G8 transporters linked to hypercholesterolemia and gallstone disease. Nutr. Rev. 66: 343-348 (2008). *
Rudling M, Parini P, Angelin B. Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat. J. Clin. Invest. 99: 2239-2245 (1997). *
Rudzki C, Ishak KG, Zimmerman HJ. Chronic intrahepatic cholestasis of sarcoidosis. Am. J. Med. 59: 373-387 (1975).
Ruiz JJ, Labayen I, Ortega FB, Moreno LA, Gonzalez-Lamuno D, Marti A, Nova E, Garcia-Fuentes M, Redondo-Figuero C, Martinez JA, Sjostrom M, Castillo MJ. Birth weight and blood lipid levels in Spanish adolescents: influence of selected APOE, APOC3 and PPAR-gamma-2 gene polymorphisms. The AVENA Study. BMC Med. Genet. 9: 98 (2008). *
Ruiz ML, M Villanueva SS, Luquita MG, Sanchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, Catania VA. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem. Pharmacol. 69: 531-539 (2005). *
Rull A, Rodr�guez F, Aragones G, Marsillach J, Beltran R, Alonso-Villaverde C, Camps J, Joven J. Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine 48: 273-279 (2009).
Rupprecht HJ. Cardiovascular secondary prevention. Clin. Res. Cardiol. 95 Suppl. 6: vi1-vi5 (2006).
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72: 137-174 (2003). *
Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50: S120-S125 (2009). *
Russell DW, Setchell KD, Shea HC. Mice deficient in 3B-hydroxy-D5-C27 steroid oxidoreductase. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 21-22 (2006). *
Russell LE, Harrison WJ, Bahta AW, Zouboulis CC, Burrin JM, Philpott MP. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp. Dermatol. 16: 844-852 (2007). *
Rutgers HC, Stradley RP, Johnson SE. Serum bile acid analysis in dogs with experimentally induced cholestatic jaundice. Am. J. Vet. Res. 49: 317-320 (1988).
Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *
Rutishauser J. The role of statins in clinical medicine - LDL-cholesterol lowering and beyond. Swiss Med. Wkly. 136: 41-49 (2006). *
Ryan AS, Bailey-Hall E, Nelson EB, Salem N Jr. The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet. Lipids 44: 817-826 (2009).
Ryan AS, Keske MA, Hoffman JP, Nelson EB. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am. J. Ther. 16: 183-192 (2009).
Sabeva NS, Rouse EJ, Graf GA. Defects in the leptin axis reduce abundance of the ABCG5 ABCG8 sterol transporter in liver. J. Biol. Chem. 282: 22397-22405 (2007). *
Sabio J, Zamora-Pasadas M, Jimenez-Jaimez J, Albadalejo F, Vargas-Hitos J, Rodriguez Del Aguila M, Hidalgo-Tenorio C, Gonzalez-Gay M, Alonso J. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 17: 849-859 (2008). *
Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A, Hidalgo-Tenorio C, Jaimez L, Martin J, Jimenez-Alonso J. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J. Rheumatol. 36: 2204-2211 (2009).
Sabol SL, Brewer HB Jr, Santamarina-Fojo S. The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J. Lipid Res. 46: 2151-2167 (2005). *
Sabry AA, Elbasyouni SR, Kalil AM, Abdel-Rahim M, Mohsen T, Sleem A. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus. Nephrology (Carlton) 11: 329-335 (2006). *
Sadovsky R, Kris-Etherton P. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad. Med. 121: 145-153 (2009).
Saez F, Chabory E, Cadet R, Vernet P, Baron S, Lobaccaro JM, Drevet JR. Liver X receptors and epididymal epithelium physiology. Asian J. Androl. 9: 574-582 (2007).
Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B(12) in patients with type 2 diabetes mellitus. J. Diabetes Complications 21: 118-123 (2007).
Saidi S, Zammiti W, Slamia LB, Ammou SB, Almawi WY, Mahjoub T. Interaction of angiotensin-converting enzyme and apolipoprotein E gene polymorphisms in ischemic stroke involving large-vessel disease. J. Thromb. Thrombolysis 27: 68-74 (2009).
Saify ZS, Hassan S, Arif M, Ahmad F, Chishti KA, Siddiqui S. A comparative study of omega-3-fatty acids obtained from marine fish and bezafibrate alone and in combination as hypolipidemic agents. Pak. J. Pharm. Sci. 13: 1-11 (2000).
Saijo Y, Yoshioka E, Fukui T, Kawaharada M, Sata F, Sato H, Kishi R. Effects of the interaction between interleukin-6 -634C/G polymorphism and smoking on serum C-reactive protein concentrations. Hypertens. Res. 30: 593-599 (2007). *
Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J. Rheumatol. 34: 1997-2004 (2007).
Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; for the JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200: 135-140 (2008).
Saji Y. The effect of decreased portal blood flow on the biliary system. Jpn. J. Surg. 18: 558-568 (1988).
Sakamoto A, Kawasaki T, Kazawa T, Ohashi R, Jiang S, Maejima T, Tanaka T, Iwanari H, Hamakubo T, Sakai J, Kodama T, Naito M. Expression of liver X receptor alpha in rat fetal tissues at different developmental stages. J. Histochem. Cytochem. 55: 641-649 (2007). *
Sakamoto S, Kusuhara H, Horie K, Takahashi K, Baba T, Ishizaki J, Sugiyama Y. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of S-8921 glucuronide, a pharmacologically active metabolite of S-8921. Drug Metab. Dispos. 36: 1553-1561 (2008). *
Sakamoto S, Kusuhara H, Miyata K, Shimaoka H, Kanazu T, Matsuo Y, Nomura K, Okamura N, Hara S, Horie K, Baba T, Sugiyama Y. Glucuronidation converting S-8921 to a potent ASBT inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther. 322: 610-618 (2007). *
Sakauchi F, Oura A, Ohnishi H, Mori M. Comparison of the clinical features of Japanese patients with primary biliary cirrhosis in 1999 and 2004: utilization of clinical data when patients applied to receive public financial aid. J. Epidemiol. 17: 210-214 (2007). *
Salaspuro MP, Sipponen P, Ikkala E, Kolho L, Makkonen HM, Miettinen TA, Rasanen JA, Siurala M. Clinical correlations and significance of orceinpositivity in chronic active hepatitis and primary biliary cirrhosis. Ann. Clin. Res. 8: 206-215 (1976).
Salazar J, Guardiola M, Ferre R, Coll B, Alonso-Villaverde C, Winklhofer-Roob BM, Rock E, Fernandez-Ballart JD, Civeira F, Pocovi M, Masana L, Ribalta J. Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol. Clin. Chem. Lab. Med. 45: 615-620 (2007). *
Saleheen D, Khanum S, Haider SR, Nazir A, Ahmad U, Khalid H, Hussain I, Shuja F, Shahid K, Habib A, Frossard PM. A novel haplotype in ABCA1 gene effects plasma HDL-C concentration. Int. J. Cardiol. 115: 7-13 (2007).
Salen G. Gallstone dissolution therapy with ursodiol. Efficacy and safety. Dig. Dis. Sci. 34: 39S-43S (1989).
Salen G, Starc T, McCrary Sisk C, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130: 1853-1857 (2006). *
Salerno-Kennedy R, Cashman KD. Relationship between dementia and nutrition-related factors and disorders: an overview. Int. J. Vitam. Nutr. Res. 75: 83-95 (2005).
Salonen J, Kesaniemi YA, Ukkola O. Association between angiotensin-converting enzyme insertion/deletion polymorphism and treatment response in type 2 diabetic patients. Eur. J. Intern. Med. 17: 115-119 (2006).
Salvioli G, Igimi H, Carey MC. Cholesterol gallstone dissolution in bile. Dissolution kinetics of crystalline cholesterol monohydrate by conjugated chenodeoxycholate-lecithin and conjugated ursodeoxycholate-lecithin mixtures: dissimilar phase equilibria and dissolution mechanisms. J. Lipid Res. 24: 701-720 (1983). *
Sanchez RA, Masnatta LD, Pesiney C, Fischer P, Ramirez AJ. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J. Hypertens. 26: 2393-2398 (2008).
Sanchez-Garrido MA, Chico Y, Gonzalez R, Ranchal I, Gonzalez-Rubio S, Hidalgo AB, Diaz-Lopez C, Costan G, Padillo FJ, De la Mata M, Ochoa B, Muntane J. Interleukin-6 is associated with liver lipid homeostasis but not with cell death in experimental hepatic steatosis. Innate Immun. 15: 337-349 (2009).
Sanchez-Mete L, Attili AF. Cholelithiasis: genetic hypothesis. Minerva Gastroenterol. Dietol. 46: 45-55 (2000).
Sanchez-Muniz FJ, Bastida S, Gutierrez-Garcia O, Carbajal A. Olive oil-diet improves the simvastatin effects with respect to sunflower oil-diet in men with increased cardiovascular risk: a preliminary study. Nutr. Hosp. 24: 333-339 (2009). *
Sandal S, Tuneva J, Yilmaz B, Carpenter DO. Effects of cholesterol and docosahexaenoic acid on cell viability and (Ca(2+))(i) levels in acutely isolated mouse thymocytes. Cell. Biochem. Funct. 27: 155-161 (2009). *
Sanderson LM, Boekschoten MV, Desvergne B, Muller M, Kersten S. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol. Genomics Dec 14 [Epub ahead of print] (2009). *
Sandhofer A, Tatarczyk T, Laimer M, Ritsch A, Kaser S, Paulweber B, Ebenbichler CF, Patsch JR. The Taq1B-variant in the cholesteryl ester-transfer protein gene and the risk of metabolic syndrome. Obesity (Silver Spring) 16: 919-922 (2008). *
Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849 (2006). *
Sandstad O, Osnes T, Urdal P, Skar V, Osnes M. Brown pigment stones in the common bile duct: reduced bilirubinate diconjugate in bile. Scand. J. Gastroenterol. 35: 198-203 (2000). *
Sanghera DK, Ortega L, Han S, Singh J, Ralhan SK, Wander GS, Mehra NK, Mulvihill JJ, Ferrell RE, Nath SK, Kamboh MI. Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med. Genet. 9: 59 (2008). *
Sanguino E, Bejarano R, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague-Dawley rats. Exp. Gerontol. 39: 1295-1306 (2004). *
Sanguino E, Roglans N, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br. J. Pharmacol. 145: 853-861 (2005). *
Santini E, Madec S, Corretti V, Ferrannini E, Solini A. Effect of statins on soluble CD40 ligand in hypercholesterolemic type 2 diabetic patients. J. Endocrinol. Invest. 31: 660-665 (2008).
Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. J. Nephrol. 18: 733-738 (2005).
Sanyal S, Bavner A, Haroniti A, Nilsson LM, Lundasen T, Rehnmark S, Witt MR, Einarsson C, Talianidis I, Gustafsson JA, Treuter E. Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 104: 15665-15670 (2007). *
Saraswat VA, Sharma BC, Agarwal DK, Kumar R, Negi TS, Tandon RK. Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J. Gastroenterol. Hepatol. 19: 1206-1211 (2004). *
Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD, Hasty AH. Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J. Nutr. 137: 1776-1782 (2007). *
Saraswathi V, Morrow JD, Hasty AH. Dietary fish oil exerts hypolipidemic effects in lean and insulin sensitizing effects in obese LDLR-/- mice. J. Nutr. 139: 2380-2386 (2009).
Sari I, Kebapcilar L, Alacacioglu A, Bilgir O, Yildiz Y, Taylan A, Yuksel A, Kozaci DL. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern. Med. 48: 1363-1368 (2009). *
Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 56: 631-638 (2007). *
Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum. 54: 1283-1290 (2006). *
Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, Bertiaux M, Steplewski K, Hurle MR, Sprecher D, McPherson R, Marcel YL. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 27: 1115-1122 (2007).
Sasaki M, Bharwani S, Jordan P, Joh T, Manas K, Warren A, Harada H, Carter P, Elrod JW, Wolcott M, Grisham MB, Alexander JS. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J. Pharmacol. Exp. Ther. 305: 78-85 (2003). *
Sasaki M, Huang SF, Chen MF, Jan YY, Yeh TS, Ishikawa A, Mollenhauer J, Poustka A, Tsuneyama K, Nimura Y, Oda K, Nakanuma Y. Expression of deleted in malignant brain tumor-1 (DMBT1) molecule in biliary epithelium is augmented in hepatolithiasis: possible participation in lithogenesis. Dig. Dis. Sci. 48: 1234-1240 (2003). *
Sasaki S, Kawai K, Honjo Y, Nakamura H. Thyroid hormones and lipid metabolism. Nippon Rinsho 64: 2323-2329 (2006).
Saseen J, Tweed E, Crawford P. What are effective medication combinations for dyslipidemia? J. Fam. Pract. 55: 70-72 (2006). *
Sassano A, Lo Iacono M, Antico G, Jordan A, Uddin S, Calogero RA, Platanias LC. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol. Cancer Ther. 8: 615-625 (2009).
Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 1946-1952 (2004). *
Sato M, Kawata Y, Erami K, Ikeda I, Imaizumi K. LXR agonist increases the lymph HDL transport in rats by promoting reciprocally intestinal ABCA1 and apo A-I mRNA levels. Lipids 43: 125-131 (2008).
Sato M, Sato K, Furuse M. Change in hepatic and plasma bile acid contents and its regulatory gene expression in the chicken embryo. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 150: 344-347 (2008). *
Sato R, Sakai J. SREBP controls cholesterol homeostasis. Seikagaku 76: 503-508 (2004).
Satoh N, Shimatsu A, Kotani K, Himeno A, Majima T, Yamada K, Suganami T, Ogawa Y. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens. Res. 32: 1004-1008 (2009).
Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 24: 123-126 (1996). *
Sauter G, Fischer S, Pahernik S, Koebe HG, Paumgartner G. Formation of cholic acid and chenodeoxycholic acid from 7 alpha-hydroxycholesterol and 27-hydroxycholesterol by primary cultures of human hepatocytes. Biochim. Biophys. Acta 1300: 25-29 (1996).
Sauter GH, Thiessen K, Parhofer KG, Jungst C, Fischer S, Jungst D. Effects of ursodeoxycholic acid on synthesis of cholesterol and bile acids in healthy subjects. Digestion 70: 79-83 (2004).
Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP. Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Pharmacol. Exp. Ther. 312: 170-178 (2005). *
Savoia C, Ebrahimian T, Lemarie CA, Paradis P, Iglarz M, Amiri F, Javeshghani D, Schiffrin EL. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clin. Sci. (Lond.) Dec 1 [Epub ahead of print] (2009). *
Savransky V, Bevans S, Nanayakkara A, Li J, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G871-G877 (2007). *
Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. 53: 3218-3224 (2008). *
Scarpa M, Romanato G, Manzato E, Ruffolo C, Marin R, Basato S, Zambon S, Filosa T, Zanoni S, Pilon F, Polese L, Sturniolo GC, D'Amico DF, Angriman I. Restorative proctocolectomy for ulcerative colitis: impact on lipid metabolism and adipose tissue and serum fatty acids. J. Gastrointest. Surg. 12: 279-287 (2008). *
Scarpioni R. Therapeutic tools for dyslipidemia in peritoneal dialysis patients. J. Nephrol. 22: 46-58 (2009).
Schack-Nielsen L, Michaelsen KF. Breast feeding and future health. Curr. Opin. Clin. Nutr. Metab. Care 9: 289-296 (2006).
Schack-Nielsen L, Michaelsen KF. Advances in our understanding of the biology of human milk and its effects on the offspring. J. Nutr. 137: 503S-510S (2007). *
Schafer G, Guler R, Murray G, Brombacher F, Brown GD. The role of scavenger receptor B1 in infection with Mycobacterium tuberculosis in a murine model. PLoS One 4: e8448 (2009). *
Schirmer BD, Winters KL, Edlich RF. Cholelithiasis and cholecystitis. J. Long. Term Eff. Med. Implants 15: 329-338 (2005).
Schleiffenbaum B, Schaer Dj, Burki D, Viollier A, Viollier E, Stettler E, Wegmuller E. Unexpected high prevalence of metabolic disorders and chronic disease among young male draftees - the Swiss Army XXI experience. Swiss Med. Wkly. 136: 175-184 (2006). *
Schloss JV. New targets for the treatment of vascular diseases and diabetes. IDrugs 1: 752-753 (1998).
Schmack B. Clinical significance of bile acids. Fortschr. Med. 97: 690-693 (1979).
Schmassmann A, Fehr HF, Locher J, Lillienau J, Schteingart CD, Rossi SS, Hofmann AF. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology 104: 1171-1181 (1993).
Schmidt A, Vogel R, Rutledge SJ, Opas EE, Rodan GA, Friedman E. Cross-talk between an activator of nuclear receptors-mediated transcription and the D(1) dopamine receptor signaling pathway. Pharmacol. Biochem. Behav. 80: 379-385 (2005). *
Schmidt EB, Koenig W, Khuseyinova N, Christensen JH. Lipoprotein-associated phospholipase A(2) concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis 196: 420-424 (2008).
Schmidt HH, Manns MP. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors? Am. J. Gastroenterol. 91: 406-407 (1996).
Schmidt RJ, Ficorilli JV, Zhang Y, Bramlett KS, Beyer TP, Borchert K, Dowless MS, Houck KA, Burris TP, Eacho PI, Liang G, Guo LW, Wilson WK, Schroepfer GJ Jr, Michael LF, Cao G. A 15-keto sterol is a liver X receptor ligand that suppresses sterol responsive element binding protein 2 activity. J. Lipid Res. 47: 1037-1044 (2006). *
Schmitt-Grohe S, Hippe V, Igel M, von Bergmann K, Posselt HG, Krahl A, Smaczny C, Wagner TO, Nikolazik W, Schubert R, Lentze MJ, Zielen S. Lipopolysaccharide binding protein, cytokine production in whole blood, and lipoproteins in cystic fibrosis. Pediatr. Res. 58: 903-907 (2005). *
Schmitz G, Buechler C. ABCA1: regulation, trafficking and association with heteromeric proteins. Ann. Med. 34: 334-347 (2002).
Schmitz G, Kaminski WE. ABC transporters and cholesterol metabolism. Front. Biosci. 6: D505-D514 (2001).
Schmitz G, Kaminski WE, Porsch-Ozcurumez M, Klucken J, Orso E, Bodzioch M, Buchler C, Drobnik W. ATP-binding cassette transporter A1 (ABCA1) in macrophages: a dual function in inflammation and lipid metabolism? Pathobiology 67: 236-240 (1999).
Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta 1735: 1-19 (2005). *
Schmitz G, Langmann T. High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy. Curr. Opin. Investig. Drugs 6: 907-919 (2005).
Schmitz G, Langmann T. Metabolic learning in the intestine: adaptation to nutrition and luminal factors. Horm. Metab. Res. 38: 452-454 (2006).
Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J. Lipid Res. 42: 1513-1520 (2001). *
Schocke MF, Zoller H, Vogel W, Wolf C, Kremser C, Steinboeck P, Poelzl G, Pachinger O, Jaschke WR, Metzler B. Cardiac phosphorus-31 two-dimensional chemical shift imaging in patients with hereditary hemochromatosis. Magn. Reson. Imaging 22: 515-521 (2004). *
Schoenfield LJ, Marks JW. Oral and contact dissolution of gallstones. Am. J. Surg. 165: 427-430 (1993).
Schoonjans K, Brendel C, Mangelsdorf D, Auwerx J. Sterols and gene expression: control of affluence. Biochim. Biophys. Acta 1529: 114-125 (2000). *
Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302: 93-109 (1996).
Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925 (1996). *
Schriml LM, Dean M. Identification of 18 mouse ABC genes and characterization of the ABC superfamily in Mus musculus. Genomics 64: 24-31 (2000). *
Schubotz R, Schneider J, Hausmann L, Muhlfellner G, Muhlfellner O, Kaffarnik H. Clinical experience with bezafibrate. Artery 8: 553-559 (1980).
Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat. Med. 7: 536-537 (2001). *
Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838 (2000). *
Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science 249: 1429-1431 (1990). *
Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halld�rsd�ttir S, Ohman KP; for the SIR Investigators. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 197: 355-362 (2008).
Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer and output in vivo in humans. J. Lipid Res. 45: 1594-1607 (2004). *
Schwarz M, Lund EG, Lathe R, Bjorkhem I, Russell DW. Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. J. Biol. Chem. 272: 23995-24001 (1997). *
Schwarz M, Lund EG, Russell DW. Two 7 alpha-hydroxylase enzymes in bile acid biosynthesis. Curr. Opin. Lipidol. 9: 113-118 (1998).
Schwarz M, Lund EG, Setchell KD, Kayden HJ, Zerwekh JE, Bjorkhem I, Herz J, Russell DW. Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J. Biol. Chem. 271: 18024-18031 (1996). *
Schwarz M, Russell DW, Dietschy JM, Turley SD. Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. J. Lipid Res. 42: 1594-1603 (2001). *
Schwarz M, Russell DW, Dietschy JM, Turley SD. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 39: 1833-1843 (1998). *
Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J. Clin. Invest. 106: 1175-1184 (2000). *
Schwiesow SJ, Nappi JM, Ragucci KR. Assessment of compliance with lipid guidelines in an academic medical center. Ann. Pharmacother. 40: 27-31 (2006).
Scott Kim W, Chan SL, Hill AF, Guillemin GJ, Garner B. Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J. Alzheimers Dis. 16: 121-131 (2009).
Sealls W, Gonzalez M, Brosnanv MJ, Black PN, Dirusso CC. Dietary polyunsaturated fatty acids (C18:2 omega6 and C18:3 omega3) do not suppress hepatic lipogenesis. Biochim. Biophys. Acta 1781: 406-414 (2008). *
Seedorf U, Aberle J. Emerging roles of PPARdelta in metabolism. Biochim. Biophys. Acta 1771: 1125-1131 (2007). *
Segawa S, Wakita Y, Hirata H, Watari J. Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. Int. J. Food Microbiol. 128: 371-377 (2008). *
Sehayek E, Yu HJ, Von Bergmann K, Lutjohann D, Stoffel M, Duncan EM, Garcia-Naveda L, Salit J, Blundell ML, Friedman JM, Breslow JL. Phytosterolemia on the island of Kosrae: a founder effect for a novel ABCG8 mutation results in a high carrier rate and increased plasma plant sterol levels. J. Lipid Res. 45: 1608-1613 (2004). *
Seki N, Bujo H, Jiang M, Shibasaki M, Takahashi K, Hashimoto N, Saito Y. A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits. Atherosclerosis 178: 1-7 (2005).
Selimoglu MA, Ertekin V, Altinkaynak S. Hyper-CK-emia in pediatric celiac disease: prevalence and clinical importance. J. Clin. Gastroenterol. 41: 667-670 (2007).
Selva DM, Hirsch-Reinshagen V, Burgess B, Zhou S, Chan J, McIsaac S, Hayden MR, Hammond GL, Vogl AW, Wellington CL. The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility. J. Lipid Res. 45: 1040-1050 (2004). *
Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J. Gastroenterol. Hepatol. 23: 102-109 (2008). *
Seol HS, Sato K, Matsubara Y, Schneider WJ, Akiba Y. Modulation of sterol regulatory element binding protein-2 in response to rapid follicle development in chickens. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 147: 698-703 (2007). *
Seres L, Cserepes J, Elkind NB, Torocsik D, Nagy L, Sarkadi B, Homolya L. Functional ABCG1 expression induces apoptosis in macrophages and other cell types. Biochim. Biophys. Acta 1778: 2378-2387 (2008). *
Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1069: 414-419 (2006). *
Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 54: 226-234 (2008). *
Serve E, Reny JL, Akhavan S, Emmerich J, Fischer AM, Tapon-Bretaudiere J. A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies. Thromb. Haemost. 98: 733-737 (2007).
Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, Weslie Tyson R, Sokol RJ, Russell DW. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J. Clin. Invest. 102: 1690-1703 (1998). *
Shaffer EA. Epidemiology of gallbladder stone disease. Best Pract. Res. Clin. Gastroenterol. 20: 981-996 (2006).
Shaffer EA. Gallstones: current concepts of pathogenesis and medical dissolution. Can. J. Surg. 23: 517-532, 557 (1980).
Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S. Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst. Rev. 1: CD001918 (2010).
Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis Dec 14 [Epub ahead of print] (2009).
Shah S, Sanford UR, Vargas JC, Xu H, Groen A, Paulusma CC, Grenert JP, Pawlikowska L, Sen S, Elferink RP, Bull LN. Strain background modifies phenotypes in the ATP8B1-deficient mouse. PLoS One 5: e8984 (2010). *
Shaikh SR, Edidin M. Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation. Am. J. Clin. Nutr. 84: 1277-1289 (2006). *
Shaikh SR, Locascio DS, Soni SP, Wassall SR, Stillwell W. Oleic- and docosahexaenoic acid-containing phosphatidylethanolamines differentially phase separate from sphingomyelin. Biochim. Biophys. Acta 1788: 2421-2426 (2009). *
Shaikh SR, Rockett BD, Salameh M, Carraway K. Docosahexaenoic acid modifies the clustering and size of lipid rafts and the lateral organization and surface expression of MHC class I of EL4 cells. J. Nutr. 139: 1632-1639 (2009). *
Shamshiev AT, Ampenberger F, Ernst B, Rohrer L, Marsland BJ, Kopf M. Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J. Exp. Med. 204: 441-452 (2007). *
Shand JH, West DW. The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat. Lipids 29: 747-752 (1994).
Shang Q, Pan L, Saumoy M, Chiang JY, Tint GS, Salen G, Xu G. The stimulatory effect of LXRalpha is blocked by SHP despite the presence of a functional LXRalpha binding site in the rabbit CYP7A1 promoter. J. Lipid Res. 47: 997-1004 (2006). *
Shang Q, Pan L, Saumoy M, Chiang JY, Tint GS, Salen GE, Xu G. An overlapping binding site in the CYP7A1 promoter allows activation of FXR to override the stimulation of LXRalpha. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G817-G823 (2007). *
Shanske AL, Bernstein L, Herzog R. Chondrodysplasia punctata and maternal autoimmune disease: a new case and review of the literature. Pediatrics 120: e436-e441 (2007). *
Shao B, Fu X, McDonald TO, Green PS, Uchida K, O'Brien KD, Oram JF, Heinecke JW. Acrolein impairs ABCA1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J. Biol. Chem. 280: 35386-36396 (2005). *
Shapira N. Modified egg as a nutritional supplement during peak brain development: a new target for fortification. Nutr. Health 20: 107-118 (2009).
Sharma B, Salunke R, Balomajumder C, Daniel S, Roy P. Anti-diabetic potential of alkaloid rich fraction from Capparis decidua on diabetic mice. J. Ethnopharmacol. Oct 15 [Epub ahead of print] (2009).
Sharma B, Salunke R, Srivastava S, Majumder C, Roy P. Effects of guggulsterone isolated from Commiphora mukul in high fat diet induced diabetic rats. Food Chem. Toxicol. 47: 2631-2639 (2009). *
Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann. Intern. Med. 151: 622-630 (2009).
Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D. Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy. Ann. Intern. Med. Aug 31 [Epub ahead of print] (2009).
Shea HC, Head DD, Setchell KD, Russell DW. Analysis of HSD3B7 knockout mice reveals that a 3alpha-hydroxyl stereochemistry is required for bile acid function. Proc. Natl. Acad. Sci. U.S.A. 104: 11526-11533 (2007). *
Shefer S, Kren BT, Salen G, Steer CJ, Nguyen LB, Chen T, Tint GS, Batta AK. Regulation of bile acid synthesis by deoxycholic acid in the rat: different effects on cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase. Hepatology 22: 1215-1221 (1995).
Shefer S, Nguyen LB, Salen G, Ness GC, Chowdhary IR, Lerner S, Batta AK, Tint GS. Differing effects of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities and mRNA levels in the rat. J. Lipid Res. 33: 1193-1200 (1992). *
Shefer S, Zaki FG, Salen G. Early morphologic and enzymatic changes in livers of rats treated with chenodeoxycholic and ursodeoxycholic acids. Hepatology 3: 201-208 (1983).
Shelly L, Royer L, Sand T, Jensen H, Luo Y. Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice. J. Lipid Res. 49: 773-781 (2008). *
Shen H, Macdonald R, Bruemmer D, Stromberg A, Daugherty A, Li XA, Toborek M, Hennig B. Zinc deficiency alters lipid metabolism in LDL receptor deficient mice treated with rosiglitazone. J. Nutr. 137: 2339-2345 (2007). *
Shen PU, Blair JL. Cholesterol crystals causing falsely elevated automated cell count. Am. J. Clin. Pathol. 125: 358-363 (2006).
Shenoy SD, Spencer TA, Mercer-Haines NA, Alipour M, Gargano MD, Runge-Morris M, Kocarek TA. CYP3A induction by liver X receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab. Dispos. 32: 66-71 (2004). *
Shepherd J. Mechanism of action of fibrates. Postgrad. Med. J. 69 Suppl. 1: S34-S41 (1993).
Sheridan DA, Price DA, Schmid M, Toms GL, Donaldson P, Neely D, Bassendine MF. Apolipoprotein B associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus (HCV) infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment. Pharmacol. Ther. 29: 1282-1290 (2009). *
Sheril A, Jeyakumar SM, Jayashree T, Giridharan NV, Vajreswari A. Impact of feeding polyunsaturated fatty acids on cholesterol metabolism of dyslipidemic obese rats of WNIN/GR-Ob strain. Atherosclerosis 204: 136-140 (2009).
Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet. Med. 24: 94-97 (2007). *
Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J. Gastroenterol. Hepatol. 7: 277-282 (1992).
Shibata N, Jishage KI, Arita M, Watanabe M, Kawase Y, Nishikawa K, Natori Y, Inoue H, Shimano H, Yamada N, Tsujimoto M, Arai H. Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis. FASEB J. 20: 2642-2644 (2006). *
Shibata S, Hayakawa K, Egashira Y, Sanada H. Roles of nuclear receptors in the up-regulation of hepatic cholesterol 7alpha-hydroxylase by cholestyramine in rats. Life Sci. 80: 546-553 (2007). *
Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br. J. Pharmacol. 130: 495-504 (2000). *
Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann. Intern. Med. 122: 899-905 (1995). *
Shih DM, Kast-Woelbern HR, Wong J, Xia YR, Edwards PA, Lusis AJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J. Lipid Res. 47: 384-392 (2006). *
Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27: 375-382 (2001). *
Shima Y, Teruya K, Ohta H. Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci. 79: 2234-2237 (2006). *
Shimada N, Coban C, Takeda Y, Mizu M, Minari J, Anada T, Torii Y, Shinkai S, Akira S, Ishii KJ, Sakurai K. A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells. Bioconjug. Chem. 18: 1280-1286 (2007). *
Shimamoto Y, Ishida J, Yamagata K, Saito T, Kato H, Matsuoka T, Hirota K, Daitoku H, Nangaku M, Yamagata K, Fujii H, Takeda J, Fukamizu A. Inhibitory effect of the small heterodimer partner on hepatocyte nuclear factor-4 mediates bile acid-induced repression of the human angiotensinogen gene. J. Biol. Chem. 279: 7770-7776 (2004). *
Shin DJ, Campos JA, Gil G, Osborne TF. PGC-1alpha activates CYP7A1 and bile acid biosynthesis. J. Biol. Chem. 278: 50047-50052 (2003). *
Shin DJ, Osborne TF. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner. J. Biol. Chem. 283: 15089-15096 (2008). *
Shin OJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J. Biol. Chem. 284: 11110-11120 (2009). *
Shindou H, Hishikawa D, Harayama T, Yuki K, Shimizu T. Recent progress on acyl-CoA:lysophospholipid acyltransferase research. J. Lipid Res. 50: S46-S51 (2009). *
Shirai N, Suzuki H. Effect of docosahexaenoic acid on brain 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in male ICR mice. J. Nutr. Biochem. 18: 488-494 (2007). *
Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol. 44: 732-741 (2006). *
Shirinskii IV, Kozlov VA, Shirinskii VS. The use of statins, a new approach to the treatment of autoimmune diseases. Vestn. Ross. Akad. Med. Nauk. 2: 26-32 (2009).
Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol. 595: 127-148 (2007).
Shneider BL. Regulation of intestinal bile acid transport in health and disease. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 44 (2006). *
Shneider BL. Intestinal bile acid transport: biology, physiology, and pathophysiology. J. Pediatr. Gastroenterol. Nutr. 32: 407-417 (2001). *
Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, Yokoi T, Yoshizato K, Suzuki H. Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol. Res. 37: 548-556 (2007). *
Shoda J, Tanaka N, Osuga T. Hepatolithiasis - epidemiology and pathogenesis update. Front. Biosci. 8: e398-e409 (2003).
Shulenin S, Schriml LM, Remaley AT, Fojo S, Brewer B, Allikmets R, Dean M. An ATP-binding cassette gene (ABCG5) from the ABCG (White) gene subfamily maps to human chromosome 2p21 in the region of the Sitosterolemia locus. Cytogenet. Cell. Genet. 92: 204-208 (2001).
Shulman AI, Mangelsdorf DJ. Retinoid X receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353: 604-615 (2005). *
Sibley C, Stone NJ. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve. Clin. J. Med. 73: 57-64 (2006). *
Siciliano M, Milani A, Marra L, Arringoli D, Rossi L. Serum bile acids in cirrhosis: correlation with liver function parameters and with the severity of the disease. Quad. Sclavo. Diagn. 22: 355-361 (1986).
Siddiqui RA, Harvey KA, Zaloga GP, Stillwell W. Modulation of lipid rafts by omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr. Clin. Pract. 22: 74-88 (2007). *
Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41: 1085-1095 (2005). *
Siest G, Ferrari L, Accaoui MJ, Batt AM, Visvikis S. Pharmacogenomics of drugs affecting the cardiovascular system. Clin. Chem. Lab. Med. 41: 590-599 (2003).
Sigal LH. Basic science for the clinician 44. Atherosclerosis: an immunologically mediated (autoimmune?) disease. J. Clin. Rheumatol. 13: 160-168 (2007).
Silveira AC, Morrison MA, Ji F, Xu H, Reinecke JB, Adams SM, Arneberg TM, Janssian M, Lee JE, Yuan Y, Schaumberg DA, Kotoula MG, Tsironi EE, Tsiloulis AN, Chatzoulis DZ, Miller JW, Kim IK, Hageman GH, Farrer LA, Haider NB, Deangelis MM. Convergence of linkage, gene expression and association data demonstrates the influence of the RAR-related orphan receptor alpha (RORA) gene on neovascular AMD: a systems biology based approach. Vision Res. Sep 25 [Epub ahead of print] (2009).
Silver DL. A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in liver. J. Biol. Chem. 277: 34042-34047 (2002). *
Sima A, Iordan A, Stancu C. Apolipoprotein E polymorphism - a risk factor for metabolic syndrome. Clin. Chem. Lab. Med. 45: 1149-1153 (2007). *
Simoni P, Sabatini L, Baraldini M, Mirasoli M, Roda A, Roda E. Pharmacokinetics and bioavailability of four modified-release ursodeoxycholic acid preparations for once-a-day administration. Int. J. Clin. Pharmacol. Res. 22: 37-45 (2002).
Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr. 54: 438-463 (1991). *
Simopoulos AP. Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: biological effects and nutritional essentiality. J. Nutr. 119: 521-528 (1989). *
Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744 (2000). *
Sinclair AJ, Begg D, Mathai M, Weisinger RS. Omega 3 fatty acids and the brain: review of studies in depression. Asia Pac. J. Clin. Nutr. 16: S391-S397 (2007).
Sinclair AJ, Murphy KJ, Li D. Marine lipids: overview "news insights and lipid composition of Lyprinol". Allerg. Immunol. (Paris) 32: 261-271 (2000).
Singh B. Psyllium as therapeutic and drug delivery agent. Int. J. Pharm. 334: 1-14 (2007). *
Singh JP, Kauffman R, Wang G, McClelland P, Bensch W, Bean J, Montrose C, Mantlo N, Wagle A. Identification of a novel selective PPARalpha agonist LY518674 that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol. Pharmacol. 68: 763-768 (2005). *
Singh MP, Horste GM, Hu W, Mausberg A, Cravens P, Eager TN, Lober S, Klingenstein R, Gmeiner P, Korth C, Kieseier BC, Stuve O. A novel class of immunosuppressive compounds effective in brain autoimmune disease. Exp. Neurol. 215: 397-400 (2009).
Singh P, Kohr D, Kaps M, Blaes F. Influence of statins on MHC class I expression. Ann. N. Y. Acad. Sci. 1173: 746-751 (2009). *
Singh V, Tiwari RL, Dikshit M, Barthwal MK. Models to study atherosclerosis: a mechanistic insight. Curr. Vasc. Pharmacol. 7: 75-109 (2009).
Singhal AK, Cohen BI, Finver-Sadowsky J, McSherry CK, Mosbach EH. Role of hydrophilic bile acids and of sterols on cholelithiasis in the hamster. J. Lipid Res. 25: 564-570 (1984). *
Sioen I, Hacquebard M, Hick G, Maindiaux V, Larondelle Y, Carpentier YA, De Henauw S. Effect of ALA-enriched food supply on cardiovascular risk factors in males. Lipids 44: 603-611 (2009).
Sironi L, Mitro N, Cimino M, Gelosa P, Guerrini U, Tremoli E, Saez E. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett. 582: 3396-3400 (2008). *
Sirvent A, Verhoeven AJ, Jansen H, Kosykh V, Darteil RJ, Hum DW, Fruchart JC, Staels B. Farnesoid X receptor represses hepatic lipase gene expression. J. Lipid Res. 45: 2110-2115 (2004). *
Sixt S, Beer S, Bluher M, Korff N, Peschel T, Sonnabend M, Teupser D, Thiery J, Adams V, Schuler G, Niebauer J. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur. Heart J. Sep 30 [Epub ahead of print] (2009).
Sjovall J. Fifty years with bile acids and steroids in health and disease. Lipids 39: 703-722 (2004).
Skakun NP, Tabachuk OE. The comparative action of isoniazid, rifampicin and ethambutol on liver function. Eksp. Klin. Farmakol. 55: 45-47 (1992).
Skibola CF, Bracci PM, Halperin E, Nieters A, Hubbard A, Paynter RA, Skibola DR, Agana L, Becker N, Tressler P, Forrest MS, Sankararaman S, Conde L, Holly EA, Smith MT. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS ONE 3: e2816 (2008). *
Skoczynska A, Dobosz T, Poreba R, Turczyn B, Derkacz A, Zoledziewska M, Jonkisz A, Lebioda A. The dependence of serum interleukin-6 level on PPAR-alpha polymorphism in men with coronary atherosclerosis. Eur. J. Intern. Med. 16: 501-506 (2005).
Skulina D, Owczarek D, Ciecko-Michalska I, Szczepanski W, Tetnowski J, Garlicka M, Janas-Skulina U. The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis. Przegl. Lek. 56: 201-204 (1999).
Sladek FM. Orphan receptor HNF-4 and liver-specific gene expression. Receptor 3: 223-232 (1993).
Smit MJ, Temmerman AM, Wolters H, Kuipers F, Beynen AC, Vonk RJ. Dietary fish oil-induced changes in intrahepatic cholesterol transport and bile acid synthesis in rats. J. Clin. Invest. 88: 943-951 (1991). *
Smit MJ, Verkade HJ, Havinga R, Vonk RJ, Scherphof GL, In 't Veld G, Kuipers F. Dietary fish oil potentiates bile acid-induced cholesterol secretion into bile in rats. J. Lipid Res. 35: 301-310 (1994). *
Smith AD, Gentile JW, Desai DM, Tuttle-Newhall JE. Palmar lipid deposits and profound hypercholesterolemia that resolved after orthotopic liver transplantation for primary biliary cirrhosis. Am. J. Gastroenterol. 102: 210-211 (2007). *
Smith AJ, de Vree JM, Ottenhoff R, Oude Elferink RP, Schinkel AH, Borst P. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice. Hepatology 28: 530-536 (1998). *
Smith JD. Insight into ABCG1-mediated cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 26: 1198-1200 (2006).
Smith JD, Bhasin JM, Baglione J, Settle M, Xu Y, Barnard J. Atherosclerosis susceptibility loci identified from a strain intercross of apolipoprotein E-deficient mice via a high-density genome scan. Arterioscler. Thromb. Vasc. Biol. 26: 597-603 (2006).
Smoak K, Madenspacher J, Jeyaseelan S, Williams B, Dixon D, Poch KR, Nick JA, Worthen GS, Fessler MB. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol. 180: 3305-3312 (2008). *
Soares da Costa CA, Alves EG, de Paula Lopes Gonzalez G, Barbosa TB, Carlos AS, Lima VD, Nascimento R, de Moura EG, Alves do Nascimento-Saba CC. Evaluation of body development, fat mass and lipid profile in rats fed with high-PUFA and -MUFA diets, after neonatal malnutrition. Br. J. Nutr. 101: 1639-1644 (2009). *
Soccio RE, Adams RM, Maxwell KN, Breslow JL. Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins: activation of StarD4 by SREBP-2 and StarD5 by endoplasmic reticulum stress. J. Biol. Chem. 280: 19410-19418 (2005). *
Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 24: 1150-1160 (2004). *
Socha P, Koletzko B, Demmelmair H, Jankowska I, Stajniak A, Bednarska-Makaruk M, Socha J. Short-term effects of parenteral nutrition of cholestatic infants with lipid emulsions based on medium-chain and long-chain triacylglycerols. Nutrition 23: 121-126 (2007).
Socha P, Nowicka G, Jankowska I, Rujner J, Pawlowska J, Socha J. Apolipoprotein E polymorphism in Alagille syndrome and progressive familial intrahepatic cholestasis. Dig. Dis. Sci. 45: 675-679 (2000). *
Soisson SM, Parthasarathy G, Adams AD, Sahoo S, Sitlani A, Sparrow C, Cui J, Becker JW. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl. Acad. Sci. U.S.A. 105: 5337-5342 (2008). *
Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Balistreri WF. Vitamin E deficiency with normal serum vitamin E concentrations in children with chronic cholestasis. N. Engl. J. Med. 310: 1209-1212 (1984).
Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology 96: 479-486 (1989).
Sola S, Amaral JD, Aranha MM, Steer CJ, Rodrigues CM. Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors. Curr. Med. Chem. 13: 3039-3051 (2006).
Solnick JV, Franceschi F, Roccarina D, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection - other Helicobacter species. Helicobacter 11 Suppl. 1: 46-51 (2006). *
Soloway RD, Crowther RS. Bacteria and cholesterol gallstones: molecular biology comes to gallstone pathogenesis. Gastroenterology 108: 934-936 (1995). *
Song C, Hiipakka RA, Liao S. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 65: 423-427 (2000).
Song CS, Echchgadda I, Baek BS, Ahn SC, Oh T, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 276: 42549-42556 (2001). *
Song KH, Chiang JY. Glucagon and cAMP inhibit cholesterol 7alpha-hydroxylase (CYP7a1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis. Hepatology 43: 117-125 (2006). *
Song KH, Ellis E, Strom S, Chiang J. Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes. Hepatology 46: 1993-2002 (2007). *
Song KH, Li T, Chiang JY. A prospero-related homeodomain protein is a novel co-regulator of hepatocyte nuclear factor 4 alpha that regulates the cholesterol 7alpha-hydroxylase gene. J. Biol. Chem. 281: 10081-10088 (2006). *
Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49: 297-305 (2009). *
Song X, Kaimal R, Yan B, Deng R. Liver receptor homolog 1 transcriptionally regulates human bile salt export pump expression. J. Lipid Res. 49: 973-984 (2008). *
Song YZ, Guo L, Yang YL, Han LS, Keiko K, Takeyori S. Failure to thrive and dyslipidemia caused by citrin deficiency: a novel clinical phenotype. Zhongguo Dang Dai Er Ke Za Zhi 11: 328-332 (2009).
Song YZ, Hao H, Ushikai M, Liu GS, Xiao X, Saheki T, Kobayashi K, Wang ZN. A difficult and complicated case study: neonatal intrahepatic cholestasis caused by citrin deficiency. Zhongguo Dang Dai Er Ke Za Zhi 8: 125-128 (2006).
Song YZ, Li BX, Chen FP, Liu SR, Sheng JS, Ushikai M, Zhang CH, Zhang T, Wang ZN, Kobayashi K, Saheki T, Zheng XY. Neonatal intrahepatic cholestasis caused by citrin deficiency: clinical and laboratory investigation of 13 subjects in mainland of China. Dig. Liver Dis. 41: 683-689 (2009).
Soni SP, Locascio DS, Liu Y, Williams JA, Bittman R, Stillwell W, Wassall SR. Docosahexaenoic acid enhances segregation of lipids between raft and non-raft domains: 2H NMR study. Biophys. J. 95: 203-214 (2008). *
Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc. Natl. Acad. Sci. U.S.A. 102: 2198-2203 (2005). *
Sonoda J, Mehl IR, Chong LW, Nofsinger RR, Evans RM. PGC-1beta controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc. Natl. Acad. Sci. U.S.A. 104: 5223-5228 (2007). *
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 194: 293-299 (2007).
Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr. Treat. Options Cardiovasc. Med. 7: 459-466 (2005).
Soska V. Nuclear receptors PPARalpha. Vnitr. Lek. 52: 628-631 (2006).
Soubrier M, Jouanel P, Mathieu S, Poujol D, Claus D, Dubost JJ, Ristori JM. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75: 22-24 (2008). *
Soubrier M, Zerkak D, Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J. Rheumatol. 33: 1766-1769 (2006).
Soulimane-Mokhtari NA, Guermouche B, Saker M, Merzouk S, Merzouk H, Hichami A, Madani S, Khan NA, Prost J. Serum lipoprotein composition, lecithin cholesterol acyltransferase and tissue lipase activities in pregnant diabetic rats and their offspring receiving enriched n-3 PUFA diet. Gen. Physiol. Biophys. 27: 3-11 (2008).
Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA1 and atherosclerosis. Vasc. Med. 10: 109-119 (2005).
Souza DR, Nakazone MA, Pinhel MA, Alvares RM, Monaco AC, Pinheiro A, Barros CF, Cury PM, Cunrath GS, Netinho JG. Association between apolipoprotein E genotype, serum lipids, and colorectal cancer in Brazilian individuals. Braz. J. Med. Biol. Res. 42: 397-403 (2009). *
Souza LL, Nunes MO, Paula GS, Cordeiro A, Penha-Pinto V, Neto JF, Oliveira KJ, das Gracas Tavares do Carmo M, Pazos-Moura CC. Effects of dietary fish oil on thyroid hormone signaling in the liver. J. Nutr. Biochem. Sep 28 [Epub ahead of print] (2009). *
Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, Helland S, Middelfart K, Odu S, Falk ES, Solvoll K, Bjorneboe GA, Drevon CA. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N. Engl. J. Med. 328: 1812-1816 (1993).
Spahis S, Vanasse M, Belanger SA, Ghadirian P, Grenier E, Levy E. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot. Essent. Fatty Acids 79: 47-53 (2008). *
Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J. Rheumatol. 33: 2440-2446 (2006).
Sparso T, Hussain MS, Andersen G, Hainerova I, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol. Genet. Metab. 90: 205-209 (2007). *
Speeckaert MM, Taes YE, De Buyzere ML, Christophe AB, Kaufman JM, Delanghe JR. Investigation of the potential association of vitamin D binding protein with lipoproteins. Ann. Clin. Biochem. Feb 9 [Epub ahead of print] (2010).
Speeckaert MM, Wehlou C, Vandewalle S, Taes YE, Robberecht E, Delanghe JR. Vitamin D binding protein, a new nutritional marker in cystic fibrosis patients. Clin. Chem. Lab. Med. 46: 365-370 (2008). *
Spier BJ, Pfau PR, Lorenze KR, Knechtle SJ, Said A. Risk factors and outcomes in post-liver transplantation bile duct stones and casts: a case-control study. Liver Transpl. 14: 1461-1465 (2008). *
Spiteller G. The relation of lipid peroxidation processes with atherogenesis: a new theory on atherogenesis. Mol. Nutr. Food Res. 49: 999-1013 (2005). *
Spiteller G. Furan fatty acids: occurrence, synthesis, and reactions. Are furan fatty acids responsible for the cardioprotective effects of a fish diet? Lipids 40: 755-771 (2005).
Spolter L, Rice LI. Enzymatic sulfation of Triton X-100. Biochim. Biophys. Acta 612: 268-285 (1980).
Sporstol M, Mousavi SA, Eskild W, Roos N, Berg T. ABCA1, ABCG1 and SR-BI: hormonal regulation in primary rat hepatocytes and human cell lines. BMC Mol. Biol. 8: 5 (2007). *
Sporstol M, Tapia G, Malerod L, Mousavi SA, Berg T. Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem. Biophys. Res. Commun. 331: 1533-1541 (2005). *
Spratt KA, Denke MA. Utility of currently available modes of therapy in reaching lipid goals. J. Am. Osteopath. Assoc. 104 (9 Suppl. 7): S14-S16 (2004). *
Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler. Thromb. Vasc. Biol. 27: 359-365 (2007). *
Sreenarasimhaiah J. Prevention or surgical treatment of gallstones in patients undergoing gastric bypass surgery for obesity. Curr. Treat. Options Gastroenterol. 7: 99-104 (2004).
Srivastava A, Choudhuri G, Mittal B. CYP7A1 (-204 A>C; rs3808607 and -469 T>C; rs3824260) promoter polymorphisms and risk of gallbladder cancer in North Indian population. Metabolism Dec 14 [Epub ahead of print] (2009). *
Srivastava A, Pandey SN, Choudhuri G, Mittal B. Role of genetic variant A-204C of cholesterol 7alpha-hydroxylase (CYP7A1) in susceptibility to gallbladder cancer. Mol. Genet. Metab. 94: 83-89 (2008). *
Srivastava A, Tulsyan S, Pandey SN, Choudhuri G, Mittal B. Single nucleotide polymorphism in the ABCG8 transporter gene is associated with gallbladder cancer susceptibility. Liver Int. 29: 831-837 (2009). *
Srivastava N. ATP binding cassette transporter A1 - key roles in cellular lipid transport and atherosclerosis. Mol. Cell. Biochem. 237: 155-164 (2002). *
Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell. Biochem. 285: 35-50 (2006). *
St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. Transport of bile acids in hepatic and non-hepatic tissues. J. Exp. Biol. 204: 1673-1686 (2001). *
Stadnicki A, Bojko B, Myczkowska K, Witalinska-Labuzek J. Selected risk factors of thrombotic complications in patients with ulcerative colitis. Wiad. Lek. 56: 341-347 (2003).
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093 (1998). *
Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470 (2005). *
Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67: 1383-1392 (2007).
Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 5: 542-553 (2008).
Stahl S, Ittrich C, Marx-Stoelting P, Kohle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, Schwarz M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42: 353-361 (2005). *
Stahlberg D, Angelin B, Einarsson K. Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. J. Lipid Res. 30: 953-958 (1989). *
Stahlberg D, Reihner E, Ewerth S, Einarsson K, Angelin B. Effects of bezafibrate on hepatic cholesterol metabolism. Eur. J. Clin. Pharmacol. 40 Suppl. 1: S33-S36 (1991).
Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H Jr, Odin JA. Atorvastatin does not improve liver biochemistries or Mayo risk score in primary biliary cirrhosis. Dig. Dis. Sci. 53: 1988-1993 (2008). *
Stanulovic V, Deric M, Popovic J. Clinical trials of statins and fibrates - a meta-analysis. Med. Pregl. 59: 213-218 (2006).
Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 29: 1467-1472 (2001). *
Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 98: 3369-3374 (2001). *
Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, Downes M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U.S.A. 103: 11323-11328 (2006). *
Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 279: 11336-11343 (2004). *
Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102: 2063-2068 (2005). *
Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K. The common C49620T polymorphism in the sulfonylurea receptor gene (ABCC8), pancreatic beta cell function and long-term diabetic complications in obese patients with long-lasting type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 115: 317-321 (2007).
Stefanutti C, Bucci A, Di Giacomo S, Fraone N, Pace A, Mareri M, Musca A, Mammarella A. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin. Drug Investig. 24: 465-477 (2004).
Steffens S, Mach F. Anti-inflammatory properties of statins. Semin. Vasc. Med. 4: 417-422 (2004).
Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver X receptor (LXR). Diabetes 53 Suppl. 1: S36-S42 (2004). *
Steffensen KR, Neo SY, Stulnig TM, Vega VB, Rahman SS, Schuster GU, Gustafsson JA, Liu ET. Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. J. Mol. Endocrinol. 33: 609-622 (2004). *
Steffensen KR, Robertson K, Gustafsson JA, Andersen CY. Reduced fertility and inability of oocytes to resume meiosis in mice deficient of the Lxr genes. Mol. Cell. Endocrinol. 256: 9-16 (2006).
Stefulj J, Panzenboeck U, Becker T, Hirschmugl B, Schweinzer C, Lang I, Marsche G, Sadjak A, Lang U, Desoye G, Wadsack C. Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. Circ. Res. 104: 600-608 (2009).
Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 60: 1057-1060 (1995).
Stegall MD, Everson GT, Schroter G, Karrer F, Bilir B, Sternberg T, Shrestha R, Wachs M, Kam I. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 25: 173-177 (1997). *
Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 64: 1755-1760 (1997).
Stegmayr BG. A survey of blood purification techniques. Transfus. Apheresis Sci. 32: 209-220 (2005).
Stein O, Dabach Y, Ben-Naim M, Halperin G, Stein Y. Lower macrophage recruitment and atherosclerosis resistance in FVB mice. Atherosclerosis 189: 336-341 (2006).
Steinberg D. An interpreted history of the cholesterol controversy. J. Lipid Res. 45: 1583-1593 (2004). *
Steinbrugger I, Haas A, Maier R, Renner W, Mayer M, Werner C, Wedrich A, El-Shabrawi Y, Schmut O, Weger M. Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Mol. Vis. 15: 609-618 (2009). *
Steinhagen-Thiessen E, Muller S, Holler HD, Lang PD. Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia. Arzneimittelforschung 37: 726-728 (1987).
Stellaard F. Use of dual isotope tracers in biomedical research. Isotopes Environ. Health Stud. 41: 275-286 (2005).
Stellaard F, Kuipers F. Assessment of modes of action and efficacy of plasma cholesterol-lowering drugs: measurement of cholesterol absorption, cholesterol synthesis and bile acid synthesis and turnover using novel stable isotope techniques. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 209-218 (2005).
Stenson BM, Ryden M, Steffensen KR, Wahlen K, Pettersson AT, Jocken JW, Arner P, Laurencikiene J. Activation of liver X receptor (LXR) regulates substrate oxidation in white adipocytes. Endocrinology 150: 4104-4113 (2009). *
Stevenson J, Brown AJ. How essential is cholesterol? Biochem. J. 420: e1-e4 (2009). *
Stewart ME, Benoit AM, Downing DT, Strauss JS. Suppression of sebum secretion with 13-cis-retinoic acid: effect on individual skin surface lipids and implications for their anatomic origin. J. Invest. Dermatol. 82: 74-78 (1984). *
Stieger B. Biliary cholesterol secretion: more lessons from plants? J. Hepatol. 38: 843-846 (2003). *
Stiehl A, Raedsch R, Czygan P, Gotz R, Manner C, Walker S, Kommerell B. Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid. Gastroenterology 79: 1192-1198 (1980).
Stiehl A, Raedsch R, Rudolph G. Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology 94: 1201-1206 (1988).
Stiehl A, Raedsch R, Rudolph G, Walker S. Effect of ursodeoxycholic acid on biliary bile acid and bile lipid composition in gallstone patients. Hepatology 4: 107-111 (1984).
Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J. Hepatol. 23: 283-289 (1995). *
Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod. Nutr. Dev. 45: 559-579 (2005). *
Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, Marz W, Wascher TC, Trauner M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis Sep 6 [Epub ahead of print] (2009).
Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, Marz W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776-784 (2007). *
Stolowich NJ, Petrescu AD, Huang H, Martin GG, Scott AI, Schroeder F. Sterol carrier protein-2: structure reveals function. Cell. Mol. Life Sci. 59: 193-212 (2002). *
Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am. J. Cardiol. 96: 53-59 (2005). *
Storvold GL, Fleten KG, Olsen CG, Follestad T, Krokan HE, Schonberg SA. Docosahexaenoic acid activates some SREBP-2 targets independent of cholesterol and ER stress in SW620 colon cancer cells. Lipids 44: 673-683 (2009).
Straka MS, Junker LH, Zacarro L, Zogg DL, Dueland S, Everson GT, Davis RA. Substrate stimulation of 7 alpha-hydroxylase, an enzyme located in the cholesterol-poor endoplasmic reticulum. J. Biol. Chem. 265: 7145-7149 (1990). *
Straniero S, Cavallini G, Donati A, Metelli MR, Tamburini I, Pietrini P, Bergamini E. Deficiency and supplementation of PUFA in the diet have similar effects on the age-associated changes in rat-plasma cholesterol levels. Mech. Ageing Dev. 129: 759-762 (2008).
Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20: 233-238 (1998). *
Stravitz RT, Hylemon PB, Heuman DM, Hagey LR, Schteingart CD, Ton-Nu HT, Hofmann AF, Vlahcevic ZR. Transcriptional regulation of cholesterol 7 alpha-hydroxylase mRNA by conjugated bile acids in primary cultures of rat hepatocytes. J. Biol. Chem. 268: 13987-13993 (1993). *
Stravitz RT, Vlahcevic ZR, Russell TL, Heizer ML, Avadhani NG, Hylemon PB. Regulation of sterol 27-hydroxylase and an alternative pathway of bile acid biosynthesis in primary cultures of rat hepatocytes. J. Steroid Biochem. Mol. Biol. 57: 337-347 (1996).
Stringer MD, Soloway RD, Taylor DR, Riyad K, Toogood G. Calcium carbonate gallstones in children. J. Pediatr. Surg. 42: 1677-1682 (2007).
Stroup D. Kinase/phosphatase regulation of CYP7A1. Front. Biosci. 10: 1678-1692 (2005).
Stulnig TM, Steffensen KR, Gao H, Reimers M, Dahlman-Wright K, Schuster GU, Gustafsson JA. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol. Pharmacol. 62: 1299-1305 (2002). *
Stuve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS. Statins as potential therapeutic agents in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 4: 237-244 (2004).
Stuve O, Youssef S, Dunn S, Slavin AJ, Steinman L, Zamvil SS. The potential therapeutic role of statins in central nervous system autoimmune disorders. Cell. Mol. Life Sci. 60: 2483-2491 (2003). *
Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N. Engl. J. Med. 357: 1561-1562 (2007). *
Su Z, Cox A, Shen Y, Stylianou IM, Paigen B. Farp2 and Stk25 are candidate genes for the HDL cholesterol locus on mouse chromosome 1. Arterioscler. Thromb. Vasc. Biol. 29: 107-113 (2009).
Subramanian S, Derosa MA, Bernal-Mizrachi C, Laffely N, Cade WT, Yarasheski KE, Cryer PE, Semenkovich CF. PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am. J. Physiol. Endocrinol. Metab. 291: E1365-E1371 (2006). *
Sugawara T, Lin D, Holt JA, Martin KO, Javitt NB, Miller WL, Strauss JF 3rd. Structure of the human steroidogenic acute regulatory protein (StAR) gene: StAR stimulates mitochondrial cholesterol 27-hydroxylase activity. Biochemistry 34: 12506-12512 (1995).
Sugden MC, Holness MJ. Role of nuclear receptors in the modulation of insulin secretion in lipid-induced insulin resistance. Biochem. Soc. Trans. 36: 891-900 (2008). *
Sugiyama E, Ishikawa Y, Li Y, Kagai T, Nobayashi M, Tanaka N, Kamijo Y, Yokoyama S, Hara A, Aoyama T. Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators-activated receptor alpha. Life Sci. 83: 19-28 (2008). *
Suk FM, Lin SY, Chen CH, Yen SJ, Su CH, Liu DZ, Hou WC, Hung LF, Lin PJ, Liang YC. Taiwanofungus camphoratus activates peroxisome proliferator-activated receptors and induces hypotriglyceride in hypercholesterolemic rats. Biosci. Biotechnol. Biochem. 72: 1704-1713 (2008). *
Sulikowska B, Czarny J, Rosc D, Odrowaz-Sypniewska G, Manitius J, Sliwka DM. Some metabolic and genetic risk factors and the progression of IgA nephropathy - preliminary report. Pol. Merkur. Lekarski. 21: 132-135 (2006).
Summerfield JA, Elias E, Sherlock S. Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. Gastroenterology 69: 998-1000 (1975).
Sun F, Xie ML, Xue J, Wang HB. Osthol regulates hepatic PPARalpha-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine Dec 28 [Epub ahead of print] (2009).
Sun H, Gong ZC, Yin JY, Liu HL, Liu YZ, Guo ZW, Zhou HH, Wu J, Liu ZQ. The association of adiponectin allele 45T/G and -11377C/G polymorphisms with type 2 diabetes and rosiglitazone response in Chinese patients. Br. J. Clin. Pharmacol. 65: 917-926 (2008). *
Sun Q, Ma J, Campos H, Rexrode KM, Albert CM, Mozaffarian D, Hu FB. Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am. J. Clin. Nutr. 88: 216-223 (2008). *
Sun YM, Tian Y, Li X, Liu YY, Wang LF, Li J, Li ZQ, Pan W. Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats. Biochem. Biophys. Res. Commun. 382: 336-340 (2009). *
Sundar PD, Feingold E, Minster RL, Dekosky ST, Kamboh MI. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol. Aging 28: 856-862 (2007).
Sundaram SS, Sokol RJ. The multiple facets of ABCB4 (MDR3) deficiency. Curr. Treat. Options Gastroenterol. 10: 495-503 (2007).
Surrenti C, Pozzi M, Biagini MR, Franco C, Lombardo R, Avanzi G. Effects of plasma exchange (PE) in primary biliary cirrhosis (PBC). A pilot study. Hepatogastroenterology 37: 128-130 (1990).
Suto J. Apolipoprotein gene polymorphisms as cause of cholesterol QTLs in mice. J. Vet. Med. Sci. 67: 583-589 (2005). *
Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor J. Hepatol. 43: 808-816 (2005). *
Suviolahti E, Lilja HE, Pajukanta P. Unraveling the complex genetics of familial combined hyperlipidemia. Ann. Med. 38: 337-351 (2006).
Suwazono Y, Kobayashi E, Uetani M, Miura K, Morikawa Y, Ishizaki M, Kido T, Nakagawa H, Nogawa K. The -1438A/G polymorphism in the 5-hydroxytryptamine receptor 2A gene is related to hyperuricemia, increased gamma-glutamyl transpeptidase and decreased high-density lipoprotein cholesterol level in the Japanese population. Int. J. Mol. Med. 17: 77-82 (2006). *
Suzuki A, Angulo P, Lymp J, St. Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41: 64-71 (2005). *
Suzuki S, Tajima T, Sassa S, Kudo H, Okayasu I, Sakamoto S. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice. Anticancer Res. 26: 4223-4228 (2006).
Suzuki T, Tamehiro N, Sato Y, Kobayashi T, Ishii-Watabe A, Shinozaki Y, Nishimaki-Mogami T, Hashimoto T, Asakawa Y, Inoue K, Ohno Y, Yamaguchi T, Kawanishi T. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J. Pharmacol. Sci. 107: 285-294 (2008). *
Suzuki T, Yoshida S, Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br. J. Nutr. 100: 297-305 (2008). *
Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol. Dial. Transplant. 23: 2918-2924 (2008).
Swahn E, von Schenck H, Olsson AG. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin. Drug Investig. 15: 473-482 (1998).
Swartz-Basile DA, Lu D, Basile DP, Graewin SJ, Al-Azzawi H, Kiely JM, Mathur A, Yancey K, Pitt HA. Leptin regulates gallbladder genes related to absorption and secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G84-G90 (2007). *
Sweeney TR, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Decreased nuclear hormone receptor expression in the livers of mice in late pregnancy. Am. J. Physiol. Endocrinol. Metab. 290: E1313-E1320 (2006). *
Swidsinski A, Ludwig W, Pahlig H, Priem F. Molecular genetic evidence of bacterial colonization of cholesterol gallstones. Gastroenterology 108: 860-864 (1995). *
Swidsinski A, Schlien P, Pernthaler A, Gottschalk U, Barlehner E, Decker G, Swidsinski S, Strassburg J, Loening-Baucke V, Hoffmann U, Seehofer D, Hale LP, Lochs H. Bacterial biofilm within diseased pancreatic and biliary tracts. Gut 54: 388-395 (2005). *
Swierczynski J, Chmielewski M, Wolyniec W, Rutkowski B. Molecular mechanism of fatty acids impact on plasma lipid profile (part II). Przegl. Lek. 64: 42-47 (2007).
Szalat A, Gershkovich P, Ben-Ari A, Shaish A, Liberman Y, Boutboul E, Gotkine M, Hoffman A, Harats D, Leitersdorf E, Meiner V. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim. Biophys. Acta 1771: 839-844 (2007). *
Szalay F. Treatment of primary biliary cirrhosis. J. Physiol. Paris 95: 407-412 (2001).
Szanto A, Benko S, Szatmari I, Balint BL, Furtos I, Ruhl R, Molnar S, Csiba L, Garuti R, Calandra S, Larsson H, Diczfalusy U, Nagy L. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol. Cell. Biol. 24: 8154-8166 (2004). *
Szklarek-Kubicka M, Fijalkowska-Morawska J, Zaremba-Drobnik D, Ucinski A, Czekalski S, Nowicki M. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study. J. Ren. Nutr. 19: 487-493 (2009). *
Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, Matsuura E. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J. Lipid Res. 48: 768-781 (2007). *
Tachibana K, Yamasaki D, Ishimoto K, Doi T. The role of PPARs in cancer. PPAR Res. 2008: 102737 (2008). *
Tachibana S, Hirano M, Hirata T, Matsuo M, Ikeda I, Ueda K, Sato R. Cholesterol and plant sterol efflux from cultured intestinal epithelial cells is mediated by ATP-binding cassette transporters. Biosci. Biotechnol. Biochem. 71: 1886-1895 (2007). *
Tachibana Y. Synthesis and structure-activity relationships of bioactive compounds using sterols. Yakugaku Zasshi 126: 1139-1154 (2006).
Tacikowski T, Milewski B, Dzieniszewski J, Nowicka G, Walewska-Zielecka B. Comparative analysis of plasma lipoprotein components assessed by ultracentrifugation in primary biliary cirrhosis and chronic hepatitis. Med. Sci. Monit. 6: 325-329 (2000). *
Tacikowski T, Nowicka G, Bujko J, Walewska-Zielecka B, Dzieniszewski J. Influence of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development. Pol. Arch. Med. Wewn. 113: 213-222 (2005).
Tada N. Physiological actions of diacylglycerol outcome. Curr. Opin. Clin. Nutr. Metab. Care 7: 145-149 (2004).
Tada N, Yoshida H. Clinical significance of triglyceride-rich lipoproteins in metabolic syndrome. Rinsho Byori 55: 439-446 (2007).
Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, Di Ilio C, Urbani A, Federici G. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin. Chem. Lab. Med. 41: 1633-1641 (2003).
Taha AY, Henderson ST, Burnham WM. Dietary enrichment with medium chain triglycerides (AC-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs: implications for treating age-related cognitive decline. Neurochem. Res. 34: 1619-1625 (2009).
Tai ES, Collins D, Robins SJ, O'Connor JJ Jr, Bloomfield HE, Ordovas JM, Schaefer EJ, Brousseau ME. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187: 153-160 (2006).
Tajika M, Matsuura A, Nakamura T, Suzuki T, Sawaki A, Kato T, Hara K, Ookubo K, Yamao K, Kato M, Muto Y. Risk factors for vitamin D deficiency in patients with Crohn's disease. J. Gastroenterol. 39: 527-533 (2004). *
Takacs T, Montet JC. In vitro dissolution of cholesterol biliary stones. Gut 37: 157-158 (1995). *
Takahashi K, Kimura Y, Nagata K, Yamamoto A, Matsuo M, Ueda K. ABC proteins: key molecules for lipid homeostasis. Med. Mol. Morphol. 38: 2-12 (2005). *
Takahashi M, Tsuboyama-Kasaoka N, Nakatani T, Ishii M, Tsutsumi S, Aburatani H, Ezaki O. Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G338-G348 (2002). *
Takahashi T, Takahashi K, Yamashina M, Maesawa C, Kajiwara T, Taneichi H, Takebe N, Kaneko Y, Masuda T, Satoh J. Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects. Diabetes Care Dec 14 [Epub ahead of print] (2009).
Takeuchi Y, Takahashi M, Sakano K, Mutoh M, Niho N, Yamamoto M, Sato H, Sugimura T, Wakabayashi K. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. Carcinogenesis 28: 1692-1696 (2007). *
Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 263: 256-273 (2008). *
Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Wong KC, Li TK, Yu T, Zhu TY, Kun EW, Yip GW, Yu CM. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 59: 1322-1331 (2008). *
Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology (Oxford) 47: 718-723 (2008). *
Tam SP, Mok L, Chimini G, Vasa M, Deeley RG. ABCA1 mediates high-affinity uptake of 25-hydroxycholesterol by membrane vesicles and rapid efflux of oxysterol by intact cells. Am. J. Physiol. Cell Physiol. 291: C490-C502 (2006). *
Tamehiro N, Sato Y, Suzuki T, Hashimoto T, Asakawa Y, Yokoyama S, Kawanishi T, Ohno Y, Inoue K, Nagao T, Nishimaki-Mogami T. Riccardin C: a natural product that functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist. FEBS Lett. 579: 5299-5304 (2005). *
Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira KI, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J. Biol. Chem. 282: 21090-21099 (2007). *
Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis L, Fielding BA, Karpe F. The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia 49: 158-168 (2006). *
Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the blue mountains eye study. Arch. Ophthalmol. 127: 656-665 (2009).
Tanaka A, Tanaka K, Shinohara H, Hatano E, Sato S, Kanazawa A, Kitai T, Higashiyama H, Nakamura Y, Yamamoto Y, Okajima H, Egawa H, Ikai I, Uemoto S, Satomura I, Ozaki N, Inomata Y, Yamaoka Y. Extension of the indication for living related liver transplantation from children to adults based on resolution of graft size mismatch in relation to tissue oxygenation and metabolic load: a case report. Transpl. Int. 9 Suppl. 1: S174-S177 (1996).
Tanaka T, Ordovas JM, Delgado-Lista J, Perez-Jimenez F, Marin C, Perez-Martinez P, Gomez P, Lopez-Miranda J. Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men. J. Lipid Res. 48: 1402-1408 (2007). *
Tanaka T, Shen J, Abecasis GR, Kisialiou A, Ordovas JM, Guralnik JM, Singleton A, Bandinelli S, Cherubini A, Arnett D, Tsai MY, Ferrucci L. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI study. PLoS Genet. 5: e1000338 (2009). *
Tancevski I, Wehinger A, Demetz E, Eller P, Duwensee K, Huber J, Hochegger K, Schgoer W, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A. Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression. Endocrinology 149: 3708-3712 (2008). *
Tancevski I, Wehinger A, Schgoer W, Eller P, Cuzzocrea S, Foeger B, Patsch JR, Ritsch A. Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice. FASEB J. 20: 1328-1335 (2006). *
Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J. Lipid Res. Nov 23 [Epub ahead of print] (2009). *
Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 284: 32336-32343 (2009). *
Tang C, Vaughan AM, Anantharamaiah GM, Oram JF. Janus kinase 2 modulates the lipid transport-mediating but not protein-stabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res. 47: 107-114 (2006). *
Tang CK, Yi GH, Yang JH, Liu LS, Wang Z, Ruan CG, Yang YZ. Oxidized LDL upregulated ATP binding cassette transporter-1 in THP-1 macrophages. Acta Pharmacol. Sin. 25: 581-586 (2004). *
Tang W, Eggertsen G, Chiang JY, Norlin M. Estrogen-mediated regulation of CYP7B1: a possible role for controlling DHEA levels in human tissues. J. Steroid Biochem. Mol. Biol. 100: 42-51 (2006).
Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler. Thromb. Vasc. Biol. 28: 448-454 (2008). *
Tang W, Ma Y, Yu L. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. Hepatology 44: 1259-1266 (2006). *
Tang W, Norlin M, Wikvall K. Glucocorticoid receptor-mediated upregulation of human CYP27A1, a potential anti-atherogenic enzyme. Biochim. Biophys. Acta 1781: 718-723 (2008). *
Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 99: 11896-11901 (2002). *
Tapola NS, Lyyra ML, Kolehmainen RM, Sarkkinen ES, Schauss AG. Safety aspects and cholesterol-lowering efficacy of chitosan tablets. J. Am. Coll. Nutr. 27: 22-30 (2008). *
Tapsell L, Batterham M, Huang XF, Tan SY, Teuss G, Charlton K, Oshea J, Warensjo E. Short term effects of energy restriction and dietary fat sub-type on weight loss and disease risk factors. Nutr. Metab. Cardiovasc. Dis. Jun 29 [Epub ahead of print] (2009).
Tarr PT, Edwards PA. ABCG1 and ABCG4 are co-expressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J. Lipid Res. 49: 169-182 (2008). *
Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, Acikel C, Ozgurtas T, Sonmez A. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 204: 222-228 (2009).
Tasduq SA, Kaiser P, Sharma SC, Johri RK. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatol. Res. 37: 845-853 (2007). *
Tasic I, Milojkovic M, Sunder-Plassmann R, Lazarevic G, Tasic NM, Stefanovic V. The association of PC-1 (ENPP1) K121Q polymorphism with metabolic syndrome in patients with coronary heart disease. Clin. Chim. Acta 377: 237-242 (2007). *
Tateyama T, Matsushiro T. Bile acid composition affecting cholesterol dissolution rate: a use of multiple regression analysis. Tohoku. J. Exp. Med. 133: 467-475 (1981). *
Tauscher A, Kuver R. ABCG5 and ABCG8 are expressed in gallbladder epithelial cells. Biochem. Biophys. Res. Commun. 307: 1021-1028 (2003). *
Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scalissi N, Speranza AC, Hirata MH. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes. Metab. 7: 605-611 (2005).
Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 9: 81-86 (2007). *
Taylor A, Tabrah S, Wang D, Sozen M, Duxbury N, Whittall R, Humphries S, Norbury G. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia. Clin. Genet. 71: 561-568 (2007). *
Taylor DR, Crowther RS, Cozart JC, Sharrock P, Wu J, Soloway RD. Calcium carbonate in cholesterol gallstones: polymorphism, distribution, and hypotheses about pathogenesis. Hepatology 22: 488-496 (1995).
Taylor JM, Borthwick F, Bartholomew C, Graham A. Over-expression of steroidogenic acute regulatory protein (StAR) increases macrophage cholesterol efflux to apolipoprotein AI. Cardiovasc. Res. Jan 18 [Epub ahead of print] (2010). *
Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann. Pharmacother. 38: 205-208 (2004).
Taziki O, Lessan-Pezeshki M, Akha O, Vasheghani F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J. Kidney Dis. Transpl. 18: 571-576 (2007).
Tazoe F, Yagyu H, Okazaki H, Igarashi M, Eto K, Nagashima SI, Inaba T, Shimano H, Osuga JI, Ishibashi S. Induction of ABCA1 by overexpression of hormone-sensitive lipase in macrophages. Biochem. Biophys. Res. Commun. 376: 111-115 (2008). *
Teillon S, Calderon G, Rios M. Diminished diet-induced hyperglycemia and dyslipidemia and enhanced expression of PPARalpha and FGF-21 in mice with hepatic ablation of brain-derived neurotrophic factor. J. Endocrinol. Jan 22 [Epub ahead of print] (2010). *
Telarovic S, Telarovic S, Mihanovic M. Cyclosporine-induced depressive psychosis in a liver transplant patient: a case report. Lijec. Vjesn. 129: 74-76 (2007).
Tellechea ML, Aranguren F, Perez MS, Cerrone GE, Frechtel GD, Taverna MJ. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men. Circ. J. 73: 2118-2124 (2009). *
Tellier E, Canault M, Poggi M, Bonardo B, Nicolay A, Alessi MC, Nalbone G, Peiretti F. HDLs activate ADAM17-dependent shedding. J. Cell. Physiol. 214: 687-693 (2008). *
Temel RE, Lee RG, Kelley KL, Davis MA, Shah R, Sawyer JK, Wilson MD, Rudel LL. Intestinal cholesterol absorption is substantially reduced in mice deficient in both ATP-binding cassette transporter A1 (ABCA1) and Acyl-CoA:Cholesterol O-acyltransferase 2 (ACAT2). J. Lipid Res. 46: 2423-2431 (2005). *
Tenenbaum A, Fisman EZ. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc. Diabetol. 3: 10 (2004). *
Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc. Diabetol. 5: 20 (2006). *
Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45: 127-153 (2008).
Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. 4: 14 (2005). *
Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197-2202 (2004).
Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. Am. J. Cardiol. 102: 434-439 (2008).
Teunissen CE, Floris S, Sonke M, Dijkstra CD, De Vries HE, Lutjohann D. 24S-Hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. J. Neurosci. Res. 85: 1499-1505 (2007). *
Teupser D, Kretzschmar D, Tennert C, Burkhardt R, Wilfert W, Fengler D, Naumann R, Sippel AE, Thiery J. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28: 2009-2015 (2008).
The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359: 789-799 (2008). *
Theilmann L, Otto G, Arnold J, Gmelin K, Stiehl A. Biliary secretion of bile acids, lipids, and bilirubin by the transplanted liver. A quantitative study in patients on cyclosporine. Transplantation 52: 1020-1023 (1991).
Theuwissen E, Plat J, Mensink RP. Consumption of oat beta-glucan with or without plant stanols did not influence inflammatory markers in hypercholesterolemic subjects. Mol. Nutr. Food Res. 53: 370-376 (2009). *
Thistle JL, Hofmann AF, Yu PY, Ott B. Effect of varying doses of chenodeoxycholic acid on bile lipid and biliary bile acid composition in gallstone patients: a dose-response study. Am. J. Dig. Dis. 22: 1-6 (1977).
Thistle JL, LaRusso NF, Hofmann AF, Turcotte J, Carlson GL, Ott BJ. Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study. Dig. Dis. Sci. 27: 161-168 (1982).
Thomas C, Landrier JF, Gaillard D, Grober J, Monnot MC, Athias A, Besnard P. Cholesterol-dependent down-regulation of mouse and human apical sodium-dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Gut 55: 1321-1331 (2006). *
Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, Cao G, Kiefer A, McCowan J, Yu KL, Grese T, Chin WW, Burris TP, Michael LF. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor. J. Biol. Chem. 278: 2403-2410 (2003). *
Thomas LA, Veysey MJ, Murphy GM, Russell-Jones D, French GL, Wass JA, Dowling RH. Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut 54: 630-635 (2005). *
Thomas TR, Liu Y, Linden MA, Rector RS. Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia. Appl. Physiol. Nutr. Metab. 32: 473-480 (2007).
Thomassen MJ, Barna BP, Malur AG, Bonfield TL, Farver CF, Malur A, Dalrymple H, Kavuru MS, Febbraio M. ABCG1 is deficient in alveolar macrophages of GM-CSF knock-out mice and patients with pulmonary alveolar proteinosis. J. Lipid Res. 48: 2762-2768 (2007). *
Thompson GR, Naoumova RP. New prospects for lipid-lowering drugs. Expert Opin. Investig. Drugs 7: 715-727 (1998).
Thompson MB. Bile acids in the assessment of hepatocellular function. Toxicol. Pathol. 24: 62-71 (1996). *
Thompson R, Jansen PL. Genetic defects in hepatocanalicular transport. Semin. Liver Dis. 20: 365-372 (2000).
Thornton SJ, Wong E, Lee SD, Wasan KM. Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism. Lipids Health Dis. 7: 21 (2008). *
Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor null mice. Circulation 116: 2182-2190 (2007). *
Thusgaard M, Christensen JH, Morn B, Andersen TS, Vige R, Arildsen H, Schmidt EB, Nielsen H. Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study. Scand. J. Infect. Dis. 41: 760-766 (2009).
Thwaites DT, Anderson CM. H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp. Physiol. 92: 603-619 (2007). *
Thymiakou E, Zannis VI, Kardassis D. Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. Biochemistry 46: 11473-11483 (2007). *
Tiala I, Suomela S, Huuhtanen J, Wakkinen J, Holtta-Vuori M, Kainu K, Ranta S, Turpeinen U, Hamalainen E, Jiao H, Karvonen SL, Ikonen E, Kere J, Saarialho-Kere U, Elomaa O. The CCHCR1 (HCR) gene is relevant for skin steroidogenesis and downregulated in cultured psoriatic keratinocytes. J. Mol. Med. 85: 589-601 (2007). *
Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 202: 152-161 (2009).
Tichauer JE, Morales MG, Amigo L, Galdames L, Klein A, Quinones V, Ferrada C, Alvarez AR, Rio MC, Miquel JF, Rigotti A, Zanlungo S. Overexpression of the cholesterol-binding protein MLN64 induces liver damage in the mouse. World J. Gastroenterol. 13: 3071-3079 (2007). *
Tiemann M, Han Z, Soccio R, Bollineni J, Shefer S, Sehayek E, Breslow JL. Cholesterol feeding of mice expressing cholesterol 7alpha-hydroxylase increases bile acid pool size despite decreased enzyme activity. Proc. Natl. Acad. Sci. U.S.A. 101: 1846-1851 (2004). *
Tietz P, Jefferson J, Pagano R, LaRusso NF. Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J. Lipid Res. 46: 1426-1432 (2005). *
Tilly-Kiesi M, Schaefer EJ, Knudsen P, Welty FK, Dolnikowski GG, Taskinen MR, Lichtenstein AH. Lipoprotein metabolism in subjects with hepatic lipase deficiency. Metabolism 53: 520-525 (2004). *
Timea C, Folhoffer A, Horvath A, Osztovits J, Gorog D, Kobori L, Papp J, Szalay F. Xanthomatosis and extreme hypercholesterolemia after laparoscopic cholecystectomy. Total reversibility following surgical treatment of iatrogenous stenosis of the common bile duct. Orv. Hetil. 147: 705-710 (2006).
Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J. Affect. Disord. 82: 447-452 (2004).
Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, Shefer S. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann. Intern. Med. 97: 351-356 (1982).
Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23: 1643-1654 (2009). *
Tiret L, Tregouet DA, Cambien F. Cholesterol gene polymorphisms and cardiovascular events. N. Engl. J. Med. 359: 92-93 (2008).
Tisseverasinghe A, Lim S, Greenwood C, Urowitz M, Gladman D, Fortin PR. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum. 54: 2211-2219 (2006). *
Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin. Drug Saf. 5: 651-666 (2006).
Tiwari A, Maiti P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov. Today 14: 523-530 (2009).
Tiwari RL, Singh V, Barthwal MK. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med. Res. Rev. 28: 483-544 (2007). *
Tjokroprawiro A. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). Acta Med. Indones. 38: 160-166 (2006).
Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol. Endocrinol. 14: 741-752 (2000). *
Toda Y, Aoki R, Ikeda Y, Azuma Y, Kioka N, Matsuo M, Sakamoto M, Mori S, Fukumoto M, Ueda K. Detection of ABCA7-positive cells in salivary glands from patients with Sjogren's syndrome. Pathol. Int. 55: 639-643 (2005). *
Tojcic J, Benoit-Biancamano MO, Court MH, Straka RJ, Caron P, Guillemette C. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab. Dispos. 37: 2236-2243 (2009).
Toker A, Kadi M, Yildirim AK, Aksoy H, Akcay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell. Biochem. Funct. 27: 176-180 (2009). *
Tolle M, Levkau B, Kleuser B, van der Giet M. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. Eur. J. Clin. Invest. 37: 171-179 (2007). *
Tomaszewski M, Charchar FJ, Barnes T, Gawron-Kiszka M, Sedkowska A, Podolecka E, Kowalczyk J, Rathbone W, Kalarus Z, Grzeszczak W, Goodall AH, Samani NJ, Zukowska-Szczechowska E. A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 29: 1316-1321 (2009).
Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J. Cytochrome P450 polymorphism - molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. Acta Pol. Pharm. 65: 307-318 (2008).
Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther. Feb 3 [Epub ahead of print] (2010). *
Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17: 985-993 (2003). *
Toomey S, Harhen B, Roche HM, Fitzgerald D, Belton O. Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 187: 40-49 (2006).
Torchia EC, Cheema SK, Agellon LB. Coordinate regulation of bile acid biosynthetic and recovery pathways. Biochem. Biophys. Res. Commun. 225: 128-133 (1996). *
Torisu T, Takata Y, Ansai T, Matsumoto T, Sonoki K, Soh I, Awano S, Yoshida A, Hamasaki T, Kagiyama S, Nakamichi I, Ohsumi T, Toyoshima K, Nishihara T, Iida M, Takehara T. Possible association of atrophic gastritis and arterial stiffness in healthy middle-aged Japanese. J. Atheroscler. Thromb. 16: 691-697 (2009).
Torma H, Berne B. Sodium lauryl sulphate alters the mRNA expression of lipid-metabolizing enzymes and PPAR signalling in normal human skin in vivo. Exp. Dermatol. 18: 1010-1015 (2009).
Torocsik D, Szanto A, Nagy L. Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. Mol. Aspects Med. 30: 134-152 (2009).
Torrini M, Marchese C, Vanzetti M, Marini V, Origone P, Garre C, Mareni C. Mutation analysis of oxisterol-binding-protein gene in patients with age-related macular degeneration. Genet. Test. 11: 421-426 (2007).
Toth PP. Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Curr. Atheroscler. Rep. 9: 81-88 (2007).
Toth PP, Dayspring TD, Pokrywka GS. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Curr. Atheroscler. Rep. 11: 71-79 (2009).
Tran N, Barraj L. Contribution of specific dietary factors to CHD in US females. Public Health Nutr. 13: 154-162 (2010).
Trasino SE, Kim YS, Wang TT. Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells. Mol. Cancer Ther. 8: 1934-1945 (2009).
Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta Oct 24 [Epub ahead of print] (2009). *
Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *
Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 18: 314-329 (2002).
Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien. Med. Wochenschr. 158: 542-548 (2008). *
Trauner M, Fickert P, Lammert F, Marschall HU. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1222-1223 (2004). *
Tregouet DA, Ricard S, Nicaud V, Arnould I, Soubigou S, Rosier M, Duverger N, Poirier O, Mace S, Kee F, Morrison C, Denefle P, Tiret L, Evans A, Deleuze JF, Cambien F. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 24: 775-781 (2004). *
Tremont SJ, Lee LF, Huang HC, Keller BT, Banerjee SC, Both SR, Carpenter AJ, Wang CC, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Fletcher T, Reinhard EJ, et al. Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1). J. Med. Chem. 48: 5837-5852 (2005). *
Tretjakovs P, Latkovskis G, Licis N, Juhnevica D, Jurka A, Bormane I, I Aivars J, Stifts A, Pirags V. Interleukin-6 gene promoter -174G/C polymorphism and insulin resistance: a pilot study. Clin. Chem. Lab. Med. 45: 1145-1148 (2007). *
Tritapepe R, Pozzi C, Caspani P, Di Padova C. Unexpected dilatation of the common bile duct after methyl tertiary butyl ether (MTBE) in rabbits. Possible implications to findings in man. Gut 30: 206-212 (1989). *
Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug resistant cells. Mol. Pharmacol. 66: 1332-1339 (2004). *
Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl. 7: 343-351 (2001). *
Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 7: 401-408 (2001). *
Trottier J, Verreault M, Grepper S, Monte D, Belanger J, Kaeding J, Caron P, Inaba TT, Barbier O. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 44: 1158-1170 (2006). *
Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg. 5: 375-380 (1999).
Trousson A, Bernard S, Petit PX, Liere P, Pianos A, El Hadri K, Lobaccaro JM, Said Ghandour M, Raymondjean M, Schumacher M, Massaad C. 25-Hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR. J. Neurochem. 109: 945-958 (2009).
Trousson A, Makoukji J, Petit PX, Bernard S, Slomianny C, Schumacher M, Massaad C. Cross-talk between oxysterols and glucocorticoids: differential regulation of secreted phopholipase A2 and impact on oligodendrocyte death. PLoS One 4: e8080 (2009). *
Trovato GM, Martines GF, Garozzo A, Tonzuso A, Timpanaro R, Pirri C, Trovato FM, Catalano D. Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int. 30: 184-190 (2010). *
Truong H, Dibello JR, Ruiz-Narvaez E, Kraft P, Campos H, Baylin A. Does genetic variation in the Delta6-desaturase promoter modify the association between alpha-linolenic acid and the prevalence of metabolic syndrome? Am. J. Clin. Nutr. 89: 920-925 (2009). *
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 136: 1593-1600 (2009). *
Tsai CT, Hwang JJ, Chiang FT, Tseng CD, Lin JL, Tseng YZ, Lai LP. ATP-binding cassette transporter A1 gene I823M polymorphism affects plasma high-density lipoprotein cholesterol level and modifies the effect of low high-density lipoprotein cholesterol on the risk of coronary artery disease. Cardiology 107: 321-328 (2007).
Tsai MH, Peng YS, Chen YC, Lien JM, Tian YC, Fang JT, Weng HH, Chen PC, Yang CW, Wu CS. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. J. Hepatol. 50: 906-915 (2009).
Tsezou A, Iliopoulos D, Malizos KN, Simopoulou T. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. J. Orthop. Res. Jan 27 [Epub ahead of print] (2010).
Tsuboi K, Tazuma S, Ochi H, Chayama K. Hydrophilic bile salts have a cytoprotective effect against cyclosporine A-induced cholestasis through enhanced canalicular membrane fluidity and transporter activity. Hepatol. Res. 25: 38-47 (2003). *
Tsuji H, Murai K, Akagi K, Fujishima M. Familial primary biliary cirrhosis associated with impaired concanavalin A-induced lymphocyte transformation in relatives. Two family studies. Dig. Dis. Sci. 37: 353-360 (1992).
Tsukanov VV, Nozdrachev KG, Tonkikh IuL, Bronnikova EP, Kupershteie Eiu. The mechanism of reverse cholesterol transport and cholelithiasis in northern nationalities. Klin. Med. (Mosk.) 85: 33-35 (2007).
Tu H, Okamoto AY, Shan B. FXR, a bile acid receptor and biological sensor. Trends Cardiovasc. Med. 10: 30-35 (2000).
Tuckey RC, Nguyen MN, Slominski A. Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin. Int. J. Biochem. Cell Biol. 40: 2619-2626 (2008). *
Tuncer I, Harman M, Mercan R, Ozturk M, Arslan I, Meral C, Turkdogan MK. The effects of ursodeoxycholic acid alone and ursodeoxycholic acid plus low-dose acetylsalicylic acid on radiolucent gallstones. Turk. J. Gastroenterol. 14: 91-96 (2003). *
Tung BY, Kowdley KV. Liver transplantation for hemochromatosis, Wilson's disease, and other metabolic disorders. Clin. Liver Dis. 1: 341-360 (1997).
Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am. J. Gastroenterol. Jan 5 [Epub ahead of print] (2010). *
Turck D. Later effects of breastfeeding practice: the evidence. Nestle Nutr. Workshop Ser. Pediatr. Program 60: 31-42 (2007).
Turhan H, Yetkin E. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? Int. J. Cardiol. 110: 276-277 (2006).
Turkcapar N, Ozyuncu N, Cinar K, Ensari A, Kucuk O, Idilman R, Duman N, Ozden A. A case of systemic lupus erythematosus presenting with protein-losing enteropathy. Turk. J. Gastroenterol. 17: 226-230 (2006). *
Turkoski BB. An ounce of prevention. Drugs used to treat hyperlipidemia (Part 1). Orthop. Nurs. 23: 58-61 (2004).
Turley SD. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin. Cardiol. 27 (6 Suppl. 3): 16-21 (2004).
Turley SD. The role of Niemann-Pick C1-like 1 (NPC1L1) in intestinal sterol absorption. J. Clin. Lipidol. 2: S20-S28 (2008). *
Turner-McGrievy GM, Barnard ND, Cohen J, Jenkins DJ, Gloede L, Green AA. Changes in nutrient intake and dietary quality among participants with type 2 diabetes following a low-fat vegan diet or a conventional diabetes diet for 22 weeks. J. Am. Diet. Assoc. 108: 1636-1645 (2008). *
Twisk J, Hoekman MF, Lehmann EM, Meijer P, Mager WH, Princen HM. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology 21: 501-510 (1995).
Twisk J, Lehmann EM, Princen HM. Differential feedback regulation of cholesterol 7 alpha-hydroxylase mRNA and transcriptional activity by rat bile acids in primary monolayer cultures of rat hepatocytes. Biochem. J. 290: 685-691 (1993). *
Tworowska-Bardzinska U, Lwow F, Kubicka E, Laczmanski L, Jedzrzejuk D, Dunajska K, Milewicz A. The vitamin D receptor gene BsmI polymorphism is not associated with anthropometric and biochemical parameters describing metabolic syndrome in postmenopausal women. Gynecol. Endocrinol. 24: 514-518 (2008).
Uchida K, Nomura Y, Kadowaki M, Arisue K, Takeuchi N, Ishikawa Y. Effects of sodium ursodeoxycholate, hyodeoxycholate and dehydrocholate on cholesterol and bile acid metabolism in rats. J. Pharmacobiodyn. 6: 346-357 (1983).
Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, Langer C, Schachtrup C, Wiekowski J, Lorkowski S, Assmann G, von Eckardstein A. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 51: 2922-2928 (2002). *
Uehara Y, Miura SI, von Eckardstein A, Abe S, Fujii A, Matsuo Y, Rust S, Lorkowski S, Assmann G, Yamada T, Saku K. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis 191: 11-21 (2007).
UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK Consensus. Curr. Med. Res. Opin. 20: 241-247 (2004). *
Ukkola O, Salonen J, Kesaniemi YA. Role of candidate genes in the lipid responses to intensified treatment in type 2 diabetes. J. Endocrinol. Invest. 28: 871-875 (2005).
Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J; Natural Standard Research Collaboration. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement. Ther. Med. 13: 279-290 (2005).
Ulven SM, Dalen KT, Gustafsson JA, Nebb HI. LXR is crucial in lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids 73: 59-63 (2005). *
Umar RK, Rinella ME. An update on nonalcoholic fatty liver disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 94-98 (2006). *
Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW, Mangelsdorf DJ. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13: 1185-1192 (2007). *
Umezawa M, Higuchi K, Mori M, Matushita T, Hosokawa M. Effect of dietary unsaturated fatty acids on senile amyloidosis in senescence-accelerated mice. J. Gerontol. A. Biol. Sci. Med. Sci. 64: 646-652 (2009).
Une M, Yamanaga K, Mosbach EH, Tsujimura K, Hoshita T. Metabolism of 7 beta-alkyl chenodeoxycholic acid analogs and their effect on cholesterol metabolism in hamsters. J. Lipid Res. 31: 1015-1021 (1990). *
Uppal H, Saini SP, Moschetta A, Mu Y, Zhou J, Gong H, Zhai Y, Ren S, Michalopoulos GK, Mangelsdorf DJ, Xie W. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45: 422-432 (2007). *
Uppal H, Zhai Y, Gangopadhyay A, Khadem S, Ren S, Moser JA, Xie W. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology 47: 1331-1342 (2008). *
Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296: 1703-1706 (2002). *
Urquizu-Padilla M, Balada E, Chacon P, Perez EH, Vilardell-Tarres M, Ordi-Ros J. Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: a prospective study. J. Rheumatol. 36: 1639-1645 (2009).
Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 95: 3584-3589 (2000). *
Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha -dependent modulation of NPC1L1 expression in mouse. J. Lipid Res. 48: 2725-2735 (2007). *
Valdivielso P, Ariza MJ, de la Vega-Roman C, Gonzalez-Alegre T, Rioja J, Ulzurrun E, Gonzalez-Santos P. Association of the -250G/A promoter polymorphism of the hepatic lipase gene with the risk of peripheral arterial disease in type 2 diabetic patients. J. Diabetes Complications 22: 273-277 (2008).
Valdivielso P, Rioja J, Garcia-Arias C, Sanchez-Chaparro MA, Gonzalez-Santos P. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. Cardiovasc. Diabetol. 8: 1 (2009).
van Berkel TJ. Bringing retinoid metabolism into the 21st century. J. Lipid Res. 50: 2337-2339 (2009). *
Van Biervliet S, Van Biervliet JP, Robberecht E. Serum zinc in patients with cystic fibrosis at diagnosis and after one year of therapy. Biol. Trace Elem. Res. 112: 205-211 (2006).
van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J. Cyst. Fibros. 7: 515-519 (2008).
van den Bosch HM, Bunger M, de Groot PJ, van der Meijde J, Hooiveld GJ, Muller M. Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting. BMC Genomics 8: 267 (2007). *
van den Bosch HM, De Wit NJ, Hooiveld GJ, Vermeulen H, van der Veen JN, Houten SM, Kuipers F, Muller M, van der Meer R. A cholesterol free, high-fat diet suppresses gene expression of cholesterol transporters in murine small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G1171-G1180 (2008). *
van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PC, Princen HM. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br. J. Pharmacol. 156: 1067-1075 (2009).
van der Net JB, Isaacs A, Dallinga-Thie GM, Kastelein JJ, Defesche JC, Steyerberg EW, Sijbrands EJ. Haplotype of the angiotensinogen gene is associated with coronary heart disease in familial hypercholesterolemia. J. Hypertens. 26: 462-467 (2008).
van der Tempel H, Tulleken JE, Limburg PC, Muskiet FA, van Rijswijk MH. Effects of fish oil supplementation in rheumatoid arthritis. Ann. Rheum. Dis. 49: 76-80 (1990). *
van der Veen JN, Havinga R, Bloks VW, Groen AK, Kuipers F. Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha. J. Lipid Res. 48: 337-347 (2007). *
van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46: 526-534 (2005). *
van der Veen JN, van Dijk TH, Vrins CL, van Meer H, Havinga R, Bijsterveld K, Tietge UJ, Groen AK, Kuipers F. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284: 19211-19219 (2009). *
van der Velde AE, Vrins CL, van den Oever K, Kunne C, Oude Elferink RP, Kuipers F, Groen AK. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 133: 967-975 (2007). *
van der Velde AE, Vrins CL, van den Oever K, Seemann I, Oude Elferink RP, van Eck M, Kuipers F, Groen AK. Regulation of direct transintestinal cholesterol excretion in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G203-G208 (2008). *
van der Vleuten GM, Kluijtmans LA, Hijmans A, Blom HJ, Stalenhoef AF, de Graaf J. The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia. Int. J. Obes. (Lond.) 30: 892-898 (2006).
van Erpecum KJ. Biliary lipids, water and cholesterol gallstones. Biol. Cell. 97: 815-822 (2005). *
van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Twisk JW, van de Stadt RJ, de Koning MH, Habibuw MR, van der Horst-Bruinsma IE, Dijkmans BA. Lipids and inflammation - serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 66: 184-188 (2007). *
van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis - a case control study. Arthritis Res. Ther. 8: R151 (2006). *
van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann. Clin. Biochem. 42: 402-404 (2005).
Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, Rijk MC, Smit AM, Zwertbroek R, Hop WC, van Berge Henegouwen GP, Schalm SW, van Buuren HR. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment. Pharmacol. Ther. 12: 965-971 (1998). *
Van Kruiningen HJ, Civco IC, Cartun RW. The comparative importance of E. coli antigen in granulomatous colitis of boxer dogs. APMIS 113: 420-425 (2005). *
Van Laethem F, Leo O. Membrane lipid rafts: new targets for immunoregulation. Curr. Mol. Med. 2: 557-570 (2002).
van Mil SW, Houwen RH, Klomp LW. Genetics of familial intrahepatic cholestasis syndromes. J. Med. Genet. 42: 449-463 (2005). *
van Nieuwerk CM, Groen AK, Ottenhoff R, van Wijland M, van den Bergh Weerman MA, Tytgat GN, Offerhaus JJ, Oude Elferink RP. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J. Hepatol. 26: 138-145 (1997). *
Van Nieuwkerk CM, Oude Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, Offerhaus GJ. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111: 165-171 (1996). *
van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res. 21: 1531-1538 (2004).
van Straten E, van Meer H, Huijkman N, van Dijk TH, Baller JF, Verkade HJ, Kuipers F, Plosch T. Fetal liver X receptor activation acutely induces lipogenesis, but does not affect plasma lipid response to a high-fat diet in adult mice. Am. J. Physiol. Endocrinol. Metab. Sep 1 [Epub ahead of print] (2009). *
van Straten EM, Bloks VW, Huijkman NC, Baller JF, van Meer H, Lutjohann D, Kuipers F, Plosch T. The liver X-receptor (LXR) gene promoter is hypermethylated in a mouse model of prenatal protein restriction. Am. J. Physiol. Regul. Integr. Comp. Physiol. Nov 4 [Epub ahead of print] (2009). *
van Straten EM, Huijkman NC, Baller JF, Kuipers F, Plosch T. Pharmacological activation of LXR in utero directly influences ABC transporter expression and function in mice but does not affect adult cholesterol metabolism. Am. J. Physiol. Endocrinol. Metab. 295: E1341-E1348 (2008). *
vanBerge-Henegouwen GP, Venneman NG, Portincasa P, Kosters A, van Erpecum KJ, Groen AK. Relevance of hereditary defects in lipid transport proteins for the pathogenesis of cholesterol gallstone disease. Scand. J. Gastroenterol. Suppl. 241: 60-69 (2004). *
Vankeerberghen L, Oppenheimer M, Opolon P, Levy VG. Treatment of intra-heptic cholestasis in primary biliary cirrhosis by long term plasmapheresis. Life Support Syst. 1 Suppl. 1: 106-111 (1983).
Vanmierlo T, Bloks VW, van Vark-van der Zee LC, Rutten K, Kerksiek A, Friedrichs S, Sijbrands E, Steinbusch HW, Kuipers F, Lutjohann D, Mulder M. Alterations in brain cholesterol metabolism in the APPSLxPS1mut mouse, a model for Alzheimer's disease. J. Alzheimers Dis. 19: 117-127 (2010).
Vanmierlo T, Bloks VW, van Vark-van der Zee LC, Rutten K, Kerksiek A, Friedrichs S, Sijbrands E, Steinbusch HW, Kuipers F, Lutjohann D, Mulder M. Alterations in brain cholesterol metabolism in the APPSLxPS1mut mouse, a model for Alzheimer's disease. J. Alzheimers Dis. Sep 11 [Epub ahead of print] (2009).
Vanmierlo T, Rutten K, Dederen J, Bloks VW, van Vark-van der Zee LC, Kuipers F, Kiliaan A, Blokland A, Sijbrands EJ, Steinbusch H, Prickaerts J, Lutjohann D, Mulder M. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging Aug 10 [Epub ahead of print] (2009).
Vantieghem K, Kissmeyer AM, Haes PD, Bouillon R, Segaert S. UVB-induced production of 1,25-dihydroxyvitamin D(3) and vitamin D activity in human keratinocytes pretreated with a sterol Delta(7)-reductase inhibitor. J. Cell. Biochem. 98: 81-92 (2006). *
Vantieghem K, Overbergh L, Carmeliet G, De Haes P, Bouillon R, Segaert S. UVB-induced 1,25(OH)(2)D(3) production and vitamin D activity in intestinal CaCo-2 cells and in THP-1 macrophages pretreated with a sterol Delta(7)-reductase inhibitor. J. Cell. Biochem. 99: 229-240 (2006). *
Varga L, Biro A, Szeplaki G, Toth L, Horvath A, Fust G, Farkas H. Anti-cholesterol antibody levels in hereditary angioedema. J. Cell. Mol. Med. 11: 1377-1383 (2007). *
Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D, Murgolo NJ, Keane K, Davis HR Jr, Hedrick J, Gustafson EL. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398: 423-430 (2006). *
Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr. Atheroscler. Rep. 8: 76-84 (2006).
Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr. Cardiol. Rep. 7: 471-479 (2005).
Vasudevan R, Ismail P, Stanslas J, Shamsudin N, Ali AB. Association of insertion/deletion polymorphism of alpha-adrenoceptor gene in essential hypertension with or without type 2 diabetes mellitus in Malaysian subjects. Int. J. Biol. Sci. 4: 362-367 (2008). *
Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J. Lipid Res. 47: 2433-2443 (2006). *
Vaya J, Schipper HM. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem. 102: 1727-1737 (2007).
Vedhachalam C, Liu L, Nickel M, Dhanasekaran P, Anantharamaiah GM, Lund-Katz S, Rothblat GH, Phillips MC. Influence of apoA-I structure on the ABCA1-mediated efflux of cellular lipids. J. Biol. Chem. 279: 49931-49939 (2004). *
Vedin LL, Lewandowski SA, Parini P, Gustafsson JA, Steffensen KR. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 30: 575-579 (2009). *
Veenema K, Solis C, Li R, Wang W, Maletz CV, Abratte CM, Caudill MA. Adequate intake levels of choline are sufficient for preventing elevations in serum markers of liver dysfunction in Mexican American men but are not optimal for minimizing plasma total homocysteine increases after a methionine load. Am. J. Clin. Nutr. 88: 685-692 (2008). *
Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Effects of n-3 fatty acids on hepatic triglyceride content in humans. J. Investig. Med. 56: 780-785 (2008).
Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu PV, Yetukuri L, Islam S, Felin J, Perkins R, Boren J, Oresic M, Backhed F. The gut microbiota modulates host energy and lipid metabolism in mice. J. Lipid Res. Dec 29 [Epub ahead of print] (2009). *
Velamakanni S, Janvilisri T, Shahi S, van Veen HW. A functional steroid-binding element in an ATP-binding cassette multidrug transporter. Mol. Pharmacol. 73: 12-17 (2008). *
Velasco J, Mariscal-Arcas M, Rivas A, Caballero ML, Hernandez-Elizondo J, Olea-Serrano F. Assessment of the diet of school children from Granada and influence of social factors. Nutr. Hosp. 24: 193-199 (2009).
Velicia Llames MR, Gonzalez Hernandez JM, Fernandez Orcajo P, Sanz Santacruz C. Symptomatic primary biliary stenosis without cholestasis. Gastroenterol. Hepatol. 18: 330-331 (1995).
Vemula M, Berthiaume F, Jayaraman A, Yarmush ML. Expression profiling analysis of the metabolic and inflammatory changes following burn-injury in rats. Physiol. Genomics 18: 87-98 (2004). *
Venkataramani A, Strong RM, Anderson DS, Gilmore IT, Stokes K, Hofmann AF. Abnormal duodenal bile composition in patients with acalculous chronic cholecystitis. Am. J. Gastroenterol. 93: 434-441 (1998). *
Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J. Biol. Chem. 275: 14700-14707 (2000). *
Venneman NG, Huisman SJ, Moschetta A, vanBerge-Henegouwen GP, van Erpecum KJ. Effects of hydrophobic and hydrophilic bile salt mixtures on cholesterol crystallization in model biles. Biochim. Biophys. Acta 1583: 221-228 (2002). *
Venneman NG, Van Brummelen SE, Van Berge-Henegouwen GP, Van Erpecum KJ. Microlithiasis: an important cause of 'idiopathic' acute pancreatitis? Ann. Hepatol. 2: 30-35 (2003). *
Venneman NG, van Erpecum KJ. Gallstone disease: primary and secondary prevention. Best Pract. Res. Clin. Gastroenterol. 20: 1063-1073 (2006).
Venneman NG, vanBerge-Henegouwen GP, van Erpecum KJ. Pharmacological manipulation of biliary water and lipids: potential consequences for prevention of acute biliary pancreatitis. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 193-198 (2005).
Venniyoor A. Cholesterol gallstones and cancer of gallbladder (CAGB): molecular links. Med. Hypotheses 70: 646-653 (2008).
Venteclef N, Delerive P. Interleukin-1 receptor antagonist induction as an additional mechanism for liver receptor homolog-1 to negatively regulate the hepatic acute phase response. J. Biol. Chem. 282: 4393-4399 (2007). *
Venteclef N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J. Biol. Chem. 283: 3694-3701 (2008). *
Venteclef N, Smith JC, Goodwin B, Delerive P. Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response. Mol. Cell. Biol. 26: 6799-6807 (2006). *
Ventura E, Durant R, Jaussent A, Picot MC, Morena M, Badiou S, Dupuy AM, Jeandel C, Cristol JP. Homocysteine and inflammation as main determinants of oxidative stress in the elderly. Free Radic. Biol. Med. 46: 737-744 (2009).
Verdi H, Sare Koytak E, Onder O, Arslan Ergul A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis. J. Investig. Med. 53: 353-359 (2005).
Vere CC, Gofita E, Fortofoiu C, Streba LA, Genunche A. Antiviral therapy effects upon hepatitis C cholestatic syndrome. Rom. J. Morphol. Embryol. 48: 51-54 (2007).
Verges B. Role for fibrate therapy in diabetes: evidence before FIELD. Curr. Opin. Lipidol. 16: 648-651 (2005).
Verges B. Clinical interest of PPARs ligands. Diabetes Metab. 30: 7-12 (2004).
Verges B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr. Med. Res. Opin. 21 Suppl. 1: S29-S40 (2005).
Vergnes L, Phan J, Strauss M, Tafuri S, Reue K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J. Biol. Chem. 278: 42774-42784 (2003). *
Verkasalo MA, Raitakari OT, Viikari J, Marniemi J, Savilahti E. Undiagnosed silent coeliac disease: a risk for underachievement? Scand. J. Gastroenterol. 40: 1407-1412 (2005). *
Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am. J. Cardiovasc. Drugs 4: 247-255 (2004).
Vernet N, Dennefeld C, Kloppfenstein M, Ruiz A, Bok D, Ghyselinck N, Mark M. Retinoid X receptor beta (RXRB) expression in Sertoli cells controls cholesterol homeostasis and spermiation. Reproduction 136: 619-626 (2008). *
Verreault M, Senekeo-Effenberger K, Trottier J, Bonzo JA, Belanger J, Kaeding J, Staels B, Caron P, Tukey RH, Barbier O. The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology 44: 368-378 (2006). *
Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in ApoE*3Leiden mice: time course and potential mechanisms. J. Lipid Res. 50: 301-311 (2009). *
Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, Giannoni M, Rimoldi L, Lauria F, Miji M, Deferrari G, Garibotto G. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int. 72: 1262-1272 (2007). *
Vestergaard M, Hamada T, Morita M, Takagi M. Cholesterol, lipids, amyloid beta, and Alzheimer's. Curr. Alzheimer Res. Dec 1 [Epub ahead of print] (2009).
Vicens M, Medarde M, Macias RI, Larena MG, Villafaina A, Serrano MA, Marin JJ. Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorg. Med. Chem. 15: 2359-2367 (2007). *
Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hanninen O, Uusitupa MI. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 32: 697-705 (1997).
Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS ONE 4: e4664 (2009). *
Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 46: 27-33 (2009).
Vijaya Padma V, Shyamala Devi CS, Ramkumar KM. Effect of fish oil pretreatment on isoproterenol-induced changes in myocardial membrane phospholipids. Nutrition 22: 1171-1176 (2006). *
Vijayakumar MV, Pandey V, Mishra GC, Bhat MK. Hypolipidemic effect of fenugreek seeds is mediated through inhibition of fat accumulation and upregulation of LDL receptor. Obesity (Silver Spring) Oct 22 [Epub ahead of print] (2009). *
Vik-Mo AO, Ferno J, Skrede S, Steen VM. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol. 9: 10 (2009). *
Vilkin A, Nudelman I, Morgenstern S, Geller A, Bar Dayan Y, Levi Z, Rodionov G, Hardy B, Konikoff F, Gobbic D, Niv Y. Gallbladder inflammation is associated with increase in mucin expression and pigmented stone formation. Dig. Dis. Sci. 52: 1613-1620 (2007). *
Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, Sanvito F, Ponzoni M, Valentinis B, Bregni M, Prinetti A, Steffensen KR, Sonnino S, Gustafsson JA, Doglioni C, Bordignon C, Traversari C, Russo V. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. Dec 27 [Epub ahead of print] (2009). *
Villalon L, Tuchweber B, Yousef IM. Low protein diets potentiate lithocholic acid-induced cholestasis in rats. J. Nutr. 122: 1587-1596 (1992). *
Vimaleswaran KS, Radha V, Mohan V. Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians. Metabolism 55: 1222-1226 (2006). *
Vink A, De Kleijn DP, Pasterkamp G. Functional role for Toll-like receptors in atherosclerosis and arterial remodeling. Curr. Opin. Lipidol. 15: 515-521 (2004).
Viturro E, de Oya M, Lasuncion MA, Gorgojo L, Moreno JM, Benavente M, Cano B, Garces C. Cholesterol and saturated fat intake determine the effect of polymorphisms at ABCG5/ABCG8 genes on lipid levels in children. Genet. Med. 8: 594-599 (2006).
Vladimirova-Kitova LG, Deneva TI, Angelova E, Bichev AN, Nikolov FP. Role of some biomarkers of atherogenic risk in the screening for molecular defects in the low density lipoprotein receptor in severe hypercholesterolemia. Folia. Med. (Plovdiv.) 50: 14-22 (2008).
Vlahcevic ZR, Eggertsen G, Bjorkhem I, Hylemon PB, Redford K, Pandak WM. Regulation of sterol 12alpha-hydroxylase and cholic acid biosynthesis in the rat. Gastroenterology 118: 599-607 (2000). *
Vlahcevic ZR, Jairath SK, Heuman DM, Stravitz RT, Hylemon PB, Avadhani NG, Pandak WM. Transcriptional regulation of hepatic sterol 27-hydroxylase by bile acids. Am. J. Physiol. 270: G646-G652 (1996).
Vlahcevic ZR, Stravitz RT, Heuman DM, Hylemon PB, Pandak WM. Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. Gastroenterology 113: 1949-1957 (1997). *
Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, Cellier C, Faith JM, Despres JP, Morgan K, Hudson TJ. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 41: 945-952 (2000). *
Volcik KA, Nettleton JA, Ballantyne CM, Boerwinkle E. Peroxisome proliferator-activated receptor-alpha genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. Am. J. Clin. Nutr. 87: 1926-1931 (2008). *
Volle DH, Mouzat K, Duggavathi R, Siddeek B, Dechelotte P, Sion B, Veyssiere G, Benahmed M, Lobaccaro JM. Multiple roles of the nuclear receptors for oxysterols LXR to maintain male fertility. Mol. Endocrinol. 21: 1014-1027 (2007). *
Volle DH, Repa JJ, Mazur A, Cummins CL, Val P, Henry-Berger J, Caira F, Veyssiere G, Mangelsdorf DJ, Lobaccaro JM. Regulation of the aldo-keto reductase gene akr1b7 by the nuclear oxysterol receptor LXRalpha (liver X receptor-alpha) in the mouse intestine: putative role of LXRs in lipid detoxification processes. Mol. Endocrinol. 18: 888-898 (2004). *
von Bergmann K, Epple-Gutsfeld M, Leiss O. Differences in the effects of chenodeoxycholic and ursodeoxycholic acid on biliary lipid secretion and bile acid synthesis in patients with gallstones. Gastroenterology 87: 136-143 (1984).
von Bergmann K, Sudhop T, Lutjohann D. Cholesterol and plant sterol absorption: recent insights. Am. J. Cardiol. 96: S10-S14 (2005). *
Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, Genin A, Van Dyke AL, Nackos E, Chander A, Gehrie E, Cron RQ, Whitehead AS. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2220-2227 (2006). *
Voshol PJ, Havinga R, Wolters H, Ottenhoff R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 114: 1024-1034 (1998). *
Voshol PJ, Koopen NR, de Vree JM, Havinga R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. Dietary cholesterol does not normalize low plasma cholesterol levels but induces hyperbilirubinemia and hypercholanemia in Mdr2 P-glycoprotein-deficient mice. J. Hepatol. 34: 202-209 (2001). *
Vrablik M, Ceska R. New strategies in the treatment of dyslipidemia: do we know how? Semin. Vasc. Med. 4: 305-310 (2004).
Vrablik M, Dobiasova M, Stulc T, Kasalova Z, Dolezalova R, Prazny M, Fait T, Ceska R. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus. Neuro. Endocrinol. Lett. 29: 146-150 (2008).
Vrins C, Vink E, Vandenberghe KE, Frijters R, Seppen J, Groen AK. The sterol transporting heterodimer ABCG5/ABCG8 requires bile salts to mediate cholesterol efflux. FEBS Lett. 581: 4616-4620 (2007). *
Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Heyman RA, Staels B, Auwerx J. Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell Biol. 16: 3350-3360 (1996). *
Vuoristo M, Farkkila M, Gylling H, Karvonen AL, Leino R, Lehtola J, Makinen J, Mattila J, Tilvis R, Miettinen TA. Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis. J. Hepatol. 27: 136-142 (1997). *
Vuoristo M, Farkkila M, Karvonen AL, Leino R, Lehtola J, Makinen J, Mattila J, Friman C, Seppala K, Tuominen J, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 108: 1470-1478 (1995). *
Wada T, Kang HS, Angers M, Gong H, Bhatia S, Khadem S, Ren S, Ellis E, Strom S, Jetten A, Xie W. Identification of oxysterol 7alpha-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor alpha (RORalpha) (NR1F1) target gene and a functional crosstalk between RORalpha and LXR (NR1H3). Mol. Pharmacol. 73: 891-899 (2008). *
Wada T, Kang HS, Jetten AM, Xie W. The emerging role of nuclear receptor RORalpha and its crosstalk with LXR in xeno- and endobiotic gene regulation. Exp. Biol. Med. (Maywood) 233: 1191-1201 (2008). *
Wagner BL, Valledor AF, Shao G, Daige CL, Bischoff ED, Petrowski M, Jepsen K, Baek SH, Heyman RA, Rosenfeld MG, Schulman IG, Glass CK. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23: 5780-5789 (2003). *
Wagner JA, Wright EC, Ennis MM, Prince M, Kochan J, Nunez DJ, Schneider B, Wang MD, Chen Y, Ghosh S, Musser BJ, Vassileva MT. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin. Pharmacol. Ther. 86: 619-625 (2009). *
Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss. Med. Wkly. 132: 83-91 (2002). *
Waite N, Lodge J, Hart K, Robertson D, Badley E, Burton S. The impact of fish-oil supplements on insulin sensitivity. J. Hum. Nutr. Diet. 21: 402-403 (2008). *
Walcher T, Haenle MM, Kron M, Hay B, Mason RA, Walcher D, Steinbach G, Kern P, Piechotowski I, Adler G, Boehm BO, Koenig W, Kratzer W; EMIL study group. Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterol. 9: 74 (2009). *
Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am. J. Pathol. 172: 1112-1126 (2008). *
Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 102: 810-815 (1992).
Walker S, Stiehl A, Raedsch R, Kloters P, Kommerell B. Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat jejunum, ileum, and colon. Digestion 32: 47-52 (1985).
Walters JR. Bile acids are physiological ligands for a nuclear receptor. Gut 46: 308-309 (2000). *
Wamil M, Andrew R, Chapman KE, Street J, Morton NM, Seckl JR. 7-Oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 149: 5909-5918 (2008). *
Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, Flores M, Postic C, Magnuson MA, Chen J, Chien KR, French S, Mangelsdorf DJ, Sucov HM. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell. Biol. 20: 4436-4444 (2000). *
Wan YJ, Cai Y, Lungo W, Fu P, Locker J, French S, Sucov HM. Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice. J. Biol. Chem. 275: 28285-28290 (2000). *
Wang D, Wang W, Duan Y, Sun Y, Wang Y, Huang P. Functional coupling of Gs and CFTR is independent of their association with lipid rafts in epithelial cells. Pflugers Arch. 456: 929-938 (2008). *
Wang DQ. New concepts of mechanisms of intestinal cholesterol absorption. Ann. Hepatol. 2: 113-121 (2003). *
Wang DQ. Prevention of cholesterol gallstones by the potent cholesterol absorption inhibitor ezetimibe in gallstone-susceptible mice. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 80 (2006). *
Wang DQ, Afdhal NH. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr. Gastroenterol. Rep. 6: 140-150 (2004).
Wang DQ, Lee SP. Physical chemistry of intestinal absorption of biliary cholesterol in mice. Hepatology 48: 177-185 (2008). *
Wang DQ, Zhang L, Wang HH. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim. Biophys. Acta 1733: 90-99 (2005). *
Wang F, Jia J. Polymorphisms of cholesterol metabolism genes CYP46 and ABCA1 and the risk of sporadic Alzheimer's disease in Chinese. Brain Res. 1147: 34-38 (2007).
Wang G, Zhang L, Li Q. Genetic polymorphisms of GSTT1, GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese population. Biochem. Biophys. Res. Commun. 341: 310-313 (2006). *
Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3: 543-553 (1999). *
Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42: 1331-1357 (2003).
Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology 131: 210-222 (2006). *
Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J. Lipid Res. 45: 438-447 (2004). *
Wang HH, Patel SB, Carey MC, Wang DQ. Quantifying anomalous intestinal sterol uptake, lymphatic transport, and biliary secretion in Abcg8(-/-) mice. Hepatology 45: 998-1006 (2007). *
Wang J, Einarsson C, Murphy C, Parini P, Bjorkhem I, Gafvels M, Eggertsen G. Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in normal and cholic acid depleted mice. J. Lipid Res. 47: 421-430 (2006). *
Wang J, Jiang W, Gao H, He B, Liu W. Clinical and pathological characteristics of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 334-337 (2002).
Wang J, Joy T, Mymin D, Frohlich J, Hegele RA. Phenotypic heterogeneity of sitosterolemia. J. Lipid Res. 45: 2361-2367 (2004). *
Wang J, Near S, Young K, Connelly PW, Hegele RA. ABCC6 gene polymorphism associated with variation in plasma lipoproteins. J. Hum. Genet. 46: 699-705 (2001).
Wang JH, Keisala T, Solakivi T, Minasyan A, Kalueff AV, Tuohimaa P. Serum cholesterol and expression of ApoAI, LXRbeta and SREBP2 in vitamin D receptor knock-out mice. J. Steroid Biochem. Mol. Biol. 113: 222-226 (2009).
Wang L, Geng C, Jiang L, Gong D, Liu D, Yoshimura H, Zhong L. The anti-atherosclerotic effect of olive leaf extract is related to suppressed inflammatory response in rabbits with experimental atherosclerosis. Eur. J. Nutr. 47: 235-243 (2008). *
Wang L, Han Y, Kim CS, Lee YK, Moore DD. Resistance of SHP-null mice to bile acid-induced liver damage. J. Biol. Chem. 278: 44475-44481 (2003). *
Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, Chua SS, Wei P, Heyman RA, Karin M, Moore DD. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2: 721-731 (2002). *
Wang M, Chen M, Zheng G, Dillard Iii B, Tallarico M, Ortiz Z, Holterman AX. Transcriptional activation by growth hormone of HNF-6-regulated hepatic genes, a potential mechanism for improved liver repair during biliary injury in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G357-G366 (2008). *
Wang M, Tan Y, Costa RH, Holterman AX. In vivo regulation of murine CYP7A1 by HNF-6: a novel mechanism for diminished CYP7A1 expression in biliary obstruction. Hepatology 40: 600-608 (2004). *
Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler. Thromb. Vasc. Biol. 27: 1837-1842 (2007). *
Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, Gallant M, Marcel YL. Differential regulation of ABCA1 expression and apoA-I lipidation by NPC1 in murine hepatocytes and macrophages. J. Biol. Chem. 282: 22525-2233 (2007). *
Wang MD, Kiss RS, Franklin V, McBride HM, Whitman SC, Marcel YL. Different intracellular trafficking of LDL- and acetylated LDL-derived cholesterol lead to distinct reverse cholesterol transport mechanisms. J. Lipid Res. 48: 633-645 (2007). *
Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 101: 9774-9779 (2004). *
Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 26: 1310-1316 (2006).
Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J. Biol. Chem. 276: 23742-23747 (2001). *
Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J. 22: 1073-1082 (2008). *
Wang PY, Weng J, Anderson RG. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 307: 1472-1476 (2005).
Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, Helgason CD, Ackerley C, Phillips MJ, Ling V. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. U.S.A. 98: 2011-2016 (2001). *
Wang S, Wu D, Lamon-Fava S, Matthan NR, Honda KL, Lichtenstein AH. In vitro fatty acid enrichment of macrophages alters inflammatory response and net cholesterol accumulation. Br. J. Nutr. 102: 497-501 (2009). *
Wang S, Wu D, Matthan NR, Lamon-Fava S, Lecker JL, Lichtenstein AH. Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse. Atherosclerosis 204: 147-155 (2009).
Wang TW, Livingstone CA, Ferns GA. Effectiveness of lipid lowering drugs in general practice: article illustrates major problem. BMJ 327: 50-51 (2003). *
Wang W, Shinto L, Connor WE, Quinn JF. Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity. J. Alzheimers Dis. 13: 31-38 (2008).
Wang XJ, Chamberlain MP, Vassieva O, Henderson CJ, Wolf CR. Relationship between hepatic phenotype and changes in gene expression in the cytochrome P450 reductase (POR) null mice. Biochem. J. 388: 857-867 (2005). *
Wang Y, Jiang ZY, Fei J, Xin L, Cai Q, Jiang ZH, Zhu ZG, Han TQ, Zhang SD. ATP binding cassette G8 T400K polymorphism may affect the risk of gallstone disease among Chinese males. Clin. Chim. Acta 384: 80-85 (2007). *
Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RA, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP. Modulation of RORalpha and RORgamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. Dec 4 [Epub ahead of print] (2009). *
Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J. Lipid Res. 45: 972-980 (2004). *
Wang Y, Liu YB, Jiang ZY, Cai Q, Jiang ZH, Han TQ, Zhang SD. Expression and regulation of megalin in gallbladder mucosa associated with cholesterol gallstone disease. Zhonghua Yi Xue Za Zhi 89: 1110-1113 (2009).
Wang Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Down-regulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J. Lipid Res. 46: 2377-2387 (2005). *
Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J. Biol. Chem. 280: 35896-35903 (2005). *
Wang Y, Rogers P, Stayrook K, Su C, Varga G, Shen Q, Nagpal S, Burris T. The selective Alzheimer's disease indicator-1 gene (seladin-1/DHCR24) is a liver X receptor target gene. Mol. Pharmacol. 74: 1716-1721 (2008). *
Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris TP. Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J. Biol. Chem. 283: 26332-26339 (2008). *
Wang Y, Santos J, Sakurai R, Shin E, Cerny L, Torday JS, Rehan VK. Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model. Pediatr. Res. 65: 150-155 (2009).
Wang YD, Chen WD, Huang W. FXR, a target for different diseases. Histol. Histopathol. 23: 621-627 (2008). *
Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 18: 1087-1095 (2008). *
Wang YF, Yang XF, Cheng B, Mei CL, Li QX, Xiao H, Zeng QT, Liao YH, Liu K. Protective effect of Astragalus polysaccharides on ATP binding cassette transporter A1 in THP-1 derived foam cells exposed to tumor necrosis factor-alpha. Phytother. Res. Aug 3 [Epub ahead of print] (2009).
Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, Didonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13: 1176-1184 (2007). *
Wang ZJ, Liu Q, Li PP, Zou CH, Shen ZF. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. Eur. J. Pharmacol. 580: 277-283 (2008). *
Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Interrelationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J. Thromb. Haemost. 5: 1637-1643 (2007). *
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 27: 95-131 (1984).
Warner FJ. Liver anti-inflammatory pathways: potential ways to control liver damage. Hepatology 45: 1327-1329 (2007). *
Wasilewska J, Jarocka-Cyrta E, Kaczmarski M. Narcolepsy, metabolic syndrome and obstructive sleep apnea syndrome as the causes of hypersomnia in children. Report of three cases. Adv. Med. Sci. 52 Suppl. 1: 207-211 (2007).
Wassall SR, Stillwell W. Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem. Phys. Lipids 153: 57-63 (2008). *
Wassall SR, Stillwell W. Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. Biochim. Biophys. Acta 1788: 24-32 (2009). *
Wassif CA, Yu J, Cui J, Porter FD, Javitt NB. 27-Hydroxylation of 7- and 8-dehydrocholesterol in Smith-Lemli-Opitz syndrome: a novel metabolic pathway. Steroids 68: 497-502 (2003).
Watanabe M. Lipoprotein abnormalities in cholestasis. II. Isolation, characterization and clinical evaluation of an additional cholestatic lipoprotein (slow-migrating HDL). Acta Med. Okayama 33: 327-341 (1979).
Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489 (2006). *
Watanabe Y, Tanaka T, Uchiyama Y, Takeno T, Izumi A, Yamashita H, Kumakura J, Iwanari H, Shu-Ying J, Naito M, Mangelsdorf DJ, Hamakubo T, Kodama T. Establishment of a monoclonal antibody for human LXRalpha: detection of LXRalpha protein expression in human macrophages. Nucl. Recept. 1: 1 (2003). *
Watarai A, Nakashima E, Hamada Y, Watanabe G, Naruse K, Miwa K, Kobayashi Y, Kamiya H, Nakae M, Hamajima N, Sekido Y, Niwa T, Oiso Y, Nakamura J. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese type 2 diabetic patients. Diabet. Med. 23: 894-899 (2006). *
Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat. Rev. Genet. 7: 163-173 (2006). *
Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 331: 815-828 (2003). *
Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292: 2329-2333 (2001). *
Watkins SM, Zhu X, Zeisel SH. Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J. Nutr. 133: 3386-3391 (2003). *
Watts G, Chan D, Ooi E, Nestel P, Beilin Lj, Barrett P. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies. Clin. Exp. Pharmacol. Physiol. 33: 877-882 (2006). *
Watts GF. Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. Curr. Control Trials Cardiovasc. Med. 2: 118-122 (2001). *
Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol. Ther. 123: 281-291 (2009). *
Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A. Screening for type 2 diabetes: literature review and economic modelling. Health Technol. Assess. 11: iii-iv, ix-xi, 1-125 (2007). *
Wavrant-De Vrieze F, Compton D, Womick M, Arepalli S, Adighibe O, Li L, Perez-Tur J, Hardy J. ABCA1 polymorphisms and Alzheimer's disease. Neurosci. Lett. 415: 154-158 (2007). *
Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369: 11-23 (1999). *
Weber MS, Steinman L, Zamvil SS. Statins - treatment option for central nervous system autoimmune disease? Neurotherapeutics 4: 693-700 (2007).
Weber MS, Youssef S, Dunn SE, Prod'homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil SS. Statins in the treatment of central nervous system autoimmune disease. J. Neuroimmunol. 178: 140-148 (2006).
Weger M, Steinbrugger I, El-Shabrawi Y, Wegscheider BJ, Weger W, Renner W, Schmut O, Haas A. Haplotype-tagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion. Mol. Vis. 13: 549-552 (2007). *
Wei J, Qiu de K, Ma X. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J. Dig. Dis. 10: 85-90 (2009). *
Weindl G, Roeder A, Schafer-Korting M, Schaller M, Korting HC. Receptor-selective retinoids for psoriasis: focus on tazarotene. Am. J. Clin. Dermatol. 7: 85-97 (2006).
Weinhofer I, Kunze M, Rampler H, Bookout AL, Forss-Petter S, Berger J. Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression: novel cross-talk in gene regulation. J. Biol. Chem. 280: 41243-41251 (2005). *
Weisse S, Kalimouttou S, Lahiani-Skiba M, Djedaini-Pilard F, Perly B, Skiba M. Investigations on topically applied vitamin A loaded amphiphilic cyclodextrin nanocapsules. J. Nanosci. Nanotechnol. 9: 640-645 (2009).
Weissglas-Volkov D, Huertas-Vazquez A, Suviolahti E, Lee J, Plaisier C, Canizales-Quinteros S, Tusie-Luna T, Aguilar-Salinas C, Taskinen MR, Pajukanta P. Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes 55: 1970-1977 (2006). *
Weng Y, Dirusso CC, Reilly AA, Black PN, Ding X. Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene: mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype. J. Biol. Chem. 280: 31686-31698 (2005). *
Wente W, Brenner MB, Zitzer H, Gromada J, Efanov AM. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin secreting cells. Endocrinology 148: 1843-1849 (2007). *
Wenzel JJ, Kaminski WE, Piehler A, Heimerl S, Langmann T, Schmitz G. ABCA10, a novel cholesterol-regulated ABCA6-like ABC transporter. Biochem. Biophys. Res. Commun. 306: 1089-1098 (2003). *
Wessel JJ, Kocoshis SA. Nutritional management of infants with short bowel syndrome. Semin. Perinatol. 31: 104-111 (2007).
West J, Logan RF, Hill PG, Khaw KT. The iceberg of celiac disease: what is below the waterline? Clin. Gastroenterol. Hepatol. 5: 59-62 (2007).
West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 16: 93-98 (1975). *
Westin S, Heyman RA, Martin R. FXR, a therapeutic target for bile acid and lipid disorders. Mini. Rev. Med. Chem. 5: 719-727 (2005).
White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N. Z. Med. J. 119: U2125 (2006).
White DB, Batayneh Z, Bachmann KA. A synergism model for PPARalpha and PXR agonist effects on HDL-cholesterol and apoA1. Front. Biosci. (Elite Ed.) 2: 399-410 (2010).
White NM, Jiang D, Burgess JD, Bederman IR, Previs SF, Kelley TJ. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L476-L486 (2007). *
Whitfield AJ, Barrett PH, Robertson K, Havlat MF, van Bockxmeer FM, Burnett JR. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin. Chem. 51: 266-269 (2005). *
Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 134-141 (1994).
Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol. 16: 1378-1385 (2002). *
Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, Wilson JG, Willson TM, Collins JL, Kliewer SA. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J. Biol. Chem. 276: 43509-43515 (2001). *
Whittall RA, Scartezini M, Li K, Hubbart C, Reiner Z, Abraha A, Neil HA, Dedoussis G, Humphries SE. Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients. Ann. Clin. Biochem. Oct 16 [Epub ahead of print] (2009).
Wiersma H, Gatti A, Nijstad N, Oude Elferink RP, Kuipers F, Tietge UJ. Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Hepatology 50: 1263-1272 (2009). *
Wiersma H, Nijstad N, de Boer JF, Out R, Hogewerf W, Van Berkel TJ, Kuipers F, Tietge UJ. Lack of Abcg1 results in decreased plasma HDL cholesterol levels and increased biliary cholesterol secretion in mice fed a high cholesterol diet. Atherosclerosis 206: 141-147 (2009).
Wierzbicki AS. Fibrates after the FIELD study: some answers, more questions. Diab. Vasc. Dis. Res. 3: 166-171 (2006).
Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes ES, Kastelein JJ, Tak PP. Sustained changes in lipid profile and macrophage migration inhibitory factor (MIF) levels after anti-TNF therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68: 1316-1321 (2009).
Wijendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu. Rev. Nutr. 24: 597-615 (2004). *
Wikiera B, Barg E, Konieczna A, Glab E, Noczynska A. The prevalence of thyroperoxidase antibodies and thyroid function in Turner's syndrome. Endokrynol. Diabetol. Chor. Przemiany. Materii. Wieku. Rozw. 12: 190-194 (2006).
Wild SH, Byrne CD, Tzoulaki I, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study. Atherosclerosis 203: 604-609 (2009).
Wilding JP, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 7 Study Group. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab. Vasc. Dis. Res. 4: 194-203 (2007).
Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler. Thromb. Vasc. Biol. 29: 843-849 (2009).
Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40: 161-169 (2008). *
Willett WC. The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. J. Cardiovasc. Med. (Hagerstown) 8 Suppl. 1: S42-S45 (2007).
Williams CN, Al-Knawy B, Blanchard W. Bioavailability of four ursodeoxycholic acid preparations. Aliment. Pharmacol. Ther. 14: 1133-1139 (2000). *
Williams MA, Frederick IO, Qiu C, Meryman LJ, King IB, Walsh SW, Sorensen TK. Maternal erythrocyte omega-3 and omega-6 fatty acids, and plasma lipid concentrations, are associated with habitual dietary fish consumption in early pregnancy. Clin. Biochem. 39: 1063-1070 (2006). *
Williamson C. Functional foods: what are the benefits? Br. J. Community Nurs. 14: 230-236 (2009).
Wilund KR, Yu L, Xu F, Hobbs HH, Cohen JC. High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/-mice. J. Lipid Res. 45 1429-1436 (2004). *
Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J. Lipid Res. 42: 1543-1551 (2001). *
Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbe E, Vermoesen A. Structure and function of sinusoidal lining cells in the liver. Toxicol. Pathol. 24: 100-111 (1996).
Wittenburg H, Lyons MA, Li R, Churchill GA, Carey MC, Paigen B. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology 125: 868-881 (2003). *
Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, Danan E, Donovan K, Hossenipour M, Simpson RJ Jr. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41: 1498-1504 (2005). *
Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy. Hig. Med. Dosw. (Online) 61: 736-759 (2007). *
Wolf G. The role of oxysterols in cholesterol homeostasis. Nutr. Rev. 57: 196-198 (1999).
Wolkoff AW, Cohen DE. Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G175-G179 (2003). *
Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F. Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J. Hepatol. 37: 556-563 (2002). *
Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 196: 180-189 (2008).
Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40: 235-243 (2006).
Wong KE, Szeto FL, Zhang W, Ye H, Kong J, Zhang Z, Sun XJ, Li YC. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am. J. Physiol. Endocrinol. Metab. 296: E820-E828 (2009). *
Woollett LA, Buckley DD, Yao L, Jones PJ, Granholm NA, Tolley EA, Heubi JE. Effect of ursodeoxycholic acid on cholesterol absorption and metabolism in humans. J. Lipid Res. 44: 935-942 (2003). *
Wooten JS, Biggerstaff KD, Ben-Ezra V. Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise. J. Appl. Physiol. 107: 794-800 (2009). *
Wooton-Kee CR, Coy DJ, Athippozhy AT, Zhao T, Jones BR, Vore M. Mechanisms for increased expression of cholesterol 7alpha-hydroxylase (Cyp7a1) in lactating rats. Hepatology 51: 277-285 (2010).
Worgall TS. Lipid metabolism in cystic fibrosis. Curr. Opin. Clin. Nutr. Metab. Care 12: 105-109 (2009).
Woudenberg J, Rembacz KP, van den Heuvel FA, Woudenberg-Vrenken TE, Buist-Homan M, Geuken M, Hoekstra M, Deelman LE, Enrich C, Henning RH, Moshage H, Faber KN. Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes. Hepatology Nov 30 [Epub ahead of print] (2009). *
Wouters K, Bilsen MV, Gorp PJ, Bieghs V, Lutjohann D, Kerksiek A, Staels B, Hofker MH, Shiri-Sverdlov R. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. Jan 28 [Epub ahead of print] (2010). *
Wrobel J, Steffan R, Bowen SM, Magolda R, Matelan E, Unwalla R, Basso M, Clerin V, Gardell SJ, Nambi P, Quinet E, Reminick JI, Vlasuk GP, Wang S, Feingold I, Huselton C, Bonn T, Farnegardh M, Hansson T, Nilsson AG, Wilhelmsson A, Zamaratski E, Evans MJ. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J. Med. Chem. 51: 7161-7168 (2008). *
Wu J, Zhang Y, Wang N, Davis L, Yang G, Wang X, Zhu Y, Breyer MD, Guan Y. Liver X receptor alpha (LXRalpha) mediates cholesterol efflux in glomerular mesangial cells. Am. J. Physiol. Renal Physiol. 287: F886-F895 (2004). *
Wu JE, Basso F, Shamburek RD, Amar MJ, Vaisman B, Szakacs G, Joyce C, Tansey T, Freeman L, Paigen BJ, Thomas F, Brewer HB Jr, Santamarina-Fojo S. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but alter aortic atherosclerosis in transgenic mice. J. Biol. Chem. 279: 22913-22925 (2004). *
Wu K, Bowman R, Welch AA, Luben RN, Wareham N, Khaw KT, Bingham SA. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. Eur. Heart J. 28: 2930-2936 (2007).
Wu MK, Cohen DE. Altered hepatic cholesterol metabolism compensates for disruption of phosphatidylcholine transfer protein in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G456-G461 (2005). *
Wu MK, Hyogo H, Yadav SK, Novikoff PM, Cohen DE. Impaired response of biliary lipid secretion to a lithogenic diet in phosphatidycholine transfer protein-deficient mice. J. Lipid Res. 46: 422-431 (2005). *
Wu X, Niu N, Brismar K, Zhu X, Wang X, Efendic S, Du T, Liu Y, Gu HF, Liu Y. Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. Clin. Biochem. 42: 17-21 (2009). *
Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J. Drugs Dermatol. 7: 373-377 (2008).
Wu Z, Martin KO, Javitt NB, Chiang JY. Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. J. Lipid Res. 40: 2195-2203 (1999). *
Wuarin J, Falvey E, Lavery D, Talbot D, Schmidt E, Ossipow V, Fonjallaz P, Schibler U. The role of the transcriptional activator protein DBP in circadian liver gene expression. J. Cell Sci. Suppl. 16: 123-127 (1992).
Wunder C, Churin Y, Winau F, Warnecke D, Vieth M, Lindner B, Zahringer U, Mollenkopf HJ, Heinz E, Meyer TF. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat. Med. 12: 1030-1038 (2006). *
Xia M, Hou M, Xia X, Zhu H, Tang Z, Wang Q, Li Y, Chi D, Yu X, Zhao T, Han P, Ma J, Ling W. Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages: the role of the PPARgamma-LXRalpha-ABCA1 pathway. J. Biol. Chem. 280: 36792-36801 (2005). *
Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet. Genomics 19: 447-457 (2009).
Xie G, Myint PK, Zhao L, Li Y, Wang H, Liang L, Wu Y. Relationship between -592A/C polymorphism of interleukin-10 (IL-10) gene and risk of early carotid atherosclerosis. Int. J. Cardiol. Dec 30 [Epub ahead of print] (2008).
Xie Y, Newberry EP, Kennedy SM, Luo J, Davidson NO. Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein (L-Fabp) knockout mice. J. Lipid Res. 50: 977-987 (2009). *
Xie Y, Yang Q, DePierre JW. The effects of peroxisome proliferators on global lipid homeostasis and the possible significance of these effects to other responses to these xenobiotics: an hypothesis. Ann. N. Y. Acad. Sci. 973: 17-25 (2002). *
Xie Z, Li H, Wang K, Lin J, Wang Q, Zhao G, Jia W, Zhang Q. Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat. Metabolism Nov 13 [Epub ahead of print] (2009). *
Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28: 249-268 (2005).
Xu G, Li H, Pan LX, Shang Q, Honda A, Ananthanarayanan M, Erickson SK, Shneider BL, Shefer S, Bollineni J, Forman BM, Matsuzaki Y, Suchy FJ, Tint GS, Salen G. FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits. J. Lipid Res. 44: 1956-1962 (2003). *
Xu G, Pan LX, Erickson SK, Forman BM, Shneider BL, Ananthanarayanan M, Li X, Shefer S, Balasubramanian N, Ma L, Asaoka H, Lear SR, Nguyen LB, Dussault I, Suchy FJ, Tint GS, Salen G. Removal of the bile acid pool upregulates cholesterol 7alpha-hydroxylase by deactivating FXR in rabbits. J. Lipid Res. 43: 45-50 (2002). *
Xu G, Pan LX, Li H, Forman BM, Erickson SK, Shefer S, Bollineni J, Batta AK, Christie J, Wang TH, Michel J, Yang S, Tsai R, Lai L, Shimada K, Tint GS, Salen G. Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits. J. Biol. Chem. 277: 50491-50496 (2002). *
Xu G, Pan LX, Li H, Shang Q, Honda A, Shefer S, Bollineni J, Matsuzaki Y, Tint GS, Salen G. Dietary cholesterol stimulates CYP7A1 in rats because farnesoid X receptor (FXR) is not activated. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G730-G735 (2004). *
Xu G, Salen G, Shefer S, Tint GS, Kren BT, Nguyen LB, Steer CJ, Chen TS, Salen L, Greenblatt D. Increased bile acid pool inhibits cholesterol 7 alpha-hydroxylase in cholesterol-fed rabbits. Gastroenterology 113: 1958-1965 (1997). *
Xu G, Salen G, Shefer S, Tint GS, Nguyen LB, Chen TS, Greenblatt D. Increasing dietary cholesterol induces different regulation of classic and alternative bile acid synthesis. J. Clin. Invest. 103: 89-95 (1999). *
Xu G, Salen G, Shefer S, Tint GS, Nguyen LB, Parker TT, Chen TS, Roberts J, Kong X, Greenblatt D. Regulation of classic and alternative bile acid synthesis in hypercholesterolemic rabbits: effects of cholesterol feeding and bile acid depletion. J. Lipid Res. 39: 1608-1615 (1998). *
Xu H, Sakakibara S, Morifuji M, Salamatulla Q, Aoyama Y. Excess dietary histidine decreases the liver copper level and serum alanine aminotransferase activity in Long-Evans Cinnamon rats. Br. J. Nutr. 90: 573-579 (2003). *
Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 98: 13919-13924 (2001). *
Xu J, Cho H, O'Malley S, Park JH, Clarke SD. Dietary polyunsaturated fats regulate rat liver sterol regulatory element binding proteins-1 and -2 in three distinct stages and by different mechanisms. J. Nutr. 132: 3333-3339 (2002). *
Xu L, Davis TA, Porter NA. Rate constants for peroxidation of polyunsaturated fatty acids and sterols in solution and in liposomes. J. Am. Chem. Soc. 131: 13037-13044 (2009). *
Xu Z, Tavares-Sanchez OL, Li Q, Fernando J, Rodriguez CM, Studer EJ, Pandak WM, Hylemon PB, Gil G. Activation of bile acid biosynthesis by the p38 mitogen-activated protein kinase (MAPK): hepatocyte nuclear factor-4alpha phosphorylation by the p38 MAPK is required for cholesterol 7alpha-hydroxylase expression. J. Biol. Chem. 282: 24607-24614 (2007). *
Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig. Dis. Sci. May 21 [Epub ahead of print] (2009). *
Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR. Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol. Endocrinol. 21: 1028-1038 (2007). *
Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern. Med. J. 37: 229-235 (2007). *
Yamada M, Murakami K, Sasaki S, Takahashi Y, Okubo H. Soft drink intake is associated with diet quality even among young Japanese women with low soft drink intake. J. Am. Diet. Assoc. 108: 1997-2004 (2008). *
Yamada M, Nagatomo J, Setoguchi Y, Kuroki N, Higashi S, Setoguchi T. Circadian rhythms of sterol 12alpha-hydroxylase, cholesterol 7alpha-hydroxylase and DBP involved in rat cholesterol catabolism. Biol. Chem. 381: 1149-1153 (2000).
Yamada N. Fibrates. Nippon Rinsho 60: 962-967 (2002).
Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl. J. Med. 347: 1916-1923 (2002). *
Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Ichihara S, Yoshida H, Satoh K, Nozawa Y. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 191: 298-304 (2007).
Yamada Y, Kato K, Yoshida T, Yokoi K, Matsuo H, Watanabe S, Ichihara S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa Y. Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals. Int. J. Mol. Med. 21: 83-89 (2008). *
Yamada Y, Kato K, Yoshida T, Yokoi K, Matsuo H, Watanabe S, Metoki N, Yoshida H, Satoh K, Ichihara S, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Lee W, Nozawa Y. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese individuals. J. Med. Genet. 45: 22-28 (2008).
Yamagishi K, Nettleton JA, Folsom AR; for the ARIC Study Investigators. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J. 156: 965-974 (2008).
Yamagishi SI, Adachi H, Matsui T, Nakamura K, Enomoto M, Fukami A, Otsuka M, Kumagae SI, Nanjo Y, Imaizumi T. Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population. Clin. Cardiol. 32: E29-E32 (2009).
Yamajuku D, Okubo S, Haruma T, Inagaki T, Okuda Y, Kojima T, Noutomi K, Hashimoto S, Oda H. Regular feeding plays an important role in cholesterol homeostasis through the liver circadian clock. Circ. Res. 105: 545-548 (2009).
Yamamoto Y, Kawamoto T, Negishi M. The role of the nuclear receptor CAR as a coordinate regulator of hepatic gene expression in defense against chemical toxicity. Arch. Biochem. Biophys. 409: 207-211 (2003). *
Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M. Estrogen receptor alpha mediates 17alpha-ethynylestradiol-causing hepatotoxicity. J. Biol. Chem. 281: 16625-16631 (2006). *
Yamanishi Y, Ikawa S, Hirayama C. Serum squalene levels in hepatobiliary diseases. Clin. Chim. Acta 88: 105-110 (1978).
Yamaoka-Tojo M, Tojo T, Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr. Vasc. Pharmacol. 6: 271-281 (2008).
Yamashina M, Kaneko Y, Maesawa C, Kajiwara T, Ishii M, Fujiwara F, Taneichi H, Takebe N, Ishida W, Takahashi K, Masuda T, Satoh J. Association of TNF-alpha gene promoter C-857T polymorphism with higher serum LDL cholesterol levels and carotid plaque formation in Japanese patients with type 2 diabetes. Tohoku J. Exp. Med. 211: 251-258 (2007). *
Yamauchi Y, Chang CC, Hayashi M, Abe-Dohmae S, Reid PC, Chang TY, Yokoyama S. Intracellular cholesterol mobilization involved in the ABCA1/apolipoprotein-mediated assembly of high density lipoprotein in fibroblasts. J. Lipid Res. 45: 1943-1951 (2004). *
Yan D, Mayranpaa MI, Wong J, Perttila J, Lehto M, Jauhiainen M, Kovanen PT, Ehnholm C, Brown AJ, Olkkonen VM. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J. Biol. Chem. 283: 332-340 (2008). *
Yan JC, Wu ZG, Li L, Zhong RQ, Kong XT. Relationship between expression of CD40-CD40 ligand system and serum cholesterol levels in patients with hypercholesterolemia. Chin. Med. J. (Engl.) 117: 1101-1103 (2004).
Yanai H, Javitt NB, Higashi Y, Fuda H, Strott CA. Expression of cholesterol sulfotransferase (SULT2B1b) in human platelets. Circulation 109: 92-96 (2004). *
Yanaura S, Ishikawa S. Effect of ursodeoxycholic acid on bile secretion and bile components. Comparison with chenodeoxycholic acid and dehydrocholic acid. Nippon Yakurigaku Zasshi 72: 689-700 (1976).
Yancey PG, Asztalos BF, Stettler N, Piccoli D, Williams DL, Connelly MA, Rothblat GH. SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients with Alagille syndrome. J. Lipid Res. 45: 1724-1732 (2004). *
Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC, Hobbs HH. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J. Biol. Chem. 281: 27816-27826 (2006). *
Yang F, Vought BW, Satterlee JS, Walker AK, Jim Sun ZY, Watts JL, DeBeaumont R, Saito RM, Hyberts SG, Yang S, Macol C, Iyer L, Tjian R, van den Heuvel S, Hart AC, Wagner G, Naar AM. An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature 442: 700-704 (2006). *
Yang MH, Son HJ, Sung JD, Choi YH, Koh KC, Yoo BC, Paik SW. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepatogastroenterology 52: 1832-1835 (2005).
Yang Q, Liu HY, Zhang YW, Wu WJ, Tang WX. Anandamide induces cell death through lipid rafts in hepatic stellate cells. J. Gastroenterol. Hepatol. Jan 4 [Epub ahead of print] (2010). *
Yang Q, O'Shea TM. Dietary Echium oil increases tissue (n-3) long-chain polyunsaturated fatty acids without elevating hepatic lipid concentrations in premature neonatal rats. J. Nutr. 139: 1353-1359 (2009). *
Yang Y, Zhang M, Eggertsen G, Chiang JY. On the mechanism of bile acid inhibition of rat sterol 12alpha-hydroxylase gene (CYP8B1) transcription: roles of alpha-fetoprotein transcription factor and hepatocyte nuclear factor 4alpha. Biochim. Biophys. Acta 1583: 63-73 (2002). *
Yao JK, Wengenack TM, Curran GL, Poduslo JF. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem. Res. 34: 102-108 (2009).
Yaqoob P. The nutritional significance of lipids rafts. Annu. Rev. Nutr. 29: 257-282 (2009). *
Yasuda T, Grillot D, Billheimer JT, Briand F, Delerive P, Huet S, Rader DJ. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. Jan 28 [Epub ahead of print] (2010).
Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand. J. Gastroenterol. 44: 471-477 (2009). *
Yatskar L, Fisher EA, Schwartzbard A. Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin. Cardiol. 29: 52-55 (2006).
Ye D, Hoekstra M, Out R, Meurs I, Kruijt JK, Hildebrand RB, Van Berkel TJ, Van Eck M. Hepatic cell-specific ATP-binding cassette (ABC) transporter profiling identifies putative novel candidates for lipid homeostasis in mice. Atherosclerosis 196: 650-658 (2008).
Ye L, Li YL, Mellstrom K, Mellin C, Bladh LG, Koehler K, Garg N, Garcia Collazo AM, Litten C, Husman B, Persson K, Ljunggren J, Grover G, Sleph PG, George R, Malm J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med. Chem. 46: 1580-1588 (2003). *
Ye P, Wang ZJ, Zhang XJ, Zhao YL. Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia. Chin. Med. J. (Engl.) 118: 1093-1098 (2005).
Yesilaltay A, Kocher O, Pal R, Leiva A, Qui�ones V, Rigotti A, Krieger M. PDZK1 is required for maintaining hepatic scavenger receptor, class B, type I (SR-BI) steady state levels but not its surface localization or function. J. Biol. Chem. 281: 28975-28980 (2006). *
Yesilaltay A, Kocher O, Rigotti A, Krieger M. Regulation of SR-BI-mediated high-density lipoprotein metabolism by the tissue-specific adaptor protein PDZK1. Curr. Opin. Lipidol. 16: 147-152 (2005).
Yilmaz S, Bayan K, Tuzun Y, Batun S, Altintas A. A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey. J. Thromb. Thrombolysis 22: 205-212 (2006). *
Yin W, Jen H, Chen J, Lin S, Young M. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab. 32: 229-235 (2006). *
Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopleovich L, Glazer RI. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 65: 3950-3957 (2005). *
Yip HK, Wang PW, Chang LT, Youssef AA, Sheu JJ, Lee FY, Wu CJ. Cytotoxic T lymphocyte antigen 4 gene polymorphism associated with ST-segment elevation acute myocardial infarction. Circ. J. 71: 1213-1218 (2007). *
Ylonen SK, Salminen I, Lyssenko V, Virtanen SM, Groop L, Aro A, Saloranta C. The Pro12Ala polymorphism of the PPAR-gamma2 gene affects associations of fish intake and marine n-3 fatty acids with glucose metabolism. Eur. J. Clin. Nutr. 62: 1432-1439 (2008). *
Yokomori H, Oda M, Wakabayashi G, Kitajima M, Yoshimura K, Nomura M, Hibi T. High expressions of caveolins on the proliferating bile ductules in primary biliary cirrhosis. World J. Gastroenterol. 11: 3710-3713 (2005). *
Yokota K, Miyoshi F, Miyazaki T, Sato K, Yoshida Y, Asanuma Y, Akiyama Y, Mimura T. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 35: 193-200 (2008).
Yokoyama A, Makishima M, Choi M, Cho Y, Nishida S, Hashimoto Y, Terui T. Induction of SREBP-1c mRNA by differentiation and LXR ligand in human keratinocytes. J. Invest. Dermatol. 129: 1395-1401 (2009). *
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369: 1090-1098 (2007). *
Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 42: 573-582 (2007). *
Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J. Gastroenterol. 37: 1028-1034 (2002). *
Yoo JY, Desiderio S. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc. Natl. Acad. Sci. U.S.A. 100: 1157-1162 (2003). *
Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 39: 732-738 (2004). *
Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp. Mol. Med. 34: 481-488 (2002). *
Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 90: 837-852 (1986).
Yoshida H, Nishikawa M, Yasuda S, Mizuno Y, Toyota H, Kiyota T, Takahashi R, Takakura Y. TLR9-dependent systemic interferon-beta production by intravenous injection of plasmid DNA/cationic liposome complex in mice. J. Gene Med. 11: 708-717 (2009).
Yoshida T, Kato K, Yokoi K, Oguri M, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nishigaki Y, Nozawa Y, Yamada Y. Association of genetic variants with chronic kidney disease in individuals with different lipid profiles. Int. J. Mol. Med. 24: 233-246 (2009).
Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Kimura S, Ishibashi S, Yamada N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21: 2991-3000 (2001). *
Yu BZ, Kaimal R, Bai S, El Sayed KA, Tatulian SA, Apitz RJ, Jain MK, Deng R, Berg OG. Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A2: role in hypocholesterolemia. J. Nat. Prod. 72: 24-28 (2009).
Yu C, Wang F, Jin C, Huang X, McKeehan WL. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J. Biol. Chem. 280: 17707-17714 (2005). *
Yu C, Wang F, Jin C, Wu X, Chan WK, McKeehan WL. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am. J. Pathol. 161: 2003-2010 (2002). *
Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275: 15482-15489 (2000). *
Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, Hobbs HH, Cohen JC. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J. Biol. Chem. 280: 8742-8747 (2005). *
Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. U.S.A. 99: 16237-16242 (2002). *
Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110: 671-680 (2002). *
Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J. Lipid Res. 45: 301-307 (2004). *
Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J. Lipid Res. 46: 1739-1744 (2005). *
Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem. 278: 15565-15570 (2003). *
Yu M, Xu XJ, Yin JY, Wu J, Chen X, Gong ZC, Ren HY, Huang Q, Sheng FF, Zhou HH, Liu ZQ. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin. Pharmacol. Ther. Jan 6 [Epub ahead of print] (2010). *
Yuasa S, Maruyama T, Yamamoto Y, Hirose H, Kawai T, Matsunaga-Irie S, Itoh H. MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 86: 193-198 (2009).
Yue L, Mazzone T. Peroxisome proliferator-activated receptor gamma stimulation of adipocyte ApoE gene transcription mediated by the liver X receptor pathway. J. Biol. Chem. 284: 10453-10461 (2009). *
Yue L, Ye F, Gui C, Luo H, Cai J, Shen J, Chen K, Shen X, Jiang H. Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation. Protein Sci. 14: 812-822 (2005). *
Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 29: 525-529 (2009). *
Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Son BH, Shin JH. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int. 29: 878-883 (2009). *
Yurko-Mauro K. Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr. Alzheimer Res. Jan 21 [Epub ahead of print] (2010).
Yvan-Charvet L, Bobard A, Bossard P, Massiera F, Rousset X, Ailhaud G, Teboul M, Ferre P, Dagher G, Quignard-Boulange A. In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 27: 1340-1345 (2007). *
Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117: 3900-3908 (2007). *
Zager RA, Johnson AC, Lund S. 'Endotoxin tolerance': TNF-alpha hyper-reactivity and tubular cytoresistance in a renal cholesterol loading state. Kidney Int. 71: 496-503 (2007). *
Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br. J. Clin. Pharmacol. 57: 298-309 (2004). *
Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: 646-654 (2008). *
Zaima N, Sugawara T, Goto D, Hirata T. Trans geometric isomers of eicosapentaenoic acid lower LXRalpha-induced cellular triacylglycerol via suppression of sterol regulatory element binding protein-1c and peroxisome-proliferator-activated receptor-gamma co-activator 1beta. J. Lipid Res. 47: 2712-2717 (2006). *
Zak A, Zeman M, Hrubant K, Vecka M, Tvrzicka E. Effect of hypolipidemic treatment on the composition of bile and the risk or cholesterol gallstone disease. Cas. Lek. Cesk. 146: 24-34 (2007).
Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators. Clinical and experimental evidence. Arterioscler. Thromb. Vasc. Biol. 26: 977-986 (2006). *
Zamora-Valdes D, Mendez-Sanchez N. Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann. Hepatol. 6: 281-283 (2007). *
Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, Zappia V, Ruggiero G, Adinolfi LE. Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J. Viral Hepat. 15: 740-746 (2008).
Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim. Biophys. Acta 1771: 972-982 (2007). *
Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch. Dermatol. 142: 1016-1022 (2006). *
Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279: 47898-47905 (2004). *
Zanlungo S, Miquel JF, Rigotti A, Nervi F. Insulin and cholesterol gallstones: new insights for a complex pathogenic relationship. Hepatology 48: 2078-2080 (2008). *
Zanlungo S, Nervi F. The ACAT2 gene encodes a gatekeeper of intestinal cholesterol absorption that regulates cholesterolemia and gallstone disease. Hepatology 33: 760-761 (2001). *
Zanlungo S, Rigotti A. Determinants of transhepatic cholesterol flux and their relevance for gallstone formation. Liver Int. 29: 323-330 (2009). *
Zanlungo S, Rigotti A, Nervi F. Hepatic cholesterol transport from plasma into bile: implications for gallstone disease. Curr. Opin. Lipidol. 15: 279-286 (2004).
Zanotti I, Poti F, Favari E, Steffensen KR, Gustafsson JA, Bernini F. Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages. Evidence for LXR-dependent and LXR-independent mechanisms of activation by cAMP. J. Pharmacol. Exp. Ther. 317: 395-401 (2006). *
Zanotti I, Poti F, Pedrelli M, Favari E, Moleri E, Franceschini G, Calabresi L, Bernini F. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J. Lipid Res. 49: 954-960 (2008). *
Zavvarreza J, Doosti M, Salehipour M, Packnegad M, Mojarrad M, Hrdary M, Emamian E. Modulation peroxisome proliferators activated receptor alpha (PPARa) and acyl coenzyme A: cholesterol acyltransferase1 (ACAT1) gene expression by fatty acids in foam cell. Lipids Health Dis. 8: 38 (2009). *
Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325: 100-104 (2009). *
Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc. Natl. Acad. Sci. U.S.A. 104: 10601-10606 (2007). *
Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116: 607-614 (2006). *
Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination. Cas. Lek. Cesk. 144: 737-741 (2005).
Zhai G, Wen P, Guo L, Chen L. Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population. Clin. Chem. Lab. Med. 44: 1313-1316 (2006).
Zhang A, Zhang M, Zhang J, Yu Y, Xie J. The influence of the Pro12Ala mutation of PPARgamma2 receptor gene on beta-cells restoration and insulin resistance in type 2 diabetes with hypertension. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25: 648-650 (2005).
Zhang AH, Gao S, Fan JL, Huang W, Zhao TQ, Liu G. Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett. 570: 25-29 (2004). *
Zhang D, Che D, Zhao S, Sun Y. Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 50: 281-285 (2007).
Zhang EY, Phelps MA, Banerjee A, Khantwal CM, Chang C, Helsper F, Swaan PW. Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry 43: 11380-11392 (2004). *
Zhang HY, Han DW, Zhao ZF, Liu MS, Wu YJ, Chen XM, Ji C. Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia. World J. Gastroenterol. 13: 3500-3507 (2007). *
Zhang J, Lewis RM, Wang C, Hales N, Byrne CD. Maternal dietary iron restriction modulates hepatic lipid metabolism in the fetuses. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288: R104-R111 (2005). *
Zhang L, Geng Y, Xiao N, Yin M, Mao L, Ren G, Zhang C, Liu P, Lu N, An L, Pan J. High dietary n-6/n-3 PUFA ratio promotes HDL cholesterol level, but does not suppress atherogenesis in apolipoprotein E-null mice. J. Atheroscler. Thromb. 16: 463-471 (2009).
Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J. Biol. Chem. 276: 41690-41699 (2001). *
Zhang P, Boudyguina E, Wilson MD, Gebre AK, Parks JS. Echium oil reduces plasma lipids and hepatic lipogenic gene expression in apoB100-only LDL receptor knockout mice. J. Nutr. Biochem. 19: 655-663 (2008). *
Zhang Q, He F, Kuruba R, Gao X, Wilson A, Li J, Billiar TR, Pitt BR, Xie W, Li S. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc. Res. 77: 560-569 (2008). *
Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51: 380-388 (2009).
Zhang SL, Lu WS, Yan L, Wu MC, Xu MT, Chen LH, Cheng H. Association between peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene polymorphisms and type 2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C. Chin. Med. J. (Engl.) 120: 1878-1885 (2007).
Zhang T, Zhou JH, Shi LW, Zhu RX, Chen MB. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett. 17: 2156-2160 (2007). *
Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajan MP, Farese RV, Stolz DB, Tso P, Koo SH, Montminty M, Unterman TG. FOXO1 regulates multiple metabolic pathways in the liver: effects on gluoconeogenic, glycolytic and lipogenic gene expression. J. Biol. Chem. 281: 10105-10117 (2006). *
Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation 117: 421-428 (2008). *
Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4